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Abstract 
Insect neuropeptides have been known as important components in regulating many 
physiological and behavioural processes in insect life such as growth, molting, metamorphosis, 
homeostasis, osmoregulation, water balance, reproduction and diuresis. Comprising of a short 
sequence of 6-15 amino acids, insect kinins and their receptors promise excellent targets for a 
novel generation of highly selective and environmental friendly insecticides.  
Belonging to the myokinin family, helicokinin I displays a high biological activity against 
Heliothis virescens in a functional bioassay. Moreover, helicokinin I inhibits weight gain and 
increases mortality after injection into larvae of Heliothis virescens, a serious agricultural pest. 
Determining the preferred conformation of the receptor bound peptide is a crucial step for the 
design of selective ligands in developing novel insecticidal agents. It is therefore more and more 
important to develop suitable strategies that aim at mimicking the structure and activity of 
biologically interesting peptides in order to design new effective insecticides. 
The first part of this thesis is dedicated to the design and synthesis of β-turn helicokinin I 
peptidomimetics. Herein, the synthesis and incorporation of 4-trans-aminopyroglutamates, as 
type VI β-turn inducers, into the native helicokinin I peptide backbone are presented. In addition, 
two convenient strategies for stabilizing the conformational preferences of helicokinin I 
analogues will be described.  
In the second part the important role of the Trp side chain on the secondary structure of 
helicokinin I will be investigated. This includes the preparation of conformationally constrained 
building blocks derived from the Trp moiety using Pictet-Spengler reaction or xanthate radical 
transfer reagents.  
The third part of this thesis deals with a cycloscan that utilizes the available hydroxy functional 
groups on Ser and Tyr residues. Formation of macrocyclic peptides using either a ring-closing 
metathesis reaction or Mitsunobu etherification is described. 
The last section focuses on further investigations of the structure-activity relationships. The use 
of conformationally constrained structures, such as β-proline amino acid and spirolactam, for 
replacing selectively helicokinin I residues is investigated.  
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I. Introduction 
1.1 Insect neuropeptides 
Insect neuropeptides are cellular components that are released from specialized neuroglandular 
cells and transported through the haemolymph to the target organs. Consisting of 5 to about 80 
amino acids linked by amide bonds, insect neuropeptides create functionally and structurally 
diverse signaling substances in insects. 
Early 1922, Stefan Kopec proposed that processes of moulting and metamorphosis in insects are 
controlled by a hormone in the brain,
[1]
 as suggested by the concept of neurosecretion that was 
first described by Berta Scharrer and Ernst Scharrer, in 1937.
[2]
 Some years later, in 1945, they 
defined the term of neurosecretory organs and gland-like nerve cell in both vertebrates and 
invertebrates, and described the similarities between the corpora cardiac-corpora allata system in 
insects.
[3]
 However, until the middle of the 1970s, there have been only two insect neuropeptides 
isolated and identified. The first pentapeptide proctolin (1, Figure 1) was isolated, from an 
extraction of adult American cockroaches Periplaneta Americana in 1975.
[4] 
It showed potent 
myotropic activity in the cockroach hindgut. The other peptide, adipokinetic hormone (AKH) (2, 
Figure 1), produced by glandular cells of the corpus cardiacum, was reported by Stone in 1976.
[5] 
In the next ten years, there were only a few insect neuropeptides isolated due to difficulties in 
isolating of those small amounts at that time. Nevertheless, in the late 1980s and early 1990s 
with the rapid improvement of separation and identification methods, such as matrix-assisted 
laser desorption/ ionization time of flight mass spectroscopy (MALDI-TOP-MS), refined high-
performance liquid chromatography (HPLC), microsequencing techniques, fast atom 
bombardment mass spectroscopy (Fab-MS) and genetic engineering technologies, the number of 
isolated and sequenced insect neuropeptides increased dramatically. Most of which were isolated 
from cockroaches (Leucophaea maderae, Periplaneta Americana, Diploptera punctata), locusts 
(Losuta migratoria) and moths (Manduca sexta, Bombyx mori and various Heliothinae species). 
In particular a significant achievement in insect neuropeptide receptor research on Drosophila 
genome, in the year 2000, opened a great opportunity for studying insect neuropeptides and their 
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receptors.
[6]
 Recently, 44 genes of the G-protein coupled receptors (GPSRs) encoded by the 
Drosophila genome have been reported.
[7]
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Figure 1: Structure of proctolin (1) and adipokinetic hormone (AKH) (2) 
 
 
 
Figure 2: Overview on functions of insect neuropeptides
[8]
 
Neuropeptides and peptide hormones are involved in many physiological processes and regulate 
every aspect of insect life. Based on their functional roles, neuropeptides can be grouped into 
four major categories (Figure 2).
[8,9]
 
 Growth and development 
 Behaviour and reproduction 
1 
2 
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 Metabolism and homeostasis 
 Muscle activity 
1.2 Neuropeptides as potential ligands for pest control 
As the largest group of all animal species, insects have extremely important roles in the 
ecological system. Besides the multifaceted beneficial aspects, for instance the pollination of 
flowering plants or killing the pests, a large number of insect species cause severe damage to 
crop and transfer serious diseases to humans and animals, such as malaria and sleeping sickness. 
Due to their great impact on humans and agriculture, 50 insect genome projects have been 
initiated and half of which have been completed.
[10,11]
 
Insecticides play a pivotal role in achieving high-yield crop production. Traditionally, 
insecticidal agents are neurotoxic compounds that contaminate the environment with toxic 
residues, endanger humans and disrupt the ecological balance. In addition, uncontrolled 
application of chemical insecticides has led to resistance in insect species. 
Apart from conventional insecticides, several other methods are used in controlling insect pests, 
such as natural product extracts from plants, natural enemies, microbial insecticides and 
recombinant baculovirus strains.
[12,13]
 However, all these applications have particular restrictions 
that prevent the replacement for neurotoxic organic insecticides. Thus, the requirements for 
developing ecofriendly, effective and non-toxic insecticides that could eventually replace the 
conventional insect control agents are essential. 
Insect neuropeptides, as presented in Figure 2, regulate the most critical functions in insect such 
as embryonic and postembryonic development, osmoregulation, muscle activity, migration and 
oviposition. Understanding the mode of action of the key functional neuropeptides may provide 
the basic physiological mechanism of the general interest from which the use of superagonist or 
antagonist may intervene in the normal growth, development and behavior of insect life. Thus, 
insect neuropeptides and their receptors promise a prime target in the development of novel 
insectidal agents that present higher levels of selectivity and environmental compatibility, which 
are absent from neurotoxic insecticides. Despite their potential, insect neuropeptides have been 
not utilized as agricultural insecticides so far because of some major drawbacks: 
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 Due to their high molecular weight and hydrophobic nature, neuropeptides are poorly 
absorbed across membrane barriers of insects, especially across the cuticle. 
 Neuropeptides are environmental fragile. 
 Neuropeptides are only partially soluble in both organic solvents and water. 
 Neuropeptides are highly susceptible to proteolytic degradation by enzymatic hydrolysis 
in the insect gut and hemolymph, and have a poor bioavailability. 
To overcome these inherent limitations in the physiological properties of peptides, the 
development of peptidomimetics represents an effective strategy to improve their biological 
effects. 
1.3 Neuropeptide receptors 
1.3.1 Insect G-protein coupled receptors 
 
G-protein coupled receptors (GPCRs) constitute the largest family of integral membrane proteins 
(Figure 3) and are responsible for transmission of extracellular signals to intracellular responses. 
More than 5,000 different GPCRs have been identified, and many of them have been implicated 
as major therapeutic targets for the treatment of human diseases.
[14]
 It is estimated that more than 
50% of current therapeutic agents on the market are targeted to these receptors.
[15]
 
GPCRs are composed of seven hydrophobic transmembrane-spanning (7TM) α-helices, from 20 
to 25 amino acid residues, with an extracellular N-terminus, an intracellular C-terminus and three 
                                                          
a
 http://www.scientificimages.co.uk/Proteins.htm 
 
Figure 3: Structure of a membrane
a 
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interhelical loops on each side of the membrane (Figure 4).
[16,17] 
Insect G-protein coupled 
receptors are classified into four families: family A, the largest group including rhodopsin-like 
receptors; family B, including secretin-like and adhesion receptors; family C, including 
metabotropic glutamate receptor; and atypical GPCRs such as Frizzled/Smoothened family. 
Binding of ligands, such as hormones and neurotransmitters, to GPCRs from the extracellular 
side of the membrane may induce various conformational changes that propagate to the 
cytoplasmic surface,
 
leading to an activation of G proteins and a consequent change in the level 
of intracellular messengers such as cAMP, Ca
2+ 
or signaling lipids.
[18,19]
 Consequently, 
controlling these activation processes and conformational changes could be a useful approach for 
the development of potential drugs with fewer side effects and more favorable pharmacological 
properties.  
 
Figure 4: Representative structure of genetic GPCRs
[17]
 
From the drug discovery and rational design point of view, GPCRs are important for drug 
design, particularly 3D-structural information of the GPCRs is considered as a key tool for 
structure-based drug designs. Although the advances in technologies for structure-based design 
have recently improved, the approaches to GPCR targets have remained challenging due to 
difficulties in purifying and crystallizing of membrane proteins.
[20,21]
 To date, only a few 3D-
structures characterized by high-resolution X-ray crystallography, namely bovine and squid 
6 
 
rhodopsin,
[20,22] β1- and β2-adrenergic receptor,
[23-25]
 and adenosine A2A receptor,
[26]
 are available. 
In particular, the first NMR-based structural determination of a detergent-solubilized GPCR was 
published in 2010.
[27]
 
1.3.2 Biologically active conformation  
Research for the biologically active neuropeptide conformation is principally based on the 
receptor-bound state. Unfortunately, this work is extremely difficult to accomplish because 
insect neuropeptides bind to GPCRs. Much attention to identify receptor-bound conformations of 
GPCR ligands in aqueous solution by NMR spectroscopy has been focused so far, such as 
pituitary adenylate cyclase-activating peptide (PACAP),
[28]
 neurotensin,
[29]
 and the backbone of 
bradykinin.
[30]
 For all other neuropeptides, however, only indirect information on the receptor 
bound conformations is currently available. The most popular strategy is based on 
conformationally restricted neuropeptide analogues as for instance cyclic peptides that can easily 
be analyzed by conventional NMR spectroscopy.
[31,32] 
Another approach, commonly employed to neuropeptides, is based on the determination of 
conformations in the membrane-bound state. According to the membrane-compartment theory, 
the target cell surface influences the receptor selection of regulatory peptides by increasing 
peptide concentration in the vicinity of the receptor and by inducing preferred conformations and 
orientations.
[33-37]
 According to the model of ligand binding to membrane-embedded receptors 
(Figure 5),
[38]
 the accumulation of ligands on the surface membrane is first directed by 
electrostatic interactions that regulate both negatively charged phospholipids in the membrane 
components and cationic ligand residues. In the next step, the ligand is reoriented in such a way 
that the hydrophobic side chains penetrate into the membrane. Subsequently, the ligand diffuses 
laterally along the membrane until a particular state from which the peptide is recognized by the 
receptor. The initial conformation of the peptide in this transition would be close to the 
membrane-bound state, but may undergo further conformational changes following an “induced-
fit” mechanism. Another outcome of surface accumulation is the decrease in the dimensionality 
of the “receptor search” by the ligand from three-dimensional to two-dimensional diffusion, 
which may be beneficial to low surface concentrations of the receptors.  
7 
 
 
Figure 5: Schematic presentation of receptor-binding mechanism:
[38]
 1. Unligated peptide in bulk solution, 2. 
Movement to the membrane and reorientation, 3. Lateral diffusion, 4. Initial recognition by the receptor, 5. Receptor 
bound state. 
During the past two decades, several membrane-bound conformations of signal peptides, such as 
neuropeptide Y,
[38]
 cholecystokinin-8,
[39]
 bradykinin,
[40]
 the endomorphins,
[41]
 enkephalins,
[42]
 
myosupressin, tachykinin and helicokinins
[43]
 have been elucidated by NMR techniques using 
dodecylphosphocholine (DPC) or sodium dodecyl-sulfate (SDS) micelles as the membrane-
mimicking environments.
[44,45] 
 
1.3.3 Insect kinin receptors as promising target sites for the development of pesticides 
G-protein coupled receptors (GPCRs) are responsible for a large number of physiological 
processes, such as sensory transduction, mediation of hormonal activity, and cell-to-cell 
communication. Thus, modern drug developments are targeted on GPCRs discovery. Upon 
determining the preferred conformation of receptor-bound peptides, the design of selective 
peptidomimetic ligands could be accomplished by far more efficiently. However, because of the 
lack of three-dimensional structures, structure-based drug designs are difficult. Instead, receptor-
binding characteristics that are deduced from structural analysis of ligands and their analogues 
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could provide a rational basis for probing receptor structures and designing conformationally 
restricted agonist or antagonists. Consequently, characterization of these designed analogues 
could offer further information on structural requirements for receptor binding and signal 
transduction. 
Table 1: Selected myokinins from various insect species
[46]
 
Insect species Name Sequence 
Cricket Acheta domesticus Achetakinin I Ser-Gly-Ala-Asp-Phe-Tyr-Pro-Trp-Gly-NH2 
  Achetakinin II Ala-Tyr-Phe-Ser-Pro-Trp-Gly-NH2 
  Achetakinin III Ala-Leu-Pro-Phe-Ser-Ser-Trp-Gly-NH2 
Mosquito Aedes aegypti Aedeskinin I          Asn-Ser-Lys-Tyr-Val-Ser-Lys-Gln-Lys-Phe-Tyr-Ser-Trp-Gly-NH2 
  Aedeskinin II Arg-Pro-Phe-His-Ala-Trp-Gly-NH2 
  Aedeskinin III Arg-Arg-Pro-Arg-Val-Phe-Tyr-Pro-Trp-Gly-NH2 
Mosquito Culex salinarius Culekinin I Arg-Pro-Phe-His-Ser-Trp-Gly-NH2 
  Culekinin II Arg-Arg-Ala-Arg-Val-Phe-Tyr-Pro-Trp-Gly-NH2 
  Culekinin III Trp-Lys-Tyr-Val-Ser-Lys-Gln-Phe-Phe-Ser-Trp-Gly-NH2 
Moth Heliothis zea Helicokinin I Tyr-Phe-Ser-Pro-Trp-Gly-NH2 
  Helicokinin II Val-Arg-Phe-Ser-Pro-Trp-Gly-NH2 
  Helicokinin III Lys-Val-Lys-Phe-Ser-Ala-Trp-Gly-NH2 
Cockroach Leucophaea maderae Leucokinin I Asp-Pro-Ala-Phe-Asn-Ser-Trp-Gly-NH2 
  Leucokinin II Asp-Pro-Gly-Phe-Ser-Ser-Trp-Gly-NH2 
  Leucokinin III Asp-Gln-Gly-Phe-Asn-Ser-Trp-Gly-NH2 
Locust Locusta migratoria Locustakinin Ala-Phe-Ser-Ser-Trp-Gly-NH2 
 
Insect kinins share a highly conserved C-terminal pentapeptide sequence Phe
1
-Xaa
2
-Xbb
3
-Trp
4
-
Gly
5
-NH2, where Xaa
2
 is Tyr, His, Ser or Asn, and Xbb
3
 is Ala, Ser, Pro (Table 1). The first 
member of insect kinin neuropeptides, Leukopyrokinin, was isolated from the cockroach 
Leucophaea maderae in 1986.
[47]
 Since then, over 30 peptides have been isolated and identified
 
from various species of Dictyoptera, Lepidoptera and Orthopera.
[48]
 The other diuretic peptide 
family in insects are the corticotrophin-releasing factor (CRF)-related peptides, consisting of 30-
37 amino acids in length, which were isolated from Tenebrio molitor, Manduca sexta, Acheta 
domesticus, Locusta migratoria. The role of the CRF-related peptides acts as diuretic hormones 
that stimulate Malpighian tubule fluid secretion through a cyclic-AMP as secondary messengers.  
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Figure 6: Myokinin mimetics with various substitutions 
at the C-terminus
[49]
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Table 2: Diuretic activity of derivatives 3 
3 X EC50 (nM) 
a NH2 0.004 
b OH 1000 
c OMe 20 
d SMe 5 
e OEt 100 
f OCH2Ph 50 
g NHMe 28 
h NMe2 Inactive 
 
Figure 7: Myokinin mimetics with various substitutions 
at the N-terminus
[50]
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Table 3: N-Terminal variations of peptide 4 
 
Xaa EC50 (nM) 
H 0.1 
Trp 0.042 
Phe 0.029 
Arg 0.020 
Ala 0.005 
Lys 0.005 
Aib 0.005 
Asp 0.002 
Leu 0.002 
Asn 0.001 
Val 0.001 
 
Initial structure-activity relationship studies on the insect kinins revealed that the intact C-
terminal pentapeptide sequences are required to elicit fully myotropic and diuretic activity, 
which therefore represents the active core sequence. Within the active domain, a series of 
alanine-substituted analogues proved that Trp and Phe are the most significant residues for full 
biological activity. Functional variations at the C-terminus of AFFPWG-X (3, Figure 6) in 
Acheta domesticus, for instance, demonstrated the importance of the C-terminal amidation 
(Table 2).
[49]
 The diuretic and myotropic activity is completely lost when the C-terminal amide 
of insect kinins is replaced with a negatively charged acid moiety, whereas the replacements by 
ester groups (3c and 3e) or thioester (3d) reduced remarkably the diuretic activity. When 
modified at the N-terminus, hexapeptide analogues aaX-FFPWG-NH2 (4, Table 3) displayed 
high stimulation of fluid secretion in the isolated cricket Malpighian tubules Ramsay assay. In 
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Table 4: Cricket Malpighian tubule secretion activity of β-amino 
acid containing insect kinin analogues and achetakinins
[53]
 
Peptide analogues EC50 (pM) 
Natural achetakinins 20-325 
Ac-Arg-Phe-Phe-[β3Pro]-Trp-Gly-NH2 (8a) 30 
Ac-Arg-[β3Phe]-Phe-Pro-Trp-Gly-NH2 (8b) 270 
Ac-Arg-Phe-Phe-Pro-[β3Trp]-Gly-NH2 (8c) 20000 
Ac-Arg-[β2homoPhe]-Phe-Pro-Trp-Gly-NH2 (8d) 22500 
Ac-Arg-Phe-Phe-Pro-[β2Trp]-Gly-NH2 (8e) 40000 
Ac-Arg-[β3Phe]-Phe-[β3Pro]-Trp-Gly-NH2 (8f) 170000 
Ac-Arg-[β3Phe]-Phe-Phe-[β3Pro]-Trp-Gly-NH2 (8g) 100 
Ac-Arg-Phe-[β3Phe]-[β3Pro]-Trp-Gly-NH2 (8h) 1000 
 
 
particular when Xaa corresponded to Asp, Leu, Asn and Val, analogues 4 demonstrated the most 
superagonistic activity in comparison with the native achetakinin.
[50]
  
Recent experiments demonstrated that several members of the insect kinins are easily hydrolyzed 
and therefore deactivated by both angiotensin-converting enzyme (ACE), which only cleaves at 
the primary hydrolysis site, and neprilysin (NEP) that cleaves insect kinins at both the primary 
and secondary hydrolysis sites.
[51]
 The most sensitive sites for hydrolysis are the amide bonds 
between Trp and Xbb (mostly Ser and Pro). To overcome this restriction, the Xbb residues of the 
C-terminal active core sequence (Phe
1
-Xaa
2
-Xbb
3
-Trp
4
-Gly
5
-NH2) are replaced by non-
proteinogenic amino acids. For instance, three kinin peptides, Phe-Phe-Aib-Trp-Gly-NH2 (5), 
pGlu-Lys-Phe-Phe-Aib-Trp-Gly-NH2 (6) and pGlu-Lys(pGlu)-Phe-Phe-Aib-Trp-Gly-NH2 (7), 
containing sterically hindered aminoisobutyric acid (Aib), demonstrated potent stimulation of 
fluid secretion in isolated Malpighian tubules of the cricket Acheta domesticus with EC50 values 
of 5.6 pM, 2.8 pM and 8.3 pM, respectively.
[52]
 Notably, all analogues demonstrate similar 
potencies at a level two- to eight-fold more active than achetakinin IV (Asn-Phe-Lys-Phe-Asn-
Pro-Trp-Gly-NH2), one of the most potent insect kinins found in the cricket. The high activities 
could be explained by the turn-
stabilizing effect of the sterically 
hindered Aib moiety that 
accelerates efficient receptor 
binding.  
Another approach enhancing both 
resistance to peptidase hydrolysis 
and biological activity utilizes β-
amino acids. Replacement of the 
critical residues Phe, Trp and Pro 
with their β3- or β2-amino acid 
counterparts was investigated. As 
shown in Table 4, the single-replacement analogue Ac-Arg-Phe-Phe-[β3Pro]-Trp-Gly-NH2 (8a) 
with an EC50 value of 30 pM showed the most potent diuretic activity on isolated Malpighian 
tubules of the cricket Acheta domesticus. In addition, the peptide 8a also enhanced resistance to 
11 
 
the endopeptidases ACE and neprilysin (NEP), which deactivate the natural insect kinins. On the 
other hand, the double-replacement analogue Ac-Arg-[β3Phe]-Phe-[β3Pro]-Trp-Gly-NH2 (8f) 
proved to be about 5700 times less potent than (8a), with an EC50 of 170,000 pM.
[53]
 Notably, all 
analogues are also blocked at the N-terminus with an Ac group that contributes to an additional 
stabilization against peptidases and aminopeptidases.
[54]
  
A more detailed knowledge of the receptor-bound conformation or a preferred conformation in 
solution is a prerequisite for the rational design of peptidomimetic analogues. Based on 
molecular dynamics simulations of leucokinin II (Asp-Pro-Gly-Phe-Ser-Ser-Trp-Gly-NH2, 9), a 
β-turn preference for the active core over residues Phe-Ser-Ser-Trp was established. The 
preferred β-turn conformations have also been proposed for the other insect kinins, such as 
leucokinins (Phe-Xaa-Ser-Trp-Gly-NH2) and achetakinins (Phe-Xaa-Pro-Trp-Gly-NH2), where 
Xaa is His, Tyr, Ser or Asn. The conformational preference of the insect kinins (type I, type II or 
type VI) depends largely on the amino acid sequence and the solvent. However, in all cases 
molecular dynamics simulations indicate that the essential side chains, Phe
1
 and Trp
4
, are always 
oriented on the same side of the mainchain backbone and interact with the receptor, whereas the 
variable residue in the position 2 (Tyr, His or Ser) points way from the Phe and Trp.
[55]
 
Owing to decreased conformational flexibility, formation of active cyclic analogues is thought an 
excellent strategy for defining the receptor-bound conformation. Based on aqueous NMR 
spectroscopy and molecular dynamics (MD) calculations to a head-to-tail cyclic peptide, 
Nachman and co-workers concluded that the cyclic achetakinin analogue cyclo(Ala
1
-Phe
2
-Phe
3
-
Pro
4
-Trp
5
-Gly
6
) (10) adopts two individual turn conformations within the C-terminal active 
pentapeptide core region.
[55]
 The more rigid of the two conformations characterizes a cis-Xaa-
Pro amide bond in the third position of a type VI β-turn over residues 1-4 (Phe2-Phe3-Pro4-Trp5). 
The other less rigid conformation has a type I β-turn over residues 2-5 (Phe3-Pro4-Trp5-Gly6), 
with a trans-Xaa-Pro amide bond. Furthermore, the aqueous NMR studies proved that the cis-
Xaa-Pro amide bond predominates over 60%, while the other is about 40%. This agrees well 
with studies on Pro
3
-containing linear peptides in which the critical aromatic residues, Phe and 
Trp, promote preferentially the formation of type VI β-turn.[55-57]  
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Figure 8: Insect kinin analogue 11 with a mimetic  
cis-amide bond  
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Table 5: Diuretic activity of insect kinin mimetics in the cricket Acheta domesticus  
and tick receptor
[58]
 
 
Peptide analogues 
Tick 
receptor 
(BmLK3 
cell line) 
Cricket diuretic 
assay 
EC50 
(µM) 
EC50 (10
-8
M) 
Ac-Arg-Phe-(2S,4S)-APy-Trp-Gly-NH2 (11a) 11.1 14 
Ac-Arg-Phe-(2R,4R)-APy-Trp-Gly-NH2 (11b) 1.6 7 
Ac-Arg-Phe-(2R,4S)-APy-Trp-Gly-NH2 (11c) N.D. 0.7 
Ac-Arg-Phe-(2S,4R)-APy-Trp-Gly-NH2 (11d) N.D. 12 
Phe-Phe-ψ[CN4]-Ala-Trp-Gly-NH2 (L,L) (11e) N.D. 34 
Phe-D-Phe-ψ[CN4]-D-Ala-Trp-Gly-NH2 (D,D) (11f) N.D. 58 
Phe-Phe-ψ[CN4]-D-Ala-Trp-Gly-NH2 (L,D)  (11g) N.D. 43 
Phe-D-Phe-ψ[CN4]-Ala-Trp-Gly-NH2 (D,L) (11h) - 22 
N.D.: An EC50 could not be determined 
 
In order to obtain more clear evidence that the predominant conformation cis-Xaa-Pro type VI β-
turn is indispensable to receptor interaction, insect kinin analogues containing either tetrazoles 
(ψ[CN4]) or 4-aminopyroglutamate (APy) were synthesized and evaluated (Table 5). NMR and 
computer modeling studies indicated that tetrazole- and APy-containing analogues induce a type 
VI turn over the residues 1–4 in aqueous solution.[59,60] Like the head-to-tail cyclic achetakinin 
analogue 10, molecular dynamics computation of tetrazole-containing peptides demonstrated that 
the most critical Phe and Trp side chains form 
an aromatic surface that is thought to be a key 
element to facilitate the receptor binding of 
insect kinins (Figure 9). Further experimental 
evidence supporting the significance of 
stereochemical requirements for the kinin 
receptor binding was obtained from the tick 
Boophilus microplus (Table 5). Three 
analogues Ac-Arg-Phe-APy(2S,4S)-Trp-Gly-
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Figure 9: A receptor interaction model of an insect kinin C-
terminal pentapeptide core region  
 
  
 
NH2 (11a), Ac-Arg-Phe-APy(2R,4R)-Trp-Gly-NH2 (11b) and Ac-Arg-Phe-APy(2R,4S)-Trp-
Gly-NH2 (11c) demonstrated intrinsic activity, whereas the fourth peptide Ac-Arg-Phe-
APy(2S,4R)-Trp-Gly-NH2 (11d) was found to be inactive. The two analogues, Phe-Phe-ψ[CN4]-
Ala-Trp-Gly-NH2 (L,L) (11e) and Phe-D-Phe-ψ[CN4]-Ala-Trp-Gly-NH2 (D,L) (11h), showed 
agonist activity with maximal response of 32% and 47% compared to FFSWGa, respectively. 
Neither of these analogues were active 
enough to allow the calculation of an 
EC50 value. An in vitro cricket diuretic 
assay showed that the most active kinin 
analogues are Phe-D-Phe-ψ[CN4]-Ala-
Trp-Gly-NH2 (D,L) (11h) and Ac-Arg-
Phe-APy(2R,4S)-Trp-Gly-NH2 (11c) with 
EC50 values of 22 and 7 nM, respectively. 
Clearly, the tetrazole-containing 
analogues showed significantly lower 
diuretic activities than the APy mimetics. 
Thus, the use of tetrazole scaffold as cis-
amide bond template for researching the 
receptor bound conformation is limited.  
It must be emphasized that the most available biological data have been obtained so far from 
organ-assay (the isolated Malpighian tubule and cockroach hindgut) or receptor assays on 
different insect species. Therefore, the results have not provided clear interpretation whether a 
insect kinin or its derivative targets specifically only one receptor or a family of closely related 
receptors. Thus, it is essential to establish a suitable biological system for testing potential 
neuropeptide on only single receptor target of one insect species. 
1.4 Helicokinin 
1.4.1 Historical perspective 
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Helicokinins belong to the insect kinins which are characterized by a common C-terminal 
pentapeptide sequence Phe
1
-Xaa
2
-Xbb
3
-Trp
4
-Gly
5
-NH2, where Xaa
2
 is Ser, and Xbb
3
 is Ala, Pro 
(Table 1). Helicokinins (Hez-KI, -KII, -KIII, Figure 10) were first isolated and sequenced by 
Blackburn, in 1995, from the insect Helicoverpa (Heliothis) zea.
[61]
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Figure 10: Various structures of helicokinin I (12): Tyr-Phe-Ser-Pro-Trp-Gly-NH2, helicokinin II (13): Val-Arg-
Phe-Ser-Pro-Trp-Gly-NH2 and helicokinin III (14): Lys-Val-Lys-Phe-Ser-Ala-Trp-Gly-NH2 
In vitro assays of helicokinins (I-III) on the isolated whole-gut of fifth instar larvae from 
Spodoptera frugiperda showed that all three peptides stimulate fluid secretion in a concentration-
dependent manner with the EC50 values of 1.0 nM, 0.2 nM and 0.6 nM, respectively.
[62]
 When 
tested on the Malpighian tubules isolated from Manduca sexta, Hez-KII was found more 
effective than either Hez-KI or Hez-KIII at inducing fluid secretion with an EC50 value of 0.6 
12 
13 
14 
15 
 
pM.
[61]
 These results suggest that Hez-KII is the most potent myotropic activity in both M. sexta 
and S. frugiperda. 
 
Figure 11: Crop pest Heliothis virescens 
b
 
 
To investigate the effects of helicokinins on water balance in Heliothis virescens (Figure 11), a 
modified Ramsay assay was developed by Seinsche.
[63]
 This in vitro assay is based on the 
assessment of increased droplet secretion from single Malpighian tubules of the larvae. The 
Ramsay assay showed that all three helicokinins induced significant myotropic effects in a dose-
dependent manner over a range from 10
-12
 to 10
-7
, with EC50 values of 2.9x10
-11
 M (Hez-KI, 12), 
2.0x10
-11
 (Hez-KII, 13) and 3.6x10
-10
 M (Hez-KIII, 14).
[63]
 At a concentration of 10
-9
 M these 
peptides increased fluid secretion by 410% (Hez-KI), 354% (Hez-KII) and 207% (Hez-KIII). 
The highest rates of the fluid secretion were observed at concentration of 10
-8
M with the 
increases of 6.1 times for Hez-KI, 5.3 times for Hez-KII and 4.2 times for Hez-KIII. In good 
agreement with the Ramsay assay, the receptor assay proved that Hez-KI is the most active 
kinin, followed by slightly less active Hez-KII and Hez-KIII, respectively.
[64]
 These findings are 
in contrast to the results gained on M. sexta and S. frugiperda, where Hez-KII is the highest 
potency in stimulating fluid secretion in isolated Malpighian tubules. In the receptor assay, the 
helicokinin receptor (HKR) of Heliothis virescens cloned from a Malpighian tubule cDNA 
library is functionally expressed in a CHO line. The activation of the HKR is analysed in living 
                                                          
b
 http://mothphotographersgroup.msstate.edu/species.php?hodges=11071 
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cells by measuring the induced calcium ion flux in the cytosol after activation of the second 
messenger cascade via G-proteins. In vivo microinjections of helicokinins into developing larval 
Heliothis viresens caused weight reduction and increased mortality within 6 days. Moreover, the 
combinations of helicokinins with ACE inhibitors (captopril, enalapril or lisinopril), which 
suppress the proteolytic degradation of insect kinins, showed that helicokinin I has the highest 
potency in in vivo activity.
[63]
 Due to its short sequence and the highest diuretic activity in 
Heliothis virescens, helicokinin I is the most promising lead structure for the development of 
metabolically stable peptidomimetics. 
1.4.2 Structure-activity relationships 
Among the helicokinins (I-III), Hez-KI displays the highest intrinsic activity compared to the 
others. Structure-activity relationships of Hez-KI were studied in both the Ramsay assay and the 
receptor assay.
[64] 
The truncation of the single amino acid tyrosine from the N-terminus of Hez-
KI (Phe-Ser-Pro-Trp-Gly-NH2) only resulted in a slight decrease in fluid secretion in the larval 
Malpighian tubules (factor 1.4). This is good agreement with the previous studies from other 
insect species.
[55]
 However, the receptor activity of the pentapeptide (Phe-Ser-Pro-Trp-Gly-NH2) 
is reduced significantly by a factor of 120. Deletion of any other amino acid in the helicokinin I 
sequence causes a complete loss of receptor activity.
[64]
 
Alanine-scans of helicokinin I demonstrate the significance of the amino acid side chains. 
Replacement of glycine or phenylalanine with alanine resulted in inactive peptides. When 
tryptophan was replaced by alanine, the biological activity decreased significantly with an EC50 
value 25 fold higher than that of the parent helicokinin I.
[64]
 Substitution of tyrosine, serine and 
proline with alanine, respectively, did not show significant differences in EC50 values, suggesting 
that residues Ser and Pro in the active core pentapeptide are not of great importance for binding 
to the receptor and therefore both residues probably function as a spacer to keep a correct 
distance between the crucial residues within C-terminus (Tyr-Phe and Trp-Gly-NH2).  
In order to evaluate the significance of the stereochemistry of the Hez-KI residues, a D-amino 
acid scan was performed. Except Tyr that could be substituted by its D-isomer, substitutions of 
the Phe and Ser residues with their D-enantiomers did not show any significant diuretic 
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Figure 13: Preferred conformation of helicokinin I 
in the presence of DPC micelles
[43]
 
 
 
activities, while a D-Trp replacement reduced receptor activity by a factor of 160. N-methylation 
of amide bond proved the importance of the C-terminal amide as hydrogen bond donor. Mono-
N-methylation of the C-terminus reduced the receptor activity by a factor around 300, while bis-
N,N-methylation led to a complete loss of biological activity. The structure-activity relationships 
of Hez-KI are summarized in Figure 12.
[64,65]
 
 
 
 
 
 
 
 
 
Figure 12: Overview of structure-activity relationships of helicokinin I
 [65]
 
1.4.3 Conformational analysis 
Previous studies confirmed that the presence 
of the C-terminal pentapeptide in the insect 
kinins is crucial for full biological activity. 
Detailed NMR spectroscopic studies in both 
dodecylphosphocholine (DPC) and sodium 
dodecyl sulfate (SDS) micelles demonstrated 
that hexapeptide helicokinin I (Tyr
1
-Phe
2
-
Ser
3
-Pro
4
-Trp
5
-Gly
6
NH2, 12) forms a C-
terminal type-I β-turn, which comprises the 
amino acid residues Ser
3
 (i), Pro
4
 (i+1),Trp
5
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(i+2) and Gly
6
 (i+3) with a trans Ser-Pro amide bond. Whereas the N-terminus seems highly 
unstructured and the flexible side chain Tyr points away from Phe and Trp residues (Figure 
13).
[43]
 As expected, in aqueous solution helicokinin I does not adopt any preferred 
conformation, proving that the β-turn is induced by the interaction of the peptide with the 
membrane. In addition, a spin-labeling experiment was observed that helicokinin I is anchored to 
the membrane by Phe
2
 and Trp
5
 residues, which are therefore postulated to be absolutely 
significant for receptor binding of helicokinin I.
 
1.5 Aims of the thesis 
Preceding investigations of helicokinin I suggest that the type-I β-turn could be regarded as a 
prime target for peptidomimetic approaches. With the aim of getting a better insight into the 
conformational prerequisites for receptor binding of helicokinin I, the main objectives of this 
dissertation are: 
 Synthesis of β-turn peptidomimetics and analysis of their preferred conformations.  
 Macrocylic helicokinin I peptidomimetics in order to evaluate the effect of global 
conformational constraints on receptor activation. 
 Design and synthesis of conformationally constrained building blocks derived from 
tryptophan moiety in order to investigate the significance of the Trp side chain to 
molecular recognition. 
 Additional structure-activity relationships of helicokinin I 
 Validating biological activity of all helicokinin I analogues synthesized in a functional 
Heliothis virescens receptor assay.  
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II. Results and discussion 
2.1  β-Turn peptidomimetics of helicokinin I  
One of the most challenging aspects of modern drug development as well as neuropeptide 
chemistry is the design and synthesis of highly potent, selective and metabolically stable 
peptidomimetics. An efficient approach for digging such biologically active compounds is the 
use of molecular scaffolds (Figure 14)
 
that induce conformational restraints and stabilize the 
secondary structure of peptides, which is a critical element for the effectiveness of protein-
receptor interactions.
 [66-68]
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Figure 14: Mimetic β-turn scaffolds 
Among the most important secondary motifs, the β-turns play a particularly important role in 
molecular recognition, biological activity and folding of peptides.
[69]
 With the aim of 
determining potent and selective therapeutic agents, a great deal of efforts have focused on the 
design and synthesis of small constrained turn mimetics for a better understanding of the 
molecular mechanisms responsible for peptide-protein or peptide-receptor interactions. For this 
reason, the peptidomimetic approaches based on the β-turn structure are very fashionable and 
have attracted a large interest in the field of medicinal chemistry. Following this trend, the first 
primary goal of this dissertation deals with the construction of β-turn helicokinin I mimetics. 
Based on previous SAR studies, the chemical modification will mainly focus on the active core 
of the C-terminal type I β-turn of helicokinin I in such a way that: 
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 The C-terminal glycine amide will spatially orient in the same direction as the parent β-
turn. 
 The two important aromatic residues Trp and Phe are kept intact.  
 The less important spacer residues either Ser or Pro are substituted by other amino acids.  
2.1.1 4-Aminopyroglutamate containing helicokinin I analogues  
It is well-known that the unique structural features of proline-containing peptides, possessing a 
cis/trans-Xaa-Pro amide bond (Figure 15), play a key role in the folding of peptides that 
influence their biological activity and in many cases only one of the two configurational isomers 
displays biological activity.
[70-73] 
Particularly, the cis-geometry of the proline amide bond induces 
the type VI β-turn where the proline residue is located at the position (i+2) of the peptide bond 
commonly. Recently, pseudo-prolines (APy or ψ[CN4]) fixed as a cis-amide bond were introduced 
to insect kinins which then adopt a type VI β-turn conformation.[59,60]  
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Figure 15: trans- and cis-Xaa-Proline peptide conformers and trans-4-aminopyroglutamic acids (APy) 
Inspired by the high activities of APy-containing achetakinin analogues reported by Nachman 
(Table 5), a modified efficient methodology to prepare 4-amino-pyroglutamates, which are then 
incorporated into helicokinin I, is presented. 
2.1.1.1 Synthesis of 4-azido-pyroglutamic acids 
Based on Nachman’s studies,[58] two trans-isomers of 4-azido-pyroglutamates 31a (2R, 4S) and 
31b (2S, 4R) were prepared in enantiomerically pure form. Though several methods have been 
reported on the synthesis of substituted pyroglutamates,
[74-78] 
most of them are inefficient 
synthetic routes to obtain an enantiopure product. 
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Our synthesis is based on the pyroglutaminol intermediates 24a and 24b (Scheme 1), which were 
easily obtained from D- and L-glutamic acids. Esterifications were carried out in methanol and 
SOCl2,
[79] 
followed by refluxing in toluene in the presence of triethylamine (TEA) to provide the 
methyl pyroglutamate esters 23a and 23b. In order to prevent racemization in the later synthetic 
steps, the methyl esters were converted into the corresponding alcohols to reduce the acidity of 
Hα. When 23a and 23b were treated with an excess of NaBH4 in iPrOH for 20 h, the desired 
products 24a and 24b were obtained in 84% yield.
[80]
  
Scheme 1: Preparation of pyroglutaminols 
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Reagents and conditions: a) MeOH, SOCl2, rt, 18 h, toluene, TEA, reflux, 3 h, 73-97%; b) NaBH4, iPrOH, rt, 20 h, 
84%. 
The introduction of an azide functional group on C-4 of the pyroglutaminols was carried out 
following two synthetic strategies. In the first route (Scheme 2), pyroglutaminols 24a and 24b 
were fully protected by silylation with (tert-butyl)dimethylsilyl chloride (TBSCl), followed by 
reaction with di(tert-butyl)dicarbonate (Boc2O) in TEA/DMAP,
[81]
 to obtain products 25a and 
25b.  
Next, a diastereoselective azidation of the protected lactams was performed according to the 
Evans methodology.
[82,83]
 The resulting enolates, prepared by addition of 1.5 equivalents of 
potassium hexamethyldisilazide (KHDMS) to the lactams 25a and 25b in THF at -78 
o
C for 50 
min, were treated with trisyl azide (2,4,6-triisopropylbenzenesulfonyl azide) at 0 
o
C for 3 min 
and quenched with AcOH. The azidation reactions were highly stereoselective, providing only 
single diastereomer 26a and 26b (Scheme 2). However, after chromatographic purifications, 26a 
and 26b were only obtained in 12% and 13 %, respectively. 
23a (2S) 24a (2S) 
23b (2R) 24b (2R) 
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Scheme 2: Azidation of pyroglutaminol derivatives 
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Reagents and conditions: a) (i) TBSCl, imidazole, DMAP, THF, 24 h, rt, 87-88%; (ii) Boc2O, DMAP, TEA, 24 h, rt, 
91%; b) KHMDS, trisyl azide, AcOH, 12-13%. 
The low conversions may probably be caused by an extensive decomposition of the triazene 
intermediates to diazo compounds. The use of KOAc which enables to effectively prevent the 
decomposition of the triazene intermediate along with acetic acid afforded no improvement in 
the yield of the azidation reaction. The stereochemistry of the azidated products (26a and 26b) 
was determined by NMR experiments. The NOESY data illustrated in Figure 16 confirm the 
required trans-products. 
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Figure 16: Observed NOESY correlations 
The low yield of azido products from the first strategy made it impossible to continue with 
further chemical transformations. Therefore, an alternative path to obtain the target compounds 
was studied. This strategy involves a four-step protocol, including the selective protection of the 
pyroglutaminols, diastereoselective hydroxylation on the C-4 of the lactam ring, mesylations and 
25a (2S) 26a (2S, 4R) 24a (2S) 
26a (2S, 4R) 26b (2R,4S) 
24b (2R) 25b (2R) 26b (2R, 4S) 
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azide displacement. Practically, treatment of lithium enolates, derived from lactams 25a and 25b 
as starting materials for hydroxylation, with the Davis reagent provides exclusively trans-4-
hydroxyl-pyroglutaminol derivatives.
[84-86]
 Nonetheless, the required stereochemistry at the 
position C-4 is opposite to the trans-4-hydroxyl-pyroglutaminol. Thus, this synthetic approach is 
unsuitable for the preparation of trans-4-azidopyroglutamic acids.  
Scheme 3: A stereoselective hydroxylation reaction of bislactam 27a 
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Reagents and conditions: a) Benzaldehyde, PTSA, toluene, reflux, 4 h, 72%; b) LDA, -78 
o
C, 50 min, MoOPD, -40 - 
-35 
o
C, 3 h, 72%; c) (i) MsCl, TEA, rt, 18 h, 88%; (ii) NaN3, DMSO, 60 
o
C, 1 h, 84%. 
It was reported that bicyclic lactams derived from pyroglutamic acid can be used as a chiral 
synthons for a highly stereoselective hydroxylation reaction.
[86]
 In addition, the selection of a 
suitable protecting group plays a crucial role for endo- or exo-attack because it serves as a 
stereocontrolling element in enolate addition reactions.
[87]
 Following this approach, a highly 
diastereoseletive hydroxylation was achieved by sequential reactions (Scheme 3 and 4). 
Treatment of pyroglutaminols with benzaldehyde in refluxing toluene in the presence of p-
toluenesulfonic acid (PTSA) as catalyst gave the corresponding hemiaminal ethers 27a and 27b 
as single diastereoisomers in 72% and 63% yields, after chromatographic purification.
[88]
 Next, 
the lactam enolate anions were readily generated by treatment of the bicyclic lactams 27a and 
27b with LDA (1.3 equiv) and subsequently oxidized with the molybdenum complex MoOPD 
(MoO5.Py.DMPU), which facilitates an endo-selective attack, at -35 to -40 
o
C for 3 h providing 
72-73% yield of 28a and 28b in diastereomerically pure form (Scheme 3 and 4).
[84,86]
  
The corresponding mesylate intermediates were prepared by treatment of alcohols 28a and 28b 
with MsCl in TEA,
[89]
 which were subsequently reacted with a large excess of NaN3 in DMSO at     
24a (2S) 27a  28a 29a 
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65 
o
C for 1 hour affording the desired azido products 29a and 29b with an inverted configuration 
at C-4.
[90] 
Scheme 4: A stereoselective hydroxylation reaction of bislactam 27b 
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Reagents and conditions: a) Benzaldehyde, PTSA, toluene, reflux, 4 h, 63%; b) LDA, -78 
o
C, 50 min, MoOPD, -40 - 
-35 
o
C, 3 h, 73%; c) (i) MsCl, TEA, rt, 18 h, 83%; (ii) NaN3, DMSO, 60 
o
C, 1 h, 82%. 
Ring opening of the hemiaminal ethers 29a and 29b was carried out under acidic conditions of 
TFA in THF/H2O for 18 h leading to the 4-azido-pyroglutaminols 30a (APy(2S, 4R)) and 30b 
(APy(2R, 4S)) in 89% and 90% yields, respectively.
[91]
 An efficient oxidation of the 
pyroglutaminols using ruthenium-mediated RuCl3-NaIO4
 
in CCl4/ACN/H2O (2/2/3)
 
yielded the 
corresponding trans-4-azidopyroglutamic acids 31a and 31b in excellent yields (88-92%) 
(Scheme 5).
[92,93]
 
Scheme 5: Preparation of 4-azido-pyroglutamic acids 
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Reagents and conditions: a) TFA, THF/H2O, rt, 18 h, 89-90%; b) RuCl3.xH2O (2 mol%), NaIO4, CCl4/ACN/H2O 
(2/2/3), rt, 16 h, 88-92%. 
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2.1.1.2 Incorporation of 4-aminopyroglutamates into helicokinin I 
With the trans-4-azidopyroglutamic acids in hand, two key tripeptides 33a and 33b were 
successfully synthesized. In the course of the reactions, the azido functional group of the acids 
was remained intact and only reduced prior to peptide-chain elongation to avoid unnecessary 
additional protecting group manipulations. Incorporation of the 4-azidopyroglutamic acids into 
dipeptide H-Trp-Gly-NH2 using O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa-
fluorophosphate (HATU) as coupling reagent resulted in the key building blocks 32a and 32b, in 
moderate yields of 60% and 65%, respectively. Next, the azido tripeptides 32a and 32b were 
subjected to catalytic hydrogenation (10% Pd/C) in MeOH at room temperature for 16 h 
providing the free amines 33a and 33b in nearly quantitative yields (95-96%) (Scheme 6). 
Scheme 6: Incorporation of 4-azido-pyroglutamic acids into dipeptide Trp-Gly-NH2 
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Reagents and conditions: a) H-Trp-Gly-NH2, HATU, DIPEA, DMF, rt, 20 h, 60-65%; b) Pd/C, H2, MeOH, rt, 16 h, 
95-96%. 
 
In order to evaluate the effect of cis-Pro amide bond on biological activity of helicokinin I, we 
used the APy residues as substituents for either a single Pro residue or the dipeptide Ser-Pro. 
Coupling of either dipeptide Boc-Tyr(tBu)-Phe-OH or tripeptide Boc-Tyr(tBu)-Phe-Ser(tBu)-OH 
to tripeptides 33a and 33b using HATU as coupling reagent produced the corresponding penta- 
and hexapeptide helicokinin I analogues (34a, 34b, 35a and 35b) in moderate yields (range 66-
68%). The resulting peptides were subsequently treated with TFA/TIPS/H2O at 0 
o
C for 4 h 
yielding the desired helicokinin I analogues in high purity (95-98%) (Scheme 7). 
 
31a (APy(2S, 4R) 
31b (APy(2R, 4S) 
 
32a (APy(2S, 4R)) 
32b (APy(2R, 4S)) 
33a (APy(2S, 4R)) 
33b (APy(2R, 4S)) 
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Scheme 7: Peptide-chain elongation  
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Reagents and conditions: a) (i) Boc-Tyr(tBu)-Phe-OH or Boc-Tyr(tBu)-Phe-Ser(tBu)-OH, HATU, DIPEA, DMF, 
rt, 22 h, 66-68%; (ii) TFA/TIPS/H2O, 0 
o
C, 4 h, 85-92%. 
 
 
2.1.2 Oxopiperazine-based helicokinin I mimic 
As a part of our ongoing project for exploring the preferred conformation of helicokinin I 
analogues, a conformationally constrained six-membered ring scaffold is established by using an 
ethylene bridge to link two adjacent Ni+1 and Ni+2 atoms (Figure 17). In this regard, the Pro 
residue is replaced by a L-valine amino acid and the (S)-3-isopropylpiperazin-2-one ring is 
formed by ethylations of amide bonds of Val and Trp. Due to its higher flexibility in respect to 
Pro residue, the piperazine scaffold is thought to be an interesting template in structure activity 
research. The isopropyl side-chain is intended to mimic part of the lipophilic pyrrolidine ring of 
proline.
[94]
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Figure 17: Protein β-turn (left) and β-turn mimetic (right) 
33a (APy(2S, 4R)) 
33b (APy(2R, 4S)) 
34a (APy(2R, 4S)): R = Tyr-Phe- CO- 
34b (APy(2S, 4R)): R = Tyr-Phe-CO- 
35a (APy(2R, 4S)): R = Tyr-Phe-Ser-CO- 
35b (APy(2S, 4R)): R = Tyr-Phe-Ser-CO- 
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The (S)-3-isopropylpiperazin-2-one scaffold was prepared from L-valine-tert-butyl ester 
hydrochloride 36 as starting material. In the synthesis, 2-nitrophenyl sulfonylchloride (NosCl) 
was chosen as an orthogonal protecting group. Upon treatment of amino ester 36 with 
NosCl/TEA,
[95]
 the corresponding sulfonamide 37 was obtained almost in quantitative yield 
(98%). Acidic hydrolysis of ester 37 with TFA gave the corresponding carboxylic acid 38 in 
96% yield.
 
 Coupling of the acid with L-tryptophan methyl ester using a classical TBTU-
mediated amidation resulted in the key sulfonamide dipeptide 39 in 92% yield. 
Scheme 8: Preparation of dipeptide 39 
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Reagents and conditions: a) (i) 2-nitrophenylsulfonyl chloride, TEA, DCM, rt, 20 h, 98%; (ii) TFA:DCM (1:1), 0 
ºC, 4 h, 96%; b) L-tryptophan methyl ester, TBTU, DIPEA, DCM, rt, 24 h, 92%. 
Scheme 9: Preparation of 2-oxo-piperazine 
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Reagents and conditions: a) 1,2-dibromoethane, K2CO3, DMF, 60 ºC, 48 h, 73%; b) 4% LiOH, THF, rt, 3 h, 100%; 
c) glycinamide hydrochloride, TBTU, DMF, rt, 24 h, 72%; d) PhSH, K2CO3, rt, 4 h, 96%. 
The key cyclization reaction was successfully accomplished by treatment of the sulfonamide 
dipeptide 39 with a large excess of 1,2-dibromoethane and K2CO3 in dimethylformamide at      
60 
º
C for 48 h.
[96,97]
 The desired 2-oxo-piperazine analogue 40 was achieved in 73% yield 
36 39 
39 40 
41 
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(Scheme 9). Hydrolysis of the methyl ester with 4% LiOH aqueous solution, followed by 
coupling with glycinamide hydrochloride, furnished the tripeptide 42 in 72% yield.
[98]
 A 
successive treatment of the sulfonamide 42 with thiophenol and K2CO3 afforded the 
corresponding free secondary amine 43 in high yield (96%).
[99]
  
Scheme 10: Peptide chain extension of 43 
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Reagents and conditions: a) Boc-Tyr(tBu)-Phe-Ser(tBu)-OH, HATU, DIPEA, DMF. 
With the key building block 43 in hand, our attention was focused on the convergent synthesis of 
the desired hexapeptide 44 (Scheme 10). Attempted reaction of tripeptide Boc-Tyr(tBu)-Phe-
Ser(tBu)-OH with the secondary amine to produce hexapeptide 44 was unsuccessful, even at 
elevated temperature (90 
o
C for 18 h) or with highly active coupling reagents such as                
O-(benzotriazol-1-yl)-N,N,N,N-tetramethyluronium tetrafluoroborate (TBTU), HATU and 
bromotri-(pyrrolidino)-phosphonium hexaﬂuorophosphate (PyBrop). This is possibly caused by 
a steric hindrance of the bulky isopropyl substituent adjacent to the secondary amine group along 
with a steric side chain around the activated carboxylate. 
After the failure of the first synthetic route, a stepwise synthesis was carried out (Scheme 11). 
Coupling of Fmoc-Ser(tBu)-OH with the secondary amine 43 using TBTU and DIPEA in DMF 
produced the N-Fmoc protected tetrapeptide 45 in excellent yield (95%), which upon mild basic 
N-Fmoc deprotection with piperidine afforded the amine 46 (98%). Incorporation of dipeptide 
Boc-Tyr(tBu)-Phe-OH into the amine 46 followed by removal of protecting groups afforded the 
2-oxopiperazine-containing helicokinin I analogue 47 in 78% overall yield. 
 
43 44 
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Scheme 11: Synthesis of peptide 47 
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Reagents and conditions: a) Fmoc-Ser(tBu)-OH, TBTU, DIPEA, DMF, 95%; b) piperidine/DCM, 98%; c) (i) Boc-
Tyr(tBu)-Phe-OH, TBTU, DMF, DIPEA, 87%; (ii) TFA/TIPS/H2O (95/2.5/2.5), 0 ºC, 3 h, 90%. 
2.1.3 Synthesis of macrocycle-bridged helicokinin I analogues 
In our ongoing research directed toward controlling the folding of helicokinin I, two medium 11-
membered ring containing helicokinin I analogues are prepared. Compared to the parent peptide, 
the novel helicokinin I analogues are formed by replacement of Ala for Pro and constrained by 
tetra-carbon spacers (Figure 18).
[100]
  
 
                                                      β-turn                                    ‘‘amide-to-amide’’β-turn mimetics  
Figure 18: β-Turn protein and β-turn mimetic 
Retrosynthetically, the macrocyclic peptide 62b is formed by utilizing a ring-closing metathesis 
(RCM) reaction from its open chain diene precursor. The diene is prepared from the coupling of 
43 47 
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N-allyl-Ala-Trp and N-allyl-Gly-NH2, which are readily synthesized by N-allylation of the 
commercially available corresponding valine ester and glycine amide (Scheme 12). 
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Scheme 12: Retrosynthesis of macrocyclic peptide 
The most efficient method for the site-selective N-alkylation of peptides was developed by 
Fukuyama.
[101]
 This involves a three-step procedure. The amine group is first activated by 
reaction with an ortho- or para-nitrobenzenesulfonyl group, followed by alkylation of alkyl 
halides on the activated nitrogen and a final deprotection of the Nosyl group. Using this standard 
protocol, the first fragment N-allyl-glycinamide 50 was obtained in good yield (77%) over a 
three-step sequence (Scheme 13). Glycinamide hydrochloride was first reacted with o-
nitrobenzenesulfonyl chloride (NosCl) in the presence of TEA in DCM/DMF to give the 
sulfonamide 48. Due to poor solubility of product 48, it was recrystallized from hot solvent 
mixture of ethanol and water to obtain a pure solid in 74% yield. Subsequent allylation of the 
62b 
60 
53 
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sulfonamide 48 in the presence of Cs2CO3 furnished product 49,
[102]
 which upon treatment with 
thiophenol and K2CO3 in acetonitrile yielded the desired N-allyl glycine amide 50. 
Scheme 13: Synthesis of N-allyl-glycinamide 
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Reagents and conditions: a) o-nitrobenzenesulfonyl chloride, DCM/DMF, TEA, 0 
o
C to rt, 24 h, 74%; b) allyl 
bromide, Cs2CO3, DMF, rt, 20 h, 98%; c) thiophenol, K2CO3, ACN, 20 h, 100%. 
 
The other N-allylated building block was prepared similarly. Commercially available L-alanine 
tert-butyl ester hydrochloride 51 was first converted into the corresponding sulfonamide using 
NosCl/TEA in DCM, which was then reacted with allyl bromide and caesium carbonate in DMF 
to provide the N-allylated alanine ester 52 in excellent yield (98%). Acidic hydrolysis of the 
ester, followed by reaction with tryptophan methyl ester hydrochloride using PyBop-mediated 
coupling in DIPEA, gave the dipeptide 54 (82%) (Scheme 14). 
Scheme 14: Preparation of N-allylated sulfonamide 54 
Cl
O
NH
3
+
O
OR
NosN
O
N
H
NosN
O
OO
N
H
54
a c
b
53: R = H
52: R = tBu 
 
Reagents and conditions: a) (i) o-nitrobenzenesulfonyl chloride, DCM, TEA, 20 h, rt, 98%; (ii) allylbromide, 
Cs2CO3, DMF, rt, 30 min, 100%; b) TFA, DCM, 4 h, rt, 100%; c) tryptophanmethylester hydrochloride, PyBop, 
DIPEA, ACN, 20 h, 82%. 
 
Saponification of the methyl ester with 4% LiOH in THF afforded the corresponding acid, which 
then reacted with the secondary amine 50 to provide the key product 55 in 60% yield (2 steps). 
However, the coupling reaction was problematic. The use of TBTU as the first coupling reagent 
51 
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Table 6: Optimal reaction conditions of the diene 55 
Coupling reagent Solvent Conditions 
Racemization ratio 
(Based on HPLC-MS)  
TBTU/DIPEA ACN 20 h, rt 60:40 
HATU/DIPEA DMF  20 h, rt 70:30 
BEP/DIPEA DMF 20 h, rt 65:35 
BOP-Cl/DIPEA ACN 16 h, rt 100:0 
PyBrOP/DIPEA THF 20 h, rt 85:15 
 
led to the racemization of the acid. To 
solve this problem, several coupling 
reagents were examined, including 
HATU, 2-bromo-1-ethyl pyridinium 
tetrafluoroborate (BEP), benzotriazol-
1-yloxytri(pyrrolidino)-phosphonium 
hexafluorophosphate (PyBOP) and 
bis(2-oxo-3-oxazolidinyl) phosphinic 
chloride (BOP-Cl) (Table 6). 
Accordingly, the desired product 55 was obtained in 75% yield, without epimerization, when 
BOP-Cl was employed in acetonitrile for 16 h at room temperature (Scheme 15).  
 
Scheme 15: Synthesis of diene 55 
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Reagents and conditions: a) (i) 4% LiOH, THF, rt, 4 h, 80%; (ii) N-allyl-glycinamide (50), BOP-Cl, DIPEA, ACN, -
10 
o
C to rt, 16 h, 75%; b) thiophenol, K2CO3, ACN, 20 h, 98%. 
Scheme 16: Convergent synthesis of hexapeptide 58 
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Reagents and conditions: Shown in Table 7 
58 
54 55 
56 
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Having the bis-N,N-allylated tripeptide 55 in hand, two synthetic strategies were used to obtain 
the final macrocyclic hexapeptide 66. The first synthetic route involved in N-Nos removal, 
elongation of the N-terminal tripeptide and macrocyclization reaction. For this reason, the N-Nos 
protected tripeptide 55 was first treated with thiophenol and K2CO3 to yield the secondary amine 
56 (98%) (Scheme 15). 
Attachment of tripeptide Boc-Tyr(tBu)-Phe-Ser(tBu)-OH to the secondary amine 56 was initially 
examined to get the hexapeptide 58 (Scheme 16). A number of standard peptide coupling 
reagents that are efficiently useful for coupling of N-alkylated amines were employed, such as 
bromotripyrrolidinophosphonium hexafluorophosphate (PyBrop), 2-bromo-3-ethyl-4-
methylthiazolium tetrafluoroborate (BEMT), HATU, 2-bromo-1-ethylpyridinium 
tetrafluoroborate (BEP), bis(trichloromethyl)-carbonate (BTC), BMIT, and 4-(4,6-bis[2,2,2-
trifluoroethoxy]-1,3,5-triazin-2-yl)-4-methylmorpholinium tetrafluoroborate (DFET)
[103]
 (Table 
7). However, the desired product 58 was not formed, even at elevated temperature and for 
prolonged reaction times. Probably, the sterically hindered side chains around the activated 
carboxylic acid intermediate prevent the coupling at the selective site.  
Table 7: Optimization of the convergent synthesis of 58 
Coupling reagent and base Solvent Conditions 
Results (based on 
HPLC/MS analysis) 
HATU/ DIPEA ACN 20 h, rt No reaction (NR) 
HATU/HOAt/NMM NMP 10 h, rt, then 50 
o
C, 10 h NR 
HATU/HOAt/DIPEA DMF or  
DCM/DMF 
10 h, rt, 50 
o
C, 8 h, 65 
o
C 6h NR 
BEP/HOAt/DIPEA DMF or  
DCM/DMF 
48 h, rt, 50 
o
C, 8 h, 65 
o
C 8h NR 
PyBrOP/DIPEA THF 48 h, rt, then 50 
o
C 8h NR 
BTC/ 2,4,6-colidine  
or 2,6-lutidine 
THF 24 h, rt, 50 
o
C, 18 h NR 
BEMT/ DIPEA DCM,  -10 
o
C to rt, 36 h, then 40 
o
C 24 h NR 
BMIT/ DIPEA DCM 24 h, rt, 45 
o
C, 24 h NR 
DFET/NMM/BF4 THF 48 h, rt, then 45 
o
C, 6 h NR 
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Due to the unsuccessful convergent synthesis, the hexapeptide 58 was prepared stepwise. 
Incorporation of Fmoc-Ser(tBu)-OH into tripeptide 56 produced the tetrapeptide 59 in a high 
yield (98%). Again, the use of HATU as a coupling reagent in acetonitrile at room temperature 
led to racemized products (in a ratio of 60:30). In order to determine the optimal reaction 
conditions, several highly active coupling reagents were tried in different solvents (Table 8). The 
results proved that PyBrop prevented efficiently the epimerization. Only 4% of racemized 
product was formed (based on HPLC-MC analysis). Upon exposure of the Fmoc-protected 
peptide 59 to DBU in DCM for 30 min followed by coupling with dipeptide Boc-Tyr(tBu)-Phe-
OH, the ring-closing metathesis precursor 58 was obtained in 52% overall yield (Scheme 17). 
Scheme 17: Elongation of peptide chain 
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Reagents and conditions: a) Fmoc-Ser(tBu)-OH, PyBrop, DIPEA, THF, rt, 20 h, 98%; b) DBU, DCM, 30 min, 82%; 
c) Boc-Tyr(tBu)-Phe-OH, HATU, DIPEA, DMF, rt, 18 h, 63%. 
Table 8: Optimizing the coupling reaction of 59  
Coupling reagent Solvent Conditions 
Racemization ratio  
(Based on HPLC-MS) 
HATU/DIPEA ACN 20 h, rt 70:30 
HATU/DIPEA ACN/DMF (1/4) 20 h, rt 70:30 
HATU/DIPEA DMF 20 h, rt 85:15 
BOPCl/DIPEA DMF  60 h, rt No reaction 
PyBrOP/DIPEA THF 20 h, rt 96:4 
56 
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The key step of the synthetic route was ring-closing metathesis reaction in order to form the 11-
membered macrocycle 61 (Scheme 18). In the first attempt the macrocyclization was carried out 
with a Grubbs 1
st
 generation catalyst (10 mol%) in refluxing CH2Cl2 for 72 h providing none of 
the desired product 61. However, when the highly active Zhan’s catalyst (10 mol%) was 
employed in the same manner, the intramolecular cyclization proceeded slowly.
[104-106] 
The 
expected macrocycle 61 was obtained in 19% yield, after 96 h refluxing. The low conversion 
was reasoned due to the bulky substituents around the diene termini that prevent them from 
coming to close proximity. Thus, this synthetic strategy was disadvantageous for preparation of 
the targeted macrocyclic peptide. 
Scheme 18: Ring-closing metathesis of diene 58 
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Reagents and conditions: a) Zhan catalyst (10 mol%), DCM, reflux, 94 h, 19%. 
In the other approach, the olefin ring-closing metathesis reaction was performed with the diene 
55 (Scheme 19). Upon treatment of 55 with the Grubbs 1
st
 generation catalyst (10 mol% loading) 
in refluxing CH2Cl2 for 60 h, the desired macrocycle 62 was only obtained in 10% yield. On the 
other hand, ring-closing metathesis of diene 55 with highly diluted solution of 1 mM using the 
2
nd
 Hoveyda-Grubbs catalyst (10 mol% loading) in refluxing DCM for 56 h afforded two 
separable products 62a and 62b in 9% and 43% yields, respectively, after flash column 
chromatography. The E-geometry of the major product 62b was established by the high coupling 
constant of the two adjacent alkene protons (JHa-Hb = 15.5 Hz) based on COSY- and 
1
H-NMR 
decoupling experiments (Figure 19). 
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Scheme 19: Ring-closing metathesis of diallylamine 55 
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Reagents and conditions: a) Hoveyda-Grubbs 2
nd
 catalyst (10 mol %), DCM, reflux, 56 h, 43% (62b), 9% (62a). 
 
Figure 19: a) 
1
H-NMR expanded alkene area of alkene 62b; b) Selective decoupling of proton at 3.91 ppm;             
c) Selective decoupling of proton at 3.58 ppm. 
The N-Nosyl deprotection of compound 62b was first tested with thiophenol and K2CO3 at room 
temperature for 18 h. However, only 10% conversion of the secondary amine 63 was found. 
Alternatively, when macrocycle 62b was treated with mercaptoethanol in the presence of DBU 
(1,8-diaza-bicyclo[5.4.0]undec-7-ene) as catalyst at room temperature for 1 h, the desired amine 
63 was obtained in excellent yield (95%). Acylation of Fmoc-Ser(tBu)-OH to the secondary 
55 62a
a 
62b 
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amine using HATU as the coupling reagent and subsequent N-Fmoc deprotection with piperidine 
in DCM provided the cyclic peptide 65, in 67% overall yield (Scheme 20).  
Scheme 20: Extension of the N-terminal peptide chain of macrocyclic peptide 62b 
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Reagents and conditions: a) HSCH2CH2OH, DBU, DMF, rt, 1 h, 95%; b) Fmoc-Ser(tBu)-OH, HATU, DIPEA, 
DMF, rt, 67%; c) Piperidine, DCM, 4 h, rt, 99%.  
Scheme 21: Synthesis of peptides 66 and 67 
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Reagents and conditions: a) Boc-Tyr (tBu)-Phe-OH, HATU, DIPEA, DMF, 24 h, 76%; b) TFA/TIPS/H2O, 0 
o
C, 4 h, 
95%; c) (i) Pd/C, H2, MeOH/ EtOAc, rt, 24 h, 97%; (ii) TFA/TIPS/H2O, 0 
o
C, 4 h, 91%. 
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The key intermediate 60 was prepared in 76% yield from the coupling of dipeptide Boc-
Tyr(tBu)-Phe-OH to amine 65, which was then converted into the desired product 66 by acidic 
deprotection. On the other hand, the saturated peptide 67 was readily obtained in 88% yield by a 
sequential reaction of hydrogenation and successive acidic deprotection (Scheme 21). 
2.2 Tryptophan-derived helicokinin I peptidomimetics 
Reduction of the conformational flexibility of the peptide backbone can be achieved not only by 
forming macrocyclic peptides, but also by constraining amino acid residues. Due to the 
restriction of the ϕ and ψ torsion angles within the amino acid residues, their incorporation into 
the peptide backbones will rigidify the backbone conformations and therefore influence on the 
orientation of the N- and C-terminus.  
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Figure 20: Conformationally constrained scaffolds derived from tryptophan and iso-tryptophan 
It has been reported that the Trp residue is somewhat less important for triggering receptor 
activation,
[64]
 and can be modified without complete loss of bioactivity. With the aim of 
exploring the significance of the Trp side chain for molecular recognition, several 
conformationally restricted structures derived from tryptophan and iso-tryptophan are aimed to 
synthesize (Figure 20). These building blocks are then incorporated into the helicokinin I 
sequence. 
 
 
68 69 70 
71 (n =1) 
72 (n = 2) 
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2.2.1 Helicokinin I analogue containing diaza-bridged heterocycle 
The synthetic route used in the preparation of the key building block 76 is shown in Scheme 22. 
Treatment of glycinamide hydrochloride with 2-bromacetaldehyde diethylacetal and NaHCO3 in 
refluxing acetonitrile for 48 h gave the product 73 in 37% yield. The low yield was due to the 
low solubility of the N-alkylated glycine amide which caused difficulty in working up and 
purifying by silica gel flash chromatography. Next, the dipeptide 74 was prepared in 98% yield 
by acylation of Fmoc-L-Trp-OH to the secondary amine 73 using TBTU as coupling reagent. 
Upon treatment of the acetal 74 with 1N HCl in acetonitrile at 0 ºC for 3 h, the tetraheterocycle 
75 was obtained in 75% yield. The cyclization occurs in a sequential process (Scheme 23). The 
acetal deprotection under acidic conditions followed by stereospecific intramolecular cyclization 
in situ of the iminium intermediate afforded the tetracyclic product 75. The secondary free amine 
76 was obtained in 76% yield by treatment of the N-Fmoc protected product 75 with piperidine 
in DCM at room temperature for 14 h. 
Scheme 22: Preparation of piperazine-3-one building block 
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Reagents and conditions: a) 2-Bromacetaldehyde diethylacetal, NaHCO3, CH3CN, reflux 48 h, 37%; b) Fmoc-L-
Trp-OH, TBTU, DIPEA, DCM, rt, 24 h, 98%; c) 1N HCl, CH3CN, 0 ºC, 3 h, 75%; d) piperidine, DCM, 14 h, 76%. 
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Scheme 23: Mechanism of the intramolecular cyclization  
The next steps were the elongation of the N-terminal tetrapeptide. Attachment of the Fmoc-Pro-
OH to the amine 76 using HATU and DIPEA yielded the peptide 77 (89%), which upon N-Fmoc 
deprotection with piperidine in DCM afforded the tripeptide 78. The corresponding hexapeptide 
was prepared in 67% yield by coupling of tripeptide Fmoc-Tyr(tBu)-Phe-Ser(tBu)-OH with the 
amine 78 using HATU. Finally, removal of N-Fmoc, Boc and tert-butyl protecting groups 
afforded the desired hexapeptide 79 in 99% yield (Scheme 24). 
Scheme 24: Synthesis of peptide 79 
 
N
H
NO
O
NH
2
NH
O N
N
NH
2
O
O
NH
N
O
N
H
N
H
O
O
OH
OH
NH
2
O
N
R
N
NO
O
NH
2
NH
77: R = Fmoc
78: R = H
b 79
a
c
76
 
Reagents and conditions: a) Fmoc-Pro-OH, HATU, DIPEA, DMF, 24 h, 89%; b) piperidine, DCM, rt, 5 h, 99%; c) 
(i) Fmoc-Tyr(tBu)-Phe-Ser(tBu)-OH, HATU, DIPEA, DMF, rt, 24 h, 67%; (ii) piperidine/ DCM, 75%; (iii) 
TFA/TIPS/H2O, 0 
º
C, 3 h, 99%. 
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2.2.2 Helicokinin I analogue containing a tetrahydro-β-carboline moiety 
Continuing to the derivatization of tryptophan residue, the tetrahydro-β-carboline 69 was 
similarly prepared according to Pictet–Spengler reaction. The acid-catalyzed intramolecular 
condensation between an iminium ion and an aromatic C-nucleophile of tryptophan ester was 
expected to give the desired product 69. Surprisingly, upon treatment of L-tryptophan methyl 
ester with 36% formaldehyde in the presence of either 1N HCl or CF3COOH acid as catalyst, no 
expected product was formed.
[107,108]
 Alternatively, exposure of 36% formaldehyde with L-
tryptophan methyl ester hydrochloride,
[109]
 which was readily prepared from esterification of 
tryptophan with methanol and thionyl chloride, afforded the key product S-methyl-1,2,3,4-
tetrahydropyrido[3,4-b]indole-3-carboxylate 69 in 67% yield after 4 h at room temperature. 
Subsequent reaction of amine 69 with Fmoc-Pro-OH using TBTU as coupling reagent resulted in 
the dipeptide 82 (90%) (Scheme 25). 
Scheme 25: Synthesis of tetrahydro-β-carboline 
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Reagents and conditions: a) SOCl2, MeOH, rt, 20 h, 93%; b) 36% HCHO, MeOH, rt, 4 h, 67%; c) (i) 82: Fmoc-L-
Pro-OH, TBTU, DMF, DIPEA, 88%; (ii) 83: Boc-L-Pro-OH, TBTU, DMF, DIPEA, 90%. 
We next attempted to convert the methyl ester 82 into the corresponding acid 85 (Scheme 26). 
First treatment of ester 82 with 4% LiOH at 0 
o
C for 4 h followed by acidification with 1N HCl 
did not provide the desired product 85, instead both methyl ester and Fmoc groups were 
simultaneously cleaved. Alternative conditions to hydrolysis were explored. Either lithium iodide 
(LiI) in refluxing ethyl acetate for 54 h or hydroxytrimethyltin (Me3SnOH) in refluxing C2H4Cl2 
for 50 h was used for the reaction.
[110-112]
 However, the conversion of the substrate was only 10% 
(based on HPLC/MS analysis). On the other hand, treatment of N-Fmoc protected product 82 
80 81 69 
82: R = Fmoc 
83: R = Boc 
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with piperidine in DCM to form the corresponding secondary amine was also unsuccessful. 
Under the mild basic conditions, an intramolecular cyclization product, diketopiperazine 
derivative 84, was obtained in 97% yield.  
Scheme 26: Attempted hydrolysis of the methyl ester 82 
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Reagents and conditions: a) piperidine, DCM, rt, 4 h, 97%; b) 4% LiOH, THF, 0 ºC, 4 h.or LiI, AcOEt, reflux, 54 h; 
or Sn(CH3)3OH, ClCH2CH2Cl, 80 ºC, 50 h.  
Scheme 27: Synthesis of peptide 88 
N
H
N
N
H
O
N
O
NH
2
O
R'
N
H
N
O
O
O
N
RHN
N
O
OH
O
N
O
NH
N
H
O
NH
2
8887: R' = H
86: R' = Boc
83
a
b
c
R = Tyr-Phe-CO
Boc
 
Reagents and conditions: a) (i) 4% LiOH, THF, rt, 4 h, 98%; (ii) glycinamide hydrochloride, TBTU, DMF, rt, 24 h, 
90%; b) TFA:TIPS:H2O (95:2.5:2.5), 0 ºC, 3 h, 87%; c) (i) Boc-Tyr(tBu)-Phe-Ser(tBu)-OH, DMF, HATU, DIPEA, 
rt, 62%; (ii) TFA:TIPS:H2O (95:2.5:2.5), 0 ºC, 3 h, 97%. 
Owing to the difficulty in removing selectively either methyl or Fmoc group, dipeptide 83 was 
prepared in 90% yield by coupling of amine 69 with Boc-Pro-OH (Scheme 25). Hydrolysis of 
the ester 83 with 4% LiOH afforded the corresponding carboxylic acid, which was then reacted 
with glycine amide hydrochloride using TBTU to give the tripeptide 86 in 88% overall yield. 
TFA-mediated deprotection and subsequent reaction with tripeptide Boc-Tyr(tBu)-Phe-Ser(tBu)-
82 84 85 
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OH using HATU as coupling reagent gave a full protected hexapeptide, which upon acidic 
deprotection afforded the desired hexapeptide 88 in 53% yield over three steps (Scheme 27). 
2.2.3 Synthesis of iso-tryptophan 
The next derivatization of tryptophan is the preparation of building block 70 (tetrahydro-5H-
pyrido[4,3-b]indole analogue). Similarly, application of the Pictet Spengler cyclization reaction 
was intended to synthesize the targeted product through a condensation of formaldehyde with 
iso-tryptophan methyl ester 89 under acidic conditions (Scheme 28). Thus, our attention was first 
focused on preparation of iso-tryptophan methyl ester 89. 
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Scheme 28: Retrosynthetic analysis of product 70 
Ethyl indole-2-carboxylate ester 91 served as starting material and was first converted into the 
corresponding primary alcohol by reduction with lithium aluminum hydride (LAH) in dry ether. 
Subsequently, the PCC-mediated oxidation of the primary alcohol furnished the 2-formylindole 
90.
[113]
 Though a qualitative analysis (TLC monitoring) showed a complete consumption of the 
starting material, only 43% of the pure aldehyde 90 was obtained after extractive work-up and 
chromatographic purification. The main reason was the instability of the resulting aldehyde that 
was over-oxidized during workup process. In the next step, a Horner–Wadsworth–Emmons type 
olefination of the aldehyde 90 with Boc-α-phosphonoglycine trimethylester using 1,1,3,3-
tetramethylguanidine as a base at room temperature for 3 days provided two separable products, 
the major Z-enamido ester 92 and its minor E-isomer in a ratio of 88/12, respectively. The Z-
configuration of the major product 92 was assigned based on NOESY experiments by a medium-
range interaction between the NH of the indole ring and the NH of enamide functional group 
(Figure 21).  
70 90 
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Scheme 29: Synthesis of isotryptophan 
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Reagents and conditions: a) (i) LAH, ether, 1 h, rt, 86%; (ii) PCC, DCM, 0 
o
C, 2 h, 43%; b) 1,1,3,3-tetramethyl-
guanidine, Boc-α-phosphonoglycine trimethylester, THF, -78 oC, 1 h, then rt, 3 days, 86%. 
 
Figure 21: NOESY spectra of enamido ester 92 
Scheme 30: Asymmetric hydrogenation  
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Reagents and conditions: 1.2 mol% [Rh(COD)(S,S)-EtDuPhos]
+
TfO
-
, MeOH, H2, rt, 3 days, or EtOAc, H2, 5 atm, rt, 
5 days. 
The key step in the synthesis was the conversion of Z-enamido ester 92 into the desired (S)-iso-
tryptophan methyl ester 89 by an asymmetric hydrogenation using Burk's catalyst 
91 90 92 
92 89 
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[Rh(COD)(S,S)-EtDuPhos]
+
TfO
-
 (1.2 mol% loading) in degassed MeOH or EtOAc. 
Unfortunately, no expected product was formed after 3-5 days at room temperature under 
hydrogen atmosphere (1-5 atm) (Scheme 30).  
Scheme 31: N-Boc protection reaction of 92 
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Reagents and conditions: Boc2O, DMAP, ACN, rt, 2 h. 
Owing to the failure of the hydrogenation of the alkene 92, we decided to protect the NH of 
indole ring with Boc group prior to exposure to the hydrogenation conditions. A direct treatment 
of the Z-enamido ester 92 with Boc2O (1.0 equiv) in the presence of DMAP as a catalyst did not 
give the targeted product 94, but undesired product 93 (Scheme 31). 
Scheme 32: Synthesis of iso-trytophan 
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Reagents and conditions: a) Boc2O, DMAP, ACN, rt, 99%; b) 1,1,3,3-tetramethylguanidine, Boc-α-
phosphonoglycine trimethylester, THF, -78 
o
C, 1 h, then rt, 3 days, 86%; c) 1.2 mol% [Rh(COD)(S,S)-
EtDuPhos]
+
TfO
-
, MeOH, H2, rt, 3 days, 5 atm (45% conversion, based on HPLC-MS).  
On the other hand, treatment of 2-formylindole 90 with Boc2O and DMAP afforded product 95 
in 99% yield. Under the same conditions as described above, the olefination reaction of aldehyde 
95 with Boc-α-phosphonoglycine trimethylester and 1,1,3,3-tetramethylguanidine led to the Z-
enamido ester 94 (86%) (Scheme 32). With the desired protected ester 94 in hand, we again 
explored the asymmetric hydrogenation using [Rh(COD)(S,S)-EtDuPhos]
+
TfO
-
 (1.2 mol%) as 
catalyst in degassed methanol. Interestingly, 45% conversion of the desired product 96 was 
found after 3 days at room temperature and 5 atm (H2). Unfortunately, we were not able to obtain 
92 93 94 
90 95 94 96 
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the pure iso-tryptophan ester 96 due to the inability of separating it from the starting material by 
silica gel flash chromatography. The successful hydrogenation suggests that protection of the NH 
indole is necessary to facilitate the asymmetric hydrogenation. For further exploration of the 
hydrogenation, the N-Boc protected enamide should be exchanged for N-Cbz enamide to reduce 
its steric hindrance.  
2.2.4 Synthesis of tryptophan-derived tricyclic analogues 
The next attention was focused on the preparation of two novel tryptophan-derived tricyclic 
analogues, azepinoindole (71) and azocinoindole (72). We intended two practical strategies to 
construct seven- and eight-membered rings. The carbon-carbon bond formation was 
accomplished by either intramolecular or intermolecular radical alkylation on C-2 of the indole 
ring utilizing radical reaction of xanthates (Scheme 33). 
  
Scheme 33: Retrosynthetic analysis of tricycles 106 and 105 
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Xanthate radical transfers 99 and 101 were readily obtained in high yield by treatment of the 
commercially available potassium O-ethyl dithiocarbonate with the corresponding 3-
bromopropanoic acid and tert-butyl-bromoacetate.
[114]
 In the first synthetic route, intramolecular 
radical cyclization, the xanthate intermediates 103 and 104 were prepared in good yields (71-
75%) by coupling of acids 99 and 102 with L-tryptophan methyl ester using TBTU and DIPEA 
in acetonitrile (Scheme 34). 
Scheme 34: Synthesis of xanthates 103 and 104 
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Reagents and conditions: a) Ethylxanthic acid potassium salt, ACN, rt, 18-20 h; b) THF, trimethylsilyldiazomethane, 
rt, 2 h, 97%; c) TFA, DCM, rt, 4 h, 98%; d) H-Trp-OMe, TBTU, DIPEA, ACN, rt, 20 h, 71-75%.  
The key step in the synthesis was the xanthate-promoted intramolecular cyclization. Lactams 105 
and 106 were initially attempted to be prepared by adding portionwise dilauroyl peroxide (DLP) 
to the boiling solution of the xanthate substrates (103 and 104) in degassed DCE for 4-6 h 
(Scheme 35).
[115,116]
 However, the expected products 105 and 106 were not formed even after 
prolonged reaction time or excess addition of the radical initiator DLP. 
Scheme 35: Attempted synthesis of 105 and 106 by an intramolecular radical cyclization  
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Reagents and conditions: Lauroyl peroxide (1.3-1.8 equiv), 1,2-dichloroethane, reflux, 6-12 h. 
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As an alternative, the intermolecular radical alkylation of xanthate esters 101 and 100 on C-2 of 
tryptophan methyl ester, which was carried out under the same conditions as described above, 
provided the 2-alkylated indole 107 (n = 1) in 40% yield, while the other desired product 108 (n 
= 2) was not formed (Scheme 36). Despite a number of efforts, preparation of the expected 
tricycle 108 failed. A plausible explanation for the failure of the alkylation may be that stability 
of the radical intermediate stabilized by a conjugative resonance. For the xanthate 101, the initial 
free radical formed is stabilized by a resonance of the adjacent carbonyl ester group and 
therefore reacts effectively with the tryptophan methyl ester, whereas the free radical derived 
from xanthate 100 is very unstable, so that the alkylation can not occur. 
Scheme 36: Intermolecular radical alkylation reaction 
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Reagents and conditions: a) Lauroyl peroxide (1.3-1.8 equiv.), 1,2-dichloroethane, reflux, 6 h; b) (i) TFA, DCM, rt, 
3 h; (ii) HATU, DIPEA, DMF, rt, 18 h, 46% overall yield. 
With the key product 107 in hand the attention was focused on the lactamization and 
chemoselective reduction to obtain the expected product 71. Ester 107 was treated with TFA at 
room temperature for 3 h to remove the Boc/tBu protecting groups and subjected to HATU as the 
coupling reagent in DIPEA and DMF to obtain the desired lactam 106 in 46% yield (Scheme 
36). In the next step, we aimed to convert the lactam ester 106 into the ester 71 by a 
chemoselective reduction (Scheme 37). When lactam 106 was treated with BH3.Me2S in 
anhydrous THF at room temperature for 6 h, a complete consumption of the starting material was 
observed (monitored by TLC).
[117,118]
 However, the undesired compound 109 was obtained as a 
107 106 
108 
100 (n = 2, R = CH3) 
101 (n = 1, R = tBu) 
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major product along with 10% of the desired ester 71 (Scheme 37). Attempts to reduce 
chemoselectively the lactam ester 106 failed. Thus, we decided to convert product 106 into the 
amino alcohol 109 (86%) by treatment with a large excess of BH3.Me2S in dry THF at room 
temperature for 6 h.  
Scheme 37: Chemoselective reduction of lactam ester 106 
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Reagents and conditions: a) BH3.Me2S/THF, 0 
o
C to rt, 6 h, 109 (86%). 
Coupling of Boc-Pro-OH with amino acohol 109 was initially attempted to obtain the dipeptide 
110 using HATU and DIPEA in DMF. However, none of the desired product was formed even 
with active coupling reagents BOP-Cl and PyBrop. From the failure of attempted couplings, it 
could be more advantageous if compound 109 is first converted into the corresponding N-Boc 
protected acid which is subsequently coupled with glycine amide and Boc-Pro-OH. 
Scheme 38: Attempted synthesis of peptide 110 
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Reagents and conditions: a) L-Boc-Pro-OH, HATU, DIPEA, DMF, rt, 12 h.  
2.3 Stabilizing secondary structure by side-chain backbone macrocyclization  
Constraint of highly flexible linear peptides by cyclization is one of the most widely used 
approaches to define the bioactive conformation of peptides. Reduction of the structural 
106 71 109 
109 110 
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flexibility can potentially enhance the selective molecular recognition and metabolic 
stability.
[119,120]
 In addition, their rigid conformations provide a valuable tool in determining 
which conformational features are related to their biological activity.  
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Figure 22: Selected macrocyclic helicokinin I analogues 
It has been demonstrated that head to tail cyclizations of helicokinin I analogues provide inactive 
macrocyclic peptides. Moreover, methylations of the C-terminal amide almost reduce its receptor 
activation,
[64]
 suggesting that any types of cyclization of N- or C-backbone to the C-terminal 
amide may provide weak or inactive peptides. One possibility of constraining the linear 
helicokinin I is based on the side chain backbone cyclization. In this study, two novel cyclic 
helicokinin I analogues are aimed to synthesize (Figure 22), in which all amino acids in the 
helicokinin sequence are intact and chemical modification is performed on the least important 
residues Ser and Tyr. 
2.3.1 Macrocyclic analogues formed by a tetra-carbon bridge 
As depicted in Scheme 39, the macrocyclic peptide 125 is retrosynthetically prepared by a ring-
closing metathesis reaction of the corresponding O-bisallyl precursor, which is derived from the 
incorporation of O-allyl-Tyr-OH into Phe-Ser(allyl)-Pro-OMe. These O-allylated building blocks 
are readily synthesized from commercially available amino acids Ser and Trp.  
111 112
? 
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Scheme 39: Retrosynthetic analysis of macrocycle 125 
The starting point of the synthetic route was the selective O-allylation of serine moiety. The 
allylation was initially attempted by reaction of N-Boc protected serine methyl ester 114, which 
was prepared by methyl esterification of serine amino acid and subsequent N-Boc protection, 
with allyl bromide and strong base NaH (1.1 equiv) in DMF (Scheme 40). However, no expected 
O-allylated product 115 was obtained.  
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 Scheme 40: Attempted allylation of N-Boc-protected serine methyl ester 
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Reagents and conditions: a) (i) SOCl2, MeOH; (ii) Boc2O, NaHCO3, THF; b) NaH, allyl bromide, DMF, 0 
o
C to rt. 
Alternatively, when the N-Boc protected serine amino acid 116 was exposed with NaH (2 equiv) 
in DMF and followed by quenching with allyl bromide (1.1 equiv), the O-allylated serine acid 
117 was obtained in 80% yield (Scheme 41). The unsuccessful allylation of methyl serine ester 
114 is due to the easy deprotonation of the Hα in strong base NaH which causes a dehydration. 
In contrast, the resulting dianion derived from the treatment of N-Boc protected serine acid 116 
with NaH prevents the C-allylation and dehydration, providing only the desired product 117.  
Scheme 41: O-allylation of serine acid 
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Reagents and conditions: a) Boc2O, 1N NaOH, tBuOH, 54%; b) allyl bromide, NaH, DMF, 80%. 
Scheme 42: Preparation of tripeptide 119 
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Reagents and conditions: a) Pro-OMe, TBTU, DIPEA, DCM, 86%; b) (i)TFA/TIPS/H2O, 3 h, 88%; (ii) Boc-Phe-
OH, TBTU, DIPEA, DCM, 91%; (iii) TFA/TIPS/H2O, 3 h, 88%. 
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Dipeptide 118 was obtained in 86% yield from reaction of the N-Boc-O-allyl-serine acid 117 
with L-proline methyl ester, which upon treatment with TFA afforded a primary amine 
intermediate. The key building block 119 was successfully prepared in 80% by coupling of the 
resulting amine with Boc-Phe-OH followed by N-Boc acidic deprotection (Scheme 42). 
The synthesis of O-allyltyrosine 123 started from L-tyrosine methyl ester hydrochloride. The N-
Boc protection of amine 120 and subsequent reaction with allyl bromide and potassium 
carbonate in DMF afforded the O-allylated tyrosine ester 122 in 95% yield. Hydrolysis of methyl 
ester with 1N NaOH in methanol provided the corresponding acid 123 in 98% yield, which was 
subsequently coupled with tripeptide 119 to furnish the key metathesis precursor 124 (94%) 
(Scheme 43). 
Scheme 43: Synthesis of diene 124 
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Reagents and conditions: a) Boc2O, TEA, DCM, 97%; b) allyl bromide, K2CO3, DMF, 98%; c) 1N NaOH, MeOH, 
18 h, rt, 98%; d) 119, DIPEA, TBTU, DCM, 94%. 
Having the required acyclic diene metathesis precursor 124, the key ring-closing metathesis 
reaction was aimed to prepare macrocycle 125. Exposure of the diene 124 (1 mM) to the 
Hoveyda-Grubbs 2
nd
 catalyst (10 mol% loading) in refluxing CH2Cl2 for 50 hours afforded 
exclusively the corresponding macrocyclic peptide 125 in excellent yield (89%) (Scheme 44). 
The stereochemistry of the cyclized product was unable to elucidate at this stage due to the 
overlapping signals of the alkene protons. However, this work was easily done at the later step. 
Based on the NOESY and 
1
H-NMR decoupling experiments of the final product 128, the E-
geometry was clearly established by high coupling constant value (JHa-Hb = 16.1 Hz) between 
120 121 124 
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two adjacent alkene protons. Therefore, it could be concluded that the ring-closing metathesis 
reaction of diene 124 formed preferentially a trans-product (Figure 23). 
Scheme 44: Ring-closing metathesis of diene 124 
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Reagents and conditions: a) Hoveyda-Grubb catalyst (10 mol%), DCM, reflux, 50 h, 89% 
 
Figure 23:a) 
1
H-NMR expanded alkene area of macrocycle 128; b) Selective decoupling of proton at 3.91 ppm; c) 
Selective decoupling of proton at 3.58 ppm. 
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After successfully achieving macrocycle 125, our attention was focused on the extension of the 
C-terminal dipeptide Trp-Gly-NH2. Upon treatment with 4% LiOH in THF/H2O (1/1), methyl 
ester 125 was converted into the corresponding carboxylic acid 126, which was then reacted with 
dipeptide H-Trp-Gly-NH2 using HATU-promoted coupling to provide the macrocyclic 
hexapeptide 127 in 98% yield (Scheme 45). With the aim of comparing the flexibility of the 
tetra-carbon bridge, two parallel synthetic pathways were carried out (Scheme 45). In one hand, 
the unsaturated cyclic peptide 127 was directly subjected to TFA/TIPS/H2O at 0 
o
C to yield the 
desired macrocyclic peptide 128 (94%). On the other hand, saturation of the double bond of the 
olefin 128 followed by acidic deprotection gave the desired saturated peptide 129 in 90% overall 
yield. 
Scheme 45: Extension of C-terminal dipeptide 
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Reagents and conditions: a) LiOH, THF/H2O, 18 h, 98%; b) H-Trp-Gly-NH2, HATU, DIPEA, DMF, 98%; c) 
TFA/TIPS/H2O, 0 
o
C, 4 h, 90-94%; d) Pd/C, H2, MeOH/ EtOAc (2/1), rt, 24 h, 98%. 
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2.3.2 Hybrid synthesis  
Encouraged by high bioactivities of the β-carboline containing helicokinin I analogue 88 and the 
macrocyclic peptide 128 (Table 11), we decided to synthesize the analogue 132 that hybridizes 
the macrocyclic moiety in 128 with the conformationally constrained tetrahydro-β-carboline 
residue (Scheme 46).  
Scheme 46: Hybrid synthesis of 132 
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Reagents and conditions: a) tetrahydro-β-carboline (69), HATU, DIPEA, DMF, rt, 20 h, 78%; b) 4% LiOH, 
THF/H2O (2/1), 5 h, 91%; c) (i) H-Gly-NH2.HCl, TBTU, DMF, DIPEA, rt, 20 h, 77%; (ii) TFA/TIPS/H2O (95:4:1), 
0 
o
C, 3 h, 86%. 
First attachment of the acid 126 to the tetrahydro-β-carboline moiety 69 employing HATU as the 
coupling reagent afforded the pentapeptide 130 in good yield (78%). Next, saponification of the 
ester 130 with 4% LiOH followed by reaction with glycine amide hydrochloride yielded the 
corresponding hexapeptide. Final acidic deprotection furnished the desired peptide 132 in 86% 
yield. 
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2.3.3 Formation of macrocyclic ether  
As continuation to our interest in the side chain backbone cyclization, a 14-membered ring ether 
was aimed to synthesize by a direct Tyr-Ser ether formation. The synthetic strategy was initially 
attempted by an intramolecular Mitsunobu cyclization reaction of tripeptide Boc-Tyr-Phe-Ser-
OMe 135, which was readily prepared in a three-step procedure. Coupling of serine methyl ester 
hydrochloride 133 with dipeptide Boc-Tyr(tBu)-Phe-OH followed by TFA-mediated 
deprotection led to an amine intermediate. Upon treatment of the amine with Boc2O, the 
cyclization precursor 135 was obtained in 92% yield (Scheme 47).  
Scheme 47: Preparation of Mitsunobu precursor 135 
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Reagents and conditions: a) Boc-Tyr(tBu)-Phe-OH, TBTU, DIPEA, DMF, rt, 89%; b) (i) TFA/TIPS/H2O (95:4:1); 0 
o
C, 5 h, 96%; (ii) Boc2O, NaHCO3, THF/H2O, rt, 18 h, 92%. 
Scheme 48: Attempted intramolecular Mitsunobu cyclization reaction 
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Reagents and conditions: a) DIAD or DEAD, PPh3, THF, 0 
o
C, 3 h, 137 (85%). 
The intramolecular etherification of the tripeptide 135 was carried out under Mitsunobu 
conditions using a mixture of triphenylphosphine and either diethyl dicarboxylate (DEAD) or 
diisopropyl azodicarboxylate (DIAD) in dry THF. Though the qualitative analysis (monitored by 
133 134 135 
135 136 137 
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TLC) indicated a complete consumption of the starting material, the cyclic ether 136 was not 
formed (Scheme 48). The 
1
H-NMR spectroscopy of the resulting product showed two proton 
signals at δ = 6.5 and 5.9 ppm, characterizing alkene protons. In addition, the Hα proton signal of 
Ser moiety was disappeared, suggesting that β-elimination occurred under Mitsunobu conditions 
(Figure 24). 
 
Figure 24: 
1
H-NMR of alkene 137 
Alternatively, the Z-Tyr-OtBu and dipeptide Boc-Phe-Ser-OMe 138 was used to explore the 
intermolecular Mitsunobu etherification reaction in the same conditions as described above 
(Scheme 49). Instead of obtaining the desired ether 139, again, only undesired β-elimination 
product 140 was formed in 49%. The byproduct was clearly confirmed by 
1
H-NMR spectroscopy 
(Figure 25).  
Scheme 49: Intermolecular Mitsunobu etherification reaction 
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Reagents and conditions: a) Boc-Phe-OH, TBTU, DIPEA, DMF, rt, 20 h, 89%; b) DIAD, toluene, rt, 48 h, 140 
(49%). 
133 138 140 139 
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Figure 25: 
1
H-NMR of product 140 
It is evident that the use of N-carbamate protected serine ester analogues (135 and 138) to 
prepare Ser-Tyr ether under Mitsunobu conditions is impossible. The relative acidity of Hα of 
the serine moiety in ester analogues 135 and 138 along with a good leaving group of the alkoxy 
phosphonium formed during the Mitsunobu process facilitates the β-elimination.  
Scheme 50: Attempted etherification reaction 
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Reagents and conditions: a) Trityl chloride (TrCl), TEA, DCM, rt, 18 h, 69%; b) Z-Tyr-OtBu, DIAD, toluene, 0 
o
C 
to rt, 48 h. 
In an effort to synthesize the Tyr-Ser ether under Mitsunobu conditions, serine methyl ester was 
alternatively protected with trityl group, a noncarbamate protecting group. The N-Tr serine 
methyl ester 141 was readily prepared in 69% yield by treatment of amine 133 with trityl 
chloride (TrCl) in the presence of TEA, which was then reacted with Z-Tyr-OtBu under 
Mitsunobu conditions in either toluene or benzene. Again, no conversion of the expected ether 
142 was found even for prolonged reaction times and heating up to 90 
o
C for 48 h (Scheme 50). 
In this case, the β-elimination of serine methyl ester did not occur and the starting material was 
133 141 142 
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recovered. It was our opinion that the existence of the steric hindrance trityl group in Ser moiety 
makes it impossible to react with Z-Tyr-OtBu. Stimulated by the reaction of hydroxyester 141 
with 4-bromophenol under Mitsunobu conditions to give an aryl-Ser ether,
[121]
 an alternative 
synthesis was pursued. This approach involves a carbon-carbon bond formation utilizing Pd-
catalyzed cross-coupling reaction between iodo aryl compound and iodo-alanine ester (Scheme 
51).  
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Scheme 51: Retrosynthesis of Tyr-Ser ether  
The synthetic strategy for preparation of ether 147 was shown in Scheme 51. We used 4-
iodophenol 143, which can facilitate the later cross-coupling reaction, as starting material for the 
synthetic route. Upon treatment of the alcohol 141 with 4-iodophenol under Mitsunobu 
conditions using DEAD/PPh3 in benzene at room temperature for 20 h, the desired ether 144 was 
successfully obtained in 83% yield, after extractive work-up and chromatographic purification 
(Scheme 52).  
Scheme 52: Preparation of the cross coupling precursors 144 and 146  
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Reagents and conditions: a) Tr-N-Ser-OMe, DEAD, PPh3, benzene, 20 h, rt, 83%; b) (i) MsCl, TEA, DCM, 0 
o
C, 30 
min, 98%; (ii) NaI, acetone, rt, 14 h, 89%. 
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144 143 
146 141 
61 
 
The other cross-coupling precursor iodoalanine 146 was prepared in a two-step procedure.
[122]
 
The serine ester 145 was first converted into its mesylate in 98% yield by reaction with 
methanesulfonyl chloride under mild basic conditions TEA, which was then treated with NaI to 
afford the iodoalanine benzyl ester 146 (Scheme 52).  
Scheme 53: Attempted cross coupling reactions 
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Reagents and conditions: a) Pd2(dba)3, P(o-Tol)3, Zn, I2, DMF, rt to 90 
o
C, 48 h; b) Pd(dppf)2Cl2.DCM, AcOK, 
DMSO, 3 h, 80 
o
C, 56%; c) Pd(OAc)2, P(o-Tol)3, N-Boc-iodoalanine benzyl ester, KF, DMF, 60 
o
C, 18 h. 
Coupling of iodoalanine 146 with iodoaryl ether 144 was initially attempted by using the Pd-
catalyzed Negishi cross coupling reaction in dry DMF at high temperature (Scheme 53). In the 
course of the reaction, zinc powder was first activated by treatment with iodide in dry DMF 
under argon atmosphere for 15 min followed by addition of N-Boc protected iodoalanine 146 to 
generate in situ the organozinc intermediate. Next, 144 and the catalytic system of Pd2dba3 (2.5 
mol%) and P(o-tol)3 (10 mol%) were added.
[123-125]
 Nevertheless, the Neghishi coupling reaction 
did not form the desired product 147, even after heating up to 90 
o
C for 48 h. Another alternative 
route to the carbon-carbon bond formation was application of the Pd-catalyzed Suzuki-Miyaura 
cross coupling reaction (Scheme 53). Following this strategy, 4-iodo-arylether 144 was first 
146 144 147 
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converted into the boronate 148 (56%) by reaction with pinacolborane in the catalysis of 
Pd(dppf)2Cl2.DCM complex and AcOK in DMSO at 80 
o
C for 3 h.
[126]
 Coupling of the boronate 
148 with the iodoalanine 146 was carried out in the presence of Pd(OAc)2 (3 mol%) and P(o-tol)3 
(9 mol%) as catalysts.
[127]
 Again, the expected product 147 was not formed. 
Due to the unsuccessful approach of the carbon-carbon bond formation, our attention turned 
towards the Mitsunobu etherification reaction. As described above the β-elimination of the N-
carbamate protected serine ester prevented the formation of Ser-Tyr ether under Mitsunobu 
conditions. In order to reduce the relative acidity of the Hα, serine ester was converted into its 
serinol derivatives. Our synthetic strategy used D-serine amino acid 149 as starting material for 
chemical transformation (Scheme 54). Esterification of acid 149 was carried out by treatment 
with SOCl2 and MeOH followed by N-Boc protection to afford the protected serine ester 150 in 
89% overall yield. The oxazolidine 151 was readily prepared in 98% upon reaction of the 
hydroxyester 150 with 2,2-dimethoxypropane (DMP) in the catalysis of BF3.Et2O. Reduction of 
ester 151 using lithium aluminum hydride (LAH) in dry THF gave the desired serinol acetonide 
152 (99%). 
Scheme 54: Preparation of N-Boc-D-serinol acetonide 
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Reagents and conditions: a) (i) MeOH, SOCl2, rt, 18 h; (ii) Boc2O, NaHCO3, THF, rt, 12 h (98% two steps); b) 2,2-
dimethoxypropane, BF3.Et2O, acetone, 98%; c) LAH, THF, rt, 20 min, 99%. 
With the serinol analogue 152 in hand, the etherification reaction was initially explored. When 
the alcohol 152 was treated with Z-Tyr-OtBu under Mitsunobu conditions in toluene at 90 °C for 
48 h, the desired ether 153 was successfully obtained in 64% yield (Scheme 55). Removal of the 
isopropylidene group with either p-toluenesulfonic acid (PTSA, 5 mol%) in methanol or AcOH-
H2O at room temperature afforded not only the expected product 154 but also the undesired 
peptide 155 in ratio of 55:45, respectively. 
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Table 9: Optimizing the macrolactamization  
Reagents and conditions Temperature 
HATU/DIPEA/ ACN rt, 40 
o
C,54 h 
HATU/DIPEA/ DMF rt; 40 
o
C or 80 
o
C 
BOP-Cl/DIPEA/DMF rt; 40 
o
C or80 
o
C 
PyBop/DIPEA/THF rt; 40 
o
C or 80 
o
C 
SOCl2/Pyridine/DCM rt, 48 h 
CMPI/DIPEA/DCM rt, 48 h 
CMPI: 2-chloro-1-methylpyridinium iodide 
 
 
Scheme 55: Etherification of serinol acetonide 
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Reagents and conditions: a) Z-Tyr-OtBu, DEAD, PPh3, toluene, 90 
o
C, 48 h, 64%; b) PTSA (5 mol%), MeOH, rt, 5 
h. 
The unselective hydrolysis of the isopropylidene protecting group prompted us an alternative 
synthetic strategy, in which the serinol acetonide 152 was coupled with dipeptide Fmoc-Tyr-Phe-
OtBu 157 to produce the ether 158 (54%). Treatment of the acetonide ester 158 with TFA 
resulted the key desired product 159 in a quantitative yield (Scheme 56). 
Scheme 56: Alternative etherification of serinol 
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Reagents and conditions: a) HATU, PheOtBu, DMF, rt, 86%; b) DEAD, PPh3, toluene, 90 
o
C, 48 h, 54%, b) 
TFA/TIPS/H2O, 0 
o
C, 3 h, 100%.  
The key step of the synthetic route is the intramolecular 
cyclization to form the 14-membered macrocycle 160 
(Scheme 57). The macrolactamization reaction was 
attempted under different conditions employing the highly 
active coupling reagents at ambient temperatures (Table 
9). HPLC/MS analyses proved evidence that adducts with 
the reagents were formed, but neither intramolecular 
156 157 158 159 
152 153 154 155 
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cyclization nor dimerization was found. The unsuccessful lactamization through the sidechain 
residues Ser and Phe was reasoned due to the inability of the backbone to occupy a necessary 
conformation for amide bond formation.  
Scheme 57: Attempted lactamization of compound 159  
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Reagents and conditions: Presented in Table 8 
2.4 Structure-activity relationships  
2.4.1 Substitution of proline by β-proline  
Like proline residue, the β-proline has also been an interesting target in peptide synthesis due to 
its ability to rigidify the secondary structure.
[128]
 In the course of our project directed towards the 
synthesis of modified helicokinin I, a β-proline amino acid is prepared and incorporated into 
helicokinin I as substituent for proline moiety. This study is aimed to evaluate how the backbone 
conformation of the modified helicokinin I analogue effects on the receptor activation. 
For preparation of N-Boc-(S)-β-proline amino acid 164, 4-(R)-hydroxy-(S)-proline (161) was 
chosen as starting material. The key intermediate 162 was prepared by a one-pot 
procedure.
[129,130] 
Decarboxylation of 4-(R)-hydroxy-(S)-proline was accomplished in refluxing 
cyclohexanol with the catalysis of 2-cylohexanone for 6 h, providing an intermediate product 3-
(R)-hydroxypyrrolidine. Treatment of the pyrrplidine analogue with Boc2O and NaHCO3 in THF 
afforded the N-Boc-pyrrolidinol 162 in 69% yield (two steps) after silica gel flash 
chromatography (Scheme 59). In the next step, the hydroxyl group of 162 was mesylated and 
subsequently displaced with a nitrile group by reaction with NaCN in DMSO at 80 
o
C for 21 h. 
The 3-cyano derivative 163 was obtained in 60% yield with a complete inversion of the 
configuration at C-3. The desired N-Boc-(S)-β-proline acid 164 was obtained in 78% yield by 
159 160 
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refluxing the nitrile 163 in concentrated HCl for 5 h and subsequent reaction with Boc2O and 
NaHCO3.  
Scheme 59: Synthesis of (3S)-carboxy pyrrolidine 
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Reagents and conditions: a) (i) Cyclohexanol, 2-cyclohexanone, reflux, 6 h; (ii) Boc2O, NaHCO3, THF, rt, 18 h, 
69% (2 steps); b) (i) MsCl, TEA, DCM, 3 h, 0 
o
C, 97%; (ii) NaCN, DMSO, 80 
o
C, 21 h, 60%; c) (i) con. HCl, 
reflux, 5 h; (ii) Boc2O, NaHCO3, THF, rt, 18 h, 78% (2 steps); d) TBTU, DIPEA, ACN, H-Trp-Gly-NH2, rt, 18 h, 
71%. 
Tripeptide 165 was readily prepared in 71% yield by reaction of the N-Boc protected β-proline 
acid 164 with dipeptide H-Trp-Gly-NH2 using HATU as coupling reagent and DIPEA in 
acetonitrile (Scheme 59). The N-Boc acidic deprotection of peptide 165 followed by reaction 
with tripeptide Boc-Tyr(tBu)-Phe-Ser(tBu)-OH resulted an intermediate hexapeptide, which 
upon treatment with TFA gave the final product 166 (86%) (Scheme 60). 
Scheme 60: Synthesis of hexapeptide 166  
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Reagents and conditions: a) (i) TFA/TIPS/H2O (95/2.5/2.5), 0 
o
C, 4 h, 100%; (ii) Boc-Tyr(tBu)-Phe-Ser(tBu)-OH, 
HATU, DIPEA, DMF, 87%; (iii) TFA/TIPS/H2O, (95/2.5/2.5), 0 
o
C, 4 h, 86%. 
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2.4.2 Spirolactam-Scan  
The use of constrained building blocks is one of the most popular approach for peptidomimetic 
design because they can enforce or stabilize a particular type of β-turn when inserted into a 
peptide backbone. In this context the conformationally constrained spirolactam 167 is used for 
directed screening of helicokinin I residues, except Gly and Ser, in order to investigate their 
defined secondary structures in receptor binding.  
2.4.2.1 Substitution of Pro-Trp dipeptide with spirolactam 
Scheme 61: Substitution of Pro-Trp with spirolactam 
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Reagents and conditions: a) H-Gly-NH2.HCl, TBTU, DIPEA, DMF, rt, 18 h, 93%; b) TFA/TIPS/H2O (95:4:1); 0 
o
C, 
3 h, 98%; c) Boc-Tyr(tBu)-Phe-Ser(tBu)-OH, HATU, DIPEA, DMF, rt, 20 h, 69%; d) TFA/TIPS/H2O (95:4:1),       
0 
o
C, 5 h, 88%. 
It can be envisioned that spirolatam 167 is somewhat similar to the dipeptide Pro-Trp sequence. 
Thus, our first synthesis used the constrained spirolactam 167 as substituent for the Pro-Trp 
167 168 169 
170 171 
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sequence in the active core domain of helicokinin I. Derived from the N-Boc-
2‐oxo‐1,2‐dihydrospiro[indole‐3,4'-piperidine]‐5‐carboxylic acid, dipeptide 169 was readily 
obtained in 91% yield by TBTU-mediated amidation with a large excess of glycine amide 
hydrochloride, followed by TFA-mediated N-Boc deprotection. Attachment of tripeptide Boc-
Tyr(tBu)-Phe-Ser(tBu)-OH to amine 169 using HATU/DIPEA furnished the pentapeptide 170 
(69%), which was then subjected to TFA/TIPS/H2O (95/4/1) at 0 
o
C for 5 hours providing the 
final pentapeptide 171 in 88% yield, after chromatographic purification (Scheme 61). 
2.4.2.2 Substitution of Trp with spirolactam 
Scheme 62: Substitution of Trp with spirolactam 
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Reagents and conditions: a) Fmoc-L-Pro-OH, HATU, DIPEA, DMF, rt, 20 h, 86%; b) Piperidine, DCM, rt, 1 h, 
97%; c) Boc-Tyr(tBu)-Phe-Ser(tBu)-OH, HATU, DIPEA, DMF, rt, 18 h, 57%; d) TFA/TIPS/H2O (95:4:1), 0 
o
C,      
5 h, 88%.  
Tripeptide 172 was prepared from the coupling of amino acid Fmoc-Pro-OH with dipeptide 169. 
In this coupling reaction, it was noted that the use of more than one molar equivalents of Fmoc-
Pro-OH led to the decrease in the yield of the amidation. Only 42% yield of the desired peptide 
169 174 
175 176 
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172 was obtained when using 1.3 molar equivalents of Fmoc-Pro-OH, whereas the yield 
increased up to 86% if 0.9 equiv was used. The reason was clear that the NH of the lactam ring 
also underwent the condensation reaction to form the undesired N,N-bisacylated product 173 
(Scheme 62). Upon treatment of peptide 172 with piperidine in DCM for 1 h and subsequent 
reaction with tripeptide Boc-Tyr(tBu)-Phe-Ser(tBu)-OH, the hexapeptide 175 was obtained in 
55% yield. Finally, exposure of the full protected hexapeptide to TFA/TIPS/H2O (95/4/1) led to 
the desired peptide 176 (88%). 
2.4.2.3 Substitution of Pro with spirolactam 
Scheme 63: Spirolactamscan at Pro position 
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Reagents and conditions: a) H-Trp-Gly-NH2, TBTU, DIPEA, DMF, rt, 20 h, 85%; b) TFA/TIPS/H2O (95:4:1), 0 
o
C, 
4 h, 95%; c) Boc-Tyr(tBu)-Phe-Ser(tBu)-OH, HATU, DIPEA, DMF, rt, 20 h, 65%; d) TFA/TIPS/H2O (95:4:1),       
0 
o
C, 5 h, 62%. 
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The desired peptide 180 was synthesized according to Scheme 63. The key building block 178 
was prepared from the coupling of acid 167 with dipeptide H-Trp-Gly-NH2 to generate the full 
protected tripeptide 177 (85%). The yield of the coupling reaction increased from 41% to 85% 
when 0.9 equiv of the acylating reagent was used instead of 1.2 equiv. Treatment of peptide 177 
with TFA followed by reaction with tripeptide Boc-Tyr(tBu)-Phe-Ser(tBu)-OH using HATU-
mediated coupling gave the hexapeptide 179. Removal of protecting groups with TFA led to the 
desired product 180 in 62% yield, after chromatographic purification.  
2.4.2.4 Substitution of Phe with spirolactam 
Scheme 64: Synthesis of peptide 187 
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Reagents and conditions: a) Boc-Pro-OH, TBTU, DIPEA, DMF, rt, 20 h, 92%; b) TFA/TIPS/H2O (95:4:1), 0 
o
C,     
4 h, 96%; c) Fmoc-Ser(tBu)-OH, HATU, DIPEA, DMF, rt, 20 h, 82%; d) Piperidine, DCM, rt, 20 min, 92 %; e) (i) 
HATU, DIPEA, DMF, rt, 20 h, 62%; (ii) TFA/TIPS/H2O (95:4:1), 0 
o
C, 4 h, 86%; f) Boc-Tyr(tBu)-OH, HATU, 
DIPEA, DMF, rt, 20 h, 10%. 
The N-Boc protected tripeptide 182 derived from the acylation of Boc-Pro-OH with dipeptide  
H-Trp-Gly-NH2 was treated with TFA to form the secondary amine 183 (96%). Attachment of 
181 
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Fmoc-Ser(tBu)-OH to the amine afforded the tetrapeptide 184 in 82% yield. Subsequent 
treatment of the N-Fmoc protected compound 184 with piperidine in DCM followed by reaction 
with acid 167 gave a full protected pentapeptide. Acidic deprotection of the protected peptide 
167 afforded the secondary amine 186 in 86% yield. Notably, the tert-butyl protecting group on 
Ser residue was also removed under acidic conditions. This caused problem for the next coupling 
reaction. Introduction of Boc-Tyr(tBu)-OH to peptide 186 using HATU as coupling reagent only 
provided the desired peptide 187 in 10% yield. For this reason, we decided to prepare the 
dipeptide 190 which was then incorporated into tetrapeptide 185 (Scheme 65). 
Scheme 65: Spiroscan at Phe position 
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Reagents and conditions: a) MeOH, SOCl2, 18 h, rt, 88%; b) Boc-Tyr(tBu)-OH, HATU, DIPEA, DMF, 74%; c) 4% 
NaOH, MeOH, 46 h, 94%; d) 185, TBTU, DIPEA, DMF, 52%; e) TFA/TIPS/H2O (95:4:1), 0 
o
C, 5 h, 96%. 
Esterification of the spirolactam acid 167 was carried out in MeOH and SOCl2 furnishing the 
corresponding methyl ester 188 (88%). Under this conditions, the N-Boc protecting group was 
also removed to form a hydrochloride salt. The resulting methyl ester was then reacted with Boc-
Tyr(tBu)-OH using HATU/DIPEA to provide the dipeptide 189 (74%), which upon exposure 
167 188 
192 191 
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with 4% NaOH in MeOH for 46 hours at room temperature led to the corresponding acid 190 in 
94% yield. Coupling of two peptides 185 and 190 resulted the desired product 191 in moderate 
yield (52%). Finally, TFA-mediated deprotection furnished the hexapeptide 192 in 96% yield, 
after silica gel flash chromatography (Scheme 65).  
2.4.2.5 Substitution of Tyr with spirolactam 
In the similar manner the replacement of Tyr with the spirolactam 167 was a convergent 
synthesis. The dipeptide ester 193 was prepared in 98% yield from acylation of the acid 167 to 
phenylalanine methyl ester. Hydrolysis of the ester with 4% NaOH in MeOH gave the 
corresponding acid 194 (Scheme 66). Attachment of the acid 194 to amine 185 provided the 
peptide 195 (62%), which after acidic deprotection furnished the desired hexapeptide 196 in 72% 
yield.  
Scheme 66: Spirolactamscan at Tyr position 
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2.4.3 C-Terminal modification 
The importance of the amidated carbonyl group of helicokinin I for its receptor binding is 
studied by replacing the amide group with hydrazine to form a hydrazide functional group. 
Chemical transformation of 197 to 198 was involved in a two-step procedure. First, the 
carboxylic acid 197 was coupled with tert-butyl carbazate using TBTU/DIPEA to furnish the full 
protected hydrazide intermediate in 90% yield. Subsequently, removal of all protecting groups 
under acidic conditions afforded the hexapeptide 198 in excellent yield (95%). 
Scheme 67: C-terminal hydrazide modification 
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Reagents and conditions: a) (i) TBTU, DIPEA, NH2NHBoc, DMF, 90%; (ii) TFA/TIPS/H2O, 95%. 
2.5  Conformational analysis 
Structure determination of peptides is a decisive step to fully understand the mode of action in 
biological events. In order to gain a deeper insight into the conformational prerequisites for 
receptor binding of peptides, several techniques were developed, such as X-ray 
crystallography,
[131]
 solution NMR,
[132]
 solid-state NMR spectroscopy of oriented static samples 
of membrane protein in phospholipid bilayers, dodecylphosphocholine (DPC) and sodium 
dodecyl sulfate (SDS).
[133]. 
Our preceding studies on determining structure of several insect 
kinins in the membrane-mimicking environment (DPC or SDS) were successfully achieved. As 
continuation of interest in interpreting relationships between the biological activity and 
197 198 
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conformational preference, detailed NMR study of several helicokinin I analogues; namely 34a, 
34b, 35a, 35b, 47, 66, 67 and 79 (Figure 26); were carried out using solution NMR in 
membrane-mimicking environment DPC. In addition, molecular dynamics simulations were also 
performed in explicit water, in the core membrane or in lipid bilayer in order to characterize 
these highly flexible peptides.  
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Figure 26: Selected helicokinin I analogues for conformational analysis 
34b (APy(2S, 4R)): R = Tyr-Phe-CO- 
35b (APy(2S, 4R)): R = Tyr-Phe-Ser-CO- 
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35a (APy(2R, 4S)): R = Tyr-Phe-Ser-CO- 
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2.5.1 Conformational characterization of the APy-containing helicokinin analogues 
The NOESY spectrum of the APy-containing pentapeptides 34a and 34b display a series of 
strong sequential NOEs. The analogue 34a presents a high number of sequential NOEs between 
protons of APy and NH, α-, β- and δ-protons of Phe. Similarly, a significant number of NOEs 
between protons of APy moiety and the δ, NH protons of tryptophan as well as strong 
correlations between protons of Trp and Gly are found in the spectra of the peptide 34b. 
Molecular dynamics simulations based on the NOE provided insights into the structure of the 
APy-containing helicokinin I analogues bound to DPC micelles. The best-fit superpositions of 
the lowest energy conformers that satisfy all of the distance and dihedral angle restraints are 
presented in Figure 27.  
 
Figure 27: Superpositions of the lowest-energy conformers of APy containing helicokinin I analogues 
Structure calculations revealed that both peptides 34a and 34b form linear and flexible peptide 
chains with little conformational preferences, in which the N-terminal tyrosine residue occupied 
two different conformational clusters. These are contributed to the 2,4-trans-arrangement of the 
carboxyl and amino functional groups in the APy residue, thus they are unable to induce the β-
turn structures. Furthermore, the molecular dynamics calculations also confirmed the higher 
34a 34b 
35a 35b 
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average values of the distances between the α-protons of Phe and Trp with 9.2 Å and 8.0 Å for 
34a and 34b, respectively. It could be concluded that a β-turn formation for both 34a and 34b is 
impossible. 
In the NOESY spectrum of peptides 35a and 35b, only sequential NOEs were observed 
corresponding to a stretched conformation with an exception of NOEs between the δ and NH 
protons of Trp and the APy moiety in 35b (Figure 28). The helicokinin analogue 35a mainly 
displays medium- and long-range contacts between the β-protons of Ser and the NH of APy as 
well as between the NH of tryptophan and the protons of APy ring. Neither mimetic 35a nor 35b 
induces predominantly unique structure. However, both peptides clearly adopt preferentially 
extended conformations, which therefore confirm no turn-like structures to be formed. 
Figure 28: An expansion of the NOESY-spectrum between sequential amide protons of peptide 35b 
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2.5.2 Conformational characterization of the 2-oxo-piperazine-containing mimetic 
For the helicokinin analogue 47, a number of medium-range interactions between the β- and δ-
protons of Phe residue and the isopropyl group on the piperazine moiety were observed. In 
addition, a significant number of NOEs between the side chain Trp and the isopropyl group are 
found. The molecular dynamics (MD) simulations in micelles confirm two distinct conformers 
for peptide 47 that induce a turn-like structure at the C-terminus and an unstructured N-terminus 
(Figure 29).  
Figure 29: Low energy conformation of 2-oxo-
piperazine containing helicokinin I analogue 47 
 
 Table 10: Dihedral angles of the main conformer of 
helicokinin analogue 47  
 
 ϕ ψ 
Tyr  143.7 ±100.4   
Phe -106.8 ± 108.0   149.8 ± 7.9   
Ser -97.1 ±5.7   157.5 ± 1.4   
Oxopiperazine -126.0 -20.9 
Trp -150.3, -136.9 -87.5; 92.0 
Gly -171.5 ± 35.9    
 
The two conformers are reasoned due to the tertiary amide bond between serine and 2-oxo-
piperazine ring. The changes in dihedral angles within the critical turn region (Ser to GlyNH2) 
resulted from the substitution of the 2-oxo-piperazine moiety with Pro. In parent helicokinin I the 
ϕ torsion angle of Pro is fixed at -75°, while it is -126° in the oxo-piperazine moiety of analogue 
47. Moreover, the ϕ and ψ torsion angles of Trp (Table 10) are also significantly different from 
native helicokinin I, which are fixed at -105.3
o
 and -18.6
o
, respectively.
[43]
 These analyses drive a 
conclusion that the 2-oxo-piperazine containing helicokinin analogue is unsuitable either to the 
type I β-turn of helicokinin I or to any other standard β-turns. 
2.5.3 Conformational analysis of the flexible macrocyclic analogues 
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The NOESY spectrum of macrocyclic peptides 66 and 67 display a reduced number of sequential 
NOEs arising from exchange-mediated line broadening regardless of temperature and field. 
These are due to the fast interchange between different conformers that lead to very low 
intensities of many signals in both TOCSY and NOESY spectra, especially of inherently weak 
amide signals. In spite of several efforts, we were unable to identify the defined structures of 
peptides 66 and 67. Therefore, their three-dimensional structures (3D) were established by 
utilizing YASARA Structure molecular modeling package (version 13.5.10) with helicokinin I as 
reference. These calculations were performed by Prof. Dr. Guiscard Seebohm at the Department 
of Myocellular Electrophysiology, University of Münster. After parameterizing the new building 
blocks by means of semi-empirical quantum mechanics in AM1/NOVA and minimizing energy 
of the conformers in AMBER using the AMBER03 force field, the preferred conformations of 
peptides 66 and 67 were constructed (Figure 30). MD simulations were carried out following 
three different models: Type A) in water, Type B) into the core of the membrane, and Type C) 
into the region of the membrane head groups (phosphate region).  
Figure 30: Low energy conformations of flexible macrocyclic scaffolds (66 and 67) 
 
Energy analyses suggest that simulations of helicokinin I, peptides 66 and 67 reach stable 
energies within 50 psec. All three peptides have similar energies in both membrane regions B 
and C, but they are significantly higher in aqueous environment confirming that three peptides 
tend to dissolve within different membrane regions rather than in water. When simulated the 
native helicokinin I was slowly expelled from the membrane core (within 0.5 ns) and remained 
stable among phosphates of the lipid head groups (5 ns simulations), whereas the 
peptidomimetics 66 and 67 stayed stable in the membrane core (within 1 ns). Rout-Mean-
66 67 
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Square-Deviation analyses (RMSD) suggest that helicokinin I residues fluctuate stronger in 
water (2.2 – 3.8Å) and slightly stronger among phosphates of the lipid head groups (0.8 – 2.2Å) 
than in the membrane core (0.7 – 1.4Å). In all cases, the helicokinin I C-terminal region (Ser-
Pro-Trp-GlyNH2) is more stable than the N-terminal residues Tyr and Phe as observed in the 
NMR studies. As expected, helicokinin I formed a type I β-turn over the residues Ser-Pro-Trp-
GlyNH2. This result is in good accordance with the previous study on helicokinin by NMR 
measurement in DPC micelles.
[43]
 It was also found that the type I β-turn conformation was the 
most stable in the membrane core (RMSD in simulation type A: 2,79 ± 0,37 Å; type B: 1,24 ± 
0,14 Å; type C: 0,87 ± 0,06 Å; errors as SEM). On the other hand, both the alkenyl- and alkyl-
bridged macrocyclic peptides 66 and 67 stabilize the loop-structures at the C-terminal domain 
(Figure 30). However, due to the higher flexibility of the alkyl-spacer macrocycle 67 adopts a 
more stretched conformation in the membrane, while the more restricted analogue 66 induces a 
loop conformation that is very similar to helicokinin I conformation in the membrane mimicking 
environment.  
2.5.4 Conformational analysis of the Trp-derived helicokinin I analogue 
Figure 31: The number of significant inter-residual distance constraints of peptide 79 in DPC-micelles (left); An 
expansion of the NOESY-spectrum between sequential amide protons (right). 
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The NOESY spectroscopy of peptide 79 displays again a decreased number of sequential NOEs. 
Only a number of medium-range contacts between the β- and δ-protons of Phe residue and the 
NH amide of Ser were found corresponding to a disordered conformation (Figure 31). In this 
case, MD simulations were not carried out. Thus, its defined conformation was not established. 
However, due to the cis-amide bond between Pro and Trp residues, it is assumed that formation 
of any turn-like structures is impossible. 
2.6 Biological data 
In order to evaluate structure-activity relationships of the helicokinin analogues for their receptor 
binding potency, all the peptidomimetics synthesized were tested on functional receptor assay of 
Heliothis virescens cloned from Mapighian tubules cDNA library. Within the scope of the 
biological validation, an inactive compound is defined as an EC50 value higher than 100 µM 
corresponding to a complete loss of receptor-binding by a factor of more than 30.000 compared 
to the parent helicokinin I, which is chosen as reference (Table 11).  
Table 11: EC50 values of helicokinin I analogues 
Compd. Receptor assay 
EC50 [µM] 
YFSPWG-NH2  
(helicokinin I)  
0.003 
 
34a >100 
34b >100 
35a >100 
35b 25.12 
47 >100 
66 1.99 
67 12.5 
79 >100 
88 1.0-1.58 
128 0.0398 
129 0.501 
132 0.63-1.25 
166 >100  
171 >100 
176 15.84 
180 3.1 
192 15.85 
196 0.003 
198 0.1-0.158 
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Encouraged by highly biological activities of 4-trans-aminopyroglutamate-achetakinin analogues 
reported by Nachman (Table 4), four diastereomeric helicokinin I analogues 34a, 34b, 35a and 
35b were synthesized (Figure 26), Surprisingly, our results found that both helicokinin I 
peptidomimetics 34a (APy(2R,4S)) and 34b (APy(2S,4R)) were inactive, even up to an EC50 
value of 100 μM (Table 11). Most importantly, a prerequisite for any β-turn formations is the 
spatial orientation of the N- and C-terminal peptide chains in the same directions. However, this 
appears not true to the APy-containing helicokinin analogues 34a and 34b, where the trans-APy 
core moiety orients the attached peptide chains into opposite directions. Thus, it prevents 
formation of a C-terminal β-turn. The NMR spectroscopic studies evidently confirmed flexible 
and stretched conformations for both diastereoisomers 34a and 34b. The results of inactive 
pentapeptides arose again a question whether the stereochemistry or the length of peptide chains 
has much influence on receptor binding. It is known that the truncated helicokinin I analogues 
with any amino acids exhibited a complete loss of bioactivity, except for the N-terminal tyrosine.
 
[64]
 In order to clarify these issues the hexapeptides 35a and 35b were prepared, which ensure 
sufficiently the length of peptide chains in comparison with the parent helicokinin I. However, 
only the peptide 35b (2S,4R) exhibited weak activity (EC50  = 25 μM), whereas its diastereomer 
35a was completely inactive (Table 11).  
Figure 32: Preferred conformation of peptide 166  
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Incorporation of β-proline in the helicokinin I provided additional evidence of the 1,3-
arrangements in the pseudo-proline moiety that plays important role for receptor binding. In this 
case analogue 166 (Figure 33) is considered as more opened conformation than helicokinin I 
because the β-Pro moiety arranges the attached peptide chains in positions 1 and 3. Not 
surprisingly, peptide 166 displays again a complete loss of biological activity (Table 11). Like 
the 1,3-connectivities in the trans-APy containing analogues, the β-Pro moiety probably orients 
the N- and C-terminus into inappropriate directions. Therefore, peptide 166 tends to adopt an 
extended conformation (Figure 32) rather than form a turn-like structure. It could be concluded 
that the main reason leading to the loss of biological activity is due to the inappropriate 
orientations of the N- and C-terminus and not simply insufficient length of the peptide chains.  
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Figure 33: Chemical structure of helicokinin I and analogue 166 
Formed by an ethylene bridge between two adjacent amide bonds within the active core domain, 
the 2-oxo-piperazine moiety in the helicokinin analogues 47 serves as 1,4-connectivity motif that 
forces the attached N- and C-terminal peptide-chains in opposite directions. As expected, the 
helicokinin I analogue 47 was found inactive, too (Table 11). The NMR spectroscopic data 
EC50 ˃100 µM 
EC50 = 0.003 µM 
166 
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revealed that helicokinin I analogue 47 induces a bowl-like structure that is absent from a β-turn 
accompanied by complete loss of receptor binding. It is noteworthy that the spatial orientations 
of the N- and C-terminal peptide-chains actually play a crucial role in receptor binding. The 1,3- 
or 1,4-arrangements of the attached C- and N-terminal peptide chains almost result in a loss of 
receptor binding potency. 
In an effort to bring the N- and C-terminus into close promixity, the macrocyclic helicokinin I 
analogues 66 and 67 were synthesized (Figure 26). In these regards, the amide bonds of Ala and 
Gly are fixed by tetra-carbon bridges and the critical Phe, Trp and Gly-NH2 residues required for 
receptor binding are retained. The difference between peptides 66 and 67 (Figure 26) displays 
through the flexibility of the bridges. The more rigid trans-alkenyl bridge in analogue 66 induces 
a loop conformation that is very similar to the helicokinin I conformation in micelles, while the 
saturated analogue 67 presents a higher degree of conformational freedom (Figure 30). The more 
constrained macrocyclic helicokinin I analogue 66 retains considerable activity in the low 
micromolar range (EC50 = 1.99 μM, Table 11) suggesting that it is possible to freeze the 
biologically active conformation needed for receptor binding in cyclic structure which can be 
analyzed conveniently with conventional NMR spectroscopic methods. Surprisingly, the more 
flexible macrocyclic helicokinin I analogue 67 demonstrates a six-fold reduced activity (EC50 = 
12.5 μM), suggesting a very specific receptor bound conformation tolerating only minor 
deviations in plasticity. Obviously, the trans-alkene bridge constrains the Trp residue in a 
direction that facilitates receptor binding and preserves the required flexibility of the critical Phe 
and GlyNH2 residues, while the larger flexibility of the alkyl-spacer in cyclic peptide 67 induces 
a more disordered conformation. Consequently, in the lowest-energy conformation the N-
terminal tripeptide-chain of macrocycle 67 adopts a considerably different position related to 
helicokinin I or macrocycle 66 (Figure 34). Differences can also be found within the 
macrocycles. For instance, the Trp carbonyl group in helicokinin I occupies an exo-position, 
whereas the corresponding carbonyl groups of Trp in peptides 66 and 67 are found in endo-
positions. In addition, the double bond in the bridge of the macrocycle 66 adopts a position 
almost identical to the Ser carbonyl group in helicokinin I, suggesting that the double bond is 
able to mimic the carbonyl group and thus contributes to the remarkable activity of compound 66 
in contrast to the saturated macrocycle 67. 
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Figure 34: Superpositions of helicokinin I (green) with macrocycles 66 (purple) and 67 (blue) 
 
In another aspect, the significance of the Trp side chain for receptor binding is clearly displayed 
by two helicokinin I peptidomimetics 79 and 88. Incorporation of the tryptophan-constrained 
analogues, in which a methylene-bridge is placed between the C-2 of the indole ring and N
α
, into 
helicokinin I has great influence on their abilities to interact with the biological target. The 
resulting analogue 79 (Figure 26) was found inactivity (Table 11). The highly conformational 
constraint of the Trp moiety perturbs drastically the backbone conformation of the helicokinin I 
analogue and does not allow the peptide backbone and side chain Trp some degree of flexibility. 
Probably, the restriction of the motional freedom of indole ring disrupts largely its shape, making 
analogue 79 unable to fit into the binding pockets of receptor. In addition, NMR spectroscopic 
studies also confirm that the peptide 79 is unable to adopt any turn-like structures. In contrast, 
the tetrahydro-β-carboline containing helicokinin analogue 88 retains considerably biological 
activity in the low micromolar range (EC50 = 1.0-1.5 μM). This suggests that the side chain 
modification is an interesting aspect in structure-activity relationship studies of helicokinin I. 
The difference between two peptidomimetics mainly involves in the limitation of ϕ and ψ torsion 
angles within the Trp moiety. It seems that the larger constraint of the ψ dihedral angle of the 
diaza-bridged heterocyclic system in analogue 79 orients the N- and C-terminal tripeptide in 
opposite directions, while the more flexible ψ torsion angle of the tetrahydro-β-carboline moiety 
in analogue 88 deviates slightly the N- and C-terminal orientation. In addition, the appropriate 
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orientations of the indole moiety and Phe residue in the same direction also facilitate the receptor 
binding potency of peptide 88 (Figure 35).  
Figure 35: Preferred conformation of peptide 88  
 
Stimulated by considerable bioactivity of the macrocyclic peptide 66, our attention focused on 
constructing macrocyclic helicokinin I analogues. For this purpose, the macrocycles 128, 129 
and 132 were successfully synthesized (Figure 37). Unlike the previous studies on head to tail 
backbone cyclization of the linear helicokinin I analogues, which provided all inactive peptides, 
the side chain to side chain cyclization analogues exhibit significantly biological activity. 
Remarkably, the flexible trans-alkene macrocycle 128 demonstrates greatly biological activity in 
nanomolar range (EC50 = 39.8 nM). Formation of the 19-membered ring probably does not 
disturb the backbone conformation of helicokinin drastically. Probably, the constraint of the 
dihedral angles of Ser residue within the turn center causes slightly deviation of the N- and C-
terminus in which the critical side chains Trp and Phe are still allowed to orient towards in the 
same side of the peptide backbone (Figure 36a). In addition, the maintenance of the correct 
distance between the N-terminal Tyr-Phe dipeptide and the C-terminal Trp-GlyNH2 dipeptide 
through Ser-Pro spacer may play a significant element to retain its biological activity. Not 
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surprisingly, the alkyl-bridge containing analogue 129 displays a considerable reduction in the 
biological activity. The saturated bridge analogue 129 shows over 12-fold decreased bioactivity 
(EC50 = 0.50 µM). These findings are consistent with the case of peptides 66 and 67. Obviously, 
the more constrained-macrocyclic-bridged analogues (66 and 128) have significant roles in 
inducing the conformational preference of helicokinin I analogues that are capable of enhancing 
the potency of receptor binding. 
Figure 36: Preferred conformation of peptide 128 (a) and peptide 132 (b) 
 
 
Interestingly, the hybridized analogue 132 also retains a considerable bioactivity in very low 
micromolar range (EC50 = 0.63-1.15 µM). Compared to the helicokinin I analogue 128, the 
analogue 132 displays largely a disturbed conformation at the C-terminus (Figure 36b). The 
tertiary amide bond of Pro residue and the carboline moiety deviates the C-terminus in 
inappropriate direction. Perhaps, both side chains Phe and Trp tend to point towards in the same 
a 
b 
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direction of the peptide backbone along with constant distance of the N- and C-terminal 
dipeptide accelerating the receptor binding potency.  
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Figure 37: Chemical structure of helicokinin derivatives 88, 128, 129 and 132 
In order to obtain more detailed general picture on three-dimensional structure-activity 
relationships of helicokinin I, a highly constrained spirolactam 167 was used as β-turn motif for 
scanning the ability of receptor binding. Five helicokinin analogues (Figure 38) were synthesized 
and tested on receptor assay. The results of biological assay confirmed that the Tyr residue is 
uncritical for receptor activation (Figure 38, 192). In addition, substitution of Pro-Trp dipeptide 
sequence with the constrained spirolactam (Figure 38, 171) leads to a complete loss of biological 
activity. These findings are in good agreement with the previous studies on helicokinin I, in 
which the deletion of any amino acid in helicokinin I sequence to form pentapeptides provided 
inactive compounds, except Tyr.
[64]
 Surprisingly, substitution of spirolactam for either Phe or 
Trp (Figure 38, 176, 192) exhibits the similar receptor binding potency in low micromolar ranges 
(EC50 = 15.84 µM). These findings are contrast to the preceding study, suggesting that Phe 
129 
EC50 = 0.501 µM 
128 
EC50 = 0.0398 µM 
 
88 
EC50 = 1.0-1.58 µM 
132 
EC50 = 0.63-1.25 µM 
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residue can be replaced somewhat by other amino acids without immediately complete loss of 
bioactivity. The spirolactamscan at position 4 reduced considerably receptor binding potency by 
a factor of 150. It demonstrated that the distance between the N-terminal dipeptide Tyr-Phe and 
the C-terminal Trp-Gly appears very important for remaining the biological activity of 
helicokinin I.  
N
H
N
NH
O
N
H
NH
2
O
OH
N
H
O
OH
NH
2
O
O
O
N
H
NH
2
O
OH
O
N
H
O
N
OH
N
NH
O
NH
O
O
NH
2
O
N
NH
O
O
NH
NH
O
NH
2
O
NH
O
N
H
OH
O
N
H
O
NH
2
OH
N
N
H
O
O
NH
2
O
OH
NH
N
O
N
H
N
H
O
NH
2
O
NH
O
OH
N
H
O
NH
2
N
H
O
N
O
OH
N
HO
N
H
O
NH-NH
2
O
NH
OH
N
H
N
H
O
O
N
H
O
NH
N
O
N
H
N
H
O
NH
2
O
NHO
OH
 
Figure 38: Chemical structure of helicokinin I derivatives 
171 
EC50 >100µM 
196 
EC50 = 0.003 µM 
180 
EC50 = 3.1 µM 
192 
EC50 = 15.85 µM 
176 
EC50 = 15.85 µM 
198 
EC50 = 0.1-0.158 µM 
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Functional variation at the C-terminus again demonstrates the importance of the C-terminal 
amidation. In agreement with the published data, peptide 198 (Figure 38) shows a reduced 
bioactivity by a factor of 50-80, indicating that the amidated C-terminus is required for 
remaining its receptor binding. 
2.7 Conclusion and outlook  
We have presented several approaches to defining the secondary structure of helicokinin I 
required for receptor binding. The primary attention was focused on establishing β-turn 
peptidomimetics. A convenient synthetic approach for preparation of the pure diastereomeric 4-
trans-aminopyroglutamates, as inducers of type VI β-turn, and their incorporation into 
helicokinin I have been described. In addition, two efficient strategies for stabilizing the 
secondary structure of helicokinin I analogues using hydrophobic linkers, ethylene or tetra-
carbon bridges, have been successful. The detailed NMR spectroscopic studies and MD 
calculations of several helicokinin I peptidomimetics provided a deeper understanding of the 
conformational flexibility and orientation of the N- and C-terminal peptide chains required for 
receptor binding. All the 1,3- and 1,4-connectivites of the N- and C-terminal peptide chains (34a, 
34b, 35a, 35b, 47, 166) lead to the complete loss of biological activity because of their 
incapability of either adopting a β-turn structure at the C-terminus or inducing appropriate 
orientations. Notably, the macrocyclic helicokinin I analogue 66 with appropriate scaffold retains 
significant biological activity in low-micromolar receptor binding, indicating specific 
conformational freedom and spatial orientation of the N- and C-terminal peptides.  
The global constraint on the secondary structure of helicokinin I by constructing macrocycles 
(128, 129 and 132) provides the most interesting results in the biological activity. The chemical 
modification on the side chains Tyr and Ser, which are not involved directly in molecular 
recognition, shows highly potent agonist in receptor activation. Remarkably, the macrocyclic 
peptide 128 is the first modified helicokinin I analogue that exhibits in nanomolar range in the 
receptor binding. Thus, macrocycle 128 may provide excellent starting-points for probing 
conformational changes in helicokinin I analogues. Surprisingly, the saturated macrocyclic 
peptides 67 and 129 formed by hydrogenation of the alkenyl-bridged peptides 66 and 128, 
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respectively, show considerably reduced receptor activation by a factor of 6-12 (Table 11). 
Probably, the higher flexibility of the alkyl spacers causes more stretched or disordered 
conformations in the membrane, while the more constrained trans-alkenyl linkers in analogues 
66 and 128 may adopt preferentially loop conformations that are highly similar to helicokinin I 
in membrane-mimicking state. 
On the other hand, the function of side chain Trp with respect to its role as anchoring tool on the 
membrane is also studied. Though several conformationally constrained structures derived from 
tryptophan residue were targeted to prepare (Figure 20), but only two analogues 79 and 88 were 
successfully synthesized. The restriction of side chain tryptophan affects obviously the global 
secondary structure of helicokinin I. The loss of the receptor binding of analogue 79 is 
contributed to the incapability of inducing any turn-like structures in which the N- and C-
terminus are extended in different direction. In contrast, the analogue 88 retains considerable 
bioactivity. This suggests that the use of conformationally constrained side chains offers 
promising aspects for structure-activity relationship researches on helicokinin I. 
Undoubtedly, the opportunity for obtaining well-defined conformations required for receptor 
binding is very narrow. Only slightly inappropriate orientations of the N- and C-terminus can 
lead to weak or inactive peptides. Expectedly, the novel helicokinin I analogues that show highly 
selective activities in the low micro- or nanomolar range may provide a useful approach for 
further exploitation of structure activity relationships and optimization of helicokinin I. The 
global or local constraints of conformation by forming macrocyclic peptidomimetics (66, 128 
and 88) are the most interesting aspects of the conformational research. In addition, the 
spirolactamscan revealed that both Phe and Trp residues can be somewhat replaced by their 
modified-analogues. Thereby, the use of conformationally constrained structures derived from 
Phe and Trp residues may present promising targets for evaluating the importance of Phe and 
Trp required for receptor binding.  
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III Experimental 
3.1 General chemistry 
All chemical reagents were purchased from commercial suppliers and used without purification. 
Dichloromethane (DCM), acetonitrile (ACN), N,N-dimethylformamide (DMF) and N,N-
diisopropylethylamine (DIPEA) were heated at reflux for 1 h over calcium hydride and distilled. 
Tetrahydrofuran (THF) was heated at reflux for several hours over LiAlH4 and then distilled. The 
instrumentation was used as follows, 
1
H-NMR: Bruker Avance 400, Bruker Avance III 600. 
13
C-NMR: 
Bruker Avance 400, Bruker Avance III 600. Infrared (IR) spectra were obtained using a FTIR: Nicolet 
PROTÉGÉ 460 E.S.P; data are presented as the frequency of absorption (cm
-1
). MS: Bruker microTOF, 
ESI-MS: Varian IT 500-MS Iontrap. LC: Preparative low-pressure chromatography (PLPC) was 
performed by using silica gel 60 μm (230–400 mesh, Macherey–Nagel) The abbreviations are used for the 
proton spectra multiplicities are: s, singlet; br, broad; bs, broad singlet; d, doublet; dd, double of doublet; 
dt, double of triplet; t, triplet; q, quartet; m, multiplet. Coupling constants (J) are reported in Hertz (Hz). 
TLC analyses were performed on silica gel 60 F254 (Merck). Detection was conducted under UV light 
(254 nm) and staining with potassium permanganate. Flash column chromatography was performed on 
silica gel (0.063-0.200 mm). 
3.2 Abbreviations 
Boc, tert-butoxycarbonyl; Fmoc, fluorenylmethyloxycarbonyl; HATU, 2-(1H-7-azabenzotriazol-1-yl)-
1,1,3,3-tetramethyluronium; PyBOP, benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluoro-
phosphate; HOAt, 1-Hydroxy-7-Azabenzotriazole; PyBOP, (Benzotriazol-1-yloxy)tripyrro-
lidinophosphoniunhexafluorophosphate; PyBrOP, Brom-tris-pyrrolidinophosphoniumhexafluoro-
phosphate; BOP-Cl, Bis(2-oxo-3-oxazolidinyl)phosphinic chloride; TBTU, O-(1H-benzotriazole-1-yl)-
N,N,N’,N’-tetramethyluronium tetrafluoroborate; TFA, trifluoroacetic acid; TIPS, triisopropylsilane; 
DIPEA, N,N-Diisopropylethylamine; TEA, triethyl amine; DBU; 1,8-diazabicyclo[5.4.0]undec-7-en; 
DIPEA, N,N-Diisopropylethylamine;  LDA, Lithium diisopropylamide; PTSA, p-toluenesulfonic acid; 
PMB, para methoxybenzyl; MoOPD, Oxodiperoxymolybdenum (pyridine)-1,3-dimethyl-3,4,5,6-tetrahydro-
2(1H)-pyrimidinone; DMF, N,N-dimethylformamide; ACN, acetonitrile; DCM, dichloromethane; THF, 
tetrahydrofuran; EtOAc, ethyl acetate; tBu, tert-Butyl; TBDPS, tert-butylchlorodiphenylsilane; Cbz (Z), 
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benzyloxycarbonyl; DMSO, dimethylsulfoxide; TIPS, triisopropylsilan; BEP, 2-Brom-1-ethyl-
pyridinium-tetrafluoroborate; Bn, Benzyl; TFE, 2,2,2-trifluorethanol; TFA, trifluoroacetic acid. 
3.3 Receptor assay  
The helicokinin receptor of Heliothis virescens was cloned from a Malpighian tubule cDNA library and 
showed about 50% homology (amino acids) to the leucokinin receptor from Lymnea stagnalis.
[134,135]
 The 
helicokinin receptor (HKR) was functionally expressed in a Chinese hamster ovary (CHO) line. The 
activation of the HKR was analyzed in living cells by measuring the induced calcium ion flux in the 
cytosol after activation of the second messenger cascade via G-proteins. Calcium ion dyes were obtained 
from Molecular Devices and were used according to the supplier’s protocol. Cells were plated in 384-well 
plates (4x10
3 
cells per well) and incubated overnight (37
o
C, 5% CO2). Cells were removed from the 
incubator, allowed to reach room temperature over the course of 10 min, and then washed with 50 µl of 
HBSS. Subsequently, the medium was replaced with 50 µl of calcium ion dye solution in HBSS, and cells 
were loaded for 1 h in the dark. Then, the plates were read on a Flex station fluorescence plate reader 
(Molecular Devices). Excitation and emission wavelengths were set to 485 nm and 525 nm, respectively. 
Measurements were made every 2.7s intervals for 100s. Basal fluorescence was determined for 15–30 s, 
followed by addition of 25µl test compounds (to assess agonist activity). Helicokinins I or II were used as 
standards and were tested in four independent experiments for evaluating EC50 values. Standard 
deviations were 2 nM for helicokinin I, 3 nM for helicokinin II and 3 nM for helicokinin III. EC50 values 
were calculated after concentration-dependent induction of calcium flux analyzed in a Flexstation 
(Molecular Devices). Finally, EC50-values were calculated as Fmax (maximal agonist signal) minus Fmin 
(baseline) according to Softmax-Pro 5.0 software (Molecular Devices). All tests compounds were 
measured in two independent experiments in ten dilution steps (in duplicates) from 0.5 nM to 10 µM. 
3.4 NMR measurements and spectra evaluation 
The NMR measurements were performed by using 2 mM solutions of the peptide in DPC or SDS 
micelles (300 mM), corresponding to a 5 mM concentration of micelles, and in MES buffer (20 mM, pH 
5.5).
[136]
 All NMR measurements were performed at these high DPC concentrations, well beyond the 
critical micelle concentration of 1.1 mM and at micelle/peptide ratios well above unity. This has been 
shown to significantly improve the quality of NMR spectra.
[137] 
Structures were computed based on data 
derived from NOESY spectra obtained at100 ms (DPC) mixing times. The software XEASY was used for 
signal integration and spectra interpretation.
[138]
 Resonances were assigned by using the sequential 
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resonance-assignment procedure developed by Wüthrich.
[139]
 Structures based solely on NOE-derived 
upper distance in the program CYANA 2.1 and, because of the problematic nature of J couplings in 
nonrigid systems, restraints derived from scalar couplings were excluded. 100 structures were initially 
computed based on the NOE restrains by using the standard simulated-annealing protocol of CYANA 
with its simplified force field in the absence of explicit solvent.
[140]
 The 20 lowest-energy conformers 
were selected to represent the NMR ensemble without further refinement. Structures were visualized in 
the program MOLMOL, which was also used to extract the values of dihedral angles.
[141]
 
3.5 MD simulations 
The models were placed into a simulation boxes and the solvent boxes were filled with water using the 
TIP3P water model, A). In case of the membrane simulations Yasaras run_membrane.mcr was used. In 
this approach a dense phosphatidylethanolamine (PEA) membrane is built, the peptide/peptidomimetic is 
placed into B) the membrane core or C) membrane lipid head region. Peptide/peptidomimetic insertion is 
done by placing a spacially “shrunken” place holder into the chosen position. Gradually increasing the 
size of the peptide/peptidomimetic to its normal size with intermediate energy minimizations guarantees 
dense packing of the model. Unrestrained high-resolution refinements and MD-simulation with explicit 
solvent molecules were run, using AMBER03 force field. The simulation parameters of the all-atoms-
mobile MD simulations were as follows: force field AMBER03, time steps 1.2 fs, temperature was 298K, 
pressure at 1 bar, pH 7.0, Coulomb electrostatics at a cut-off 7.86, 0.9% NaCl, solvent density 0.997. The 
average structures, RMSDs, secondary structures and side-chain fluctuations of heavy atoms (RMSFs) 
were analysed using macros “md_analyze”, “md_analyzers”, “md_analyzemul” and “md_analyzesecstr” 
in Yasara Structure.  
3.6 Synthesis of APy-containing helicokinin I analogues 
General procedure for synthesis of methyl 5-oxopyrrolidine-2-carboxylate 
A stirred suspension solution of glutamic acid (1 equiv) in MeOH (50 mL) was added dropwise SOCl2 (6 
equiv) at 0 
o
C. After stirring at room temperature for 20 h, the reaction mixture was concentrated under 
reduced pressure to provide the methyl glutamate ester as a colorless oil. This raw material was then 
dissolved in toluene (150 mL) and refluxed for 2 h in the presence of TEA (1.0 equiv). The solvent was 
removed to yield a colorless oil product. 
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(S)-Methyl-5-oxopyrrolidine-2-carboxylate (TVC-063, 23a) 
Starting material S-glutamic acid (2 g, 13.59 mmol) yielded 23a (1.57 g, 80%). 
1
H-NMR
 
(600 MHz, CDCl3): δ = 4.2 (m, 1H, 1-H), 3.7 (s, 3H, 6-H), 2.4 (m, 1H, 2-
H), 2.2 (m, 1H, 2-H), 2.3 (m, 2H, 3-H). 
13
C-NMR (150 MHz, CDCl3): δ = 178.1 
(5-C), 172.4 (4-C), 55.3 (1-C), 52.5 (6-C), 29.2 (3-C), 24.7 (2-C). IR (neat) ν (cm-
1
): 3244.3 (NH), 1669.9 (CO). HPLC-ESI-MS: m/z (%) = 144.0 (100) [M+H]
+
. HR-ESI-MS (m/z): 
calcd. for C6H10NO3 [M+H]
+ 
144.0655; found 144.0657. Rf = 0.21 (EtOAc). 
(R)-Methyl-5-oxopyrrolidine-2-carboxylate (TVC-064, 23b) 
Starting material R-glutamic acid (10 g, 67.97 mmol) afforded 23b (8.4 g, 100%). 
1
H-NMR
 
(400 MHz, CDCl3): δ = 4.2 (m, 1H, 1-H), 3.7 (s, 3H, 6-H), 2.4 (m, 1H, 2-
H), 2.2 (m, 1H, 2-H), 2.3 (m, 2H, 3-H). 
13
C-NMR (100 MHz, CDCl3): δ = 177.9 
(5-C), 172.4 (4-C), 55.2 (1-C), 52.5 (6-C), 29.3 (3-C), 24.8 (2-C). IR (neat) ν (cm-1): 3242.3 (NH), 1667.3 
(CO). HPLC-ESI-MS: m/z (%) = 144.0 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C6H10NO3
 
[M+H]
+ 
144.0655; found 144.0657. Rf = 0.22 (EtOAc). 
General procedure for reduction of methyl-5-oxopyrrolidine-2-carboxylate 
A solution of methyl-5-oxopyrrolidine-2-carboxylate (1.0 equiv) in isopropanol was treated with NaBH4 
(4.0 equiv) for 20 h at room temperature. The reaction mixture was then acidified with 5% citric acid. The 
solvent was removed to dryness and the residue was dissolved in 60% EtOAc/MeOH. The precipitate was 
filtered off and the filtrate was evaporated to obtain a solid. The solid was redissolved in DCM and 
filtered again. Removal of the solvent afforded an oily product. 
(S)-5-(Hydroxymethyl)pyrrolidin-2-one (TVC-069, 24a) 
Starting material (S)-methyl-5-oxopyrrolidine-2-carboxylate 23a (9.8 g, 68.46 
mmol) in isopropanol (60 mL) gave 24a (6.54 g, 83%). 
1
H-NMR
 
(400 MHz, CDCl3): δ = 3.7 (br, 1H, 1-H), 3.67 (m, 1H, 5-H), 3.5 (m, 1H, 
5-H), 2.3 (m, 2H, 3-H), 2.12 (m, 1H, 2-H), 1.7 (m, 1H, 2-H). 
13
C-NMR (100 MHz, CDCl3): δ = 179.3 (4-
C), 66.7 (5-C), 56.3 (1-C), 30.1 (3-C), 22.5 (2-C). IR (neat) ν (cm-1): 3229.3 (NH), 1669.3 (CO). HPLC-
ESI-MS: m/z (%) = 116.0 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C5H10NO2
 
[M+H]
+ 
116.0706; 
found 116.0706. Rf = 0.18 (EtOAc/EtOH, 5/1). 
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(R)-5-(Hydroxymethyl)pyrrolidin-2-one (TVC-067, 24b) 
Starting material (R)-methyl-5-oxopyrrolidine-2-carboxylate 23b (42 mg, 0.29 mmol) 
in isopropanol (8 mL) afforded product 24b (28 mg, 83%). 
1
H-NMR
 
(600 MHz, CDCl3): δ = 3.7 (bs, 1H, 1-H), 3.56 (dd, J = 3.4 Hz, J = 11.4 
Hz, 1H, 5-H), 3.37 (dd, J = 7.0 Hz, J = 11.4 Hz, 1H, 5-H), 3.0 (br, 1H, NH), 2.3 (m, 2H, 3-H), 2.12 (m, 
1H, 2-H), 1.7 (m,1H, 2-H). 
13
C-NMR (150 MHz, CDCl3): δ = 179.3 (4-C), 65.4 (5-C), 56.2 (1-C), 30.0 
(3-C), 22.4 (2-C). IR (neat) ν (cm-1): 3369.3 (NH), 1675.3 (CO). HPLC-ESI-MS: m/z (%) = 116.0 (100) 
[M+H]
+
. HR-ESI-MS (m/z): calcd. for C5H10NO2
 
[M+H]
+ 
116.0706; found 116.0706. Rf = 0.18 
(EtOAc/EtOH, 5/1). 
General procedure for synthesis of 3-phenyl-hexahydropyrrolo[1,2-c]oxazol-5(3H)-one 
A mixture of compound 24a or 24b (1.0 equiv), benzaldehyde (1.3 equiv) and p-toluensulfonic acid 
monohydrate (0.05 equiv) in toluene (30 mL) was stirred at room temperature overnight and afterward 
refluxed under a Dean-Stark water separator for 6 h. The solvent was then removed under reduced 
pressure. The residue was purified by silica gel column chromatography using EtOAc/CyH (1/1) as eluent 
to afford desired product as colourless oil. 
(3R,7aS)-3-Phenyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (TVC-086, 27a) 
Starting material 24a (100 mg, 0.87 mmol) provided 27a (136 mg, 77%).     
   = + 2.1 (c 
1.158, MeOH). 
1
H-NMR (600 MHz, CDCl3): δ = 7.4 (d, J = 7.2 Hz, 2H, 9-H), 7.33 (t, J = 7.0 Hz, 2H, 
8-H), 7.3 (m, 1H, 10-H), 6.3 (s, 1H, 6-H), 4.2 (t, J = 8 Hz, 1H, 5-H), 4.1 (m, 1H, 1-H), 
3.5 (t, J = 8 Hz, 1H, 5-H), 2,8 (m, 1H, 3-H), 2,6 (m, 1H, 3-H), 2,3 (m, 1H, 2-H), 1.9 (m, 
1H, 2-H). 
13
C-NMR (150 MHz, CDCl3): δ = 178.0 (4-C), 138.7 (7-C), 128.5 (9-C), 128.4 (8-C), 125.9 
(10-C), 87.1 (6-C), 71.6 (5-C), 58.7 (1-C), 33.4 (3-C), 23.0 (2-C). IR (neat) ν (cm-1): 1662.9 (CO). 
HPLC-ESI-MS: m/z (%) = 204.1 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C12H14NO2
 
[M+H]
+ 
204.1019; found 204.1018. Rf = 0.35 (CyH/EtOAc, 1/1).  
(3S,7aR)-3-Phenyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (TVC-098, 27b) 
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Starting material 24b (780 mg, 6.77 mmol) afforded product 27b (860 mg, 63%).     
   = 
-7.2 (c 0.575, MeOH). 
1
H-NMR (400 MHz, CDCl3): δ = 7.4 (d, J = 7.2 Hz, 2H, 9-H), 7.36-7.26 (m, 3H, 8-H, 
10-H), 6.3 (s, 1H, 6-H), 4.2 (t, J = 8 Hz, 1H, 4-H), 4.1 (m, 1H, 1-H), 3.5 (t, J = 8 Hz, 1H, 
5-H), 2,8 (m, 1H, 3-H), 2,6 (m, 1H, 3-H), 2,3 (m, 1H, 2-H), 1.9 (m, 1H, 2-H). 
13
C-NMR 
(100 MHz, CDCl3): δ = 178.0 (4-C), 138.8 (7-C), 128.4 (9-C), 128.4 (8-C), 125.9 (10-C), 87.1 (6-C), 71.6 
(5-C), 58.7 (1-C), 33.3 (3-C), 23.1 (2-C). IR (neat) ν (cm-1): 1673.9 (CO). HPLC-ESI-MS: m/z (%) = 
204.1 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C12H14NO2 [M+H]
+
 204.1019; found 204.1017. Rf = 
0.4 (CyH/EtOAc, 1/1) 
General procedure for hydroxylation reaction 
Diisopropylamine (1.4 equiv) was added dropwise to a solution of n-BuLi (2.5 M in n-hexane, 1.4 equiv) 
in dry THF at 0 
o
C. After stirring for 20 min, the resulting solution was cooled to -78 
o
C and a precooled 
solution of 3-phenyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (1.0 equiv) in THF was added. The 
reaction mixture was stirred for 50 min and then pumped into a suspension of MoOPD (1.3 equiv) in 
THF. The reaction mixture was allowed to warm up to -40 - -35 
o
C and stirred for 3 h. The resulting 
solution was quenched with a saturated solution of Na2SO3, extracted with EtOAc, washed with 5% HCl 
and dried over MgSO4. Removal of the solvent and column chromatography using EtOAc/CyH (1/1) as 
eluent solvent provided an oily product. 
(3R,6S,7aS)-6-Hydroxy-3-phenyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (TVC-094, 28a)  
Starting material 27a (450 mg, 2.21 mmol) afforded 28a (350 mg, 72%). 
1
H-NMR
 
(400 MHz, CDCl3): δ = 7.45 (m, 2H, 8-H), 7.4-7.36 (m, 3H, 9-H, 10-H), 6.34 
(s, 1H, 6-H), 5.6 (dd, J = 8.5 Hz, J = 10.5 Hz, 1H, 3-H), 4.4 (dd, J = 7 Hz, J = 10.5 Hz, 
1H, 5-H), 3.6 (dd, J = 1.5 Hz, J = 8 Hz, 1H, 5-H), 4.05 (m, 1H, 1-H), 2,98 (m, 1H, 2-H), 
2,14 (m, 1H, 2-H). 
13
C-NMR (100 MHz, CDCl3): δ = 169.8 (4-C), 137.3 (7-C), 129.1 
(10-C), 128.6 (9-C), 125.9 (8-C), 87.2 (6-C), 78.7 (3-C), 72.4 (5-C), 54.1 (1-C), 33.3 (3-
C). IR (neat) ν (cm-1): 1683.3 (CO). HPLC-ESI-MS: m/z (%) = 220.1 (100) [M+H]+. HR-ESI-MS 
(m/z): calcd. for C12H13NO3Na [M+Na]
+ 
242.0786; found 242.0787. Rf = 0.17 (CyH/EtOAc, 1/1). 
 (3S,6R,7aR)-6-Hydroxy-3-phenyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (TVC-099, 28b)  
Starting material 27b (750 mg, 3.69 mmol) yielded 28b (590 mg, 73%). 
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1
H-NMR
 
(400 MHz, CDCl3): δ = 7.46 (m, 2H, 8-H), 7.44-7.36 (m, 3H, 9-H, 10-H), 6.35 
(s, 1H, 6-H), 4.76 (dd, J = 8.5 Hz, J = 10.5 Hz, 1H, 3-H), 4.3 (dd, J = 8 Hz, 1H, 5-H), 
3.64 (t, J = 8 Hz, 1H, 5-H), 4.03 (dt, J = 1.5 Hz, J = 7.3 Hz, 1H, 1-H), 2,86 (m, 1H, 2-H), 
1.87 (m, 1H, 2-H). 
13
C-NMR (100 MHz, CDCl3): δ = 176.5 (4-C), 137.8 (7-C), 128.8 (10-
C), 128.5 (9-C), 126.0 (8-C), 86.8 (6-C), 72.5 (3-C), 72.4 (5-C), 54.5 (1-C), 33.3 (3-C). IR 
(neat) ν (cm-1): 1683.3 (CO). HPLC-ESI-MS: m/z (%) = 220.1 (100) [M+H]+. HR-ESI-
MS (m/z): calcd. for C12H13NO3Na
 
[M+Na]
+
 242.0788; found 242.0787. Rf = 0.32 (EtOAc).  
General procedure for mesylation reaction 
Methanesulfonyl chloride (2.0 equiv) was added dropwise into a solution of 6-hydroxy-3-
phenyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (1.0 equiv) and TEA (5.0 equiv) in DCM at 0 
o
C. The 
reaction mixture was allowed to stir at room temperature for 20 h, then it was diluted with DCM, washed 
with H2O, brine solution and dried over MgSO4. The solvent was removed and the crude material was 
purified by silica gel column chromatography (CyH/EtOAc, 3/1) to yield the desired product. 
(3R,6S,7aS)-5-Oxo-3-phenylhexahydropyrrolo[1,2-c]oxazol-6-yl-methanesulfonate (TVC-096)  
Starting material (3R,6S,7aS)-6-hydroxy-3-phenyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one 28a (340 
mg, 1.55 mmol) gave TVC-096 (408 mg, 89%) as a colourless oily product. 
1
H-NMR
 
(400 MHz, CDCl3): δ = 7.45 (m, 2H, 8-H), 7.40-7.38 (m, 3H, 9-H, 10-H), 
6.35 (s, 1H, 6-H), 5.59 (dd, J = 8.5 Hz, J = 10.5 Hz, 1H, 3-H), 4.38 (dd, J = 8.5 Hz, 
1H, 5-H), 3.67 (t, J = 8.2 Hz, 1H, 5-H), 4.06 (t, J = 7.3 Hz, 1H, 1-H), 3.32 (s, 3H, 11-
H), 2,99 (m, 1H, 2-H), 2.15 (m, 1H, 2-H). 
13
C-NMR (100 MHz, CDCl3): δ = 169.8 (4-
C), 137.3 (7-C), 129.1 (10-C), 128.6 (9-C), 126.0 (8-C), 87.2 (6-C), 78.6 (3-C), 72.4 (5-
C), 54.1 (1-C), 39.9 (11-C), 33.5 (3-C). IR (neat) ν (cm-1): 1689.9 (CO). HPLC-ESI-
MS: m/z (%) = 298.1 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C13H15NO5SNa 
[M+Na]
+ 
320.0563; found 320.0563. Rf = 0.38 (EtOAc). 
 (3S,6R,7aR)-5-Oxo-3-phenylhexahydropyrrolo[1,2-c]oxazol-6-yl-methanesulfonate (TVC-101) 
Alcohol (3S,6R,7aR)-6-hydroxy-3-phenyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one 28b (590 mg, 2.69 
mmol) yielded product TVC-101 (670 mg, 84%) as a colourless oil. 
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1
H-NMR
 
(400 MHz, CDCl3): δ = 7.45 (m, 2H, 8-H), 7.40-7.38 (m, 3H, 9-H, 10-H), 6.35 
(s, 1H, 6-H), 5.59 (dd, J = 8.5 Hz, J = 10.5 Hz, 1H, 3-H), 4.39 (dd, J = 8.5 Hz, 1H, 5-
H), 3.66 (t, J = 8.2 Hz, 1H, 5-H), 4.05 (t, J = 7.1 Hz, 1H, 1-H), 3.32 (s, 3H, 11-H), 2,99 
(m, 1H, 2-H), 2.15 (m, 1H, 2-H). 
13
C-NMR (100 MHz, CDCl3): δ = 169.8 (4-C), 137.3 
(7-C), 129.1 (10-C), 128.6 (9-C), 126.0 (8-C), 87.2 (6-C), 78.7 (3-C), 72.4 (5-C), 54.1 
(1-C), 39.9 (11-C), 33.3 (3-C). IR (neat) ν (cm-1): 1714.9 (CO). HPLC-ESI-MS: m/z 
(%) = 298.1 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C13H15NO5SNa [M+Na]
+ 
320.0563; found 320.0563. Rf = 0.26 (CyH/EtOAc, 3/1). 
General procedure for azido formation 
A stirred solution of mesylate TVC-096 or TVC-101 (1.0 equiv) and NaN3 (2.0 equiv) in DMSO was 
warmed to 60 
o
C for 1 h. The reaction mixture was then quenched with EtOAc and the organic phase was 
washed with H2O, brine solution and dried over MgSO4. Flash chromatography (EtOAc/CyH, 4/1) 
afforded an oily product. 
(3R,6R,7aS)-6-Azido-3-phenyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (TVC-104, 29a) 
Mesylate TVC-096 (383 mg, 1.29 mmol) yielded 29a (267 mg, 85%).  
1
H-NMR
 
(400 MHz, CDCl3): δ = 7.47 (m, 2H, 8-H), 7.41-7.38 (m, 3H, 9-H, 10-H), 
6.32 (s, 1H, 6-H), 4.33 (dd, J = 3.2 Hz, J = 8.3 Hz, 1H, 3-H), 4.28 (d, J = 8.0 Hz, 1H, 
5-H), 3.5 (t, J = 8.0 Hz, 1H, 5-H), 4.23 (t, J = 7.0 Hz, 1H, 1-H), 2.3-2.2 (m, 2H, 2-H). 
13
C-NMR (100 MHz, CDCl3): δ = 172.9 (4-C), 137.7 (7-C), 128.9 (10-C), 128.6 (9-C), 
125.9 (8-C), 87.1 (6-C), 71.4 (5-C), 63.3 (3-C), 57.1 (1-C), 30.3 (3-C). IR (neat) ν (cm-
1
): 2103.3 (N3), 1697.5 (CO). HPLC-ESI-MS: m/z (%) = 245.0 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. 
for C12H12N4O2Na [M+Na]
+ 
245.1033; found 267.0855. Rf = 0.25 (CyH/EtOAc, 4/1). 
 (3S,6S,7aR)-6-Azido-3-phenyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (TVC-102, 29b) 
Mesylate TVC-101 (587 mg, 1.97 mmol) afforded 29b (397 mg, 82%). 
1
H-NMR
 
(600 MHz, CDCl3): δ = 7.47 (m, 2H, 8-H), 7.41-7.38 (m, 3H, 9-H, 10-H), 6.33 
(s, 1H, 6-H), 4.33 (dd, J = 3.2 Hz, J = 8.3 Hz, 1H, 3-H), 4.3 (dd, J = 8.0 Hz, 1H, 5-H), 
3.5 (t, J = 8.3 Hz, 1H, 5-H), 4.2 (t, J = 7.3 Hz, 1H, 1-H), 2.32-2.22 (m, 2H, 2-H). 
13
C-
NMR (150 MHz, CDCl3): δ = 172.9 (4-C), 137.7 (7-C), 128.8 (10-C), 128.5 (9-C), 
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125.9 (8-C), 87.1 (6-C), 71.4 (5-C), 63.3 (3-C), 57.1 (1-C), 30.5 (3-C). IR (neat) ν (cm-1): 2105.3 (N3), 
1704.5 (CO). HPLC-ESI-MS: m/z (%) = 245.0 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for 
C12H13N4O2
 
[M+H]
+
 245.1033; found 245.1039. Rf = 0.27 (CyH/EtOAc, 4/1). 
General procedure for ring-opening of oxazolidine  
A solution of 6-azido-3-phenyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (1.0 equiv) in THF/H2O (1/1) 
was treated with TFA at room temperature for 18 h. The reaction mixture was concentrated under reduced 
pressure and subjected to silica gel column chromatography using EtOAc (with 1% TEA) as eluent to 
yield product as a yellow oil. 
(3R,5S)-3-Azido-5-(hydroxymethyl)pyrrolidin-2-one (TVC-110, 30a) 
Starting material 29a (100 mg, 0.41 mmol) gave 30a (54.2 mg, 85%). 
1
H-NMR
 
(400 MHz, CDCl3): δ = 4.3 (d, J = 8.5 Hz, 1H, 3-H), 3.74 (dd, J = 2.8 Hz, J = 
11.3 Hz, 1H, 5-H), 3.54 (dd, J = 5.2 Hz, J = 11.3 Hz, 1H, 5-H), 3.8 (m, 1H, 1-H), 2.3 (m, 
1H, 2-H), 2.08 (m, 1H, 2-H). 
13
C-NMR (100 MHz, CDCl3): δ = 175.1 (4-C), 64.9 (5-C), 59.1 (3-C), 53.8 
(1-C), 30.2 (2-C). IR (neat) ν (cm-1): 2105.5 (N3), 1688.5 (CO). HPLC-ESI-MS: m/z (%) = 179.0 (100) 
[M+Na]
+
. HR-ESI-MS (m/z): calcd. for C5H8N4O2Na
 
[M+Na]
+ 
179.0539; found 179.0538. Rf = 0.16 
(EtOAc, 1% TEA). 
 (3S,5R)-3-Azido-5-(hydroxymethyl)pyrrolidin-2-one (TVC-103, 30b)  
Starting material 29b (100 mg, 0.41 mmol) afforded 30b (55.4 mg, 86%).  
1
H-NMR
 
(400 MHz, CDCl3): δ = 4.3 (t, J = 8.0 Hz, 1H, 3-H), 3.75 (dd, J = 2.6 Hz, J = 
11 Hz, 1H, 5-H), 3.52 (dd, J = 5.0 Hz, J = 11 Hz, 1H, 5-H), 3.8 (m, 1H, 1-H), 2.3 (m, 1H, 
2-H), 2.1 (m, 1H, 2-H). 
13
C-NMR (100 MHz, CDCl3): δ = 175.1 (4-C), 64.9 (5-C), 59.1 
(3-C), 53.8 (1-C), 30.2 (2-C). IR (neat) ν (cm-1): 2103.3 (N3), 1683.5 (CO). HPLC-ESI-MS: m/z (%) = 
179.0 (100) [M+Na]
+
, 335.1 (15) [2M+Na]
+
. Rf = 0.17 (EtOAc, 1% TEA). 
General procedure for oxidation reaction 
To a solution of 3-azido-5-(hydroxymethyl)pyrrolidin-2-one (1.0 equiv) and NaIO4 (3.2 equiv) in the 
mixture of solvent ACN/CCl4/H2O (7 mL, 1/1/1.5), RuCl3.xH2O (2 mol%). was added. The reaction was 
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stirred at room temperature for 14 h, then iPrOH was added. After stirring further 30 min, the reaction 
mixture was filtered through a Celite pad and the filtrate was concentrated under reduced pressure to 
dryness. Flash chromatography eluting DCM/MeOH (6/1, 1% AcOH) afforded a solid product. 
(2S,4R)-4-azido-5-oxopyrrolidine-2-carboxylic acid (TVC-111, 31a) 
Alcohol 30a (46.7 mg, 0.3 mmol) furnished acid 31a (47 mg, 92%). 
1
H-NMR
 
(400 MHz, CD3OD): δ = 4.3 (t, J = 8.2 Hz, 1H, 3-H), 4.09 (d, J = 7.2 Hz, 
1H, 1-H), 2.52 (m, 1H, 2-H), 2.2 (m, 1H, 2-H). 
13
C-NMR (100 MHz, CD3OD): δ = 
176.3 (4-C), 60.2 (3-C), 55.9 (1-C), 33.4 (2-C). IR (neat) ν (cm-1): 2103.5 (N3), 1687.5 (CO). HPLC-
ESI-MS: m/z (%) = 193.0 (100) [M+Na]
+
. HR-ESI-MS (m/z): calcd. for C5H6N4O3Na [M+Na]
+ 
193.0332; found 193.0332. Rf = 0.23 (DCM/MeOH, 6/1, 0.5% AcOH). 
 (2R,4S)-4-Azido-5-oxopyrrolidine-2-carboxylic acid (TVC-107, 31b) 
Alcohol 30b (110.0 mg, 0.7 mmol) yielded acid 31b (105 mg, 88%). 
1
H-NMR (400 MHz, CD3OD): δ = 4.3 (t, J = 8.2 Hz, 1H, 3-H), 4.14 (d, J = 8.2 Hz, 
1H, 1-H), 2.53 (m, 1H, 2-H), 2.2 (m, 1H, 2-H). 
13
C-NMR (100 MHz, CD3OD): δ = 
176.1 (4-C), 60.0 (3-C), 55.9 (1-C), 33.2 (2-C). IR (neat) ν (cm-1): 2108.5 (N3), 1695.5 
(CO). HPLC-ESI-MS: m/z (%) = 193.0 (100) [M+Na]
+
. HR-ESI-MS (m/z): calcd. for C5H6N4O3Na 
[M+Na]
+
 193.0332; found 193.0332. Rf = 0.42 (DCM/MeOH, 6/1, 1% AcOH).  
General procedure for synthesis of TVC-109 and TVC-112 
 
To a solution of acid 31a or 31b (1.0 equiv), dipeptide TFA*H-Trp-Gly-NH2 (1.1 equiv) and HATU (1.1 
equiv) in DMF, DIPEA (4.0 equiv) was added dropwise. The reaction mixture was stirred at room 
temperature for 18 h. The solvent was removed under reduced pressure and the residue was purified by 
column chromatography silica gel, using DCM/MeOH (10/1) as eluent, to provide solid products.  
(2R,4S)-N-((S)-1-((2-Amino-2-oxoethyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-4-azido-5-
oxopyrrolidine-2-carboxamide (TVC-109, 32b) 
Starting material 31b (46 mg, 0.27 mmol) afforded tripeptide TVC-109 (67 mg, 60%). 
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1
H-NMR
 
(400 MHz, CD3OD): δ = 7.6 (d, J = 7.8 Hz, 1H, 9-H), 7.36(d, 
J = 7.8 Hz, 1H, 12-H), 7.14 (s, 1H, 7-H), 7.12 (t, J = 7.4 Hz, 1H, 11-
H), 7.04 (t, J = 7.4 Hz, 1H, 10-H), 4.7 (dd, J = 6.5 Hz, J = 8.8 Hz, 1H, 
4-H), 4.1 (dd, J = 3.0 Hz, J = 8.4 Hz, 1H, 17-H), 4.0 (t, J = 8.4 Hz, 1H, 
15-H), 3.9 (d, J = 17 Hz, 1H, 2-H), 3.7 (d, J = 17 Hz, 1H, 2-H), 3.40 
(m, 1H, 5-H), 3.2 (m, 1H, 5-H), 2.0-1.9 (m, 2H, 16-H). 
13
C-NMR (100 
MHz, CD3OD): δ = 176.8 (18-C), 174.4 (14-C),174.2 (3-C), 174.1 (1-
C), 138.0 (13-C), 128.7 (8-C), 124.6 (7-C), 122.6 (11-C), 119.9 (10-C), 
119.0 (9-C), 112.4 (12-C), 110.8 (6-C), 59.4 (15-C), 55.8 (4-C), 54.9 (17-C), 43.2 (2-C), 33.2 (16-C), 
28.6 (5-C). IR (neat) ν (cm-1): 2112.5 (N3), 1653.5 (CO). HPLC-ESI-MS: m/z (%) = 413.2 (100) 
[M+H]
+
. HR-ESI-MS (m/z): calcd. for C18H20N8O4Na [M+Na]
+ 
435.1500; found 435.1498. Rf = 0.23 
(DCM/MeOH, 6/1). 
(2S,4R)-N-((S)-1-((2-Amino-2-oxoethyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-4-azido-5-
oxopyrrolidine-2-carboxamide (TVC-112, 32a) 
Starting material 31a (37 mg, 0.21 mmol) yielded peptide TVC-112 
(58.7 mg, 66%). 
1
H-NMR
 
(600 MHz, CD3OD): δ = 7.6 (d, J = 7.8 Hz, 1H, 9-H), 
7.36(d, J = 7.8 Hz, 1H, 12-H), 7.14 (s, 1H, 7-H), 7.12 (t, J = 7.4 Hz, 
1H, 11-H), 7.04 (t, J = 7.4 Hz, 1H, 10-H), 4.7 (dd, J = 6.5 Hz, J = 8.8 
Hz, 1H, 4-H), 4.1 (dd, J = 3.0 Hz, J = 8.4 Hz, 1H, 17-H), 4.0 (t, J = 8.4 
Hz, 1H, 15-H), 3.9 (d, J = 17 Hz, 1H, 2-H), 3.7 (d, J = 17 Hz, 1H, 2-
H), 3.40 (m, 1H, 5-H), 3.2 (m, 1H, 5-H), 2.0-1.9 (m, 2H, 16-H). 
13
C-NMR (150 MHz, CD3OD): δ = 
176.7 (18-C), 174.4 (14-C),174.3 (3-C), 174.2 (1-C), 138.0 (13-C), 128.7 (8-C), 124.7 (7-C), 122.6 (11-
C), 119.9 (10-C), 119.3 (9-C), 112.5 (12-C), 110.7 (6-C), 59.1 (15-C), 56.2 (4-C), 55.0 (17-C), 43.2 (2-
C), 33.2 (16-C), 28.3 (5-C). IR (neat) ν (cm-1): 2112.5 (N3), 1653.5 (CO). HPLC-ESI-MS: m/z (%) = 
413.2 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C18H20N8O4Na [M+Na]
+ 
435.1500; found 435.1498. 
Rf = 0.20 (DCM/MeOH, 7/1). 
General procedure for hydrogenation  
A suspension of azide compound and Pd/C (10 wt%) in MeOH was stirred under hydrogen atmosphere 
for 16 h. The Pd/C catalyst was removed by filtration through a Celite pad. Removal of the solvent gave 
the desired product as a solid. 
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(2S,4R)-4-Amino-N-((S)-1-((2-amino-2-oxoethyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-5-oxo-
pyrrolidine-2-carboxamide (TVC-114, 33a) 
Azide TVC-112 (60 mg, 0.15 mmol) provided amine 33a (53.8 mg, 
96%).  
1
H-NMR
 
(400 MHz, DMSO-d6): δ = 10.8 (s, 1H, NH), 8.3 (bs. 2H, 
NH), 8.26 (s, 1H, NH), 7.6 (d, J = 7.6 Hz, 1H, 9-H), 7.3 (d, J = 7.6 
Hz, 1H, 12-H), 7.1 (bs, 1H, 7-H), 7.0 (br, 1H, 11-H), 6.9 (t, J = 7.4 
Hz, 1H, 10-H), 4.5 (m, 1H, 4-H), 4.0 (d, J = 8.5 Hz, 1H, 15-H), 3.7 
(dd, J = 2.0 Hz,  J = 17 Hz, 1H, 2-H), 3.6 (dd, J = 2.0 Hz, J = 17 Hz, 
1H, 2-H), 3.5 (overlap, 1H, 17-H), 3.17 (m, 1H, 5-H),.3.0 (m, 1H, 5-
H). 2.2-2.1 (m, 2H, 16-H). 
13
C-NMR (100 MHz, DMSO-d6): δ = 174.3 (18-C), 171.9 (14-C),171.5 (3-C), 
170.8 (1-C), 136.0 (13-C), 127.2 (8-C), 125.7 (7-C), 120.8 (11-C), 118.4 (10-C), 118.2 (9-C), 111.3 (12-
C), 109.7 (6-C), 54.8 (4-C), 53.8 (15-C), 49.1 (17-C), 41.9 (2-C), 32.2 (16-C), 27.4 (5-C). IR (neat) ν 
(cm
-1
):1673.8 (CO). HPLC-ESI-MS: m/z (%) = 387.1 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for 
C18H23N6O4
 
[M+H]
+ 
387.1775; found 387.1774. Rf = 0.11 (DCM/MeOH, 1/1). 
(2R,4S)-4-Amino-N-((S)-1-((2-amino-2-oxoethyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-5-oxo-
pyrrolidine-2-carboxamide (TVC-115, 33b)  
Azide TVC-109 (90 mg, 0.22 mmol) yielded free amine 33b (80.4 
mg, 95%). 
1
H-NMR
 
(600 MHz, CD3OD): δ = 7.6 (d, J = 7.6 Hz, 1H, 9-H), 7.3 
(d, J = 7.6 Hz, 1H, 12-H), 7.1 (bs, 1H, 7-H), 7.0 (br, 1H, 11-H), 6.9 (t, 
J = 7.4 Hz, 1H, 10-H), 4.5 (m, 1H, 4-H), 4.0 (d, J = 8.5 Hz, 1H, 15-
H), 3.7 (dd, J = 2.0 Hz, J = 17 Hz, 1H, 2-H), 3.6 (dd, J = 2.0 Hz, J = 
17 Hz, 1H, 2-H), 3.5 (overlap, 1H, 17-H), 3.17 (m, 1H, 5-H),.3.0 (m, 
1H, 5-H). 2.2-2.1 (m, 2H, 16-H). 
13
C-NMR (150 MHz, CD3OD): δ = 179.3 (18-C), 174.8 (14-C),174.5 
(3-C), 174.6 (1-C), 138.5 (13-C), 128.8 (8-C), 125.1 (7-C), 121.4 (11-C), 120.4 (10-C), 119.7 (9-C), 
112.5 (12-C), 111.2 (6-C), 56.5 (4-C), 55.2 (15-C), 51.6 (17-C), 42.6 (2-C), 34.9 (16-C), 29.0 (5-C). IR 
(neat) ν (cm-1):1674.4 (CO). HPLC-ESI-MS: m/z (%) = 387.1 (100) [M+H]+. HR-ESI-MS (m/z): calcd. 
for C18H23N6O4
 
[M+H]
+ 
387.1775; found 387.1774. Rf = 0.09 (DCM/MeOH, 1/1). 
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General procedure for preparation of penta- or hexapeptide 
To a solution of tripeptide H-APy-Trp-Gly-NH2 (1.0 equiv) and dipeptide Boc-Tyr(tBu)-Phe-OH (1.2 
equiv) or tripeptide Boc-Tyr(tBu)-Phe-Ser(tBu)-OH (1.2 equiv) in DMF, HATU (1.3 equiv) and DIPEA 
(5 equiv) were added. The resulting solution was stirred for 20 h at room temperature and the solvent was 
removed to dryness. The residue was purified by silica gel column chromatography eluting DCM/MeOH 
(8/1). 
tert-Butyl-((S)-1-(((S)-1-(((3R,5S)-5-(((S)-1-((2-amino-2-oxoethyl)amino)-3-(1H-indol-3-yl)-1-oxo-
propan-2-yl)carbamoyl)-2-oxopyrrolidin-3-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-3-(4-(tert-
butoxy)phenyl)-1-oxopropan-2-yl)carbamate (TVC-132)  
Amine 33a (40 mg, 103.5 µmol) yielded product 
TVC-132 (58 mg, 66%) as a solid. 
1
H-NMR
 
(400 MHz, DMSO-d6): δ = 7.6 (d, J = 
8.0 Hz, 1H, 9-H), 7.32 (d, J = 8.0 Hz, 1H, 12-H), 
7.25-7.24 (m, 4H, 25-H, 26-H), 7.18 (m, 1H, 25-
H), 7.17 (s, 1H, 7-H), 7.06 (overlap, 3H, 11-H, 30-
H), 6.98 (t, J = 7.2 Hz, 1H, 10-H), 6.85 (d, J = 8.0 
Hz, 2H, 31-H), 4.57 (overlap, 1H, 20-H), 4.54 (t, J 
= 7.0 Hz, 1H, 4-H), 4.30 (q, J = 9.0 Hz, 1H, 17-H), 4.13 (m, 1H, 27-H), 4.02 (m, 1H, 15-H), 3.7 (dd, J = 
5.0 Hz, J = 17.0 Hz, 1H, 2-H), 3.6 (dd, J = 5.0 Hz, J = 17.0 Hz, 1H, 2-H), 3.17-3.0 (m, 2H, 5-H), 2.94 
(m, H, 21-H), 2.83 (overlap, 1H, 21-H), 2.82 (m, 1H, 28-H), 2.59 (t, J = 10.0 Hz, 1H, 28-H), 2.11 (t, J = 
9.2 Hz, 1H, 16-H), 1.83 (t, J = 9.3 Hz, 1H, 16-H), 1.28 (s, 9H, 34-H), 1.25 (s, 9H, 37-H). 
13
C-NMR (100 
MHz, DMSO-d6): δ = 176.5 (18-C), 172.0 (3-C), 171.5 (19-C), 171.4 (14-C), 171.2 (26-C), 170.8 (1-C), 
155.0 (35-C), 153.3 (32-C), 139.4 (22-C), 136.0 (13-C), 130.2 (30-C), 129.8 (24-C), 128.4 (23-C), 126.8 
(25-C), 127.2 (8-C), 123.8 (31-C), 124.2 (7-C), 121.4 (11-C), 118.8 (9-C), 118.2 (10-C), 111.7 (12-C), 
109.7 (6-C), 78.0 (33-C), 77.5 (36-C), 56.2 (27-C), 53.9 (4-C), 52.7 (15-C), 48.6 (17-C), 42.4 (2-C), 37.4 
(28-C), 33.0 (16-C), 29.0 (37-C), 28.4 (34-C), 27.8 (5-C). IR (KBr) ν (cm-1): 1643.8 (CO). HPLC-ESI-
MS: m/z (%) = 870.5 (100) [M+NH4]
+
, 853.4 (50) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C45H56N8O9Na 
[M+Na]
+ 
875.4062; found 875.4065. Rf = 0.23 (DCM/MeOH, 7/1). 
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tert-Butyl-((S)-1-(((S)-1-(((3S,5R)-5-(((S)-1-((2-amino-2-oxoethyl)amino)-3-(1H-indol-3-yl)-1-
oxopropan-2-yl)carbamoyl)-2-oxopyrrolidin-3-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-3-(4-
(tert-butoxy)phenyl)-1-oxopropan-2-yl)carbamate (TVC-131) 
Amine 33b (50 mg, 129.4 µmol) afforded product 
TVC-131 (75 mg, 68 %) as a solid. 
1
H-NMR
 
(600 MHz, CD3OD): δ = 7.6 (d, J = 8.0 
Hz, 1H, 9-H), 7.35 (d, J = 8.0 Hz, 1H, 12-H), 7.28-
7.25 (m, 4H, 23-H, 24-H), 7.21 (m, 1H, 25-H), 7.16 
(s, 1H, 7-H), 7.1 (overlap, 2H, 11-H, 30-H), 7.03 (t, 
J = 7.2 Hz, 1H, 10-H), 6.89 (d, J = 8.0 Hz, 2H, 31-
H), 4.68 (t, J = 7.0 Hz, 1H, 4-H), 4.36 (t, J = 9.0 
Hz, 1H, 17-H), 4.23 (dd, J = 5.0 Hz, J = 10.0 Hz, 1H, 27-H), 4.19 (dd, J = 2.0 Hz, J = 9.0 Hz, 1H, 15-
H), 3.9 (d, J = 17.0 Hz, 1H, 2-H), 3.68 (d, J = 17.0 Hz, 1H, 2-H), 3.36 (m, 1H, 5-H), 3.17 (overlap, 2H, 
5-H, 21-H), 2.98 (m, 1H, 21-H), 2.96 (m, 1H, 28-H), 2.67 (m, 1H, 21-H), 2.18 (m, 1H, 16-H), 2.08 (m, 
1H, 16-H), 1.36 (s, 9H, 34-H), 1.31 (s, 9H, 37-H). 
13
C-NMR (150 MHz, CD3OD): δ = 174.7 (3-C), 174.2 
(14-C), 174.1 (26-C), 173.2 (1-C), 157.8 (35-C), 148.6 (32-C), 138.2 (22-C), 138.0 (13-C), 129.4 (30-C), 
129.1 (24-C), 128.0 (23-C), 126.2 (25-C), 127.7 (8-C), 123.7 (31-C), 123.1 (7-C), 121.1 (11-C), 119.9 
(10-C), 119.2 (9-C), 112.4 (12-C), 110.7 (6-C), 80.8 (33-C), 79.5 (36-C), 56.3 (27-C), 54.0 (4-C), 53.3 
(15-C), 49.3 (17-C), 41.8 (2-C), 36.8 (28-C), 31.8 (16-C), 27.8 (34-C), 27.2 (37-C), 27.0 (5-C). IR (KBr) 
ν (cm-1): 1639.8 (CO). HPLC-ESI-MS: m/z (%) = 870.5 (100) [M+NH4]
+
, 853.4 (50) [M+H]
+
. HR-ESI-
MS (m/z): calcd. for C45H56N8O9Na
 
[M+Na]
+ 
875.4062; found 875.4065. Rf = 0.25 (DCM/MeOH, 7/1). 
tert-Butyl-((S)-1-(((S)-1-(((S)-1-(((3S,5R)-5-(((S)-1-((2-amino-2-oxoethyl)amino)-3-(1H-indol-3-yl)-1-
oxopropan-2-yl)carbamoyl)-2-oxopyrrolidin-3-yl)amino)-3-(tert-butoxy)-1-oxopropan-2-yl)amino)-
1-oxo-3-phenylpropan-2-yl)amino)-3-(4-(tert-butoxy)phenyl)-1-oxopropan-2-yl)carbamate (TVC-
118)  
Starting material 33b (46 mg, 119.0 µmol) 
provided the solid product TVC-118 (79 
mg, 66%). 
1
H-NMR
 
(600 MHz, DMSO-d6): δ = 10.8 
(s, 1H, NH), 8.3 (m, 2H, NH), 8.1 (bs, 2H, 
NH), 8.0 (d, J = 8.0 Hz, 1H, NH), 7.9 (d, J 
= 8.0 Hz, 1H, NH), 7.58 (d, J = 8.0 Hz, 1H, 
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9-H), 7.3 (d, J = 8.0 Hz, 1H, 12-H), 7.25-7.23 (m, 5H, 25-H, 26-H, 27-H), 7.16 (overlap, 1H, 7-H), 7.05 
(overlap, 2H, 32-H), 7.03 (overlap, 1H, 11-H), 6.96 (t, J = 7.0 Hz, 1H, 10-H), 6.84 (t, J = 8.0 Hz, 2H, 33-
H), 4.65 (m, 1H, 22-H), 4.58 (q, J = 8.3 Hz, 1H, 4-H), 4.33 (q, J = 5.0 Hz, 1H, 20-H), 4.23 (q, J = 9.0 
Hz, 1H, 17-H), 4.08 (overlap, 2H, 15-H, 29-H), 3.7(dd, J = 6.0 Hz, 17.0 Hz, 1H, 2-C), 3.6 (dd, J = 6.0 
Hz, 17.0 Hz, 1H, 2-C), 3.46 (bs, 1H, 35-H), 3.17 (dd, J = 5.0 Hz, J = 14.0 Hz, 1H, 5-H), 3.06 (dd, J = 5.0 
Hz, J = 14.0 Hz, 1H, 23-H), 2.99 (m, 1H, 5-H), 2.8 (m, 2H, 23-H, 30-H), 2.6 (t, J = 10.0 Hz, 1H, 30-H), 
1.98 (m, 2H, 16-H), 1.28 (s, 9H, 37-H), 1.25 (s, 9H, 37-H), 1.12 (s, 9H, 42-H). 
13
C-NMR (150 MHz, 
DMSO-d6): δ = 177.4 (18-C), 174.3 (3-C), 172. 7 (19-C), 171.3 (21-C), 170.2 (14-C), 169.5 (28-C), 154.9 
(40-C), 153.3 (34-C), 137.5 (24-C), 136.0 (13-C), 130.1 (32-C), 129.9 (26-C), 128.6 (25-C), 127.3 (8-C), 
126.6 (27-C), 126.1 (31-C), 124.1 (7-C), 123.4 (33-C), 121.3 (11-C), 118.9 (9-C), 118.7 (10-C), 111.8 
(12-C), 109.7 (6-C), 77.9 (38-C), 77.5 (36-C), 72.8 (41-C), 62.5 (35-C), 56.3 (29-C), 54.0 (4-C), 53.8 (20-
C), 52.8 (15-C), 49.2 (17-C), 42.5 (2-C), 38.1 (23-C), 37.4 (30-C), 32.8 (16-C), 28.4 (37-C), 28.9 (39-C), 
27.8 (5-C). IR (neat) ν (cm-1): 1668.4 (CO). HPLC-ESI-MS: m/z (%) = 996.5 (100) [M+H]+. HR-ESI-
MS (m/z): calcd. for C52H69N9O11Na [M+Na]
+ 
1018.5009; found 1018.4996. Rf = 0.26 (DCM/MeOH, 
15/1). 
tert-Butyl-((S)-1-(((S)-1-(((S)-1-(((3R,5R)-5-(((S)-1-((2-amino-2-oxoethyl)amino)-3-(1H-indol-3-yl)-1-
oxopropan-2-yl)carbamoyl)-2-oxopyrrolidin-3-yl)amino)-3-(tert-butoxy)-1-oxopropan-2-yl)amino)-
1-oxo-3-phenylpropan-2-yl)amino)-3-(4-(tert-butoxy)phenyl)-1-oxopropan-2-yl)carbamate (TVC-
116)  
Starting material 33a (50 mg, 129.4 
µmol) furnished the solid product 
TVC-116 (127.3 mg, 98%). 
1
H-NMR
 
(600 MHz, CD3OD): δ = 
7.6 (d, J = 7.6 Hz, 1H, 9-H), 7.3 (d, 
J = 7.6 Hz, 1H, 12-H), 7.3-7.2 (m, 
5H, 25-H, 26-H, 27-H), 7.16 (s, 1H, 
7-H), 7.12 (overlap, 1H, 32-H), 7.1 
(overlap, 1H, 11-H), 7.05 (t, J = 7.6 Hz, 1H, 10-H), 6.9 (d, J = 7.7 Hz, 1H, 33-H), 4.67 (t, J = 7.5 Hz, 1H, 
22-H), 4.64 (t, J = 7.0 Hz, 1H, 29-H), 4.44 (t, J = 5.0 Hz, 1H, 20-H), 4.4 (t, J = 9.0 Hz, 1H, 17-H), 4.29 
(dd, J = 5 Hz, J = 10.0 Hz, 1H, 4-H), 4.19 (d, J = 7.5 Hz, 1H, 15-H), 3.9 (d, J = 17 Hz, 1H, 2-H), 3.66 
(overlap, 1H, 35-H), 3.57 (t, J = 5.0 Hz, 1H, 35-H), 3.6 (d, J = 17 Hz, 1H, 2-H), 3.02 (overlap, 1H, 5-
H),.2.71 (t, J = 11.0 Hz, 1H, 5-H). 2.3-2.2 (m, 2H, 16-H), 1.32 (18H, 39-H, 37-H), 1.28 (s, 9H, 42-H). 
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13
C-NMR (150 MHz, CD3OD): δ = 177.4 (18-C), 174.3 (21-C), 174.3 (28-C),174.4 (19-C), 173 (3-C), 
172.2 (14-C), 171.6 (1-C), 155.2 (40-C), 148.7 (34-C), 138.1 (13-C), 133.7 (24-C), 130.8 (26-C), 130.4 
(31-C), 130.0 (33-C), 129.6 (25-C), 128.6 (27-C), 126.1 (8-C), 124.7 (7-C), 123.0 (32-C), 122.7 (11-C), 
119.9 (10-C), 119.3 (9-C), 112.4 (12-C), 110.7 (6-C), 80.7 (38-C), 79.5 (36-C), 61.1 (35-C), 55.8 (4-C), 
54.4 (29-C), 53.7 (20-C), 53.4 (15-C), 49.8 (17-C), 41.9 (2-C), 38.9 (23-C), 38.5 (30-C), 32.3 (16-C), 
29.2 (37-C, 37-C), 28.7 (42-C), 27.8 (5-C). IR (neat) ν (cm-1): 1670.3 (CO). HPLC-ESI-MS: m/z (%) = 
996.5 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C52H69N9O11Na [M+Na]
+ 
1018.5009; found 
1018.4996. Rf = 0.29 (DCM/MeOH, 10/1). 
General procedure for N-Boc and O-tBu deprotection 
Peptides were treated with TFA/TIPS/H2O (2 mL, 95:4:1) at 0 
o
C for 4-5 h. The reaction mixtures were 
concentrated under reduced pressure, then purified by silica gel column chromatography using 
DCM/MeOH (gradient from 8/1 to 5/1, 0.1% TEA). The products were lyophilized in ACN/H2O to obtain 
white powders. 
(2R,4S)-N-((S)-1-((2-Amino-2-oxoethyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-4-((S)-2-((S)-2-
amino-3-(4-hydroxyphenyl)propanamido)-3-phenylpropanamido)-5-oxo-pyrrolidine-2-carbox-
amide (TVC-135, 34a) 
 
Pentapeptide TVC-131 (16 mg, 19 µmol) yielded product 
34a (11.2 mg, 86%).  
1
H-NMR
 
(600 MHz, CD3OD): δ = 7.6 (d, J = 7.7 Hz, 1H, 
9-H), 7.36 (d, J = 8.2 Hz, 1H, 12-H), 7.29-7.28 (m, 4H, 23-
H, 24-H), 7.22 (m, 1H, 25-H), 7.16 (s, 1H, 7-H), 7.1 
(overlap, 2H, 11-H, 30-H), 7.04 (t, J = 7.7 Hz, 1H, 10-H), 
6.78 (d, J = 9.0 Hz, 2H, 31-H), 4.68 (t, J = 7.0 Hz, 1H, 4-
H), 4.65 (t, J = 6.0 Hz, 1H, 20-H), 4.37 (t, J = 9.0 Hz, 1H, 
17-H), 4.02 (dd, J = 5.0 Hz, J = 8.0 Hz, 1H, 27-H), 4.19 (dd, J = 2.0 Hz, J = 9.0 Hz, 1H, 15-H), 3.9 (d, J 
= 17.0 Hz, 1H, 2-H), 3.66 (d, J = 17.0 Hz, 1H, 2-H), 3.34 (m, 1H, 5-H), 3.19 (overlap, 3H, 5-H, 21-H, 
28-H), 2.98 (m, 1H, 21-H), 2.93 (m, 1H, 28-H), 2.20- 2.18 (m, 2H, 16-H). 
13
C-NMR (150 MHz, 
CD3OD): δ = 177.5 (18-C), 174.6 (3-C), 174.4 (19-C), 174.2 (14-C), 172.9 (26-C), 169.6 (1-C), 158.3 
(32-C), 138.1 (22-C), 138.0 (13-C), 130.3 (30-C), 128.8 (24-C), 128.0 (23-C), 126.4 (25-C), 128.7 (8-C), 
123.0 (7-C), 121.1 (11-C), 118.4 (10-C), 117.4 (9-C), 112.4 (12-C), 115.4 (31-C), 110.7 (6-C), 54.8 (4-
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C), 54.1 (27-C), 53.3 (15-C), 49.3 (17-C), 41.7 (2-C), 36.1 (28-C), 31.7 (16-C), 27.1 (5-C). HPLC-ESI-
MS: m/z (%) = 697.3 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C36H41N8O7
 
[M+H]
+ 
697.3093; found 
697.3094.  
(2S,4R)-N-((S)-1-((2-Amino-2-oxoethyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-4-((S)-2-((S)-2-
amino-3-(4-hydroxyphenyl)propanamido)-3-phenylpropanamido)-5-oxopyrro-lidine-2-carbox-
amide (TVC-134, 34b) 
Peptide TVC-132 (16.5 mg, 19.3 µmol) provided 34b (12.4 
mg, 92%). 
1
H-NMR
 
(600 MHz, CD3OD): δ = 7.6 (d, J = 7.8 Hz, 1H, 
9-H), 7.35 (d, J = 8.0 Hz, 1H, 12-H), 7.27-7.24 (m, 4H, 23-
H, 24-H), 7.2 (m, 1H, 25-H), 7.15 (s, 1H, 7-H), 7.09 
(overlap, 2H, 11-H, 30-H), 7.03 (t, J = 7.3 Hz, 1H, 10-H), 
6.78 (d, J = 9.0 Hz, 2H, 31-H), 4.62 (t, J = 7.0 Hz, 1H, 4-
H), 4.63 (t, J = 7.0 Hz, 1H, 20-H), 4.35 (t, J = 9.2 Hz, 1H, 
17-H), 4.02 (d, J = 7.0 Hz, 1H, 27-H), 4.1 (d, J = 8.0 Hz, 1H, 15-H), 3.9 (d, J = 17.0 Hz, 1H, 2-H), 3.63 
(d, J = 17.0 Hz, 1H, 2-H), 3.32 (m, 1H, 5-H), 3.18 (t, J = 8.0 Hz, 1H, 5-H), 3.13 (dd, J = 4 Hz, J = 13.4 
Hz, 1H, 28-H), 3.07 (m, 1H, 21-H), 2.98 (t, J = 5.0 Hz, 1H, 21-H), 2.93 (dd, J = 4 Hz, J = 13.4 Hz, 1H, 
28-H), 2.18 (t, J = 10.0 Hz, 1H, 16-H), 1.94 (m, 1H, 16-H). 
13
C-NMR (150 MHz, CD3OD): δ = 177.4 
(18-C), 174.7 (3-C), 174.5 (19-C), 174.2 (14-C), 172.6 (26-C), 169.4 (1-C), 158.2 (32-C), 138.0 (22-C), 
137.9 (13-C), 130.2 (30-C), 129.0 (24-C), 128.1 (23-C), 126.4 (25-C), 127.7 (8-C), 123.2 (7-C), 121.1 
(11-C), 118.4 (10-C), 117.9 (9-C), 112.4 (12-C), 116.9 (31-C), 110.6 (6-C), 54.8 (4-C), 54.3 (27-C), 53.3 
(15-C), 48.9 (17-C), 41.8 (2-C), 36.2 (28-C), 32.1 (16-C), 27.0 (5-C). HPLC-ESI-MS: m/z (%) = 697.3 
(100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C36H41N8O7
 
[M+H]
+ 
697.3093; found 697.3094. 
(2R,4S)-N-((S)-1-((2-Amino-2-oxoethyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-4-((S)-2-((S)-2-
((S)-2-amino-3-(4-hydroxyphenyl)propanamido)-3-phenylpropanamido)-3-hydroxypropanamido)-
5-oxopyrrolidine-2-carboxamide (TVC-119, 35a) 
Peptide TVC-118 (30 mg, 30 µmol) yielded product 35a (19 mg, 81%). 
1
H-NMR
 
(400 MHz, CD3OD): δ = 7.6 (d, J = 8.1 Hz, 1H, 9-H), 7.35 (d, J = 7 Hz, 1H, 12-H), 7.28-7.25 
(m, 4H, 25-H, 26-H), 7.2 (m, 1H, 27-H), 7.16 (s, 1H, 7-H), 7.1 (d, J = 8.0 Hz, 2H, 32-H), 7.1 (overlap, 
1H, 11-H), 7.05 (t, J = 7.0 Hz, 1H, 10-H), 6.8 (d, J = 8.0 Hz, 2H, 33-H), 4.74 (dd, J = 6.0 Hz, J = 9.0 Hz, 
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1H, 22-H), 4.68 (t, J = 8.0 Hz, 1H, 4-H), 4.41 
(overlap, 1H, 17-H, 20-H), 4.18 (d, J = 7.3 Hz, 
1H, 15-H), 4.02 (dd, J = 5.0 Hz, J = 8.4 Hz, 29-
H), 3.9 (d, J = 17.0 Hz, 1H, 2-H), 3.83-3.78 (m, 
2H, 35-H), 3.68 (d, J = 17.0 Hz, 1H, 2-H), 3.35 
(d, J = 6.0 Hz, 1H, 5-H), 3.18 (m, 1H, 5-H), 3.22 
(overlap, 1H, 23-H), 3.0 (m, 1H, 23-H), 3.18 
(overlap, 1H, 30-H), 2.92 (m, 1H, 30-H), 2.2-2.16 
(m, 2H, 16-H). 
13
C-NMR (100 MHz, CD3OD): δ = 177.8 (18-C), 174.5 (3-C), 174.1 (21-C), 172.9 (19-
C), 172.1(14-C) , 172.2 (28-C), 169.9 (1-C), 158.3 (34-C), 138.2 (24-C), 138.0 (13-C), 131.6 (31-C), 
130.3 (32-C), 128.9 (26-C), 128.3 (25-C), 127.9 (8-C), 126.5 (27-C), 123.2 (7-C), 121.3 (11-C), 118.5 
(10-C), 118.0 (9-C), 115.6 (33-C), 112.0 (12-C), 110.7 (6-C), 61.7 (35-C), 55.3 (20-C), 55.0 (22-C), 54.7 
(4-C), 54.3 (29-C), 53.4 (15-C), 49.5 (17-C), 41.8 (2-C), 37.2 (23-C), 36.2 (30-C), 32.0 (16-C), 27.2 (5-
C). HPLC-ESI-MS: m/z (%) = 784.2 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C39H46N9O9
 
[M+H]
+ 
784.3413; found 784.3410. 
(2S,4R)-N-((S)-1-((2-Amino-2-oxoethyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-4-((S)-2-((S)-2-
((S)-2-amino-3-(4-hydroxyphenyl)propanamido)-3-phenylpropanamido)-3-hydroxypropanamido)-
5-oxopyrrolidine-2-carboxamide (TVC-117, 35b) 
Peptide TVC-116 (40 mg, 0.04 mmol) afforded 
35b (30 mg, 95%). 
1
H-NMR
 
(600 MHz, CD3OD): δ = 7.61 (d, J = 
8.1 Hz, 1H, 9-H), 7.36 (d, J = 7 Hz, 1H, 12-H), 
7.3-7.25 (m, 4H, 25-H, 26-H), 7.23 (m, 1H, 27-
H), 7.16 (s, 1H, 7-H), 7.12 (d, J = 8.0 Hz, 2H, 32-
H), 7.11 (overlap, 1H, 11-H), 7.05 (t, J = 7.0 Hz, 
1H, 10-H), 6.8 (d, J = 8.0 Hz, 2H, 33-H), 4.7 (dd, J = 6.0 Hz, J = 9.0 Hz, 1H, 22-H), 4.64 (t, J = 8.0 Hz, 
1H, 4-H), 4.43 (t, J = 5.0 Hz, 1H, 20-H), 4.18 (dd, J = 1.2 Hz, J = 9.0 Hz, 1H, 15-H), 4.02 (dd, J = 5.0 
Hz, J = 8.4 Hz, 29-H), 3.9 (d, J = 17.0 Hz, 1H, 2-H), 3.89 (dd, J = 5.0 Hz, J = 11.0 Hz, 1H, 35-H), 3.76 
(overlap, 1H, 35-H), 3.6 (d, J = 17.0 Hz, 1H, 2-H), 3.34 (m, 1H, 5-H), 3.2 (m, 1H, 5-H), 3.22 (overlap, 
1H, 23-H), 3.0 (m, 1H, 23-H), 3.19 (overlap, 1H, 30-H), 2.94 (m, 1H, 30-H), 2.32 (m, 1H, 16-H), 2.25 
(m, 1H, 16-H). 
13
C-NMR (150 MHz, CD3OD): δ = 177.7 (18-C), 174.7 (3-C), 174.4 (19-C), 174.3 (21-
C), 173.0 (14-C) , 172.2 (28-C), 171.0 (1-C), 158.1 (34-C), 138.1 (13-C), 138.0 (24-C), 130.1 (32-C), 
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129.6 (31-C), 128.6 (26-C), 128.1 (25-C), 127.9 (8-C), 126.5 (27-C), 123.7 (7-C), 121.0 (11-C), 118.3 
(10-C), 117.6 (9-C), 115.4 (33-C), 112.4 (12-C), 110.7 (6-C), 61.5 (35-C), 55.1 (22-C), 55.0 (20-C), 54.8 
(4-C), 54.2 (29-C), 53.4 (15-C), 49.4 (17-C), 41.9 (2-C), 37.0 (23-C), 36.2 (30-C), 32.0 (16-C), 26.8 (5-
C). HPLC-ESI-MS: m/z (%) = 784.2 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C39H46N9O9
 
[M+H]
+ 
784.3413; found 784.3410. 
 
3.7 Synthesis of 2-oxo-piperazine containing helicokinin I analogue TVC-051 (47) 
tert-Butyl-(2S)-3-methyl-2-(2-nitrobenzenesulfonamido)butanoate (TVC-002, 37) 
To a stirred solution of L-valine-tert-butylester hydrochloride (2.20 g, 
10.49 mmol) and TEA (2.9 ml, 20.98 mmol) in DCM  (15 mL) at 0 
o
C, a 
solution of 2-nitrophenylsulfonyl chloride (2.79 g, 12.59 mmol) in DCM 
(20 mL) was added dropwise. After stirring at room temperature for 20 h, 
DCM (100 mL) was added. The organic phase was washed with H2O (2x10 mL), brine solution and dried 
over Na2SO4. Removal of the solvent and flash chromatography (eluent: CyH/EtOAc, 20/1) provided 37 
(3.7 g, 98%) as a brown solid. 
1
H-NMR (600 MHz, CDCl3): δ = 8.07 (m, 1H, 7-H), 7.91 (m, 1H, 10-H), 7.70 (m, 2H, 8-H, 9-H), 6.05 
(d, J = 9.79 Hz, NH), 3.88 (dd, J = 9.82 Hz, J = 5.1 Hz, 1H, 2-H), 2.13 (m, 1H, 3-H), 1.4 (s, 9H, 12-H), 
1.03 (d, J = 6.82 Hz, 3H, 4-H), 0.94 (d, J = 6.82 Hz, 3H, 4’-H). 13C-NMR (150 MHz, CDCl3): δ = 169.7 
(C-1), 147.8 (C-6), 134.4 (C-5), 133.4 (C-8), 132.8 (C-9), 130.5 (C-10), 124.5 (C-7), 82.4 (C-11), 62.7 
(C-2), 31.6, 31.3 (C-3), 27.6 (C-12), 17.3 (C-4). IR (KBr) ν (cm-1): 3340.5 (NH), 1712.4 (CO). HPLC-
ESI-MS: m/z (%) = 257.0 (100), 376.1 (71) [M+NH4]
+
. HR-ESI-MS (m/z): calcd. for C15H22N2O6SNa
 
[M+Na]
+
 381.1096; found 381.1091. Rf = 0.4 (CyH/EtOAc, 15/1)  
(2S)-3-Methyl-2-(2-nitrobenzenesulfonamido)butanoic acid (TVC-003, 38) 
A solution of (S)-tert-butyl-3-methyl-2-(2-nitrophenylsulfonamido)butanoate 
37 (100 mg, 0.28 mmol) in TFA/DCM (2 mL, 1/1) was stirred at 0 
o
C for 3 h. 
The solvent was evaporated under diminished pressure. The crude product was 
purified by silica gel column chromatography (EtOAc, 1% AcOH) to afford 
acid 38 (74 mg, 87%) as a yellow solid. 
1
H-NMR (600 MHz, CDCl3): δ = 8.10 (m, 1H, 7-H), 7.94 (m, 1H, 10-H), 7.75 (m, 2H, 8-H. 9-H), 6.04 
(d, J = 9.67 Hz, 1H, NH), 4.08 (dd, J = 9.46 Hz, J = 4.78 Hz, 1H, 2-H), 2.25 (m, 1H, 3-H), 1.06 (d, J = 
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6.83 Hz, 3H, 4-H), 0.96 (d, J = 6.83 Hz, 3H, 4’-H). 13C-NMR (150 MHz, CDCl3): δ = 175.6 (1-C), 147.6 
(6-C), 134 (5-C), 133.8 (8-C), 132.9 (9-C), 130.3 (10-C), 125.5 (7-C), 61.7 (2-C), 31.3 (3-C), 18.9 (4-C), 
17.2 (4’-C). IR (KBr) ν (cm-1): 3350.2 (NH), 1713.9 (CO). HPLC-ESI-MS: m/z (%) = 320.1 (100) 
[M+NH4]
+
, 303.1 (24) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C11H14N2O6SNa
 
[M+Na]
+
 325.0470, found 
325.0465. Rf = 0.21 (EtOAc/AcOH, 10/0.1).  
Methyl-(2S)-3-(1H-indol-3-yl)-2-[(2S)-3-methyl-2-(2-nitrobenzenesulfonamido)butanamido] 
propanoate (TVC-005, 39) 
To a solution of (2S)-3-methyl-2-(2-nitrophenyl-sulfonamido)- 
butanoic acid 38 (70 mg, 0.23 mmol), L-trytophanmethyl ester 
(60.6 mg, 0.28 mmol) and TBTU (89.2 mg, 0.28 mmol) in DCM 
(5 mL), DIPEA (0.11 mL, 0.69 mmol) was added dropwise. 
After stirring at room temperature for 24 h, the solvent was 
removed under reduced pressure to dryness. The residue was 
dissolved in EtOAc (150 mL), washed with H2O (2x10 mL), brine solution and dried over MgSO4. 
Evaporation of the solvent and flash chromatography (eluent: CyH/EtOAc, 5/2) afforded product 39 (106 
mg, 91%) as a slightly yellow solid. 
1
H-NMR (600 MHz, CDCl3): δ = 8.16 (s, 1H, NH), 7.91 (dd, J = 7.89 Hz, J = 1.34 Hz, 1H, 7-H), 7.75 
(dd, J = 8.0 Hz, J = 1.15 Hz, 1H, 10-H), 7.56 (dt, J = 7.7 Hz, J = 1.3 Hz, 1H, 9-H), 7.48 (d, J = 7.90 Hz, 
1H, 17-H), 7.42 (dt, J = 7.8 Hz, J = 1.3 Hz, 1H, 8-H), 7.38 (d, J = 8.4 Hz, 1H, 20-H), 7.23 (dt, J = 7.2 
Hz, J = 1.0 Hz, 1H, 4-H), 7.15 (dt, J = 7.9 Hz, J = 1.0 Hz, 1H, 18-H), 7.03 (d, J = 2.30 Hz, 1H, 15-H), 
4.67 (m, 1H, 12-H), 3.77 (dd, J = 8.45 Hz, J = 5.17 Hz, 1H, 2-H), 3.65 (s, 3H, OCH3), 3.15 (d, J = 5.80 
Hz, 2H, 13-H), 2.10 (m, 1H, 3-H), 0.85 (d, J = 6.81 Hz, 3H, 4-H), 0.77 (d, J =6.81 Hz, 4’-H). 13C-NMR 
(150 MHz, CDCl3): δ = 171.7 (1-C), 169.6 (11-C), 147 (6-C), 136.2 (21-C), 133.8 (5-C), 133.6 (9-C), 
132.7 (8-C), 130.2 (10-C), 127.3 (16-C), 125.4 (7-C), 122.9 (15-C), 122.4 (4-C), 114.7 (18-C), 118.4 (17-
C), 111.4 (20-C), 109.6 (14-C), 63.02 (2-C), 52.8 (-OCH3), 52.4 (12-C), 31.25 (3-C), 27.6 (13-C), 24.0 
(4-C), 17.1 (4’-C). IR (KBr) ν (cm-1): 3358 (NH), 1735.6, 1669.9 (CO). HPLC-ESI-MS: m/z (%) = 
503.2 (100) [M+H]
+
, 525.2 [M+Na]
+
. HR-ESI-MS (m/z): calcd. for C23H26N4O7SNa [M+Na]
+
 525.1414; 
found 525.1414. Rf = 0.15 (CyH/EtOAc, 3/2). 
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Methyl-(2S)-3-(1H-indol-3-yl)-2-[(3S)-4-(2-nitrobenzenesulfonyl)-2-oxo-3-(propan-2-yl)piperazin-1-
yl]propanoate (TVC-010, 40)  
A suspension of 39 (110 mg, 0.22 mmol), K2CO3 (136 mg, 0.98 
mmol) and 1,2-dibromoethane (0.4 mL, 2.4 mmol) in DMF (5 mL) 
was stirred at 60 
o
C for 48 h. After that time EtOAc (50 mL) was 
added. The resulting solution was washed with H2O, brine solution 
and dried over Na2SO4. The solvent was evaporated in vacuo. Flash 
chromatography (EtOAc/CyH, 3/2) provided a solid product 40 (83 mg, 74%). 
1
H-NMR (600 MHz, CDCl3): δ = 8.2 (s, 1H, NH), 7.96 (dd, J = 7.69 Hz, J = 1.55 Hz, 1H, 9-H), 7.68 (m, 
1H, 12-H), 6.67 (m, 1H, 11-H), 7.61 (dd, J = 7.5 Hz, J = 1.7 Hz, 1H, 10-H), 7.52 (d, J = 7.9 Hz, 1H, 22-
H), 7.33 (d, J = 8.2 Hz, 1H, 4-H), 7.17 (dt, J = 7.5 Hz, J = 1 Hz, 1H, 20-H), 7.09 (dt, J = 7.6 Hz, J = 0.8 
Hz, 1H, 21-H), 7.02 (d, J = 2.2 Hz, 1H, 17-H), 5.18 (dd, J = 11 Hz, J = 5 Hz, 1H, 2-H), 4.08 (dd, J = 7.8 
Hz, J = 1.2 Hz, 1H, 4-H), 3.77 (dt, J = 3.8 Hz, J = 1 Hz, 1H, 6-H), 3.64 (s, 3H, 24-H) 3.44 (dd, J = 4.9 
Hz, J = 0.75 Hz, 1H, 15-H), 3.33 (m, 1H, 6-H), 3.20 (dd, J = 15.5 Hz, J = 11.2 Hz, 1H, 15-H), 3.14 (dd, 
J = 7 Hz, J = 4.7 Hz, 2H, 5-H), 1.83 (sept, J = 7 Hz, 1H, 13-H), 0.72 (dd, J = 6.8 Hz, 6H, 14-H). 
13
C-
NMR (150 MHz, CDCl3): δ = 170.5 (1-C), 167.1 (3-C), 148.1 (8-C), 136.2 (18-C), 133.8 (11-C), 132.9 
(7-C), 131.9 (10-C), 130.8 (12-C), 126.9 (23-C), 124.2 (9-C), 122.8 (17-C), 122.2 (20-C), 14.6 (21-C), 
118.1 (22-C), 111.4 (4-C), 110.5 (16-C), 64.5 (4-C), 57.5 (2-C), 52.1(24-C), 43.2 (5-C), 40.6 (6-C), 31.4 
(13-C), 24.1 (15-C), 14.5 (14-C), 14.3 (14’-C). IR (KBr) ν (cm-1): 3411.3 (NH), 1739.6, 1652.5 (CO). 
HPLC-ESI-MS: m/z (%) = 529.2 [M+H]
+
, 546.2 [M+NH4]
+
. HR-ESI-MS (m/z): calcd. for 
C25H28N4O7SNa
 
[M+Na]
+
 551.1576; found 551.1571. Rf = 0.11 (EtOAc/CyH, 3/2).  
(2S)-3-(1H-Indol-3-yl)-2-[(3S)-4-(2-nitrobenzenesulfonyl)-2-oxo-3-(propan-2-yl)piperazin-1-yl]-
propanoic acid (TVC-018, 41) 
Methyl ester 40 (1.5 g, 2.84 mmol) in THF (30 mL) was treated with 
a solution of 4% LiOH (28.38 mmol). After stirring at room 
temperature for 3 h, the reaction mixture was acidified with 1N HCl 
to pH ≈ 4 and extracted with EtOAc (3x100 mL). The combined 
organic phases were washed with H2O (2x10 mL), brine solution and 
dried over Na2SO4. Removal of the solvent under reduced pressure 
gave pure solid product 41 (1.42 g, 97%). 
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1
H-NMR (600 MHz, DMSO-d6): δ = 10.77 (s, 1H, NH), 7.96 (dd, J = 7.96 Hz, J = 1.12 Hz, 1H, 9-H), 
7.91 (dd, J = 7.95 Hz, J = 1.16 Hz, 1H, 12-H), 7.86 (dt, J = 7.6 Hz, J = 1.23 Hz, 1H, 11H) ,7.77 (dt, J = 
7.85 Hz, J = 1.3 Hz, 1H, 10-H), 7.48 (d, J = 7.9 Hz, 1H, 22-H), 7.3 (d, J = 8.1 Hz, 1H, 4-H), 7.07 (d, J = 
2,1 Hz, 1H, 17-H), 7.04 (dt, J = 7.96 Hz, J = 0.87 Hz, 1H, 20-H), 6.95 (dt, J = 7.8 Hz, J = 0.74 Hz, 1H, 
21-H), 5.20 (dd, J = 11.3 Hz, J = 4.7 Hz, 1H, 2-H), 3.84 (d, J = 7.65 Hz, 1H, 4-H), 3.68 (m, 1H, 6-H), 
3.35 (m, 1H, 6-H), 3.34 (m, 1H, 5-H), 3.25 (dd, J = 15.3 Hz, J = 4.5 Hz, 1H, 15-H), 3.1 (m, 1H, 15-H), 
3.08 (m, 1H, 5-H), 1.70 (sept, J = 7 Hz, 1H, 13-H), 0.6 (d, J = 6.8 Hz, 3H, 14-H), 0.51 (d, J = 6.7 Hz, 
3H, 14’-H). 13C-NMR (150 MHz, DMSO-d6): δ = 171.4 (1-C), 165.0 (2-C), 147.0 (8-C), 136.0 (18-C), 
134.9 (11-C), 132.4 (10-C), 130.9 (7-C), 130 (12-C), 126.7 (23-C), 124.2 (9-C), 123.3 (17-C), 120.8 (20-
C), 118.2 (21-C), 117.9 (22-C), 111.2 (4-C), 109.4 (16-C), 63.6 (4-C), 56.0 (2-C), 40.8 (5-C), 40.7 (6-C), 
30.8 (13-C), 23.6 (15-C), 19.8 (14-C), 18.9 (14’-C). IR (KBr) ν (cm-1): 3418.9 (NH), 1716.9, 1646.4 
(CO). HPLC-ESI-MS: m/z (%) = 515.2 (100) [M+H]
+
, 532.2 (10) [M+NH4]
+
. HR-ESI-MS (m/z): calcd. 
for C24H26N4O7SNa
 
[M+Na]
+
 537.1412; found 537.1414. Rf= 0.22 (DCM/MeOH. 5/1). 
(2S)-N-(Carbamoylmethyl)-3-(1H-indol-3-yl)-2-[(3S)-4-(2-nitrobenzenesulfonyl)-2-oxo-3-(propan-2- 
yl)piperazin-1-yl]propanamide (TVC-026, 42) 
To a solution of (S)-3-(1H-indol-3-yl)-2-((S)-3-isopropyl-4-((2-
nitrophenyl)sulfonyl)-2-oxopiperazin-1-yl)propanoic acid 41 (730 
mg, 1.42 mmol), H-Gly-NH2*HCl (235 mg, 2.13 mmol), TBTU 
(592 mg, 1.84 mmol) and HOBt*H2O (282 mg, 1.84 mmol) in DMF 
(10 mL), DIPEA (0.7 mL, 4.26 mmol) was added dropwise. The 
reaction mixture was stirred at room temperature for 18 h, then 
diluted with EtOAc (250 mL). The organic layer was washed with 
H2O (3x15 mL), brine solution (2x15 mL) and dried over MgSO4. 
Flash chromatography (EtOAc/EtOH, 10/1) yielded product 42 (580 mg, 72%) as a solid. 
1
H-NMR (600 MHz, CDCl3): δ = 8.25 (s, 1H, NH), 8.03 (d, J = 8.1 Hz, 1H, 9-H), 7.7 (m, 1H, 11-H), 
7.67 (overlap, 1H, 17-H), 7.6 (m, 1H, 10-H), 7.52 (d, J = 7.7 Hz, 1H, 22-H), 7.33 (d, J = 8.1 Hz, 1H, 4-
H), 7.18 (t, J = 7.1 Hz, 1H, 20-H), 7.10 (t, J = 7.1 Hz, 1H, 21-H), 7.01 (d, J = 2.2 Hz, 1H, 12-H), 5.33 (q, 
J = 7.3 Hz, J = 8.9 Hz, 1H, 2-H), 4.0 (dd, J = 1.1 Hz, J = 7.8 Hz, 1H, 4-H), 3.78-3.73 (m, 2H, 5-H), 3.82 
(m, 1H, 6-H), 3.36 (m, 1H, 6-H), 3.32 (m, 2H, 15-H), 3.27 (m, 2H, 24-H), 1.97-1.92 (m, 1H, 13-H), 0.85 
(d, J = 6.7 Hz, 3H, 14-H), 0.71 (d, J = 6.8 Hz, 3H, 14-H). 
13
C-NMR (150 MHz, CDCl3): δ = 174.0 (25-
C), 172.4 (1-C), 169.8 (3-C), 149.5 (8-C), 138.2 (7-C), 135.8 (12-C), 133.5 (11-C), 133.4 (18-C), 132.2 
(9-C), 128.4 (23-C), 125.9 (10-C), 124.5 (17-C), 122.6 (20-C), 114.9 (21-C), 114.2 (22-C), 112.4 (4-C), 
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110.6 (16-C), 65.8 (4-C), 58.6 (2-C), 43.3 (5-C), 43.2 (24-C), 41.7 (6-C), 32.6 (13-C), 25.2 (15-C), 20.02 
(14-C). IR (KBr) ν (cm-1): 3392.0 (NH), 1733.5 (CO). HPLC-ESI-MS: m/z (%) = 571.2 (100) [M+H]+, 
588.2 (27) [M+NH4]
+
, 593.2 (28) [M+Na]
+
. HR-ESI-MS (m/z): calcd. for C26H30N6O7SNa [M+Na]
+
 
593.1794; found 593.1789. Rf = 0.32 (DCM/MeOH, 20/1).  
(2S)-N-(Carbamoylmethyl)-3-(1H-indol-3-yl)-2-[(3S)-2-oxo-3-(propan-2-yl)piperazin-1-yl]propan-
amide (TVC-032, 43) 
A suspension of compound 42 (20 mg, 0.04 mmol) and K2CO3 (14.5 
mg, 0.11 mmol) in ACN (3 mL) was treated with thiophenol (8 mg, 
0.07 mmol) for 4 h at room temperature. The reaction mixture was then 
filtered through a Celite pad and washed with EtOAc. The filtrate was 
concentrated and the residue was purified by silica gel column 
chromatography eluting DCM/MeOH (5/1) to afford desired product 43 
(13 mg, 96%) as a solid. 
1
H-NMR (400 MHz, CD3OD): δ = 7.52 (d, J = 7.8 Hz, 1H, 4-H), 7.32 (d, J = 8.0 Hz, 1H, 16-H), 7.11 (s, 
1H, 14-H), 7.08 (dt, J = 1.1 Hz, J = 8.0 Hz, 1H, 18-H), 7.01 (dt, J = 1 Hz, J = 8 Hz, 1H, 17-H), 5.18 (dd, 
5.9 Hz, 10 Hz, 1H, 4-H), 3.83 (q, J = 17 Hz, J = 4 Hz, 2H, 7-H), 3.41 (d, J = 4.3 Hz, 1H, 8-H), 3.14 (d, J 
= 10.8 Hz, 1H, 8-H), 3.38 (br, 2H, 12-H), 3.29 (overlap, 1H, 6-H), 2.94 (dd, J = 2.1 Hz, J = 13 Hz, 1H, 2-
H), 2.65 (dd, J = 3.7 Hz, J = 11.4 Hz, 1H, 2-H), 2.23-2.27 (m, 1H, 9-H), 0.87 (d, J = 7.1 Hz, 3H, 11-H), 
0.54 (d, J = 6.9 Hz, 3H, 10-H). 
13
C-NMR (100 MHz, CD3OD): δ = 174.4 (1-C), 173.3 (3-C), 173.1 (5-C), 
138.2 (15-C), 128.6 (20-C), 124.2 (14-C), 122.5 (17-C), 114.8 (19-C), 114.2 (18-C), 112.4 (16-C), 111.1 
(13-C), 65.3 (6-C), 60.1 (4-C), 47.04 (8-C), 43.3 (7-C), 42.6 (2-C), 31.2 (9-C), 24.6 (12-C), 18.7 (10-C), 
16.7 (11-C). IR (KBr) ν (cm-1): 3405.7 (NH), 1668.2, 1623.5 (CO). HPLC-ESI-MS: m/z (%) = 386.2 
(100) [M+H]
+
, 408.2 (45) [M+Na]
+
. HR-ESI-MS (m/z): calcd. for C20H27N5O3Na [M+Na]
+
 408.2012; 
found 408.2006. Rf = 0.136 (DCM/MeOH, 6/1). 
9H-Fluoren-9-ylmethyl-N-[(2S)-3-(tert-butoxy)-1-[(2S)-4-[(1S)-1-[(carbamoylmethyl)-carbamoyl]-2-
(1H-indol-3-yl)ethyl]-3-oxo-2-(propan-2-yl)piperazin-1-yl]-1-oxopropan-2-yl]carbamate (TVC-042, 
45) 
To a stirred solution of Fmoc-L-Ser(tBu)-OH (180 mg, 0.47 mmol) and amine 43 (145 mg, 0.38 mmol) in 
DMF (12 mL), HATU (46 mg, 0.52 mmol) and DIPEA (0.23 mL, 1.4 mmol) were added. After stirring at 
room temperature overnight, EtOAc (300 mL) was added. The mixture was washed with H2O and brine 
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solution. The solvent was removed and the residue was purified by silica gel column chromatography 
(EtOAc/EtOH, 20/1) to obtain product TVC-042 (335 mg, 95%) as a solid.  
1
H-NMR (400 MHz, CDCl3): δ = 8.67 (s, 1H, NH), 8.0 (s, 
1H, NH), 7.74 (d, J = 7.32 Hz, 2H, 33-H), 7.55 (d, J = 7.3 
Hz, 2H, 30-H), 7.55 (d, J = 7.3 Hz, 1H, 4-H), 7.38 (t, J = 
7.32 Hz, 2H, 32-H), 7.3 (m, 1H, 16-H), 7.28 (overlap, 2H, 
31-H), 7.1 (t, J = 7.6 Hz, 1H, 17-H), 7.09 (t, J = 7.5 Hz, 
1H, 18-H), 7.0 (s, 1H, 14-H), 6.1 (s, 1H, NH), 5.9 (s, 1H, 
NH), 5.6 (d, J = 8.1 Hz, 1H, NH), 5.3 (m, 1H, 4-H), 4.78 
(d, J = 6.9 Hz, 1H, 6-H), 4.71 (d, J = 5.4 Hz, 1H, 22-H), 
4.35 (d, J = 4 Hz, 2H, 27-H), 4.2 (t, J = 6.8 Hz, 1H, 28-
H), 3.96 (m, 1H, 8-H), 3.84 (m, 1H, 2-H), 3.73 (m, 1H, 2-
H), 3.54 (m, 1H, 7-H), 3.41 (m, 1H, 7-H), 3.41 (overlap, 2H, 23-H), 3.38 (m, 1H, 8-H), 3.37 (m, 1H, 12-
H), 3.22 (m, 1H, 12-H), 1.92 (br, 1H, 9-H), 1.1 (s, 9H, 25-H), 0.82 (d, J = 6.3 Hz, 3H, 11-H), 0.77 (d, J = 
6.3 Hz, 3H, 10-H). 
13
C-NMR (100 MHz, CDCl3): δ = 171.5 (3-C), 171.1 (1-C), 170.6 (5-C), 170.6 (21-
C), 169.0 (26-C), 155.0 (15-C),143.6 (20-C),141.3 (29-C), 136.2 (34-C), 127.7 (30-C), 127.0 (31-C), 125 
(32-C), 122.9 (14-C), 122.6 (17-C), 14.9 (33-C), 14.7 (18-C), 110 (13-C), 74.0 (24-C), 67.1 (27-C), 63 
(23-C), 60.7 (6-C), 57.4 (4-C), 51.1 (22-C), 47.1 (28-C), 43 (7-C), 42.7 (2-C), 41.6 (8-C), 32.2 (9-C), 27.3 
(25-C), 24.1 (12-C), 14.6 (11-C, 10-C). IR (KBr) ν (cm-1): 3428.0 (NH), 1656.9 (CO). HPLC-ESI-MS: 
m/z (%) = 751.4 (100) [M+H]
+
, 769.4 (4) [M+NH4]
+
, 773.4 (11) [M+Na]
+
. HR-ESI-MS (m/z): calcd. for 
C42H50N6O7Na [M+Na]
+
 773.3639; found 773.3633. Rf = 0.22 (EtOAc/EtOH, 15/1). 
(2S)-2-[(3S)-4-[(2S)-2-Amino-3-(tert-butoxy)propanoyl]-2-oxo-3-(propan-2-yl)piperazin-1-yl]-N-
(carbamoylmethyl)-3-(1H-indol-3-yl)propanamide (TVC-046, 46) 
A solution of TVC-042 (170 mg, 226.4 µmol) in DCM (10 mL) was 
treated with piperidine (335 µL, 340 µmol) for 5 h at room 
temperature. The reaction mixture was concentrated to dryness, then 
purified by silica gel column chromatography (EtOAc/EtOH, 5/1) to 
provide TVC-046 (116 mg, 98%) as a solid. 
1
H-NMR (600 MHz, CD3OD): δ = 7.6 (d, J = 7.9 Hz, 1H, 4-H), 
7.32 (d, J = 8.1 Hz, 1H, 16-H), 7.12 (s, 1H, 14-H), 7.08 (dt, J = 0.8 
Hz, J = 7.8 Hz, 1H, 17-H), 7.0 (dt, J = 1.1 Hz, J = 7.1 Hz, 1H, 18-
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H), 5.3 (t, J = 7.7 Hz, 1H, 4-H), 4.55 (d, J = 8.8 Hz, 1H, 6-H), 3.9 (m, 1H, 8-H), 3.84 (overlap, 1H, 22-
H), 3.84 (overlap, 2H, 2-H), 3.51 (m, 1H, 8), 3.49 (br, 2H, 7-H), 3.37 (d, J = 8.4 Hz, 2H, 12-H), 3.32 (m, 
2H, 23-H), 1.76 (m, 1H, 9-H), 1.12 (s, 9H, 25-H), 0.70 (d, J = 6.9 Hz, 3H, 11-H), 0.59 (d, J = 6.7 Hz, 3H, 
10-H). 
13
C-NMR (150 MHz, CD3OD): δ = 174.2 (3-C), 174.1 (1-C), 172.8 (5-C), 170.7 (21-C), 138.1 
(15-C), 128.6 (20-C), 124.0 (14-C), 122.0 (17-C), 120.0 (18-C), 14.3 (4-C), 112.5 (16-C), 110.8 (13-C), 
74.7 (24-C), 65.7 (23-C), 62.3 (6-C), 59.4 (4-C), 52.6 (22-C), 44.3 (7-C), 43.2 (2-C), 42.7 (8-C), 33.1 (9-
C), 27.7 (25-C), 25.3 (12-C), 4.95 (11-C, 10-C). IR (KBr) ν (cm-1): 3416.2 (NH), 1657.1, 1641.1 (CO). 
HPLC-ESI-MS: m/z (%) = 529.3 (100) [M+H]
+
, 551.3 (16) [M+Na]. HR-ESI-MS (m/z): calcd. for 
C27H41N6O5
 
[M+H]
+
 529.3138; found 529.3133. Rf = 0.18 (EtOAc/EtOH, 2/1). 
tert-Butyl-N-[(1S)-1-{[(1S)-1-{[(2S)-3-(tert-butoxy)-1-[(2S)-4-[(1S)-1-[(carbamoylmethyl)-carbamo- 
yl]-2-(1H-indol-3-yl)ethyl]-3-oxo-2-(propan-2-yl)piperazin-1-yl]-1-oxopropan-2-yl]carbamoyl}-2-
phenylethyl]carbamoyl}-2-[4-(tert-butoxy)phenyl]ethyl]carbamate (TVC-048, 44) 
To a solution of amine TVC-046 (70 mg, 132.4 
µmol) and Boc-Tyr(tBu)-Phe-OH (81 mg, 165.5 
µmol) in DMF/ACN (8 mL, 6/4), HATU (68 mg, 
179 µmol) and DIPEA (66 µl, 397 µmol) were 
added. After stirring at room temperature for 24 h, 
the solvent was removed under reduced pressure. 
Flash chromatography (EtOAc/EtOH, 20/1) 
afforded product 44 (115 mg, 87%) as a yellow 
solid. 
1
H-NMR (400 MHz, CD3OD): δ = 7.97 (s, 1H, NH), 7.62 (d, J = 7.9 Hz, 1H, 419-H), 7.32 (d, J = 8.0, 
1H, 16-H), 7.2 (m, 2H-35-H), 7.2 (m, 2H, 29-H), 7.1 (m, 2H, 28-H), 7.1 (s, 1H, 14-H), 7.08 (overlap, 1H, 
18-H), 7.08 (m, 1H, 30-H) 7.03 (t, J = 7,1 Hz, 1H, 17-H), 6.9 (d, J = 8.3 Hz, 2H, 36-H), 5.36 (d, J = 8.25, 
1H, 4-H), 4.76 (overlap, 1H, 22-H), 4.6 (t, J = 6.9 Hz, 1H, 25-H), 4.47 (d, J = 8.4 Hz, 1H, 6-H), 4.21 (d, 
J = 5 Hz, 1H, 33-H), 3.84-3.87 (m, 2H, 2-H), 3.82-3.86 (m, 1H, 7-H), 3.46-3.47 (m, 1H, 7-H), 3.48-3.52 
(m, 2H, 8-H), 3.45-3.43 (m, 2H, 23-H), 3.36-3.38 (m, 2H, 12-H), 3.03 (m, 1H, 26-H), 2.85 (m, 1H, 26-H), 
2.95 (m, 1H, 33-H), 2.66 (m, 1H, 33-H), 1.49-1.53 (m, 1H, 9-H, 39-H), 1.34 (s, 9H, 41-H), 1.30 (s, 9H, 
44-H), 1.11 (s, 9H), 0.61 (d, J = 6.8 Hz, 3H, 10-H), 0.53 (d, J = 6.6 Hz, 3H, 11-H). 
13
C-NMR (100 MHz, 
CD3OD): δ = 174.1 (24-C), 174.0 (31-C), 172.8 (3-C), 172.6 (1-C), 171.8 (21-C), 170.7 (5-C), 157.6 (42-
C), 155.3 (37-C), 138.1 (15-C), 138 (27-C), 133.7 (34-C), 130.8 (28-C), 130.4 (29-C), 129.5 (35-C), 
128.6 (20-C), 127.8 (30-C), 125.2 (6-C), 124.5 (14-C), 122.6 (18-C), 120 (17-C), 114.3 (19-C), 112.5 
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(16-C), 110.8 (13-C), 80.7 (38-C), 79.5 (40-C), 75.0 (43-C), 63.1 (23-C), 62.6 (6-C), 58.8 (4-C), 57.4 (32-
C), 55.4 (25-C), 43.7 (7-C), 42.9 (8-C), 43.2 (2-C), 38.8 (26-C), 38.5 (33-C), 33.0 (9-C), 29.2 (44-C), 
28.7 (39-C), 27.7 (41-C), 25.3 (12-C), 20.2 (1-C), 14.9 (11-C). IR (KBr) ν (cm-1): 3834.2 (NH), 1655.2 
(CO). HPLC-ESI-MS: m/z (%) = 995.6 (39.4) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C54H75N8O10 
[M+H]
+
 995.5606; found 995.5601. Rf = 0.26 (EtOAc/EtOH, 15/1). 
(2S)-2-[(2S)-2-Amino-3-(4-hydroxyphenyl)propanamido]-N-[(2S)-1-[(2S)-4-[(1S)-1-[(carbamoyl- 
methyl)carbamoyl]-2-(1H-indol-3-yl)ethyl]-3-oxo-2-(propan-2-yl)piperazin-1-yl]-3-hydroxy-1-
oxopropan-2-yl]-3-phenylpropanamide (TVC-051, 47) 
Hexapeptide 44 (50 mg, 50.2 µmol) was treated 
with TFA/TIPS/H2O (2 mL, 95/2.5/2.5) at 0 
o
C for 
4 h. After removal of the solvent, the residue was 
dissolved in ACN/H2O (2 mL, 1/1) and lyophilized 
to provide product 47 (35.5 mg, 90%) as a white 
powder.  
1
H-NMR (400 MHz, DMSO-d6): δ = 10.8 (d, J = 2 
Hz, 1H, NH), 9.2 (br, s, 1H, NH), 8.4 (d, J = 8 Hz, 
1H, NH), 8.2 (t, J = 5.7 Hz, 1H, NH), 8.1 (br, s, 1H, 
NH), 7.27 (s, 1H, NH), 7.64 (d, J = 7.8 Hz, 1H, 19-
H), 7.31 (d, J = 8.0 Hz, 16-H), 7.4-7.13 (m, 6H, 14-H, 28-H, 29-H, 30-H), 7.05 (t, J = 8.0 Hz, 19-H), 6.9 
(overlap, 1H, 18-H), 6.96 (d, J = 8.5 Hz, 2H, 35-H), 6.66 (d, J = 8.5 Hz, 2H, 36-H), 5.4 (dd, J = 4.9 Hz,  
J = 11 Hz, 1H, 4-H), 4.7 (q, J = 6.7 Hz, 1H, 22-H), 4.6 (q, J = 8 Hz, 1H, 25-H), 4.3 (d, J = 8.5 Hz, 1H, 6-
H), 3.8 (m, 1H, 7-H), 3.66 (d, J = 5.8 Hz, 1H, 2-H), 3.58 (m, 1H, 23-H), 3.50 (m, 1H, 2-H), 3.5 (m, 1H, 
8-H), 3.41 (m, 1H, 32-H), 3.4 (m, 1H, 7-H), 3.38 (m, 1H, 8-H), 3.3 (m, 1H, 12-H), 3.12 (m, 1H, 12-H), 
2.92 (m, 1H, 26-H), 2.77 (m, 1H, 33-H), 2.73 (m, 1H, 26-H), 2.45 (m, 1H, 33-H), 1.44 (m, 1H, 9-H), 0.53 
(d, J = 7.0 Hz, 3H, 10-H), 0.40 (d, J = 7.0 Hz, 3H, 11-H). 
13
C-NMR (100 MHz, DMSO-d6): δ = 155.9 
(37-C), 136.1 (15-C), 130.1 (34-C), 129.2 (28-C), 127.8 (29-C), 127.0 (35-C), 126.2 (30-C), 126.8 (20-
C), 123.4 (14-C), 120.7 (17-C), 118.5 (19-C), 118.1 (18-C), 114.9 (36-C), 111.5 (16-C), 106.7 (13-C), 
61.0 (23-C), 60.3 (6-C), 55.6 (4-C), 55.4 (32-C), 52.8 (25-C), 50.9 (22-C), 41.8 (2-C), 41.2 (7-C), 40.8 (8-
C), 38.5 (33-C), 37.7 (26-C), 30.9 (9-C), 24.2 (12-C), 14.3 (10-C), 14.2 (11-C). IR (KBr) ν (cm-1): 
3423.41 (NH), 1651.7 (CO). HPLC-ESI-MS: m/z (%) = 783.4 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. 
for C41H51N8O8
 
[M+H]
+
 783.3830; found 783.3824. 
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3.8 Synthesis of flexible cyclic helicokinin analogues TVC-113 (66) and TVC-158 (67) 
 
2-(4-Nitrophenylsulfonamido)acetamide (TVC-052, 48) 
 To a suspension of glycinamide hydrochloride (500 mg, 4.52 mmol) and 
TEA (1.57 mL, 11.3 mmol) in DCM (30 mL) at - 20 to -15 
o
C, a solution of 
4-nitrobenzenesulfonyl chloride (982 mg, 4.43 mmol) in DCM/DMF (17 mL, 
15/2) was added dropwise. The reaction mixture was stirred further for 1 h, 
and then the solid was collected and crystallized from EtOH/H2O to obtain product 48 (850 mg, 72%) as a 
white solid. 
1
H-NMR (400 MHz, DMSO-d6):δ = 8.39 (d, J = 8.97 Hz, 2H, 5-H), 8.27 (s, 1H, NH), 8.05 (d, J = 8.97 
Hz, 2H, 4-H), 7.31 (s, 1H, NH), 7.06 (s, 1H, NH), 3.49 (s, 2H, 1-H). 
13
C-NMR (100 MHz, DMSO-d6): δ 
= 169.1 (2-C), 149.4 (6-C), 146.1 (3-C), 128.1 (4-C), 124.3 (5-C), 44.7 (1-C). IR (KBr) ν (cm-1): 3415.41 
(NH), 1688.7 (CO). HPLC-ESI-MS: m/z (%) = 260.0 (8) [M+H]
+ 
282.0 (12) [M+Na]
+
. HPLC-ESI-MS: 
m/z (%) = 260.0 (100) [M+H]
+
. Rf = 0.23 (EtOAc). 
2-(N-Allyl-4-nitrophenylsulfonamido)acetamide (TVC-055, 49) 
A suspension of 2-(4-nitrophenylsulfonamido)acetamide 48 (30 mg, 0.12 
mmol) and Cs2CO3 (40 mg, 0.21 mmol) in DMF (4 mL) was stirred for 30 
min at room temperature, followed by dropwise addition of allyl bromide (20 
µL, 0.23 mmol). After stirring for 20 h, the mixture was quenched with 
AcOEt (100 mL), washed with H2O, brine solution and dried over MgSO4. Removal of the solvent gave 
product 49 (35.4 mg, 100%) as a white solid. 
1
H-NMR
 
(400 MHz, DMSO-d6): δ = 8.39 (d, J= 8.9 Hz, 2H, 5-H), 8.1 (d, J = 8.9 Hz, 2H, 4-H), 7.4, 7.1 
(s, 2H, NH2), 5.7 (m, 1H, 8-H), 5.21-5.15 (m, 2H, 9-H), 3.9 (d, J = 6.4 Hz, 2H, 7-H), 3.81 (s, 2H, 1-H). 
13
C-NMR (100 MHz, DMSO-d6):δ = 172.3 (2-C), 151.6 (6-C), 146.7 (3-C), 132.1 (8-C), 128.5 (4-C), 
125.1 (5-C), 120.0 (9-C), 51.3 (7-C), 48.6 (2-C). IR (KBr) ν (cm-1): 3204.8, 3434.8, 1675.5. HPLC-ESI-
MS: m/z (%) = 300.1 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C11H13N3O5SNa [M+Na]
+ 
322.0468; 
found 322.0465. Rf = 0.28 (CyH/EtOAc, 3/2). 
2-(Allylamino)acetamide (TVC-060, 50) 
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 To a stirred suspension of 2-(N-allyl-4-nitrophenylsulfonamido)acetamide 49 (4.20 g, 
14.03 mmol) and K2CO3 (5.8 g, 42.1 mmol) in ACN (120 mL), thiophenol (2.87 mL, 28.1 
mmol) was added. After 20 h, the solvent was removed under reduced pressure. The 
residue was extracted with EtOAc by using a Soxhlet extractor to obtain a crude product 
which was purified by silica gel column chromatography using DCM/MeOH (6/1) providing 50 (1.62 g, 
98%) as an oily product. 
1
H-NMR
 
(600 MHz, DMSO-d6): δ = 7.26 (bs, 1H, NH), 7.02 (bs, 1H, NH), 5.8 (m, 1H, 4-H), 5.1 (dd, J = 
1.8 Hz, J = 17.2 Hz, 1H, 5-H), 5.04 (dd, J = 1.8 Hz, J = 17.2 Hz, 1H, 5-H), 3.1 (d, J = 5.7 Hz, 2H, 3-H), 
3.0 (s, 2H, 2-H). 
13
C-NMR (150 MHz, DMSO-d6): δ = 173.0 (1-C), 136 (4-C), 115 (5-C), 51.2 (2-C), 
50.8 (3-C). IR (neat) ν (cm-1): 3304.9, 1653.5. HPLC-ESI-MS: m/z (%) = 115.09 (100) [M+H]+. HR-
ESI-MS (m/z): calcd. for C5H10N2O
 
[M+H]
+ 
115.0870; found 115.0866. Rf = 0.16 (EtOH/EtOAc, 1/1). 
(S)-tert-Butyl-2-(4-nitrophenylsulfonamido)propanoate (TVC-053) 
To a solution of H-Ala-OtBu*HCl (5 g, 27.52 mmol) and 4-
nitrobenzenesulfonyl chloride (6.7 g, 30.28 mmol) in DCM (100 mL) at 
0 
o
C, TEA (8.2 mL, 63.31 mmol) was added dropwise. The reaction 
mixture was allowed to warm up to room temperature and stirred for 20 
h. After that time, the solution was diluted with DCM (300 mL), washed with H2O (2x25 mL), brine 
solution (30 mL) and dried over MgSO4. Removal of the solvent and flash chromatography (CyH/EtOAc, 
5/1) yielded desired product (S)-tert-butyl-2-(4-nitrophenylsulfonamido)propanoate TVC-053 (8.74 g, 
98%.) as a solid. 
1
H-NMR (600 MHz, CDCl3): δ = 8.33 (d, J = 8.9 Hz, 2H, 6-H), 8.04 (d, J = 8.9 Hz, 2H, 5-H), 5.46 (d, J 
= 8.5 Hz, 1H, NH), 3.93 (q, J = 7.1 Hz, 1H, 2-H), 1.38 (d, J = 7.1 Hz, 3H, 3-H), 1.3 (s, 9H, 9-H). 
13
C-
NMR (150 MHz, CDCl3): δ = 170.9 (1-C), 150.1 (7-C), 146.1 (4-C), 128.5 (5-C), 124.2 (6-C), 83.0 (8-
C), 52.2 (2-C), 27.7 (9-C), 19.9 (3-C). IR (neat) ν (cm-1): 3304.9, 1653.5. HPLC-ESI-MS: m/z (%) = 348 
(80) [M+NH4]
+
, 683.2 (30) [2M+Na]
+
. Rf = 0.16 (CyH/EtOAc, 5/1). 
 
(S)-tert-Butyl-2-(N-allyl-4-nitrophenylsulfonamido)propanoate (TVC-054, 52) 
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To a stirred suspension of (S)-tert-butyl-2-(4-nitrophenylsulfonamido)- 
propanoate TVC-053 (6.3 g, 19.07 mmol) and Cs2CO3 (6.6 g, 34.33 
mmol) in DMF (100 mL) at 0 
o
C, a solution of allyl bromide (3.13 mL, 
38.14 mmol) in DCM (20 mL) was added dropwise within 30 min. The 
reaction mixture was stirred for 20 h at room temperature and diluted with AcOEt (500 mL). The 
resulting mixture was washed with H2O, brine solution and dried over Na2SO4. Removal of the solvent 
under diminished pressure afforded (S)-tert-butyl-2-(N-allyl-4-nitrophenylsulfonamido)propanoate 52 
(7.19 g, 100%) as a yellow oil. 
1
H-NMR
 
(400 MHz, CDCl3): δ = 8.31 (d, J = 8.9 Hz, 2H, 6-H), 8.01 (d, J = 8.9 Hz, 2H, 5H), 5.86-5.79 
(m, 1H, 11-H), 5.23 (dd, J = 1.3 Hz, J = 17.2 Hz, 1H, 12-H), 5.14 (dd, J = 1.2 Hz, J = 10.2 Hz, 1H, 12-
H), 4.59 (q, J = 7.3 Hz, 1H, 2-H), 1.45 (d, J = 7.3 Hz, 3H, 3-H), 1.35 (s, 9H, 9-H). 
13
C-NMR (100 MHz, 
CDCl3): δ = 169.9 (1-C), 149.9 (7-C), 146.2 (4-C), 134.8 (11-C), 128.6 (5-C), 124.0 (6-C), 116.1 (12-C), 
82.4 (8-C), 56.4 (2-C), 48.4 (10-C), 27.8 (9-C), 17.2 (3-C). IR (neat) ν (cm-1): 2980.2, 1730.3 (CO). 
HPLC-ESI-MS: m/z (%) = 371.2 (50) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C16H22N2O6SNa [M+Na]
+ 
393.1091; found 393.1073. Rf = 0.28 ( CyH/EtOAc, 10/1). 
(S)-2-(N-Allyl-4-nitrophenylsulfonamido)propanoic acid (TVC-056, 53) 
TFA (20 mL, 271 mmol) was added dropwise to a cooled solution of (S)-
tert-butyl-2-(N-allyl-4-nitrophenyl-sulfonamido)propanoate 52 (6.7 g, 18.1 
mmol) in DCM (40 mL) at 0 
o
C and continuously stirred for 4 h. 
Evaporation of the solvent provided pure acid 53 (5.6 g, 100%) as a brown 
oil. 
1
H-NMR
 
(400 MHz, CDCl3): δ = 8.33 (d, J = 8.93 Hz, 2H, 6-H), 8.02 (d, J = 8.90 Hz, 2H, 5-H), 5.84-
5.74 (m, 1H, 9-H), 5.24 (dd, J = 1.2 Hz, J = 17.2 Hz, 1H, 10-H), 5.16 (dd, J = 1.2 Hz, J = 10.2 Hz, 1H, 
10-H), 4.68 (q, J = 7.3 Hz, 1H, 2-H), 1.51 (d, J = 7.3 Hz, 3H, 3-H). 
13
C-NMR (100 MHz, CDCl3): δ = 
175.3 (1-C), 150.0 (7-C), 145.8 (4-C), 133.9 (9-C), 128.6 (5-C), 124.1 (6-C), 118.8 (10-C), 55.5 (2-C), 
48.7 (8-C), 16.6 (3-C). IR (KBr) ν (cm-1): 3456.2, 3112.5, 1719.5 (CO). HPLC-ESI-MS: m/z (%) = 315 
(70) [M+H]
+
, 337.0 (100) [M+Na]
+
. Rf = 0.28 (CyH/EtOAc, 10/1). 
Methyl-2-((S)-2-(N-allyl-4-nitrophenylsulfonamido)propanamido)-3-(6,7-dihydro-1H-indol-3-yl)- 
propanoate (TVC-057, 54) 
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To a suspension of acid 53 (3 g, 9.54 mmol), L-Trp-
OMe*HCl (2.92 g, 11.5 mmol) and PyBOP (5.96 g, 11.5 
mmol) in ACN (40 mL), DIPEA (5.5 mL, 33.11 mmol) was 
added dropwise. After stirring at room temperature for 20 h, 
AcOEt (400 mL) was added. The resulting solution was 
washed with H2O, brine solution and dried over MgSO4. Flash chromatography (EtOAc/CyH, 1/3) gave 
54 (4.1 g, 84%) as a yellow solid. 
1
H-NMR
 
(400 MHz, CDCl3): δ = 8.30 (s, 1H, NH), 8.24 (d, J = 8.9 Hz, 2H, 6-H), 7.87 (d, J = 8.9 Hz, 
2H, 5-H), 7.56 (d, J = 7.8 Hz, 1H, 19-H), 7.37 (d, J = 8.0 Hz, 1H, 16-H), 7.16 (t, J = 7.1 Hz, 1H, 17-H), 
7.13 (m, 2H, 14-H, 18-H), 6.66 (d, J = 7.0 Hz, 1H, NH), 5.24 (m, 1H, 9-H), 5.0 (dd, J = 1.5 Hz, J = 17.0 
Hz, 1H, 10-H), 4.81 (dd, J = 1.0 Hz, J = 10.0 Hz, 1H, 10-H), 4.72 (q, J = 7.3 Hz, 1H, 2-H), 4.43 (q, J = 
7.2 Hz, 1H, 11-H), 3.73 (s, 3H, 22-H), 3.59 (dd, J = 5.7 Hz, J = 16 Hz, 2H, 8-H), 3.37 (dd, J = 5.0 Hz, J 
= 14.8 Hz, 2H, 12-H), 1.2 (d, J = 7.2 Hz, 3H, 3-H). 
13
C-NMR (100 MHz, CDCl3): δ = 172.5 (21-C), 
170.1 (1-C), 150.5 (7-C), 146.0 (4-C), 136.8 (15-C), 133.5 (9-C), 128.7 (5-C), 127.6 (20-C), 124.8 (6-C), 
123.8 (14-C), 122.9 (17-C), 120.3 (18-C), 119.5 (10-C), 118.9 (19-C), 111.8 (16-C), 110.1 (13-C), 56.1 
(11-C), 53.2 (2-C), 52.9 (22-C), 48.0 (8-C), 27.8 (12-C), 14.7 (3-C). IR (KBr) ν (cm-1): 3414.41 (NH), 
1720.6, 1683.7 (CO). HPLC-ESI-MS: m/z (%) = 515.2 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for 
C24H26N4O7SNa [M+Na]
+ 
537.1413; found 537.1414. Rf = 0.24 (CyH/EtOAc, 3/2). 
2-((S)-2-(N-Allyl-4-nitrophenylsulfonamido)propanamido)-3-(6,7-dihydro-1H-indol-3-yl)propanoic 
acid (TVC-059) 
Methyl ester 54 (2.5 g, 4.86 mmol) in THF (40 mL) was 
treated with a solution of 4% LiOH (35 mL, 1.63 g, 38.9 
mmol). After stirring for 4 h, the reaction mixture was 
acidified with 1N HCl to pH ≈ 4 and extracted with EtOAc 
(2x200 mL). The combined organic phases were washed 
with H2O (2x20 mL), brine (20 mL) and dried over MgSO4. Removal of the solvent under reduced 
pressure afforded acid TVC-059 (1.93 g, 79%) as a yellow solid.  
1
H-NMR
 
(600 MHz, CDCl3): δ = 8.05 (d, J = 8.8 Hz, 2H, 6-H), 7.72 (d, J = 8.8 Hz, 2H, 5-H), 7.53 (d, J 
= 7.9 Hz, 1H, 19-H), 7.29 (d, J = 9.2 Hz, 1H, 16-H), 7.10 (t, J = 7.9 Hz, 1H, 17-H), 7.07 (s, 1H, 14-H), 
7.04 (t, J = 7.8 Hz, 1H, 18-H), 5.21 (m, 1H, 9-H), 4.90 (d, J = 17.0 Hz, 1H, 10-H), 4.73 (d, J = 10.0 Hz, 
1H, 10-H), 4.55 (m, 1H, 11-H), 4.40 (q, J = 7.2 Hz, 1H, 2-H), 3.50 (d, J = 6 Hz, 1H, 8-H), 3.45 (dd, J = 
6.8 Hz, 1H, 8-H), 3.35 (dd, J = 5 Hz, 1H, 12-H), 3.12 (dd, J = 8.0 Hz, 1H, 12-H), 1.08 (d, J = 7.2 Hz, 
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3H, 3-H). 
13
C-NMR (150 MHz, CDCl3): δ = 173.4 (21-C), 170 (1-C), 149.9 (7-C), 145.1 (4-C), 136.2 
(15-C), 133.4 (9-C), 128.2 (6-C), 127.1 (20-C), 124.1 (5-C), 123.4 (14-C), 121.9 (17-C), 119.2 (18-C), 
118.5 (19-C), 118.2 (10-C), 111.3 (16-C), 109.2 (13-C), 55.5 (2-C), 52.8 (11-C), 47.5 (8-C), 27.0 (12-C), 
14.6 (3-C). IR (KBr) ν (cm-1): 3420.8 (NH), 1722.6, 1670.7 (CO). HPLC-ESI-MS: m/z (%) = 501.1 
(100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C24H26N4O7SNa [M+Na]
+ 
523.1258; found 523.1254. Rf = 
0.44 (EtOAc, 0.1% AcOH). 
(S)-N-Allyl-2-((S)-2-(N-allyl-4-nitrophenylsulfonamido)propanamido)-N-(2-amino-2-oxoethyl)-3-
(1H-indol-3-yl)propanamide (TVC-065, 55) 
A solution of acid TVC-059 (228 mg, 2.0 mmol), 2-(allylamino)-
acetamide 50 (1.0 g, 2.0 mmol) and BOP-Cl (570 mg, 2.24 mmol) in 
ACN (40 mL) at -10 
o
C was added dropwise DIPEA (0.73 mL, 4.4 
mmol). The reaction mixture was allowed to stir at room temperature 
for 16 h and diluted with EtOAc (300 mL). The resulting solution 
was washed with H2O (2x30 mL), brine solution and dried over 
MgSO4. Removal of the solvent and flash chromatography using 
EtOAc as eluent provided 55 (897 mg, 75%) as a yellow solid. 
1
H-NMR
 
(400 MHz, CDCl3): δ = 8.23 (d, J = 8.9 Hz, 2H, 25-H), 7.85 (d, J = 8.9 Hz, 2H, 24-H), 7.5 (d, J 
= 7.8 Hz, 1H, 21-H), 7.4 (d, J = 8 Hz, 1H, 18-H), 7.25 (overlap, 1H, 16-H), 7.2 (m, 1H, 19-H), 7.1 (t, J = 
7 Hz, 1H, 20-H), 5.7 (m, 1H, 12-H), 5.25 (d, J = 10 Hz, 1H, 13-H), 5.18 (d, J = 17 Hz, 1H, 13-H), 5.08 
(m, 1H, 9-H), 4.9 (d, J = 16 Hz, 1H, 10-H), 4.7 (d, J = 10 Hz, 1H, 10-H), 4.77 (overlap, 1H, 4-H), 4.4 
(overlap, 1H, 1-H), 4.32 (d, J = 16 Hz, 1H, 6-H), 3.7 (d, J = 16 Hz, 1H, 6-H), 4.2 (m, 1H, 11-H), 3.8 (m, 
1H, 11-H), 3.6 (dd, J = 7.4 Hz, J = 15 Hz, 1H, 8-H), 3.46 (dd, J = 7.4 Hz, J = 15 Hz, 1H, 8-H), 3.2 (dq, J 
= 6 Hz, J = 14 Hz, 2H, 14-H), 1.02 (d, J = 7.2 Hz, 3H, 3-H). 
13
C-NMR (100 MHz, CDCl3): δ = 172.8 (2-
C), 171.2 (5-C), 170.4 (7-C), 150.1 (26-C), 145.3 (23-C), 136.5 (17-C), 133.0 (9-C), 131.9 (12-C), 128.3 
(24-C),126.9 (22-C), 124.4 (25-C), 124.0 (16-C), 122.6 (19-C), 119.9 (20-C), 118.9 (10-C), 118.2 (13-C), 
118.0 (21-C), 111.7 (18-C), 109.3 (15-C), 55.1 (1-C), 51.5 (11-C), 50.0 (6-C), 49.7 (4-C), 47.0 (8-C), 
28.1 (14-C), 14.2 (3-C). IR (KBr) ν (cm-1): 3411.8 (NH), 1686.2, 1647.4 (CO). HPLC-ESI-MS: m/z (%) 
= 597.0 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C28H32N6O7SNa [M+Na]
+ 
619.1945; found 
619.1945. Rf = 0.43 (EtOAc). 
2-((3S,6S,E)-3-((1H-Indol-3-yl)methyl)-6-methyl-7-(4-nitrophenylsulfonyl)-2,5-dioxo-1,4,7-triaza-
cycloundec-9-en-1-yl)acetamide (TVC-126, 62b) 
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To a solution of compound 55 (220 mg, 368 µmol) in degassed 
(40 min with argon) DCM (240 mL), Hoveyda-Grubbs catalyst 2
nd
 
generation (1,3-bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene) 
dichloro(o-isoprop-oxyphenylmethylene)-ruthenium (23 mg, 38.6 
µmol) was added. The reaction mixture was refluxed for 66 h, 
then concentrated and subjected to silica gel column 
chromatography (DCM/MeOH, 30/1). The desired product 2-
((3S,6S,E)-3-((1H-indol-3-yl)methyl)-6-methyl-7-(4-nitrophenylsulfonyl)-2,5-dioxo-1,4,7-triazacyclo-
undec-9-en-1-yl)acetamide TVC-126 (90 mg, 43%) was obtained as a yellow solid.  
1
H-NMR
 
(600 MHz, DMSO-d6): δ = 10.7 (s, 1H, NH), ), 8.4 (d, J = 8.7 Hz, 2H, 23-H), 8.2 (d, J = 8.7 
Hz, 2H, 22-H), 7.85 (bs, 1H, NH), 7.6 (bs, 1H, 19-H), 7.3 (overlap, 1H, 16-H), 7.06 (t, J = 7.5 Hz, 1H, 
17-H), 7.02 (s, 1H, 14-H), 6.97 (t, J = 7.5 Hz, 1H, 18-H), 5.75 (bs, 1H, 5-H), 5.15 (bs, 1H, 4-H), 4.73 (m, 
1H, 10-H), 4.58 (d, J = 7.0 Hz, 1H, 7-H), 4.16 (d, J = 14.0 Hz, 1H, 3-H), 3.92 (br, 2H, 6-H), 3.9 (m, 2-
H), 3.67 (d, J = 16 Hz, 1H, 2-H), 3.58 (t, J = 12 Hz, 1H, 3-H), 3.24 (m, 1H, 12-H), 2.8 (d, J = 11.0 Hz, 
1H, 12-H), 1.51 (s, 3H, 8-H). 
13
C-NMR (150 MHz, DMSO-d6): δ = 170.7 (9-C), 170.4 (11-C), 169.9 (1-
C), 149.6 (24-C), 146.3 (21-C), 133.1 (5-C), 129.2 (22-C), 124.7 (23-C), 127.5 (20-C), 124.4 (4-C), 123.8 
(14-C), 121.1 (17-C), 118.9 (19-C), 118.5 (18-C), 111.5 (16-C), 110.6 (13-C), 54.8 (7-C), 51.9 (6-C), 
51.4 (2-C), 50.9 (10-C), 46.1 (3-C), 27.6 (12-C), 13.8 (8-C). IR (KBr) ν (cm-1): 2978.8 (NH), 1656.2 
(CO). HPLC-ESI-MS: m/z (%) = 569.2 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C26H28N6O7SNa 
[M+Na]
+ 
591.1634; found 591.1632. Rf = 0.17 (DCM/MeOH, 20/1). 
2-((3S,6S,E)-3-((1H-Indol-3-yl)methyl)-6-methyl-2,5-dioxo-1,4,7-triazacycloundec-9-en-1-yl)-
acetamide (TVC-133, 63) 
A solution of TVC-126 (64 mg, 112.5 µmol) and DBU (46 µml, 340 mmol) in 
DMF (5 mL) was treated with 2-mercaptoethanol (98 µmL, 120 µmol) at room 
temperature for 1 h. The solvent was then removed and the crude material was 
purified by silica gel column chromatography (EtOAc/EtOH, 1/1) to provide 
product 63 (41.1 mg, 95%) as a solid. 
1
H-NMR (400 MHz, CD3OD): δ = 7.55 (d, J = 8.1 Hz, 1H, 19-H), 7.34 (d, J = 
8.15 Hz, 1H, 16-H), 7.09 (t, J = 7.0 Hz, 1H, 17-H), 7.01 (t, J = 7.0 Hz, 1H, 18-
H), 5.62 (dd, J = 3.0 Hz, J = 15.7 Hz, 1H, 5-H), 5.39 (t, J = 13.0 Hz, 1H, 4-H), 4.29 (dd, J = 4.0 Hz, J = 
11.0 Hz, 1H, 10-H), 4.12 (m, 1H, 6-H), 3.8 (d, J = 14.0 Hz, 1H, 6-H), 3.53 (m, 1H, 3-H), 3.46 (m, 1H, 
12-H), 3.29 (dd, J = 4.0 Hz, J = 15.6 Hz, 1H, 12-H), 3.07 (t, J = 11.3 Hz, 1H, 3-H), 2.84 (m, 1H, 7-H), 
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1.08 (d, J = 7.5 Hz, 3H, 8-H). 
13
C-NMR (100 MHz, CD3OD): δ = 174.1 (9-C), 173.6 (11-C), 164.9 (1-
C), 138.1 (15-C), 131.1 (5-C), 129.5 (20-C), 124.7 (4-C), 123.0 (14-C), 122.7 (17-C), 119.7 (19-C), 119.5 
(18-C), 112.7 (16-C), 112.2 (13-C), 55.5 (7-C), 54.4 (10-C), 50.9 (2-C), 49.9 (3-C), 49.2 (6-C), 25.1 (12-
C), 17.6 (8-C). IR (KBr) ν (cm-1): 3420.7 (NH), 1652.2 (CO). HPLC-ESI-MS: m/z (%) = 569.2 (100) 
[M+H]
+
. HR-ESI-MS (m/z): calcd. for C20H25N5O3Na [M+Na]
+ 
406.1851; found 406.1850. Rf = 0.13 
(EtOH/EtOAc, 1/1). 
(9H-Fluoren-9-yl)methyl-(S)-1-((2S,5S,E)-5-((1H-indol-3-yl)methyl)-7-(2-amino-2-oxoethyl)-2-
methyl-3,6-dioxo-1,4,7-triazacycloundec-9-en-1-yl)-3-tert-butoxy-1-oxopropan-2-yl-carbamate 
(TVC-141, 64) 
To a solution of 2-((3S,6S,E)-3-((1H-indol-3-yl)-
methyl)-6-methyl-2,5-dioxo-1,4,7-triazacycloun-dec-
9-en-1-yl)acetamide 63 (46 mg, 120 µmol) and Fmoc-
L-Ser(tBu)-OH (92 mg, 240 µmol) in DMF (4 mL), 
HATU (95.6 mg, 252 µmol) and DIPEA (80 µmL, 480 
µmol) were added. The reaction mixture was stirred 
for 24 h at room temperature and concentrated under 
reduced pressure. The residue was purified by silica 
gel column chromatography (EtOAc/EtOH, 25/1) to afford 64 (60 mg, 67%) as a solid. 
1
H-NMR (600 MHz, CD3OD): δ = 7.83 (m, 2H, 33-H), 7.7 (d, J = 7.1 Hz, 1H, 19-H), 7.65 (d, J = 8.6 
Hz, 2H, 30-H), 7.28 (m, 1H, 16-H), 7.41 (m, 2H, 32-H), 7.23 (m, 2H, 31-H), 7.0 (m, 1H, 17-H), 6.98 (m, 
1H, 18-H), 5.82 (bs, 1H, 5-H), 5.65 (bs, 1H, 4-H), 4.73 (br, 1H, 10-H), 4.72 (m, 1H, 7-H), 4.4 (bs, 3H, 
22-H, 27-H), 4.2 (br, 1H, 28-H), 4.01 (m, 2H, 6-H), 3.96-3.7 (m, 2H, 2-H), 3.6-3.5 (m, 2H, 23-H), 3.33 
(m, 2H, 3-H), 3.35-3.23 (m, 2H, 12-H), 3.29 (dd, J = 4.0 Hz, J = 15.6 Hz, 1H, 12-H), 3.07 (t, J = 11.3 
Hz, 1H, 3-H), 1.45 (s, 3H, 8-H), 1.2 (s, 9H, 25-H). 
13
C-NMR (150 MHz, CD3OD): δ = 174.4 (9-C), 174.0 
(21-C), 173.4 (11-C), 157.9 (26-C), 145.3 (29-C), 142.6 (34-C), 137.5 (15-C), 131.1 (5-C), 128.3 (4-C), 
127.6 (20-C), 127.4 (32-C), 126.6 (31-C), 125.0 (30-C), 124.8 (19-C), 123.0 (14-C), 120.7 (17-C), 119.3 
(33-C), 118.2 (18-C), 110.9 (16-C), 110.2 (13-C), 74.8 (24-C), 66.6 (27-C), 62.2 (23-C), 54.0 (10-C), 
53.8 (7-C), 52.8 (C-6), 52.6 (2-C), 47.2 (22-C), 46.9 (28-C), 42.4 (3-C), 26.8 (12-C), 26.2 (25-C), 13.3 (8-
C). IR (KBr) ν (cm-1): 3422.7 (NH), 1637.9 (CO). HPLC-ESI-MS: m/z (%) = 749.4 (100) [M+H]+. HR-
ESI-MS (m/z): calcd. for C42H48N6O7Na [M+Na]
+ 
771.3479; found 771.3477. Rf = 0.39 (EtOAc/EtOH, 
25/1). 
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2-((3S,6S,E)-3-((1H-Indol-3-yl)methyl)-7-((S)-2-amino-3-tert-butoxypropanoyl)-6-methyl-2,5-dioxo-
1,4,7-triazacycloundec-9-en-1-yl)acetamide (TVC-144, 65) 
A solution of (9H-fluoren-9-yl)methyl-(S)-1-((2S,5S,E)-5-((1H-indol-3-yl)methyl)-7-(2-amino-2-
oxoethyl)-2-methyl-3,6-dioxo-1,4,7-tri-azacyclo-undec-9-en-1-yl)-3-tert-butoxy-1-oxopropan-2-yl-
carbamate 64 (50 mg, 66.8 µmol) in DCM (6.0 mL) was treated with piperidine (57 mg, 668 µmol) for 4 
h at room temperature. Removal of the solvent and flash chromatography (EtOAc/EtOH, 1/1) yielded 
product 65 (35 mg, 99%) as a solid. 
1
H-NMR (400 MHz, CD3OD): δ = 7.7 (d, J = 8.1 Hz, 1H, 19-H), 
7.32 (d, J = 8.1 Hz, 1H, 16-H), 7.08 (m, 1H, 17-H), 7.07 (overlap, 
1H, 14-H), 7.02 (t, J = 7.1 Hz, 1H, 18-H), 5.85 (bs, 1H, 5-H), 5.33 
(bs, 1H, 4-H), 4.61 (d, J = 7.2 Hz, 1H, 7-H), 4.29 (br, 1H, 10-H), 4.01 
(m, 1H, 6-H), 4.00 (br, 1H, 22-H), 3.92 (m, 1H, 2-H), 3.89 (m, 1H, 3-
H), 3.78 (overlap, 2H, 6-H, 23-H), 3.63 (m, 1H, 3-H),  3.57 (m, 1H, 2-
H), 3.53 (m, 1H, 23-H), 3.37 (m, 1H, 12-H), 3.06 (m, 1H, 12-H), 1.6 
(s, 3H, 8-H), 1.2 (s, 9H, 25-H). 
13
C-NMR (100 MHz, CD3OD): δ = 
174.4 (9-C), 173.8 (11-C), 168.2 (21-C), 166.7 (1-C), 137.9 (15-C), 
131.6 (5-C), 129.3 (4-C), 128.2 (20-C), 123.5 (14-C), 120.9 (17-C), 118.2 (19-C), 118.0 (18-C), 110.8 
(16-C), 108.8 (13-C), 74.8 (24-C), 62.9 (23-C), 56.2 (22-C), 56.1 (10-C), 54.0 (7-C), 51.9 (C-6), 52.0 (2-
C), 45.9 (3-C), 27.0 (12-C), 26.2 (25-C), 12.3 (8-C). IR (KBr) ν (cm-1): 3446.7 (NH), 1646.9 (CO). 
HPLC-ESI-MS: m/z (%) = 527.2 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C27H39N6O5
 
[M+H]
+ 
527.2975; found 527.2976. Rf = 0.36 (EtOAc/EtOH, 1/1). 
tert-Butyl-(S)-1-((S)-1-((S)-1-((2S,5S,E)-5-((1H-indol-3-yl)methyl)-7-(2-amino-2-oxoethyl)-2-methyl-
3,6-dioxo-1,4,7-triazacycloundec-9-en-1-yl)-3-tert-butoxy-1-oxopropan-2-ylamino)-1-oxo-3-phenyl-
propan-2-ylamino)-3-(4-tert-butoxyphenyl)-1-oxopropan-2-ylcarbamate (TVC-146, 60) 
DIPEA (50 µl, 303 µmol) was added to a 
solution of 65 (32 mg, 60.8 µmol), Boc-
Tyr(tBu)-Phe-OH (35.3 mg, 73 µmol) and 
HATU (30 mg, 80 µmol) in DMF (2 mL). 
The reaction mixture was stirred for 20 h and 
followed by evaporation of the solvent. 
Flash chromatography (EtOAc/EtOH, 10/1) 
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gave pure product 60 (46 mg, 76%) as a solid. 
1
H-NMR
 
(600 MHz, DMSO-d6): δ = 7.68 (m, 1H, 19-H), 7.3 (m, 1H, 16-H), 7.25-7.20 (m, 4H, 28-H, 29-
H), 7.14 (t, J = 7.0 Hz, 1H, 30-H), 7.09 (overlap, 2H, 35-H), 7.03 (overlap, 1H, 17-H), 7.01 (s, 1H, 14-H), 
6.96 (t, J = 7.5 Hz, 1H, 18-H), 6.83 (d, J =8.4 Hz, 2H, 36-H), 5.76 (br, 1H, 5-H), 5.2 (br, 1H, 4-H), 4.78 
(br, 1H, 22-H), 4.7 (m, 1H, 25-H), 4.68 (bs, 1H, 7-H), 4.6 (m, 1H, 10-H), 4.1 (br, 1H, 32-H), 3.92 (m, 2H, 
6-H), 3.9 (overlap, 1H, 2-H), 3.7 (overlap, 1H, 2-H), 3.58 (br, 1H, 23-H), 3.37 (overlap, 1H, 23-H), 3.27 
(m, 2H, 3-H), 3.2 (overlap, 1H, 12-H), 2.8 (m, 1H, 12-H), 3.1 (m, 1H, 26-H), 2.98 (m, 1H, 26-H), 2.8 (m, 
1H, 33-H), 2.6 (t, J = 11.3 Hz, 1H, 33-H), 1.45 (s, 3H, 8-H), 1.26 (s, 9H, 39-H), 1.15 (s, 9H, 42-H), 1.26 
(s, 9H, 44-H). 
13
C-NMR (150 MHz, DMSO-d6): δ = 174.3 (9-C), 173.7 (11-C), 173.2 (24-C), 172.9 (31-
C), 154.2 (37-C), 138.4 (27-C), 136.6 (15-C), 131.8 (5-C), 130.4 (35-C), 129.8 (29-C), 128.3 (28-C), 
126.5 (30-C), 126.0 (4-C), 123.6 (36-C), 123.4 (14-C), 121.2 (17-C), 118.7 (19-C), 118.5 (18-C), 111.5 
(16-C), 77.5 (38-C), 72.8 (43-C), 72.2 (41-C), 62.8 (23-C), 56.2 (32-C), 53.8 (7-C), 53.6 (25-C), 53.3 (10-
C), 52.2 (2-C), 49.9 (22-C), 46.6 (6-C), 43.1 (3-C), 38.0 (26-C), 37.3 (33-C), 28.5 (39-C), 28.3 (44-C), 
27.7 (12-C), 27.2 (42-C), 13.8 (8-C). IR (KBr) ν (cm-1): 3419.3 (NH), 1653.9 (CO). HPLC-ESI-MS: m/z 
(%) = 1015.5 (100) [M+Na]
+
. HR-ESI-MS (m/z): calcd. for C54H72N8O10Na [M+Na]
+ 
1015.5264; found 
1015.5264. Rf = 0.17 ( DCM/ MeOH, 20/1). 
tert-Butyl-(S)-1-((S)-1-((S)-1-((2S,5S)-5-((1H-indol-3-yl)methyl)-7-(2-amino-2-oxoethyl)-2-methyl-
3,6-dioxo-1,4,7-triazacycloundecan-1-yl)-3-tert-butoxy-1-oxopropan-2-ylamino)-1-oxo-3-phenyl-
propan-2-ylamino)-3-(4-tert-butoxyphenyl)-1-oxopropan-2-ylcarbamate (TVC-155) 
A suspension of 60 (28 mg, 28.19 µmol) 
and Pd/C (20 wt%, 5.6 mg) in 
MeOH/EtOAc (6 mL, 2/1) was stirred at 
room temperature under a hydrogen 
atmosphere for 20 h. The Pd/C catalyst was 
removed by filtration over a Celite pad. 
Removal of the solvent yielded pure 
product TVC-155 (18 mg, 97%) as a brown 
solid. 
1
H-NMR (600 MHz, CD3OD): δ = 7.62 (m, 1/3H, 19-H), 7.43 (d, J = 8.3 Hz, 2/3H, 19-H), 7.37 (d, J = 
7.5 Hz, 1H, 16-H), 7.27-7.20 (m, 5H), 7.12 (overlap, 2H, 35-H), 7.1 (overlap, 1H, 17-H), 7.09 (s, 1H, 14-
H), 7.03 (t, J = 7.5 Hz, 1H, 18-H), 6.91 (d, J =8.4 Hz, 2H, 36-H), 4.8 (m, 1H, 22-H), 4.59 (t, J = 7.3 Hz, 
1H, 25-H), 4.55 (d, J = 7.0 Hz, 1H, 7-H), 4.36 (dd, J = 4.0 Hz, J = 10.3 Hz, 1H, 32-H), 4.22 (m, 1H, 10-
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H), 4.06 (d, J = 16.2 Hz, 1H, 2-H), 3.86 (d, J = 16.2 Hz, 1H, 2-H), 3.62 (m, 1H, 23-H), 3.49 (overlap, 1H, 
12-H), 3.48 (overlap, 1H, 23-H), 3.47 (t, J = 6.0 Hz, 2H, 3-H), 3.39 (m, 2H, 6-H), 3.18 (m, 1H, 12-H), 
3.17 (m, 1H, 26-H), 3.07 (dd, J = 4.0 Hz, J = 14.3 Hz, 1H, 33-H), 2.84 (m, 1H, 26-H), 2.61 (t, J = 11.3 
Hz, 1H, 33-H), 1.6 (m, 2H, 5-H), 1.55 (m, 2H, 4-H), 1.36 (s, 9H, 39-H), 1.15 (s, 9H, 42-H), 1.38 (overlap, 
3H, 8-H), 1.3 (s, 9H, 44-H). 
13
C-NMR (150 MHz, CD3OD): δ = 174.0 (9-C), 173.2 (11-C), 173.0 (24-C), 
172.6 (31-C), 155.2 (37-C), 138.0 (27-C), 137.6 (15-C), 129.4 (35-C), 129.2 (29-C), 127.8 (28-C), 126.3 
(30-C), 123.8 (36-C), 123.4 (14-C), 121.0 (17-C), 118.5 (18-C), 117.3 (19-C), 111.0 (16-C), 79.5 (43-C), 
74.7 (41-C), 61.5 (23-C), 56.6 (32-C), 56.0 (10-C), 54.7 (7-C), 52.7 (25-C), 50.2 (22-C), 49.8 (2-C), 46.6 
(6-C), 40.1 (3-C), 37.5 (26-C), 37.1 (33-C), 27.6 (44-C), 27.3 (39-C), 26.4 (5-C), 26.2 (42-C), 25.6 (12-
C), 24.9 (4-C), 13.5 (8-C). IR (KBr) ν (cm-1): 3420.3 (NH), 1654.9 (CO). HPLC-ESI-MS: m/z (%) = 
996.6 (80) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C54H74N8O10Na [M+Na]
+ 
1017.5420; found 1017.5440. 
Rf = 0.22 (DCM/MeOH, 20/1). 
General procedure for N-Boc and O-tBu deprotection 
Peptide 60 or TVC-155 was treated with TFA/TIPS/H2O (2 mL, 95/3.75/1.25) at 0 
o
C for 4-5 h. After that 
time, the solution was evaporated and the residue was purified by silica gel column chromatography 
(DCM/MeOH, 4/1, 0.1% TEA). The pure products were dissolved in ACN/H2O (2 mL, 1/1) and 
lyophilized to provide white powders. 
(S)-N-((S)-1-((2S,5S,E)-5-((1H-Indol-3-yl)methyl)-7-(2-amino-2-oxoethyl)-2-methyl-3,6-dioxo-1,4,7-
triazacycloundec-9-en-1-yl)-3-hydroxy-1-oxopropan-2-yl)-2-((S)-2-amino-3-(4-hydroxyphenyl) 
propanamido)-3-phenylpropanamide (TVC-113, 66)  
Starting material 60 (10 mg, 2.01 µmol) afforded 
product 66 (6.8 mg, 86%). 
1
H-NMR
 
(400 MHz, DMSO-d6): δ = 7.6 (m, 1H, 
19-H), 7.3 (m, 1H, 16-H), 7.3-7.24 (m, 4H), 7.18 (t, 
J = 7.0 Hz, 1H, 30-H), 7.03 (overlap, 2H, 35-H), 
7.03 (overlap, 1H, 17-H), 7.01 (s, 1H, 14-H), 6.97 (t, 
J = 7.5 Hz, 1H, 18-H), 6.69 (d, J =8.4 Hz, 2H, 36-
H), 5.78 (br, 1H, 5-H), 5.44 (br, 1H, 4-H), 4.88 (m, 
1H, 25-H), 4.79 (br, 1H, 22-H), 4.69 (bs, 1H, 7-H), 4.67 (m, 1H, 10-H), 4.07 (overlap, 1H, 23-H), 4.05 
(m, 2H, 6-H), 3.96 (m, 1H, 2-H), 3.94 (br, 1H, 32-H), 3.89 (br, 1H, 23-H), 3.88 (m. 1H, 2-H): 3.52 
N
N
H
N
O
O
NH
NH
2
O
N
H
N
H
NH
2
O
OH
O
O
OH
1213
1
2
3
4
5
6
7
8
9
10
11
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
126 
 
(overlap, 1H, 3-H), 3.41 (overlap, 1H, 3-H), 3.2 (overlap, 1H, 12-H), 3.16 (m, 1H, 12-H), 3.1 (m, 2H, 26-
H, 33-H), 2.99 (m, 1H, 26-H), 2.9 (m, 1H, 33-H), 1.44 (s, 3H, 8-H). 
13
C-NMR (100 MHz, DMSO-d6): δ 
= 174.1 (9-C), 173.8 (11-C), 173.6 (24-C), 173.2 (31-C), 155.2 (37-C), 134.4 (27-C), 136.2 (15-C), 131.9 
(5-C), 131.8 (35-C), 129.8 (29-C), 129.4 (4-C), 128.5 (28-C), 126.8 (30-C), 123.9 (14-C), 121.2 (17-C), 
118.9 (19-C), 118.6 (18-C), 115.8 (36-C), 111.7 (16-C), 64.1 (23-C), 57.2 (32-C), 54.7 (22-C), 54.3 (10-
C), 54.1 (7-C), 51.4 (25-C), 52.0 (2-C), 51.7 (6-C), 47.8 (3-C), 37.3 (26-C), 36.3 (33-C), 27.7 (12-C), 
15.3 (8-C). HPLC-ESI-MS: m/z (%) = 781.4 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C41H49N8O8
 
[M+H]
+ 
1017.5420; found 781.3626. 
(S)-N-((S)-1-((2S,5S)-5-((1H-Indol-3-yl)methyl)-7-(2-amino-2-oxoethyl)-2-methyl-3,6-dioxo-1,4,7-
triazacycloundecan-1-yl)-3-hydroxy-1-oxopropan-2-yl)-2-((S)-2-amino-3-(4-hydroxy-phenyl)-
propanamido)-3-phenylpropanamide (TVC-158, 67)  
Starting material TVC-155 (24 mg, 26.46 µmol) 
yielded product 67 (22 mg, 91%).  
1
H-NMR (600 MHz, CD3OD): δ = 7.61 (d, J = 7.5 
Hz, 1H, 19-H), 7.35 (d, J = 7.5 Hz, 1H, 16-H), 7.28-
7.19 (m, 5H), 7.19 (s, 1H, 14-H), 7.1 (overlap, 1H, 
17-H), 7.08 (d, J = 8.0 Hz, 2H, 35-H), 7.03 (t, J = 7.5 
Hz, 1H, 18-H), 6.78 (d, J =8.4 Hz, 2H, 36-H), 4.81 
(m, 1H, 22-H), 4.67 (t, J = 7.3 Hz, 1H, 25-H), 4.63 
(m, 1H, 7-H), 4.10 (m, 1H, 10-H), 4.01 (m, 1H, 32-H), 4.0 (m, 1H, 2-H), 3.85 (m, 1H, 2-H), 3.79 (m, 1H, 
23-H), 3.65 (overlap, 1H, 23-H), 3.36 (overlap, 2H, 12-H), 3.47 (t, J = 6.0 Hz, 2H, 3-H), 3.38 (m, 2H, 6-
H), 3.15 (m, 1H, 26-H), 3.13 (m, 1H, 33-H), 2.98 (m, 1H, 26-H), 2.94 (m, 1H, 33-H), 1.59 (m, 2H, 5-H), 
1.54 (m, 2H, 4-H), 1.36 (s, 3H, 7-H). 
13
C-NMR (150 MHz, CD3OD): δ = 174.0 (9-C), 173.2 (11-C), 
173.0 (24-C), 172.6 (31-C), 155.2 (37-C), 138.0 (27-C), 137.6 (15-C), 129.4 (35-C), 129.2 (29-C), 127.8 
(28-C), 126.3 (30-C), 123.8 (36-C), 123.4 (14-C), 121.0 (17-C), 118.5 (18-C), 117.3 (19-C), 111.0 (16-
C), 79.5 (43-C), 74.7 (41-C), 61.5 (23-C), 56.6 (32-C), 56.0 (10-C), 54.7 (7-C), 52.7 (25-C), 50.2 (22-C), 
49.8 (2-C), 46.6 (6-C), 40.1 (3-C), 37.5 (26-C), 37.1 (33-C), 27.6 (44-C), 27.3 (39-C), 26.4 (5-C), 26.2 
(42-C), 25.6 (12-C), 13.5 (8-C). HPLC-ESI-MS: m/z (%) = 783.4 (100) [M+H]
+
. HR-ESI-MS (m/z): 
calcd. for C41H50N8O8Na [M+Na]
+ 
805.3644; found 805.3664. 
3.9 Synthesis of hexapeptide TVC-044 (79) 
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2-[(2,2-Diethoxyethyl)amino]acetamide (TVC-001, 73) 
A suspension solution of glycinamide hydrochloride (2.5 g, 22.16 mmol) 
and NaHCO3 (4.84g, 57.62 mmol) in ACN (120 mL) was added 2-
bromacetaldehyde diethylacetal (3.33 mL, 22.16 mmol). After refluxing 
for 44 h, the hot reaction mixture was filtered through a Celite pad and washed with EtOAc. The filtrate 
was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography 
using EtOAc/EtOH (4/1) to afford product 73 (1.56 g, 37%) as a brown oil.  
1
H-NMR
 
(400 MHz, CDCl3): δ = 7.18 (s, 1H, NH), 5.61 (s, 1H, NH), 4.53 (t, J = 5.11 Hz, 1H, 4-H), 3.69 
(quin, J = 7.06 Hz, 2H, 5-H), 3.53 (quin, J = 7.05 Hz, 7-H), 3.29 (s, 2H, 2-H), 2.75 (d, J = 5.12 Hz, 3-H), 
1.22 (t, J = 7.05 Hz, 6H, 6,8-H). 
13
C-NMR (100 MHz, CDCl3): δ = 114.87 (1-C), 101 (4-C), 62.56 (5-C, 
7 -C), 52.15 (2-C), 52.09 (3-C), 15.31 (6-C, 8-C). IR (KBr) ν (cm-1): 3350.6, 1714.5, 1168.1. HPLC-ESI-
MS: m/z (%) = 145 (100), 213 (20) [M+Na]
+
. HR-ESI-MS (m/z): calcd. for C8H18N2O3Na
 
[M+Na]
+
 
213.1215; found 213.1210. Rf = 0.37 (EtOAc/EtOH, 4/1).  
9H-Fluoren-9-ylmethyl-N-[(1S)-1-[(carbamoylmethyl)(2,2-diethoxyethyl)carbamoyl]-2-(1H-indol-3-
yl)ethyl]carbamate (TVC-004, 74) 
To a stirred solution of 73 (100 mg, 0.48 mmol), Fmoc-Trp-OH (278 
mg, 0.65 mmol) and HATU (254.6 mg, 0.67 mmol) in DCM (4 mL), 
DIPEA (0.2 ml, 1.2 mmol) was added. After stirring for 20 h at room 
temperature, the solvent was removed. The residue was dissolved in 
EtOAc (40 mL), washed with H2O (2x10 mL), brine solution (2x10 
mL) and dried over Na2SO4. Removal of the solvent and column 
chromatography, using EtOAc as eluent, yielded product 74 (290 mg, 
100%) as a yellow solid. 
1
H-NMR (400 MHz, CDCl3): δ = 8.6 (s, 1H, NH), 7.74 (d, J = 7.5 
Hz, 2H, 27-H, 30-H), 7.7 (d, J = 7.7 Hz, 1H, 14-H), 7.53 (d, J = 7.5 
Hz, 2H, 24-H, 33-H), 7.38 (t, J = 7.5 Hz, 2H, 26-H, 31-H), 7.33 (m, 1H, 17-H), 7.28 (m, 2H, 25-H, 32-
H), 7.17 (m, 1H, 16-H), 7.10 (m, 1H, 15-H), 7.06 (s, 1H, 4-H), 6.2 (br, 1H, NH), 5.85 (d, J = 7.3 Hz, 1H, 
NH), 5.8 (br, 1H, NH), 5.7 (d, J = 8 Hz, 1H, NH), 5.00 (q, J = 6.6 Hz, 1H, 10-H), 4.5 (t, J = 5 Hz, 1/3 H, 
4-H), 4.3 (m, 2H, 21-H), 4.17 (t, J = 5.7 Hz, 2/3H, 4-H), 4.15 (br, 1H, 22-H), 3.97 (q, J = 16 Hz, 2H, 2-
H), 3.46-3.38, 3.29-3.25 (m, 4H, 5-H, 7-H), 3.3, 3.17 (m, 4H, 11-H, 3-H), 1.02 (m, 6H, 6-H, 8-H). 
13
C-
NMR (100 MHz, CDCl3): δ = 173.7, 171, 156.1 (C=O), 143.7, 141.2 (C-23), 136.2 (C-18), 127.7 (C-28), 
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127.2 (C-13), 127.0 (C-25), 125.1 (C-24), 123.7 (C-4), 122.3 (C-16), 14.9 (C-27), 14.7 (C-15), 118.5 (C-
14), 109.6 (C-12), 101.2 (C-4), 67.1 (C-21), 63.6, 63.4 (C-7, C-5), 52.1 (C-2), 51.8 (C-3), 51.2 (C-10), 
47.2 (C-22), 29.7 (C-11), 15.2, 15.1 (C-6, C-8). IR (KBr) ν (cm-1): 3421.9 (NH), 1684.9, 1636.6 (CO). 
HPLC-ESI-MS: m/z (%) = 553.2 (100) [M-C2H5O]
+
, 616.3 (7.6) [M+NH4]
+
, 621.3 (16) [M+Na]
+
. HR-
ESI-MS (m/z): calcd. for C34H38N4O6Na [M+Na]
+
 621.2684; found 621.2684. Rf = 0.4 (EtOAc).  
9H-Fluoren-9-ylmethyl-(1S,12S)-14-(carbamoylmethyl)-13-oxo-3,14,16-triazatetracyclo-
[10.3.1.0
2,10
.0
4,9
]-hexadeca-2(10),4(9),5,7-tetraene-16-carboxylate (TVC-007, 75) 
A stirred solution of 74 (120 mg, 0.2 mmol) in CH3CN (8 mL) at 0 
o
C was 
added dropwise 1N HCl (4 mL). After stirring further for 3 h at 0 
o
C, 
EtOAc (20 mL) was added. The organic phase was washed with H2O, 
saturated NaHCO3, brine solution and dried over Na2SO4. The solvent was 
removed and the residue was purified by silica gel column chromatography 
(EtOAc/EtOH, 10/1) to provide pure product 75 (79 mg, 75%) as a yellow 
solid. 
1
H-NMR (600 MHz, CDCl3): δ = 8.4 (s, 1H, NH), 8.03 (s, 1H, NH), 7.78 
(d, J = 7.2 Hz, 2H, 23-H, 26-H), 7.58 (m, 2H, 20-H, 29-H), 7.45 (d, J = 7.8 
Hz, 1H, 11-H), 7.32 (overlap, 1H, 14-H), 7.39 (m, 2H, 22-H, 27-H), 7.30 (m, 2H, 21-H, 28-H), 7.18 (m, 
1H, 13-H), 7.12 (m, 1H, 12-H), 5.5 (br, 1/2H, 7-H), 5.29 (s, 1H, NH), 5.06 (br, 1/2H, 4-H), 4.99 (br, 
1/2H, 7-H), 4.85 (overlap, 1/.2H, 4-H), 4.58 (q, J = 5.4 Hz, 2H, 17-H), 4.32 (d, J = 16 Hz, 1H, 2-H), 
4.26-4.24 (m, 1H, 18-H), 3.92, 3.67 (d, J = 12 Hz, 1H, 6-H), 3.48 (d, J = 16 Hz, 1H, 2-H), 3.38, 3.22 (d, J 
= 12 Hz, 1H, 6-H), 3.07, 2.96 (m, 2H, 5-H). 
13
C-NMR (150 MHz, CDCl3): δ = 170.0, 169.9, 153.9 (CO), 
143 (C-4), 141 (C-24), 136.1 (C-15), 129.7 (C-8), 127.9 (C-22), 127.3 (C-21), 126.3 (C-10), 124.7 (C-
20), 123.0 (C-13), 120.3 (C-23), 118.8 (C-11), 114.5 (C-12), 111.4 (C-14), 108.8 (C-9), 67.8 (C-17), 54.1 
(C-4), 53.4 (C-6), 50.4 (C-2), 47.3 (C-18), 45.96 (C-7), 26.1 (C-5). IR (KBr) ν (cm-1): 3254.5 (NH), 
1683.9, 1639.3 (CO). HPLC-ESI-MS: m/z (%) = 507.1 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for 
C30H26N4O4Na
 
[M+Na]
+
 529.1852; found 529.1806. Rf = 0.11 (EtOAc/EtOH, 10/1).  
2-[(1S,12S)-13-Oxo-3,14,16-triazatetracyclo[10.3.1.0
2,10
.0
4,9
]hexadeca-2(10),4(9),5,7-tetraen-14-yl]- 
acetamide (TVC-009, 76) 
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A stirred solution of 75 (70 mg, 0.14 mmol) in DCM (4 mL) was treated with piperidine (0.14 mL, 1.4 
mmol) at room temperature for 18 h. The solvent was evaporated and the crude product was purified by 
silica gel column chromatography (DCM/MeOH, 5/1) to furnish 76 (30 mg, 76%) as a 
white solid. 
1
H-NMR (400 MHz, DMSO-d6): δ = 10.82 (s, 1H, NH), 7.36 (d, J = 7.76 Hz, 1H, 14-
H), 7.30 (d, J = 8.02 Hz, 1H, 11-H), 7.04 (dt, J = 7.0 Hz, J = 1.07 Hz, 1H, 11-H), 6.93 
(dt, J = 7.86 Hz, J = 0.9 Hz, 1H, 12-H), 4.27 (d, J = 4 Hz, 1H, 7-H), 4.12 (d, J = 16 
Hz, 1H, 2-H), 3.94 (dd, J = 11.0 Hz, J = 4.5 Hz, 1H, 6-H), 3.83 (d, J = 5 Hz, 1H, 4-H), 
3.24 (d, J = 11.0 Hz, 1H, 6-H), 2.91 (dd, J = 15.0 Hz, J = 6.0 Hz, 1H, 5-H), 2.77 (d, J 
= 15 Hz, 1H, 5-H). 
13
C-NMR (100 MHz, DMSO-d6): δ = 170.9 (1-C), 169.7 (3-C), 
135.4 (15-C), 134.5 (8-C), 126.4 (10-C), 120.7 (13-C), 118.4 (12-C), 117.4 (11-C), 111.1 (14-C), 106.5 
(9-C), 54.6 (6-C), 53.2 (4-C), 48.9 (2-C), 45.0 (7-C), 26.3 (5-C). IR (KBr) ν (cm-1): 3382.1 (NH), 1627.4 
(CO). HPLC-ESI-MS: m/z (%) = 268.1 (100) [M-NH4]
+
, 185.1 [M+H]
+
, 307.1 [M+Na]
+
. HR-ESI-MS 
(m/z): calcd. for C15H16N4O2Na [M+Na]
+
 307.1171; found 307.1165. Rf = 0.15 (MeOH/DCM, 2/5). 
9H-Fluoren-9-ylmethyl-(2S)-2-[(1S,12S)-14-(carbamoylmethyl)-13-oxo-3,14,16-triazatetracyclo-
[10.3.1.0
2,10
.0
4,9
]hexadeca-2(10),4(9),5,7-tetraene-16-carbonyl]pyrrolidine-1-carboxylate (TVC-034, 
77) 
A solution of 76 (250 mg, 0.88 mmol) and Fmoc-L-Pro-OH (385.7 mg, 
1.14 mmol) in DMF (10 mL) was added HATU (434.5 mg, 1.14 mmol) 
and DIPEA (0.44 mL, 3.52 mmol). After stirring at room temperature for 
28 h, the reaction mixture was quenched with EtOAc (200 mL), washed 
with H2O and brine solution. The crude product was chromatographed 
eluting EtOAc/EtOH (15/1) to yield the desired product 77 (474 mg, 
89% yield) as a yellow solid. 
1
H-NMR (600 MHz, CDCl3): δ = 9.0 (s, 1H, NH, ), 7.74 (dd, J = 3.3 
Hz, J = 7.5 Hz, 2H, 28-H), 7.53 (d, J = 7.5 Hz, 1H, 25-H), 7.49 (d, J = 
7.5 Hz, 1H, 25’-H), 7.45 (d, J = 7.9 Hz, 1H, 11-H), 7.39 (q, J = 7 Hz, 2H, 27-H), 7.32-7.29 (m, 3H, 14-H, 
26-H), 7.16 (t, J = 7.8 Hz, 1H, 13-H), 7.09 (t, J = 7.4 Hz, 12-H), 6.8 (s, 1H, NH), 5.97 (d, J = 3.8 Hz, 1H, 
7-H), 5.29 (overlap, 1H, 4-H), 4.63 (t, J = 6.9 Hz, 1H, 17-H), 4.46 (d, J = 16.9 Hz, 1H, 2-H), 4.27 (m, 
1H, 22-H), 4.13 (overlap, 1H, 22-H), 4.13 (br., 1H, 23-H), 4.01 (dd, J = 4.3 Hz, J = 11.8 Hz, 1H, -H), 
3.65 (m, 1H, 20-H), 3.6 (m, 1H, 20-H), 3.37 (d, J = 15.1 Hz, 1H, 5-H), 3.28 (d, J = 16.9 Hz, 1H, 2-H), 
3.26 (d, J = 11.8 Hz, 1H, 6-H), 3.18 (dd, J = 5.6 Hz, J = 15.6 Hz, 1H, 5-H), 2.20-2.13 (m, 2H, 18-H, 4-
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H), 2.10-2.07 (m, 1H, 4-H), 1.97-1.92 (m, 1H, 18-H). 
13
C-NMR (150 MHz, CDCl3): δ = 40.6 (1-C), 
168.2 (16-C), 162.5 (3-C), 155.2 (21-C), 143.6 (24-C), 141.2 (29-C), 136.3 (15-C), 129.96 (8-C), 127.9 
(27-C), 127.2 (26-C), 126.1 (10-C), 125.1 (28-C), 122.7 (13-C), 120.08 (12-C), 120.04 (25-C), 118.4 (11-
C), 111.4 (14-C), 108.2 (9-C), 67.7 (22-C), 56.3 (4-C), 55.6 (17-C), 52.4 (6-C), 50.8 (2-C), 47.0 (20-C), 
46.9 (23-C), 44.4 (7-C), 30.6 (4-C), 27.1 (5-C), 25.1 (4-C). IR (KBr) ν (cm-1): 3308.2 (NH), 1662.9 (CO). 
HPLC-ESI-MS: m/z (%) = 604.2 (100) [M+H]
+
, 587.2 (25) [M-NH3]
+
. HR-ESI-MS (m/z): calcd. for 
C35H33N5O5Na
 
[M+Na]
+
 626.2379; found 626.2374. Rf = 0.37 (AcOEt/EtOH, 6/1). 
2-[(1S,12S)-13-Oxo-16-[(2S)-pyrrolidine-2-carbonyl]-3,14,16-triazatetracyclo[10.3.1.0
2,10
.0
4,9
] 
hexadeca-2(10),4(9),5,7-tetraen-14-yl]acetamide (TVC-035, 78)  
Compound 77 (286 mg, 0.47 mmol) in DCM (15 mL) was treated with 
piperidine (0.47 mL, 4.74 mmol) at room temperature for 20 h. Afterward, the 
reaction mixture was concentrated under reduced pressure. The residue was 
subjected to silica gel column chromatography using EtOH/EtOAc (gradient 
from 40/60 to 90/10, 2% TEA) to afford 78 (180 mg, 99%) as a solid. 
1
H-NMR (600 MHz, CD3OD): δ = 7.41 (dd, J = 7.9 Hz, 1H, 11-H), 7.35 (dd, J 
= 8.1 Hz, 1H, 14-H), 7.12 (t, J = 7.8 Hz, 1H, 13-H), 7.02 (m, 1H, 12-H), 6.0 (d, 
J = 3.9 Hz, 3/5H, 7-H), 5.6 (d, J = 3.6 Hz, 2/5H, 7-H), 5.4 (d, J = 5.4 Hz, 2/5H, 4-H), 5.1 (s, 3/5H, 4-H), 
4.25 (dd, J = 16.6 Hz, 1H, 2-H), 4.16 (dd, J = 4.2 Hz, 2/5H, 6-H), 4.12 (t, J = 7 Hz, 3/5H, 17-H), 4.03 
(dd, J = 4.3 Hz, 3/5H, 6-H), 3.97 (t, J = 6.7 Hz, 2/5H, 17-H), 3.68 (dd, J = 16.6 Hz, 1H, 2-H), 3.55 (d, J 
= 11.9 Hz, 2/5H, 6-H), 3.46 (dd, J = 11.4 Hz, 3/5H, 6-H), 3.2-3.16 (m, 2H, 5-H), 3.12-3.10 (m, 2/5H, 20-
H), 3.04 (m, 3/5H, 20-H), 2.87-2.84 (m, 3/5H, 20-H), 2.80-2.77 (m, 2/5H, 20-H), 2.3 (m, 2/5H, 18-H), 2.2  
(m, 3/5H, 18-H), 1.8  (m, 1H, 18-H), 1.9-1.8 (m, 2H, 4-H). 
13
C-NMR (150 MHz, CD3OD): δ = 173.1 (1-
C), 172.5, 172.4 (3-C), 171.3, 170.8 (16-C), 138.06 (15-C), 131.6, 131.2 (8-C), 127 (10-C), 123.4, 123.2 
(13-C), 120.6, 120.5 (12-C), 118.9 (11-C), 112.5 (14-C), 109.2, 108.2 (9-C), 59.2, 58.7 (17-C), 56.4, 53.5 
(4-C), 55.4, 54.4 (6-C), 50.7, 50.2 (2-C), 49.2, 45.5 (7-C), 47.9 (20-C), 31.9, 31.7 (18-C), 28.2, 25.9 (5-
C), 27.3 (4-C). IR (KBr) ν (cm-1): 3339.5 (NH), 1669.1 (CO). HPLC-ESI-MS: m/z (%) = 383.2 (100) 
[M+H]
+
. HR-ESI-MS (m/z): calcd. for C20H24N5O3
 
[M+H]
+
 382.1879; found 382.1874. Rf = 0.2 
(EtOH/TEA, 98/2). 
9H-Fluoren-9-ylmethyl-[(1S)-1-{[(1S)-1-{[(2S)-3-(tert-butoxy)-1-[(2S)-2-[(12S)-14-(carbamoyl-
methyl)-13-oxo-3,14,16-triazatetracyclo[10.3.1.0
2,10
.0
4,9
]hexadeca-2(10),4(9),5,7-tetraene-16-
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carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]carbamoyl}-2-phenylethyl]carbamoyl}-2-[4-(tert-
butoxy)phenyl]ethyl]carbamate (TVC-037) 
A solution of tripeptide Fmoc-Tyr(tBu)-Phe-Ser(tBu)-OH (170 mg, 0.23 mmol) and 78 (99 mg, 0.26 
mmol) in DMF (9 mL) was added HATU (103 mg, 0.27 mmol) and followed by DIPEA (0.11 mL, 0.68 
mmol). After stirring at room temperature for 20 h, the reaction mixture was quenched with EtOAc (200 
mL), washed with H2O and brine solution. Flash chromatography (EtOAc/EtOH, 40/1) afforded pure 
product TVC-037 (170 mg, 67%) as a white solid. 
1
H-NMR (600 MHz, CDCl3): δ = 10.4 
(s, 1H, NH), 8.26 (d, J = 9.5 Hz, 1H, 
NH), 8.0 (s, 1H, NH), 7.8 (d, J = 5.3 
Hz, 1H, NH), 7.56 (m, 2H, 49-H), 7.37 
(m, 2H, 48-H), 7.31 (t, J = 7.5 Hz, 1H), 
7.29 (t, J = 6.4 Hz, 1H), 7.22 (t, J = 
7.5 Hz, 1H), 7.17 (t, J = 7.4 Hz, 1H, 
10-H), 7.09 (m, 3H, 35-H, 9-H), 6.84 
(m, 2H, 36-H), 5.36 (m, 1H, 14-H), 5.1, 4.62 (m, 1H, 17-H), 4.83 (d, J = 5.0 Hz, 1H, 4-H), 4.46 (dd, J = 
4.3 Hz, J = 12.0 Hz, 1H, 22-H), 4.31 (d, J = 16.8 Hz, 1H, 2-H), 4.12 (m, 1H, 43-H), 3.84 (d, J = 16.9 Hz, 
1H, 2-H), 3.42 (d, J = 15.5 Hz, 1H, 5-H), 3.4 (d, J = 15.5 Hz, 2H, 23-H), 3.16 (d, J = 5.6 Hz, 1H, 5-H), 
2.90, 2.51 (m, 2H, 20-H), 2.20, 1.93 (m, 2H, 18-H), 2.06 (overlap, 1H, 19-H), 1.56 (overlap, 1H, 19-H), 
1.51 (s, 9H, 39-H), 1.09, (s, 9H, 41-H).
13
C-NMR (150 MHz, CDCl3): δ = 171.4 (31-C), 170.6 (24-C), 
170.5 (21-C), 169.9 (16-C), 169.1 (3-C), 167.7 (1-C), 155.4 (42-C), 154.4 (37-C), 143.8, 143.6 (50-C), 
141.3, 141.2 (45-C), 137.5 (27-C), 136.6, 136.3, 136.2 (12-C), 131.3 (34-C), 130.3, 130.2 (13-C), 129.9, 
129.7 (35-C), 128.5, 128.2 (29-C), 127.7, 127.6 (48-C), 127.1 (28-C), 126.9, 126.7 (47-C), 126.1 (7-C), 
125.4 (30-C), 125.0, 124.8 (46-C),124.5, 124.7 (36-C), 122.8, 122.4 (9-C), 120.0 (49-C), 118.4, 118.3 (8-
C), 114.7, 114.5 (10-C), 106.5 (6-C), 80.8 (38-C), 78.3(40-C), 67.3, 65.6 (43-C), 47.3, 46.9 (44-C), 61.2, 
60.3 (23-C), 57.4, 55.7 (17-C), 54.7 (4-C), 52.8 (22-C, 14-C), 51.9 (2-C), 47.7 (20-C), 30.8 29.7 (18-C), 
29.1, 28.8, 27.3, 27.1 (29-C, 41-C), 25.7 (19-C). IR (KBr) ν (cm-1): 3406.9 (NH), 1660.4 (CO). HPLC-
ESI-MS: m/z (%) = 1113.5 (100) [M+H]
+
, 1130.5 (79.9) [M+NH4]
+
. HR-ESI-MS (m/z): calcd. for 
C64H72N8O10Na [M+Na]
+
 1135.5269; found 1135.4933. Rf = 0.23 (EtOAc/EtOH, 40/1). 
(2S)-2-[(2S)-2-Amino-3-[4-(tert-butoxy)phenyl]propanamido]-N-[(2S)-3-(tert-butoxy)-1-[(2S)-2-
[(1S)-14-(carbamoylmethyl)-13-oxo-3,14,16-triazatetracyclo[10.3.1.0
2,10
.0
4,9
] hexadeca-2(10),4(9),5,7-
tetraene-16-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]-3-phenylpropanamide (TVC-041) 
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To a solution of TVC-037 (125 mg, 54 µmol) in DCM (12 mL), piperidine (0.2 mL, 100 µmol) was 
added and stirred at room temperature for 4 h. After removing the solvent, the crude product was purified 
on silica gel column chromatography eluting AcOEt/EtOH (10/1) to afford TVC-041 (75 mg, 75%) as a 
white solid. 
1
H-NMR (600 MHz, CDCl3): δ = 8.6, 7.97, 
7.68 (s, 1H, NH), 7.45 (d, J = 7.8 Hz, 1H, 
8-H), 7.30 (m, 1H, 11-H), 7.26 (m, 3H, 28-
H, 30-H), 7.17 (t, J = 7.0 Hz, 1H, 10-H), 
7.11 (overlap, 1H, 9-H), 7.08 (overlap, 2H, 
29-H), 7.02 (d, J = 8.3 Hz, 2H, 35-H), 6.90 
(d, J = 8.4 Hz, 2H, 36-H), 6.37 (s, NH), 
5.89 (d, J = 3.8 Hz, 1H, 14-H), 5.37 (d, J = 
5.3 Hz, 1H, 4-H), 4.8 (d, J = 17.3 Hz, 1H, 2-H), 4.76 (m, 1H, 25-H), 4.67 (q, J = 6.4 Hz, 1H, 22-H), 4.61 
(t, J = 7.3 Hz, 1H, 17-H), 4.03-4.0 (m, 1H, 15-H), 3.2 (d, J = 11.6 Hz, 1H, 15-H), 3.78 (m, 1H, 20-H), 
3.72 (m, 1H, 20-H), 3.63 (dd, J = 4 Hz, J = 8.6 Hz, 1H, 32-H), 3.49 (m, 1H, 23-H), 3.34 (d, J = 15.6 Hz, 
1H, 5-H), 3.25 (t, J = 8.4 Hz, 1H, 23-H), 3.15 (dd, J = 5.6 Hz, J = 15.6 Hz, 1H, 5-H), 3.03 (t, J = 6.7 Hz, 
2H, 26-H), 3.0 (overlap, 1H, 2-H), 2.96 (m, 1H, 5-H), 2.96 (m, 1H, 20-H), 2.46 (dd, J = 8.8 Hz, 1H, 33-
H), 2.23 (m, 1H, 18-H), 2.09 (m, 2H, 19-H), 1.31 (s, 9H, 39-H), 1.09 (s, 9H, 41-H). 
13
C-NMR (150 MHz, 
CDCl3): δ = 175.3 (24-C), 171.0 (31-H), 170.3 (16-C), 169.8 (3-C), 168.3 (1-C), 154.2 (37-C), 136.4 (27-
C), 136.3 (12-C), 131.9 (13-C), 129.9 (7-C), 129.8 (35-C), 129.5 (29-C), 128.6 (28-C), 126.9 (30-C), 
126.2 (34-C), 124.2 (36-C), 122.7 (10-C), 120.0 (8-C), 118 (9-C), 111.3 (11-C), 108.9 (6-C), 78.3 (38-C), 
73.7 (40-C), 61.3 (23-C), 56.7 (4-C), 55.8 (32-C), 55.7 (17-C), 53.4 (25-C), 52.5 (15-C), 51.7 (22-C), 
51.2 (2-C), 47.6 (20-C), 44.5 (14-C), 39.6 (33-C), 37.5 (26-C), 29.8 (18-C), 26.9 (5-C), 25.8 (19-C). IR 
(KBr) ν (cm-1): 3410.9 (NH), 1659.4, 1639.3 (CO). HPLC-ESI-MS: m/z (%) = 891.4 (100) [M+H]+, 
913.4 (45) [M+Na]
+
. HR-ESI-MS (m/z): calcd. for C49H63N8O8 [M+H]
+
 891.4769; found 891.4763. Rf = 
0.16 (EtOAc/EtOH, 10/1).  
(2S)-2-[(2S)-2-Amino-3-(4-hydroxyphenyl)propanamido]-N-[(2S)-1-[(2S)-2-[(1S)-14-(carbamoyl-
methyl)-13-oxo-3,14,16-triazatetracyclo[10.3.1.0
2,10
.0
4,9
]hexadeca-2(10),4(9),5,7-tetraene-16-
carbonyl]pyrrolidin-1-yl]-3-hydroxy-1-oxopropan-2-yl]-3-phenylpropanamide (TVC-044, 79) 
Peptide TVC-041 (35 mg, 22 µmol) was treated with 
TFA/TIPS/H2O (2 mL, 95/2.5/2.5) for 4 h at 0 ºC. After 
that, the solvent was evaporated under reduced 
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pressure. The residue was purified by silica gel column chromatography using DCM/MeOH (4/1, 0.1% 
TEA). The pure product 79 (33.1 mg, 94 %) was dissolved in ACN/H2O (3 mL, 1/1) and lyophilized to 
afford white powder. 
1
H-NMR (600 MHz, DMSO-d6): δ = 11.0 (s, 1H, NH), 8.72 (s, 1H, NH), 8.7 (s, 1H, NH), 7.42 (d, J = 
7.8 Hz, 1H, 8-H), 7.35 (d, J = 8.2 Hz, 1H, 11-H), 7.28 (m, 2H, 29-H), 7.21 (m, 3H, 28-H,  30-H), 7.1 
(overlap, 1H, 9-H), 7.05 (d, J = 8.4 Hz, 2H, 35-H), 6.99 (t, J = 7.6 Hz, 1H, 10-H), 6.7 (d, J = 8.4 Hz, 2H, 
36-H), 5.76 (d, J = 4 Hz, 1H, 14-H), 5.37 (d, J = 4.4 Hz, 1H, 4-H), 4.89 (t, J = 7.2 Hz, 1H, 17-H), 4.7 (m, 
1H, 25-H), 4.58-4.57 (m, 1H, 22-C), 4.3 (d, J = 16.8 Hz, 1H, 2-C), 3.9 (br, 1H, 32-H), 3.85 (dd, J = 4.3 
Hz, J = 12 Hz, 1H, 15-H), 3.75 (m, 1H, 20-H), 3.66 (m, 1H, 23-H), 3.46 (m, 1H, 23-H), 3.61 (m, 1H, 20-
H), 3.38 (d, J = 10.4 Hz, 1H, 15-H), 3.26 (d, J = 16.8 Hz, 1H, 2-H), 3.11 (m, 2H, 5-H), 3.07 (d, J = 8.3 
Hz, 1H, 26-H), 2.97 (m, 1H, 1H, 33-H), 2.79 (m, 1H, 26-H), 2.76 (m, 1H, 1H, 33-H), 2.14 (m, 1H, 18-H), 
2.08 (m, 1H, 19-H), 1.89 (m, 1H, 19-H), 1.79 (m, 1H, 18-H). 
13
C-NMR (150 MHz, DMSO-d6): δ = 173.1 
(24-C), 172.8 (31-C), 172.7 (16-C), 171.0 (21-C), 170.8 (3-C), 169.9 (1-C), 158.3 (37-C), 138.1 (27-C), 
138.07 (12-C), 131.7 (34-C), 131.6 (25-C), 130.3 (29-C), 129.7 (28-C), 127.9 (30-C), 127.5 (13-C), 125.8 
(7-C), 123.0 (10-C), 120.0 (9-C), 118.9 (8-C), 116.9 (36-C), 112.5 (11-C), 108.6 (6-C), 62.5 (23-C), 57.9 
(17-C), 57.6 (4-C), 56.1 (25-C), 55.6 (22-C), 54.9 (32-C), 53.8 (15-C), 51.4 (2-C), 48.9 (20-C), 46.1 (14-
C), 38.6 (26-C), 37.8 (33-C), 30.8 (18-C), 28.0 (19-C), 26.5 (5-C). IR (KBr) ν (cm-1): 3397.4 (NH), 
1669.9 (CO). HPLC-ESI-MS: m/z (%) = 779.4 (100) [M+H]
+
, 801.4 (39) [M+Na]
+
. HR-ESI-MS (m/z): 
calcd. for C41H47N8O8
 
[M+H]
+
 779.3517; found 779.3511. 
3.10 Synthesis of hexapeptide TVC-050 (88) 
(S)-Methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate (TVC-020, 69) 
A solution of L-Trp-OMe*HCl (800 mg, 3.14 mmol) in MeOH/H2O (10 mL, 
10/1) was added dropwise 36% formaldehyde (24 mg, 0.27 mmol) in MeOH (2 
mL). After stirring at room temperature for 16 h, the reaction mixture was 
concentrated under diminished pressure to dryness. The residue was dissolved in 
H2O (10 mL) and neutralized with NaHCO3. The aqueous solution was extracted 
with EtOAc (3x50 mL). The combined organic phases were washed with brine solution (2x20 mL) and 
dried over Na2SO4. Removal of the solvent and flash chromatography (EtOAc/EtOH, 20/1) provided 69 
(400 mg, 55%) as a white solid. 
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1
H-NMR (400 MHz, CDCl3): δ = 7.98 (s, 1H, NH), 7.5 (d, J = 7.5 Hz, 1H, 7-H), 7.3 (d, J = 7.9 Hz, 1H, 
10-H), 7.18 (dt, J = 1.5 Hz, J = 7.1 Hz, 1H, 8-H), 7.12 (dt, J = 0.9 Hz, J = 7.2 Hz, 1H, 9-H), 4.1 (s, 2H, 3-
H), 3.83 (overlap, 1H, 2-H), 3.82 (s, 3H, 13-H), 3.14 (dd, J = 4.7 Hz, J = 15.2 Hz, 1H, 1-H), 2.95 (dd, J = 
9.6 Hz, J = 15.2 Hz, 1H, 1-H). 
13
C-NMR (100 MHz, CDCl3): δ = 173.8 (12-C), 135.9 (11-C), 131.9 (4-
C), 127.2 (6-C), 121.7 (8-C), 114.5 (9-C), 117.8 (7-C), 110.7 (10-C), 107.3 (5-C), 55.9 (2-C), 52.1 (13-
C), 42.1 (3-C), 25.4 (1-C). IR (KBr) ν (cm-1): 3176.8 (NH), 1733.5 (CO). HPLC-ESI-MS: m/z (%) = 231 
(100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C13H15N2O2 [M+H]
+
 231.1134; found 231.1137. Rf = 0.12 
(AcOEt/EtOH, 20/1). 
(S)-Methyl-2-((S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carbonyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxylate (TVC-040, 83)  
To a solution of 69 (15.0 mg, 0.07 mmol), Boc-L-Pro-OH (16.1 mg, 
0.07 mmol) and HATU (30 mg, 0.08 mmol) in DMF (3 mL), 
DIPEA (0.032 mL, 0.02 mmol) was added. After stirring at room 
temperature for 24 h, EtOAc (300 mL) was added. The resulting 
solution was washed with H2O, brine solution and dried over 
MgSO4. Flash chromatography (eluent: CyH/EtOAc, 1/1) afforded 
solid product 83 (25 mg, 90%). 
1
H-NMR (400 MHz, CD3OD): δ = 7.97 (s, 1/2H, NH), 7.42 (t, J = 7.6 Hz, 1H, 7-H), 7.3 (t, J = 8.1 Hz, 
1H, 10-H), 7.1-7.0 (m, 1H, 9-H), 7.02-6.9 (m, 1H, 9-H), 5.8 (dd, J = 1.6 Hz, J = 6.0 Hz, 1/2H, 2-H), 5.79 
(dd, J = 1.5 Hz, J = 6.0 Hz, 1/2H, 2-H), 4.9 (dd, J = 3.7 Hz, J = 8.6 Hz, 1H, 15-H), 5.2 (d, J = 16.2 Hz, 
1/2H, 3-H), 5.0 (d, J = 15.4 Hz, 1/2H, 3-H) 4.75 (d, J = 15.4 Hz, 1H, 3-H), 3.6 (s, 3H, 13-H), 3.56-3.46 
(m, 2H, 18-H), 3.53-3.50 (m, 1H, 1-H), 3.1-3.0 (m, 1H, 1-H), 2.43-2.33 (m, 1H, 16-H), 2.05-2.01 (m, 1H, 
16-H), 1.99-1.88 (m, 2H, 17-H), 1.4 (s, 5H, 21-H), 1.2 (s, 4H, 21-H). 
13
C-NMR (100 MHz, CD3OD): δ = 
176.1, 175.4 (12-C), 172.9, 172.3 (14-C), 156.4, 155.8 (4-C), 138.3 (11-C), 127.0 (6-C), 129.0 (4-C), 
122.7-122.5 (9-C), 120.1, 120.06 (8-C), 118.6, 118.5 (7-C), 112.0, 111.9 (10-C), 106.6, 105.6 (5-C), 81.4 
(20-C), 58.9, 58.7 (15-C), 53.0 (13-C), 52.9 (2-C), 48.1, 47.7 (18-C), 42.5, 42.4 (3-C), 30.8, 29.8 (16-C), 
28.7, 28.5 (21-C), 25.0, 24.6 (17-C), 23.7, 23.4 (3-C). IR (KBr) ν (cm-1): 3440.7 (NH), 1740.9, 1675.3 
(CO). HPLC-ESI-MS: m/z (%) = 328.2 (100) [M-Boc]
+
, 428.2 (8) [M+H]
+
. HR-ESI-MS (m/z): calcd. 
for C23H29N3O5Na
 
[M+Na]
+
 450.2005; found 450.1990. Rf = 0.26 (EtOAc/CyH, 1/1). 
(S)-2-((S)-1-(tert-Butoxycarbonyl)pyrrolidine-2-carbonyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]-
indole-3-carboxylic acid (TVC-043) 
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Methyl ester 83 (25 mg, 55 µmol) in THF (6 mL) was treated with 5% LiOH (2 mL) at room temperature 
for 5 h. Afterward, the reaction mixture was cooled to 0 
oC and acidified with 1N HCl to pH≈4. The 
reaction mixture was extracted with EtOAc (3x50 mL), washed 
with H2O, brine solution and dried over MgSO4. Removal of the 
solvent afforded pure product TVC-043 (23mg, 95%) as a solid. 
1
H-NMR (600 MHz, CD3OD): δ = 7.42 (t, J = 7.9 Hz, 1H, 7-H), 
7.3-7.29 (m, 1H, 10-H), 7.08-7.07 (m, 1H, 9-H), 7.02-6.98 (m, 
1H, 8-H), 5.8 (d, J = 6 Hz, 1/2H, 2-H), 5.76 (d, J = 6 Hz, 1/2H, 2-H), 5.1 (d, J = 15.3 Hz, 1H, 3-H), 4.76-
4.78 (m, 1H, 3-H), 4.9 (dd, J = 3.6 Hz, J = 8.5 Hz, 1H, 14-H), 3.58-3.54 (m, 2H, 17-H), 3.51-3.44 (m, 
1H, 1-H), 3.0-2.97 (m, 1H, 1-H), 2.4-2.3 (m, 1H, 15-H), 2.05-2.03 (m, 1H, 15-H), 1.94-1.89 (m, 2H, 16-
H), 1.45 (s, 5H, 20-H), 1.3 (s, 4H, 20-H). 
13
C-NMR (150 MHz, CD3OD): δ = 176.0, 175.3 (12-C), 174.8, 
174-1 (13-C), 155.8, 156.4, 156.3 (18-C), 138.4, 138.2 (11-C), 129.7 (4-C), 128.1, 127.9 (6-C), 122.4, 
122.3 (9-C), 118.4, 118.3 (7-C), 114.8, 114.7 (8-C), 111.7, 111.6 (10-C), 108.8, 106.9, 105.8 (5-C), 81.4, 
81.3 (4-C), 59.3, 58.4 (14-C), 52.6, 52.5 (2-C), 47.9, 47.5 (17-C), 42.1, 40.4 (3-C), 30.6, 29.5 (15-C), 
28.5, 28.2 (20-C), 24.8, 23.5 (1-C), 24.3, 23.9 (16-C). IR (KBr) ν (cm-1): 3440.4 (NH), 1726.1, 1676.1 
(CO). HPLC-ESI-MS: m/z (%) = 414.2 (5) [M+H]
+
, 314.2 (100) [M-Boc]
+
. HR-ESI-MS (m/z): calcd. 
for C22H27N3O5Na
 
[M+Na]
+
 436.1848; found 436.1867. Rf = 0.31 (DCM/MeOH, 4/1). 
(S)-tert-Butyl-2-((S)-3-((2-amino-2-oxoethyl)carbamoyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-
2-carbonyl)pyrrolidine-1-carboxylate (TVC-045, 86)  
To a solution of acid TVC-043 (120 mg, 0.29 mmol) and 
glycinamide hydrochloride (42 mg, 0.38 mmol) in DMF (4 mL), 
TBTU (112 mg, 0.35 mmol) and DIPEA (0.2 mL, 1.16 mmol) were 
added. After stirring at room temperature for 20 h, the solvent was 
removed under reduced pressure. The residue was subjected to silica 
gel column chromatography, using AcOEt/EtOH (15/1) as eluent, to 
yield product 86 (120 mg, 88%) as a yellow solid. 
1
H-NMR (400 MHz, CDCl3): δ = 9.0 (s, 1H, NH), 8.16 (s, 1H, NH), 8.0 (s, 1H, NH), 7.46 (d, J = 7.1 Hz, 
1H, 7-H), 7.2 (d, J = 7.6 Hz, 1H, 10-H), 7.08-7.02 (m, 2H, 9-H, 8-H), 6.3 (s, 1/2H, NH), 5.36 (d, J = 17.2 
Hz, 1H, 3-H), 4.36 (d, J = 17.2 Hz, 1H, 3-H), 5.1 (d, J = 5.0 Hz, 1H, 2-H), 4.8-4.77 (m, 1H, 14-H), 3.78-
3.72 (m, 2H, 21-H), 3.64-3.62 (m, 1H, 1-H), 3.52-3.50 (m, 2H, 17-H), 2.92-2.90 (m, 1H, 1-H), 2.22-2.4 
(m, 1H, 15-H), 2.0 (br., 1H, 15-H), 2.14-2.1 (m, 1H, 16-H), 1.96-1.91 (m, 1H, 16-H), 1.43 (s, 4H, 20-H), 
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1.37 (s, 5H, 20-H). 
13
C-NMR (150 MHz, CDCl3): δ = 173.1 (12-C), 171.7 (22-C), 169.8 (13-C), 155 (18-
C), 136.4 (11-C), 128.7 (4-C), 126.5 (6-C), 121.7 (9-C), 118.0 (7-C), 114.4 (8-C), 111.0 (10-C), 105.6 (5-
C), 80.8 (4-C), 59.0 (2-C), 56.5 (14-C), 47.0 (17-C), 43.3 (21-C), 39.2 (3-C), 29.9 (15-C), 28.3 (20-C), 
24.8 (16-C), 22.7 (1-C). IR (KBr) ν (cm-1): 3410.0 (NH), 1665.1 (CO). HPLC-ESI-MS: m/z (%) = 492.2 
(23) [M+Na]
+
, 470.2 (36) [M+H]
+
, 370.2 (100) [M-Boc]
+
 HR-ESI-MS (m/z): calcd. for C24H31N5O5Na 
[M+Na]
+
 492.2223; found 492.2217. Rf = 0.13 (EtOAc/EtOH, 20/1). 
(S)-N-(2-Amino-2-oxoethyl)-2-((S)-pyrrolidine-2-carbonyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b] 
indole-3-carboxamide (TVC-047, 87)  
Tripeptide 86 (80 mg, 0.17 mmol) was treated with TFA/TIPS/H2O (2 
mL, 95/2.5/2.5) at 0 ºC for 3 h. Afterward, the solvent was removed 
under reduced pressure and the crude product was purified by silica 
gel column chromatography using DCM/MeOH (2/1, 1% TEA) to 
furnish 87 (55 mg, 87%) as a solid. 
1
H-NMR (600 MHz, CD3OD): δ = 7.44 (d, J = 7.9 Hz, 1H, 7-H), 7.26 (d, J = 8.1 Hz, 1H, 10-H), 7.06 (q, 
J = 7.3, 1H, 9-H), 7.01-6.99 (m, 1H, 8-H), 5.6 (dd, J = 2.2 Hz, J = 6.0 Hz, 1/2H, 2-H), 5.2 (d, J = 6 Hz, 
1/2H, 2-H), 5.26 (d, J = 17 Hz, 1/2H, 3-H), 5.0 (d, J = 15 Hz, 1/2H, 3-H), 4.8 (overlap, 1/2H, 3-H), 4.46 
(d, J = 17 Hz, 1/2H, 3-H), 4.2 (t, J = 7.1 Hz, 1H, 14-H), 3.82 (d, J = 12.7 Hz, 1/2H, 18-H), 3.8 (d, J = 
12.6 Hz, 1/2H, 18-H), 3.71 (d, J = 17 Hz, 1/2H, 18-H), 3.68 (d, J = 17 Hz, 1/2H, 18-H), 3.57 (d, J = 15.8 
Hz, 1/2H, 1-H), 3.4 (d, J = 16.5 Hz, 1/2H, 1-H), 3.09-3.06 (m, 1H, 1-H), 3.18-3.15 (m, 1H, 17-H), 2.89-
2.84 (m, 1H, 17-H), 2.37-2.32 (m, 1H, 15-H), 1.97-1.95 (m, 1/2H, 15-H), 1.83-1.8 (m, 1/2H, 15-H), 1.91-
1.87 (m, 1H, 16-H), 1.83-1.82 (m, 1H, 16-H). 
13
C-NMR (150 MHz, CD3OD): δ = 176.1, 175.6 (12-C), 
174.1 (13-C), 173.2, 172.4 (4-C), 138.3 (11-C), 130.4 (4-C), 127.9 (6-C), 122.5 (9-C), 118.6 (7-C), 112.1 
(10-C), 112.0 (8-C), 106.6 (5-C), 59.7 (14-C), 56.7, 54.7 (2-C), 48.1, 47.9 (17-C), 43.2 (18-C), 42.9, 40.6 
(3-C), 31.4, 30.7 (15-C), 27.1, 27.07 (16-C), 24.3, 23.7 (1-C). IR (KBr) ν (cm-1): 3426.6 (NH), 1674.1 
(CO). HPLC-ESI-MS: m/z (%) = 370.2 (100) [M+H]
+
, 392.2 (10) [M+Na]
+
. HR-ESI-MS (m/z): calcd. 
for C4H23N5O3Na [M+Na]
+
 392.1699; found 392.1693. Rf =0.21 (DCM/MeOH, 2/1, 1% TEA). 
tert-Butyl-((S)-1-(((S)-1-(((S)-1-((S)-2-((S)-3-((2-amino-2-oxoethyl)carbamoyl)-2,3,4,9-tetrahydro-
1H-pyrido[3,4-b]indole-2-carbonyl)pyrrolidin-1-yl)-3-(tert-butoxy)-1-oxo-propan-2-yl)amino)-1-
oxo-3-phenylpropan-2-yl)amino)-3-(4-(tert-butoxy)phenyl)-1-oxopropan-2-yl)carbamate (TVC-049) 
To a solution of the amine 87 (35 mg, 95 µmol) and tripeptide Boc-Tyr(tBu)-Phe-Ser(tBu)-OH (71 mg, 
114 µmol) in DMF (6 mL), HATU (45 mg, 118 µmol) and DIPEA (50 µL, 285 µmol) were added. The 
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reaction mixture was stirred at room temperature overnight and DMF was removed under reduced 
pressure. The crude product was purified 
by silica gel column chromatography 
(EtOAc/EtOH, 20/1) to afford the desired 
product TVC-049 (57 mg, 62%) as a 
solid. 
1
H-NMR (400 MHz, CD3OD): δ = 7.44 
(m, 1H, 4-H), 7.35-7.25 (m, 5H, 27-H, 
28-H, 29-H), 7.27 (m, 1H, 13-H), 7.1 
(overlap, 2H, 34-H), 7.05 (overlap. 1H, 
10-H), 6.99 (m, 1H, 11-H), 6.87 (dd, J = 
8.4 Hz, J = 11 Hz, 2H, 35-H), 5.63 (m, 1/2H, 4-H), 5.42 (d, J = 5.4 Hz, 1/2H, 4-H), 5.34 (d, J = 17.2 Hz, 
1H, 2-H, 8-H), 5.06 (m, 1H, 26-H), 4.75 (m, 1H, 21-H), 4.68 (br, 1H, 24-H), 4.32 (d, J = 17.2 Hz, 1H, 2-
H), 4.23 (m, 1H, 31-H), 3.81 (br, 1H, 19-H), 3.78 (br, 1H, 19-H), 3.62 (m, 1H, 22-H), 3.48 (m, 1H, 22-H), 
3.42-3.33 (m, 1H, 5-H), 3.06-3.02 (m, 1H), 2.96 (m, 1H, 32-H), 2.95 (m, 1H, 25-H), 2.67 (m, 1H, 25-H), 
2.33 (m, 1H, 17-H), 2.4-2.12 (m, 2H, 18-H), 1.94 (m, 1H, 17-H), 1.35, 1.30, 1.29 (27H). 
13
C-NMR (100 
MHz, CD3OD): δ = 174.7 (23-C), 174.2 (30-C), 174.1 (20-C), 173.9 (3-C), 173.4 (15-C), 172.9 (1-C), 
165.0 (41-C), 155.3 (36-C), 130.0 (34-C), 125.2 (33-C), 129.5 (27-C), 129.4 (28-C), 127.7 (26-C), 140.9/ 
136.4, 133.7, 130.3/ 130.1, 122.5/122.3, 14.9/120.0, 118.7, 112.0/111.9, 106.4 , 79.5 (37-C), 75.0 (39-C), 
74.9 (42-C), 62.6, 62.2 (21-C), 59.4, 58.7 (16-C), 57.2 (31-C), 55.4 (24-C), 57.2, 54.1, 53.6 (21-C), 49.2, 
48.7 (19-C), 39.8 (2-C), 38.9 (25-C), 38.5 (32-C), 30.3 (17-C), 26.3, 25.8 (18-C), 23.6, 23.7. IR (KBr) ν 
(cm
-1
): 3421.1 (NH), 1655.3 (CO). HPLC-ESI-MS: m/z (%) = 979.6 (100) [M+H]
+
, 1001.6 (45) 
[M+Na]
+
. HR-ESI-MS (m/z): calcd. for C53H70N8O10Na [M+Na]
+
 1001.5113; found 1001.5107. Rf = 0.27 
(EtOAc/EtOH, 15/1). 
(2S)-2-[(2S)-2amino-3-(4-hydroxyphenyl)propanamido]-N-[(2S)-1-[(2S)-2-[(3S)-3-[(carbamoyl-
methyl)carbamoyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-2-carbonyl]pyrrolidin-1-yl]-3-
hydroxy-1-oxopropan-2-yl]-3-phenylpropanamide (TVC-050, 88) 
Peptide TVC-049 (47 mg, 48.0 µmol) was treated with TFA/TIPS/H2O (2 mL, 95/2.5/2.5) at 0 ºC for 4 h. 
Afterward, the mixture was concentrated under diminished pressure and subjected to silica gel column 
chromatography (eluent: DCM/MeOH, 4/1, 0.1% TEA). The product 88 (36 mg, 96%) was dissolved in 
ACN/H2O (2 mL, 1/1) and lyophilized to give white powder. 
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1
H-NMR (400 MHz, DMSO-d6): δ = 10.85 (d, J = 
2.6 Hz, 1H, NH), 8.4 (br, 1/2H, NH), 8.3 (d, J = 7.6 
Hz, 1/2H, NH), 8.2 (d, J = 7.6 Hz, 1H, NH), 7.8 (d, 
J = 5.6 Hz, 1/2H, NH), 7.4 (t, J = 7.7 Hz, 1H, 10-
H), 7.31 (m, 1H, 13-H), 7.2-7.17 (m, 5H, 27-H, 28-
H, 29-H), 7.03 (m, 1H, 12-H), 6.97 (overlap, 1H, 
11-H), 6.96 (m, 2H, 34-H), 6.65 (dd, J = 4.7, J = 
8.4 Hz, 2H, 35-H), 5.56 (d, J = 6.2 Hz, 1/2H, 4-H), 
5.42 (d, J = 6.2 Hz, 1/2H, 4-H), 5.2 (d, J = 17.2, 
1/2H, 8-H), 5.12 (d, J = 15.2, 1/2H, 8-H), 5.04 (br, 1H, 16-H), 4.7 (d, J = 15.6, 1/2H, 8-H), 4.4 (d, J = 
17.5, 1/2H, 8-H), 4.65 (m, 1H, 24-H), 4.65 (m, 1H, 21-H), 3.69-3.63 (m, 2H, 19-H), 3.67 (overlap, 1H, 
22-H), 3.62 (m, 1H, 2-H), 3.56 (m, 1H, 2-H), 3.52 (m, 1H, 22-H), 3.47 (m, 1H, 32-H), 3.4 (m, 1H, 5-H), 
2.82 (m, 1H, 5-H), 3.00-2.95 (m, 1H, 25-H), 2.82 (m, 1H, 25-H), 2.78 (m, 1H, 32-H), 2.26 (m, 1H, 17-H), 
2.01 (m, 1H, 18-H), 1.88 (m, 1H, 18-H), 1.77 (m, 1H, 17-H). 
13
C-NMR (100 MHz, DMSO-d6): δ = 
171.9, 171.4, 170.7, 170.6, 170.5, 170.3, 169.3, 168.5, 169.2, 155.9 (36-C), 137.3 (14-C), 136.1 (33-C), 
135.9 (7-C), 134.3, 130.2 (34-C), 129.3 (27-C), 127.8 (28-C), 126.2 (29-C), 120.8, 120.7, 115.0 (35-C), 
118.3, 117.5, 110.9, 110.8, 104.7, 104.4, 61.2, 61.0 (22-C), 56.8, 57.4 (16-C), 55.3, 55.20 (31-C), 54.2, 
50.9 (4-C), 53.4, 53.3 (21-C), 52.9, 52.8 (24-C), 47.0, 46.2 (19-C), 42.0, 41.8 (2-C), 41.1, 37.8 (8-C), 38.0 
(32-C), 37.8 (25-C), 28.6, 27.5 (17-C), 24.8, 24.6 (18-C), 22.5, 22.3 (5-C). IR (KBr) ν (cm-1): 3427.7 
(NH), 1642.6 (CO). HPLC-ESI-MS: m/z (%) = 767.4 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for 
C40H46N8O8Na [M+Na]
+
 789.3336; found 789.3331. 
3.11 Preparation of isotryptophan amino acid 
(1H-Indol-2-yl)methanol (TVC-244) 
To a suspension of LiAlH4 (61 mg, 1.6 mmol) in dry ether (5 mL) at 0° C under 
argon atmosphere, a solution of ethyl-indole-2-carboxylate (200 mg, 1.06 mmol) in 
ether (5 mL) was added slowly. The reaction mixture was stirred at room 
temperature for 1 h and H2O (3 mL) was added. The white precipitate was removed by filtration through a 
Celite pad. The filtrate was dried over MgSO4 and concentrated to afford indole-2-carbinol TVC-244 
(134 mg, 86%) as a solid. 
1
H-NMR (400 MHz, CDCl3): δ = 7.62 (d, J = 8.0 Hz, 1H, 8-H), (d, J = 8.0 Hz, 1H, 8-H), 7.32 (d, J = 8.0 
Hz, 1H, 5-H), 7.22 (t, J = 8.0 Hz, 1H, 6-H), 7.14 (t, J = 8.0 Hz, 1H, 7-H), 6.42 (m, 1H, 3-H), 4.78 (s, 2H, 
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1-H). 
13
C-NMR (100 MHz, CDCl3): δ = 137.5 (9-C), 136.4 (2-C), 128.1 (4-C), 122.1 (6-C), 120.7 (8-C), 
119.9 (7-C), 110.9 (5-C), 100.6 (3-C), 58.6 (1-C). IR (KBr) ν (cm-1): 3256.3, 2843.7. HPLC-ESI-MS: 
m/z (%) = 148 (10) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C9H8NO [M-H]
+
 146.0612; found 146.0611. 
Rf = 0.5 (CyH/EtOAc, 10/1). 
1H-Indole-2-carbaldehyde (TVC-245, 90) 
To a solution of indole-2-carbinol TVC-244 (250 mg, 1.7 mmol) in DCM (5 mL) at 
0 
o
C, PCC (732 mg, 3.4 mmol) in DCM (5 mL) was added. The reaction mixture 
was stirred further for 2 h and iPrOH (4 mL) was added. After stirring for 40 min, 
the solvent was removed and the residue was subjected to silica gel column chromatography using 
CyH/EtOAc (20/1) to get the 1H-indole-2-carbaldehyde 90 (118 mg, 48%) as a white solid. 
1
H-NMR (400 MHz, CDCl3): δ = 9.81 (s, 1H, CHO), 7.72 (d, J = 8.0 Hz, 1H, 8-H), 7.47 (d, J = 8.0 Hz, 
1H, 5-H), 7.34 (t, J = 8.0 Hz, 1H, 6-H), 7.32 (s, 1H, 3-H), 7.12 (t, J = 8.0 Hz, 1H, 7-H). 
13
C-NMR (100 
MHz, CDCl3): δ = 183.9 (1-C), 140.2 (9-C), 137.8 (2-C), 128.6 (4-C), 126.4 (6-C), 122.6 (8-C), 120.2 (7-
C), 114.2 (3-C), 112.1 (5-C). IR (KBr) ν (cm-1): 1675.9 (CO). HPLC-ESI-MS: m/z (%) = 146.1 (100) 
[M+H]
+
. HR-ESI-MS (m/z): calcd. for C9H8NO [M+H]
+
 146.0601; found 146.0600. Rf = 0.51 
(CyH/EtOAc, 10/1). 
(Z)-Methyl-2-((tert-butoxycarbonyl)amino)-3-(1H-indol-2-yl)acrylate (TVC-255, 92) 
A solution of N-Boc-phosphonoglycine trimethyl ester (123 mg, 0.41 mmol) 
in THF (2 mL) was cooled to -78 
o
C and followed by addition of 1,1,3,3-
tetramethylguanidine (53 µL, 0.41 mmol). The reaction mixture was stirred 
for 5 min at this temperature and the aldehyde 90 (40 mg, 0.28 mmol) in 
THF was added. After stirring for 1h, the dry-ice bath was removed and the 
reaction mixture was allowed to stir at room temperature for 3 days. Flash 
chromatography (CyH/EtOAc, 10/1) afforded 92 (76 mg, 88%) as a white solid. 
1
H-NMR (400 MHz, CDCl3): δ = 9.17 (s, 1H, NH), 7.64 (d, J = 8.0 Hz, 1H, 7-H), 7.52 (s, 1H, 3-H), 7.37 
(d, J = 8.0 Hz, 1H, 10-H), 7.27 (t, J = 8.0 Hz, 1H, 9-H), 7.13 (t, J = 8.0 Hz, 1H, 8-H), 6.85 (s, 1H, 5-H), 
3.88 (s, 3H, 12-H), 1.48 (s, 9H, 15-H). 
13
C-NMR (100 MHz, CDCl3): δ = 165.9 (1-C), 154.8 (13-C), 
137.9 (11-C), 132.1 (4-C), 128.4 (2-C), 127.7 (6-C), 124.9 (3-C), 124.7 (9-C), 121.4 (7-C), 120.5 (8-C), 
110.6 (5-C), 110.2 (10-C), 81.7 (14-C), 52.6 (12-C), 28.0 (15-C). IR (KBr) ν (cm-1): 3348.1, 1697.9, 
1680.1. HPLC-ESI-MS: m/z (%) = 339.2 (40) [M+Na]
+
, 655.3 (30) [2M+Na]
+
. HR-ESI-MS (m/z): 
calcd. For C17H20N2O4Na [M+Na]
+
 339.1315; found 339.1316. Rf = 0.54 (CyH/EtOAc, 4/1). 
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tert-Butyl-2-formyl-1H-indole-1-carboxylate (TVC-270, 95) 
Aldehyde 90 (20 mg, 0.14 mmol) in ACN (2 mL) at 0 
o
C was added Boc2O (36 mg, 
0.15 mmol) and DMAP (3.3 mg, 0.03 mmol). After stirring at room temperature for 
4 h, the reaction mixture was quenched with EtOAc, washed with H2O, brine 
solution and dried over MgSO4. Removal of solvent afforded desired product 95 
(33.6 mg, 99%) as a white solid. 
1
H-NMR (400 MHz, CDCl3): δ = 10.45 (s, 1H, CHO), 8.18 (d, J = 8.0 Hz, 1H, 5-H), 7.69 (d, J = 8.0 Hz, 
1H, 8-H), 7.51 (t, J = 8.0 Hz, 1H, 6-H), 7.45 (s, 1H, 3-H), 7.31 (t, J = 8.0 Hz, 1H, 7-H), 1.74 (s, 9H, 12-
H). 
13
C-NMR (100 MHz, CDCl3): δ = 184.1 (1-C), 149.8 (10-C), 137.9 (9-C), 137.8 (2-C), 128.3 (7-C), 
127.5 (4-C), 123.8 (6-C), 123.3 (8-C), 116.4 (3-C), 116.2 (5-C), 85.0 (11-C), 28.2 (12-C). IR (KBr) ν 
(cm
-1
): 1722.8, 1663.1 (CO). HPLC-ESI-MS: m/z (%) = 268.1 (10) [M+Na]
+
. HR-ESI-MS (m/z): calcd. 
For C14H15NO3Na [M+Na]
+
 268.0944; found 268.0943. Rf = 0.50 (CyH/EtOAc, 8/1). 
tert-Butyl-2-[(1Z)-2-{[(tert-butoxy)carbonyl]amino}-3-methoxy-3-oxoprop-1-en-1-yl]-1H-indole-1-
carboxylate (TVC-271, 94) 
A solution of N-Boc-phosphonoglycine trimethyl ester (114.5 mg, ) in THF 
(2 mL) was cooled to -78 
o
C and followed by addition of 1,1,3,3-
tetramethylguanidine (50 µL). The reaction was stirred for 5 min at this 
temperature and solution of 90 (63 mg, 0.26 mmol) in THF (2 mL) was 
added dropwise. After stirring for 1 h, the dry-ice bath was removed and the 
reaction mixture was allowed to stir at room temperature for 3 days. Flash 
chromatography (CyH/EtOAc, 5/1) afforded product 94 (86.4 mg, 80%) as 
a white solid. 
1
H-NMR (400 MHz, CDCl3): δ = 8.16 (d, J = 8.0 Hz, 1H, 7-H), 7.83 (s, 1H, 3-H), 7.56 (d, J = 8.0 Hz, 
1H, 10-H), 7.32 (t, J = 8.0 Hz, 1H, 9-H), 7.26 (t, J = 8.0 Hz, 1H, 8-H), 7.0 (s, 1H, 5-H), 6.18 (s, 1H, NH), 
3.87 (s, 3H, 12-H), 1.70 (s, 9H, 18-H), 1.43 (s, 9H, 15-H). 
13
C-NMR (100 MHz, CDCl3): δ = 165.7 (1-C), 
152.7 (13-C), 150.1 (16-C), 136.7 (11-C), 133.1 (4-C), 129.0 (2-C), 125.5 (6-C), 124.9 (3-C), 123.2 (9-
C), 121.1 (7-C), 121.0 (8-C), 115.7 (10-C), 112.2 (5-C), 84.7 (17-C), 81.1 (14-C), 52.5 (12-C), 28.2 (18-
C), 28.1 (15-C). IR (KBr) ν (cm-1): 1722.8, 1662.3 (CO). HPLC-ESI-MS: m/z (%) = 434 (20) 
[M+NH4]
+
. HR-ESI-MS (m/z): calcd. for C22H28N2O6Na [M+Na]
+
 439.1840; found 439.1807. Rf = 0.18 
(CyH/EtOAc, 8/1). 
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3.12 Synthesis of Trp-derived tricyclic ester 
(S)-Methyl-3-(2-(2-(tert-butoxy)-2-oxoethyl)-1H-indol-3-yl)-2-((tert-butoxycarbonyl)amino) 
propanoate (TVC-250, 107) 
Lauroyl peroxide (326 mg, 0.82 mmol) in 1,2-dichloroethane (4 mL) was 
added portionwise to a solution of Boc-Trp-OMe (200 mg, 0.63 mmol) in 
degassed 1,2-dichloroethane (3 mL) heated at reflux. After refluxing for 6 
h, the solvent was removed. Flash chromatography (using gradient of 
CyH/EtOAc, from 10/1 to 4/1) yielded the desired product 107 (106.4 mg, 
40%) as a brown solid. 
1
H-NMR (400 MHz, CDCl3): δ = 7.56 (d, J = 8.0 Hz, 1H, 9-H), 7.32 (d, J = 8.0 Hz, 1H, 6-H), 7.18 (t, J = 
8.0 Hz, 1H, 7-H), 7.11 (t, J = 8.0 Hz, 1H, 8-H), 4.36 (m, 1H, 2-H), 3.78 (s, 2H, 12-H), 3.19 (m, 2H, 3-H), 
1.51 (s, 9H, 16-H), 1.42 (s, 9H, 19-H). 
13
C-NMR (100 MHz, CDCl3): δ = 178.3 (1-C), 170.6 (13-C), 
154.3 (17-C), 135.6 (10-C), 129.1 (5-C), 127.7 (11-C), 122.5 (7-C), 120.1 (8-C), 118.5 (9-C), 111.0 (6-
C), 107.9 (4-C), 82.6 (15-C), 80.4 (18-C), 56.0 (2-C), 32.9 (12-C), 28.3 (19-C), 27.9 (16-C), 26.8 (3-C). 
IR (KBr) ν (cm-1): 3364.3, 1698.9. HPLC-ESI-MS: m/z (%) = 455.3 (10) [M+Na]+, 333.2 (80) [M-
Boc]
+
. HR-ESI-MS (m/z): calcd. for C23H32N2O6Na [M+Na]
+
 455.1556; found 455.2153. Rf = 0.3 
(CyH/EtOAc, 6/1). 
(S)-Methyl-4-oxo-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole-2-carboxylate (TVC-260, 106) 
Solution of 107 (15 mg, 34.7 µmol) in TFA/TIPS/H2O (2 mL, 95/2.5/2.5) was 
stirred at 0 
o
C for 3 h. The reaction mixture was then concentrated under 
reduced pressure to dryness. The residue was dissolved in DMF (1 mL) and 
followed by addition of HATU (20.4 mg, 54 µmol) and DIPEA (30 µL, 200 
mmol). After stirring at room temperature for 24 h, the solvent was removed. 
The residue was subjected to flash chromatography using CyH/EtOAc (gradient from 1/4 to 1/1) to afford 
the pure product 106 (7.2 mg, 57%) as a brown solid. 
1
H-NMR (400 MHz, CDCl3): δ = 7.34 (d, J = 8.0 Hz, 1H, 9-H), 7.29 (overlap, 1H, 12-H), 7.12 (t, J = 8.0 
Hz, 1H, 11-H), 7.03 (d, J = 8.0 Hz, 1H, 9-H), 4.70 (dd, J = 2.6 Hz, J = 12.0 Hz, 1H, 2-H), 4.09 (m, 1H, 6-
H), 3.85 (s, 3H, 14-H), 3.52 (d, J = 16.6 Hz, 1H, 6-H), 3.38 (m, 1H, 3-H), 2.99 (m, 1H, 3-H). 
13
C-NMR 
(100 MHz, CDCl3): δ = 171.2 (1-C), 134.9 (8-C), 124.4 (5-C), 122.0 (10-C), 119.3 (11-C), 117.3 (12-C), 
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110.9 (9-C), 106.8 (4-C), 53.6 (2-C), 53.1 (14-C), 34.8 (6-C), 29.4 (3-C). IR (KBr) ν (cm-1): 3423.5, 
2925.8, 1743.3, 1645.6. HPLC-ESI-MS: m/z (%) = 259.1 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for 
C14H14N2O3Na [M+Na]
+
 281.0897; found 281.0897. Rf = 0.35 (EtOAc). 
(2S)‐1,2,3,4,5,6‐hexahydroazepino[4,5‐b]indol‐2‐ylmethanol (TVC-274, 109) 
A solution of 106 (30 mg, 0.12 mmol) in dry THF (3 mL) was added dropwise 
94% BH3.SMe2 (38 mg, 45 µL) in THF at 0 
o
C. The reaction mixture was allowed 
to warm up to room temperature and stirred for 6h. Methanol (excess) was added 
to the reaction mixture, stirred for 4 hours and concentrated under reduced 
pressure. Water (10 mL) was added and the reaction mixture was extracted using EtOAc (3x20 mL). The 
combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under 
reduced pressure to give the product 109 (21 mg, 86%) as a solid.  
1
H-NMR (400 MHz, CDCl3): δ = 7.45 (d, J = 8.0 Hz, 1H, 12-H), 7.30 (d, J = 8.0 Hz, 1H, 9-H), 7.09 (t, J 
= 8.0 Hz, 1H, 10-H), 7.03 (t, J = 8.0 Hz, 1H, 11-H), 3.94 (dd, J = 2.2 Hz, J = 7.5 Hz, 1H, 1-H), 3.73 (m, 
1H, 1-H), 3.45 (overlap, 1H, 2-H), 3.32 (m, 2H, 7-H), 3.23 (m, 1H, 3-H), 3.00 (m, 1H, 3-H), 1.62 (m, 2H, 
6-H). 
13
C-NMR (100 MHz, CDCl3): δ = 136.6 (8-C), 134.7 (5-C), 128.1 (13-C), 120.9 (10-C), 118.7 (11-
C), 116.9 (12-C), 110.4 (9-C), 107.6 (4-C), 61.8 (1-C), 61.3 (2-C), 44.6 (7-C), 28.7 (6-C), 23.3 (3-C). IR 
(KBr) ν (cm-1): HPLC-ESI-MS: m/z (%) = 210.1(10) [M+Na]. HR-ESI-MS (m/z): calcd. for C13H17N2O 
[M+H]
+
: 217.1335, found: 217.1327. Rf = 0.16 (EtOAc). 
3.13 Synthesis of macrocyclic peptides 128 and 129 
(2S)-2-{[(tert-Butoxy)carbonyl]amino}-3-(prop-2-en-1-yloxy)propanoic acid (TVC-143, 117)  
To a stirred suspension of NaH (27 mg, 1.12 mmol) in DMF (0.5 mL) at 0 °C, a 
solution of Boc-Ser-OH (105 mg, 0.51 mmol) in DMF (1 mL) was added 
dropwise. After 10 min, allyl bromide (51 µL, 0.59 mmol) was added and the 
reaction mixture was allowed to warm up to room temperature. After stirring for 
20 h, the solvent was removed under reduced pressure. The residue was dissolved 
with H2O (10 mL) and extracted with EtOAc (2x20 mL). The aqueous phase was 
acidified with 1M HCl at 0 
oC to pH≈2 and extracted with EtOAc (3x40 mL). The combined organic 
phases were washed with brine solution and dried over MgSO4. Removal of the solvent yielded oily 
product 117 (100 mg, 80%). 
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1
H-NMR
 
(400 MHz, CDCl3): δ = 7.2 (br, 1H, OH), 5.91 (m, 1H, 5-H), 5.45 (s, 1H, NH), 5.26 (m, 2H, 6-
H), 4.48 (br, 1H, 2-H), 4.03 (dt, J = 1.5 Hz, J = 5.5 Hz, 2H, 4-H), 3.92 (d, J = 8.3 Hz, 1H, 3-H), 3.73 (dd, 
J = 3.5 Hz, J = 8.3 Hz, 1H, 3-H), 1.47 (s, 9H, 9-H). 
13
C-NMR (100 MHz, CDCl3): δ = 174.8 (1-C), 155.7 
(7-C), 134.1 (5-C), 117.9 (6-C), 80.3 (8-C), 72.3 (4-C), 69.6 (3-C), 53.8 (2-C), 28.7 (9-C). IR (KBr) ν 
(cm
-1
): 2986.9, 1705.9. HPLC-ESI-MS: m/z (%) = 268.1 (100) [M+Na]
+
. HR-ESI-MS (m/z): calcd. for 
C11H19NO5Na [M+Na]
+ 
268.1156; found 268.1155. Rf = 0.45 (EtOAc). 
Methyl-(2S)-1-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-3-(prop-2-en-1-yloxy)propanoyl]-pyrrolidine-
2-carboxylate (TVC-145, 118) 
A solution of 117 (162 mg, 0.66 mmol), Pro-OMe*HCl (131.3 mg, 0.79 
mmol) and HATU (300 mg, 0.79 mmol) in DMF (4 mL) was added 
DIPEA (0.5 mL, 4.5 mmol). After stirring at room temperature for 20 h, 
the solvent was removed under reduced pressure. Flash chromatography 
(eluent: CyH/EtOAc, 3/1) provided oily product 118 (220 mg, 93%). 
1
H-NMR
 
(600 MHz, CDCl3): δ = 5.89 (m, 1H, 10-H), 5.29 (d, J = 17.2 
Hz, 1H, 11-H), 4.67 (d, J = 7.1 Hz, 1H, 7-H), 4.53 (dd, J = 4.0 Hz, J = 8.3 Hz, 1H, 2-H), 4.05 (dd, J = 5.0 
Hz, J = 17.6 Hz, 2H, 8-H), 3.78 (m, 1H, 5-H), 3.73 (m, 1H, 5-H), 3.72 (s, 3H, 12-H), 3.64 (d, J = 6.5 Hz, 
2H, 8-H), 2.21 (m, 1H, 4-H), 2.05 (m, 1H, 3-H), 1.99 (m, 2H, 3-H, 4-H), 1.43 (s, 9H, 15-H). 
13
C-NMR 
(150 MHz, CDCl3): δ = 172.2 (6-C), 169.4 (1-C), 134.6 (10-C), 116.7 (11-C), 79.7 (14-C), 72.2 (9-C), 
70.3 (8-C), 58.8 (2-C), 52.2 (7-C), 51.8 (12-C), 46.7 (5-C), 29.0 (4-C), 28.1 (15-C), 24.7 (3-C). IR (KBr) 
ν (cm-1): 2982.3, 1705.7, 1645.9. HPLC-ESI-MS: m/z (%) = 357.1 (50) [M+H]+, 257.1 (100) [M-
Boc+H]
+
. HR-ESI-MS (m/z): calcd. for C17H28N2O6Na [M+Na]
+ 
379.1840; found 379.1844. Rf = 0.28 
(CyH/EtOAc, 2/1). 
(2S)-1-[(2S)-2-(Methoxycarbonyl)pyrrolidin-1-yl]-1-oxo-3-(prop-2-en-1-yloxy)propan-2-aminium-
trifluoroacetate (TVC-147)  
Product 118 (73 mg, 0.2 mmol) was treated with TFA/TIPS/H2O (2 mL, 
95/4/1) at 0 
o
C for 3 h. Afterward, the reaction mixture was concentrated 
under diminished pressure to provide TVC-147 (51.1 mg, 97%) as a TFA 
salt. 
1
H-NMR
 
(400 MHz, CD3OD): δ = 5.90 (m, 1H, 10-H), 5.30 (m, 2H, 11-H), 
4.55 (dd, J = 5.3 Hz, J = 8.7 Hz, 1H, 2-H), 4.44 (dd, J = 4.0 Hz, J = 8.0 Hz, 
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1H, 7-H), 4.13 (d, J = 5.4 Hz, 2H, 9-H), 3.90 (dd, J= 4.0 Hz, J = 11.0 Hz, 2H, 8-H), 3.75 (m, 1H, 5-H), 
3.73 (s, 3H, 12-H), 3.70 (overlap, 1H, 8-H), 3.66 (m, 1H, 5-H), 2.32 (m, 1H, 3-H), 2.06 (m, 2H, 4-H), 
2.02 (m, 1H, 3-H). 
13
C-NMR (100 MHz, CD3OD): δ = 173.4 (6-C), 166.6 (1-C), 133.2 (10-C), 116.7 (11-
C), 72.6 (9-C), 66.4 (8-C), 59.2 (2-C), 52.2 (7-C), 51.3 (12-C), 46.8 (5-C), 28.3 (3-C), 24.6 (4-C). IR 
(KBr) ν (cm-1): 2988.2, 1652.7. HPLC-ESI-MS: m/z (%) = 257.1 (100) [M-CF3COOH+H]
+
. HR-ESI-
MS (m/z): calcd. for C12H20N2O4Na [M+Na]
+ 
279.1340; found 279.1815.  
Methyl-(2S)-1-[(2S)-2-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-3-phenyl-propanamido]-3-(prop-2- 
en-1-yloxy)propanoyl]pyrrolidine-2-carboxylate (TVC-148)  
A stirred solution of Boc-Phe-OH (180 mg, 0.68 mmol), TBTU (218 mg, 0.68 mmol) and TVC-147 (145 
mg, 0.57 mmol) in DCM (8 mL) was added dropwise DIPEA (0.38 mL, 2.26 mmol). After stirring at 
room temperature for 18 h, the solvent was removed. The crude 
product was purified by silica gel column chromatography using 
CyH/EtOAc (5/2) as eluent to give product TVC-148 (264 mg, 
93%) as a solid. 
1
H-NMR
 
(600 MHz, CDCl3): δ = 7.28 (t, J = 7.0 Hz, 2H, 17-H), 
7.23 (t, J = 7.0 Hz, 1H, 18-H), 7.19 (d, J = 7.7 Hz, 2H, 16-H), 5.86 
(m, 1H, 10-H), 5.29 (d, J = 10.0 Hz, 1H, 11-H), 5.20 (d, J = 11.0 Hz, 1H, 11-H), 4.91 (d, J = 6.5 Hz, 7-
H), 4.49 (dd, J = 4.3 Hz, J = 8.0 Hz, 1H, 2-H), 4.4 (bs, 1H, 13-H), 3.8 (m, 1H, 5-H), 3.72 (s, 3H, 19-H), 
3.68 (m, 1H, 5-H), 3.64 (m, 1H, 8-H), 3.58 (m, 1H, 8-H), 3.09 (m, 2H, 14-H), 2.2 (m, 1H, 3-H), 2.0 
(overlap, 1H, 3-H, 4-H), 2.06 (m, 1H, 4-H), 1.42 (s, 9H, 22-H). 
13
C-NMR (150 MHz, CDCl3): δ = 172.1 
(12-C), 170.8 (6-C), 168.5 (1-C), 155.4 (20-C), 134.2 (10-C), 134.0 (15-C), 129.4 (16-C), 128.5 (18-C), 
126.9 (17-C), 117.0 (11-C), 80.1 (21-C), 72.1 (9-C), 69.5 (8-C), 58.7 (2-C), 55.5 (13-C), 52.1 (19-C), 
50.7 (7-C), 47.2 (5-C), 38.1 (14-C), 28.8 (3-C), 28.0 (22-C), 24.7 (4-C). IR (KBr) ν (cm-1): 2989.2, 
1635.4. HPLC-ESI-MS: m/z (%) = 504.3 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C26H37N3O7Na 
[M+Na]
+ 
526.2524; found 526.2528. Rf = 0.18 (CyH/EtOAc, 5/2). 
(1S)-1-{[(2S)-1-[(2S)-2-(Methoxycarbonyl)pyrrolidin-1-yl]-1-oxo-3-(prop-2-en-1-yloxy)-propan-2-
yl]carbamoyl}-2-phenylethan-1-aminium trifluoroacetate (TVC-149, 119)  
A solution of TVC-148 (70 mg, 0.14 mmol) in TFA/TIPS/H2O (2 
mL, 95/4/1) was stirred at 0 
o
C for 3 h. After that time, the 
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mixture was concentrated under reduced pressure to afford product 119 (70.4 mg, 98%) as TFA salt. 
1
H-NMR
 
(400 MHz, CD3OD): δ = 7.37-7.31 (m, 5H, 16-H, 17-H, 18-H), 5.96 (m, 1H, 10-H), 5.34 (d, J = 
17.0 Hz, 1H, 11-H), 5.22 (d, J = 10.0 Hz, 1H, 11-H), 4.91 (d, J = 6.5 Hz, 7-H), 4.47 (dd, J = 4.3 Hz, J = 
8.0 Hz, 1H, 2-H), 4.22 (bs, 1H, 13-H), 3.79 (m, 2H, 5-H), 3.72 (s, 3H, 19-H), 3.80 (m, 2H, 8-H), 3.28 (m, 
1H, 14-H), 3.05 (m, 1H, 14-H), 2.3 (m, 1H, 3-H), 2.03 (overlap, 1H, 3-H, 4-H), 2.02 (m, 1H, 4-H). 
13
C-
NMR (100 MHz, CD3OD): δ = 170.1 (12-C), 169.8 (6-C), 168.9 (1-C), 136.8 (10-C), 134.7 (15-C), 131.6 
(18-C), 131.2 (17-C), 129.9 (16-C), 118.7 (11-C), 74.9 (9-C), 71.2 (8-C), 61.5 (2-C), 56.5 (13-C), 53.8 
(19-C, 7-C), 49.6 (5-C), 39.4 (14-C), 30.8 (3-C), 27.3 (4-C). IR (KBr) ν (cm-1): 2992.5, 1669.5, 1627.1. 
HPLC-ESI-MS: m/z (%) = 404.3 (100) [M-CF3COOH+H]
+
. HR-ESI-MS (m/z): calcd. for 
C21H29N3O5Na [M+Na]
+ 
426.1999; found 426.1998. Rf = 0.23 (EtOAc/EtOH, 13/1). 
Methyl-(2S)-2-{[(tert-butoxy)carbonyl]amino}-3-(4-hydroxyphenyl)propanoate (TVC-136, 121) 
To a cooled suspension of L-Tyr-OMe*HCl (500 mg, 2.16 mmol) in DCM (5 mL) 
at 0 °C, TEA (0.75 mL, 5.4 mmol) and Boc2O (495 mg, 2.37 mmol) in DCM (5 mL) 
were added. The mixture was allowed to warm up to room temperature and stirred 
overnight. The solvent was removed and the crude product was subjected to silica 
gel flash chromatography using CyH/EtOAc (3/1) to yield 121 as an oily product  
(618 mg, 97%). 
1
H-NMR (600 MHz, CDCl3): δ = 6.99 (d, J = 8.0 Hz, 2H, 5-H), 6.75 (d, J = 8.0 Hz, 2H, 6-H), 4.56 (m, 
1H, 2-H), 3.73 (s, 3H, 11-H), 3.05-2.99 (m, 2H, 3-H), 1.44 (s, 9H, 10-H). 
13
C-NMR (150 MHz, CDCl3): δ 
= 172.6 (1-C), 155.3 (8-C), 155.0 (7-C), 127.6 (4-C), 115.4 (6-C), 80.1 (9-C), 54.4 (2-C), 52.3 (11-C), 
37.6 (3-C), 28.5 (10-C). IR (KBr) ν (cm-1): 3353.6, 2975.6, 1681.6. HPLC-ESI-MS: m/z (%) = 196.1 
(100) [M-Boc+H]
+
. HR-ESI-MS (m/z): calcd. for C15H21NO5Na [M+Na]
+ 
318.1317; found 318.1318. Rf 
= 0.37 (CyH/EtOAc, 3/1). 
Methyl-(2S)-2-{[(tert-butoxy)carbonyl]amino}-3-[4-(prop-2-en-1-yloxy)phenyl]propanoate (TVC-
138, 122) 
A suspension solution of 121 (470 mg, 1.59 mmol) and K2CO3 (484 mg, 3.5 
mmol) in DMF (8 mL) was added dropwise allyl bromide (0.28 mL, 3.18 mmol). 
The reaction mixture was stirred for 20 h at room temperature. The solid was then 
removed by filtration through a Celite pad and washed with EtOAc. Removal of 
the solvent to dryness gave 122 (526 mg, 99%) as an oily product. 
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1
H-NMR (600 MHz, CDCl3): δ = 7.0 (d, J = 8.5 Hz, 2H, 5-H), 6.83 (d, J = 8.5 Hz, 2H, 6-H), 6.05 (m, 
1H, 11-H), 5.4 (q, 1H, 13-H), 5.26 (q, 1H, 13-H), 4.54 (m, 2H, 11-H), 4.50 (m, 1H, 2-H), 3.70 (s, 3H, 14-
H), 3.0 (br, 2H, 3-H), 1.41 (s, 9H, 10-H). 
13
C-NMR (150 MHz, CDCl3): δ = 172.0 (1-C), 157.7 (8-C), 
133.3 (12-C), 130.0 (5-C), 128.1 (4-C), 117.6 (13-C), 114.8 (6-C), 79.8 (9-C), 69.6 (11-C), 54.5 (2-C), 
52.3 (14-C), 37.9 (3-C), 28.5 (10-C). IR (KBr) ν (cm-1): 2986.9, 1705.9. HPLC-ESI-MS: m/z (%) = 
358.1 (20) [M+Na]
+
, 236.1 (100) [M-Boc+H]
+
. HR-ESI-MS (m/z): calcd. for C18H25NO5Na [M+Na]
+ 
358.1630; found 358.1630. Rf = 0.36 (CyH/EtOAc, 5/1). 
(2S)-2-{[(tert-Butoxy)carbonyl]amino}-3-[4-(prop-2-en-1-yloxy)phenyl]propanoic acid (TVC-140, 
123)  
Ester 122 (144 mg, 0.43 mmol) in MeOH (2 mL) was treated with 1N NaOH (0.64 
mmol) at room temperature for 24 h. Afterward, the solution was acidified with 1N 
HCl and extracted with EtOAc (3x40 mL). The combined organic phases were 
washed with brine solution and dried over MgSO4. Removal of the solvent yielded 
123 (135.6 mg, 98%) as an oily product. 
1
H-NMR (600 MHz, CDCl3): δ = 7.1 (d, J = 8.0 Hz, 2H, 5-H), 6.8 (d, J = 8.0 Hz, 
2H, 6-H), 6.1 (m, 1H, 12-H), 5.4 (dd, J = 2.0 Hz, J = 17.6 Hz, 2H, 13-H), 4.59 (br, 
1H, 2-H), 4.5 (d, J = 5 Hz, 2H, 11-H), 3.1 (m, 1H, 3-H), 3.0 (m, 1H, 3-H), 1.4 (s, 
9H, 10-H). 
13
C-NMR (150 MHz, CDCl3): δ = 176.4 (1-C), 157.7 (8-C), 155.5 (7-C), 133.2 (12-C), 130.0 
(5-C), 128.1 (4-C), 117.4 (13-C), 115.0 (6-C), 80.2 (9-C), 68.7 (11-C), 54.4 (2-C), 36.9 (3-C), 28.2 (10-
C). IR (KBr) ν (cm-1): 2930.8, 1713.4. HPLC-ESI-MS: m/z (%) = 344.2 (20) [M+Na]+, 222.2 (100) [M-
Boc+H]
+
. HR-ESI-MS (m/z): calcd. for C17H23NO5Na [M+Na]
+ 
344.1474; found 344.1471. Rf = 0.29 
(CyH/EtOAc, 6/1). 
Methyl-(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-3-[4-(prop-2-en-1-yloxy) 
phenyl]propanamido]-3-phenylpropanamido]-3-(prop-2-en-1-yloxy)propanoyl]-pyrrolidine-2-
carboxylate (TVC-150, 124) 
A solution of 119 (140 mg, 0.347 mmol), 123 (134 mg, 0.416 
mmol) and TBTU (137 mg, 427 mmol) in DCM (4 mL) was 
added DIPEA (0.23 mL, 1.39 mmol). After being stirred at 
room temperature for 20 h, the reaction mixture was 
concentrated under reduced pressure. The residue was 
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purified by silica gel column chromatography (CyH/EtOAc, 3/1) to give 124 (236.4 mg, 96%) as a solid. 
1
H-NMR (600 MHz, CDCl3): δ = 7.24-7.22 (m, 3H, 13-H, 14-H), 7.10 (overlap, 2H, 12-H), 7.09 (d, J = 
8.2 Hz, 2H, 3-H), 6.84 (d, J = 8.2 Hz, 2H, 2-H), 6.06 (m, 1H, 27-H), 5.90 (m, 1H, 30-H), 5.42 (d, J = 17.0 
Hz, 1H, 28-H), 5.29 (overlap, 28-H, 31-H), 5.18 (d, J = 11.0 Hz, 1H, 31-H), 4.83 (q, J = 6.5 Hz, 1H, 15-
H), 4.65 (q, J = 6.5 Hz, 1H, 6-H), 4.52 (m, 2H, 26-H), 4.51 (overlap, 1H, 21-H), 4.27 (bs, 1H, 8-H), 4.0 
(m, 2H, 29-H), 3.78 (m, 1H, 18-H), 3.72 (s, 3H, 32-H), 3.67 (m, 1H, 18-H), 3.59 (d, J = 6.5 Hz, 2H, 16-
H), 3.05 (m, 1H, 5-H), 2.97 (overlap, 3H, 5-H, 10-H), 2.21 (m, 1H, 20-H), 2.08 (m, 1H, 19-H), 2.01 
(overlap, 2H, 19-H, 20-H), 1.40 (s, 9H, 25-H). 
13
C-NMR (150 MHz, CDCl3): δ = 172.1 (7-C), 171.1 (9-
C), 169.9 (17-C), 168.3 (22-C), 157.6 (23-C), 156.1 (1-C), 134.3 (30-C), 134.1 (11-C), 133.3 (27-C), 
130.4 (12-C), 128.5 (13-C), 126.8 (14-C), 117.4 (28-C), 116.8 (31-C), 114.8 (2-C), 129.2 (3-C), 79.9 (24-
C), 72.2 (29-C), 69.7 (16-C), 68.7 (26-C), 59.0 (21-C), 55.8 (8-C), 54.6 (6-C), 52.1 (32-C), 50.8 (15-C), 
47.0 (18-C), 38.2 (5-C), 37.2 (10-C), 29.0 (20-C), 28.3 (25-C), 24.6 (19-C). IR (KBr) ν (cm-1): 3285.6, 
1635.6. HPLC-ESI-MS: m/z (%) = 707.4 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C38H50N4O9Na 
[M+Na]
+ 
729.3470; found 729.3466. Rf = 0.18 (CyH/EtOAc, 3/1). 
Methyl-(2S)-1-[(4E,9S,12S,15S)-12-benzyl-15-{[(tert-butoxy)carbonyl]amino}-11,14-dioxo-2,7-dioxa-
10,13-diazabicyclo[15.2.2]henicosa-1(19),4,17,20-tetraene-9-carbonyl]pyrrolidine-2-carboxylate 
(TVC-151, 125) 
A solution of 124 (163 mg, 0.163 mmol) in degassed (for 40 
min with argon) DCM (150 mL) was added Hoveyda-Grubb 
catalyst 2
nd
 generation (14.5 mg, 10 mol%). The reaction 
mixture was refluxed for 50 h and the solvent was removed. 
Flash chromatography using CyH/EtOAc (1/1) as eluent 
afforded 125 (140 mg, 89%) as a yellow solid product. 
1
H-NMR (600 MHz, CDCl3): δ = 7.20-7.14 (m, 5H, 12-H, 13-
H, 14-H), 7.04 (m, 2H, 3-H), 6.74 (d, J = 8.5 Hz, 2H, 2-H), 
5.70 (bs, 2H, 27-H, 28-H), 4.78 (t, J = 7.1 Hz, 1H, 15-H), 4.62 (bs, 2H, 26-H), 4.45 (t, J = 7.1 Hz, 1H, 6-
H), 4.41 (m, 1H, 21-H), 4.24 (bs, 1H, 8-H), 4.06 (d, J = 12.0 Hz, 1H, 29-H), 3.84 (d, J = 11.0 Hz, 1H, 29-
H), 3.75 (m, 1H, 18-H), 3.70 (s, 3H, 30-H), 3.51 (m, 1H, 18-H), 3.35 (m, 1H, 16-H), 3.29 (t, J = 8.5 Hz, 
1H, 16-H), 2.97 (m, 1H, 5-H), 2.92 (m, 2H, 10-H), 2.89 (m, 1H, 5-H), 2.17 (m, 1H, 20-H), 2.03 (m, 1H, 
19-H), 1.97 (overlap, 2H, 19-H, 20-H), 1.44 (s, 9H, 25-H). 
13
C-NMR (150 MHz, CDCl3): δ = 172.1 (7-
C), 169.8 (17-C), 168.5 (22-C), 156.4 (23-C), 156.1 (1-C), 136.1 (11-C), 130.8 (27-C), 130.2 (3-C), 129.6 
(28-C), 129.0 (12-C), 128.2 (13-C), 126.7 (14-C), 115.1 (2-C), 79.8 (24-C), 70.1 (29-C), 68.5 (16-C), 
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66.7 (26-C), 58.8 (21-C), 55.2 (8-C), 54.3 (6-C), 52.3 (30-C), 49.7 (15-C), 46.8 (18-C), 37.7 (10-C, 5-C), 
28.8 (20-C), 28.1 (25-C), 24.4 (19-C). IR (KBr): ν (cm-1) 3286.1, 2971.8, 1635.3. HPLC-ESI-MS: m/z 
(%) = 679.4 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C36H46N4O9Na [M+Na]
+ 
701.3157; found 
701.3158. Rf = 0.13 (CyH/EtOAc, 2/3).  
(2S)-1-[(4E,9S,12S,15S)-12-Benzyl-15-{[(tert-butoxy)carbonyl]amino}-11,14-dioxo-2,7-dioxa-10,13-
diazabicyclo[15.2.2]henicosa-1(19),4,17,20-tetraene-9-carbonyl]pyrrolidine-2-carboxylic acid (TVC-
152, 126) 
Methyl ester 125 (50 mg, 0.074 mmol) in THF/H2O (3 mL, 
1/1) was added 4% aqueous LiOH (31 mg, 0.74 mmol). The 
reaction mixture was stirred at room temperature for 18 h, then 
acidified with 1N HCl at 0 
oC to pH≈4 and extracted with 
AcOEt (3x60 mL). The combined organic phases were washed 
with brine solution and dried over MgSO4. Removal of the 
solvent gave 126 (46.5 mg, 98%) as a white solid. 
1
H-NMR (600 MHz, CD3OD): δ = 7.24-7.19 (m, 5H, 12-H, 
13-H, 14-H), 7.07 (d, J = 8.2 Hz, 2H, 3-H), 6.80 (d, J = 8.2 Hz, 2H, 2-H), 5.85 (m, 1H, 28-H), 5.75 (dt, J 
= 5.0 Hz, J = 16.0 Hz, 1H, 27-H), 4.78 (t, J = 7.1 Hz, 1H, 15-H), 4.67 (d, J = 5.0 Hz, 2H, 26-H), 4.54 (t, J 
= 7.1 Hz, 1H, 6-H), 4.34 (t, J = 7.0 Hz, 1H, 21-H), 4.31 (t, J = 7.0 Hz, 1H, 8-H), 4.06 (d, J = 12.0 Hz, 1H, 
29-H), 3.85 (d, J = 11.0 Hz, 1H, 29-H), 3.72 (br, 1H, 18-H), 3.70 (s, 3H, 30-H), 3.43 (m, 1H, 18-H), 3.40 
(m, 1H, 16-H), 3.06 (t, J = 8.5 Hz, 1H, 16-H), 3.04 (m, 1H, 5-H), 2.96-2.90 (m, 2H, 10-H), 2.89 (m, 1H, 
5-H), 2.21 (m, 1H, 20-H), 2.02 (overlap, 2H, 19-H, 20-H), 1.93 (m, 1H, 19-H), 1.44 (s, 9H, 25-H). 
13
C-
NMR (150 MHz, CD3OD): δ = 174.5 (22-C), 172.4 (7-C), 169.5 (17-C), 156.8 (23-C), 154.1 (1-C), 136.6 
(11-C), 130.5 (27-C), 129.9 (3-C), 129.8 (28-C), 128.8 (12-C), 127.9 (13-C), 126.1 (14-C), 114.7 (2-C), 
79.8 (24-C), 69.9 (29-C), 67.8 (16-C), 66.8 (26-C), 59.0 (21-C), 55.2 (8-C), 53.9 (6-C), 50.0 (15-C), 46.7 
(18-C), 37.5 (5-C) 36.9 (10-C), 28.7 (20-C), 27.4 (25-C), 24.1 (19-C). IR (KBr) ν (cm-1): 3309.7, 1637.9. 
HPLC-ESI-MS: m/z (%) = 665.3 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C35H44N4O9Na [M+Na]
+ 
687.3001; found 687.3001. Rf = 0.41 (EtOAc). 
tert-Butyl-N-[(4E,9S,12S,15S)-12-benzyl-9-[(2S)-2-{[(1S)-1-[(carbamoylmethyl)carbamoyl]-2-(1H-
indol-3-yl)ethyl]carbamoyl}pyrrolidine-1-carbonyl]-11,14-dioxo-2,7-dioxa-10,13-diazabicyclo 
[15.2.2]henicosa-1(19),4,17,20-tetraen-15-yl]carbamate (TVC-153, 127) 
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To a solution of 126 (32 mg, 48.14 µmol), TVC-108 (15 mg, 57.8 µmol) and HATU (22 mg, 57.8 µmol) 
in DMF (1 mL), DIPEA (40 µL, 241 µmol) was added. The reaction mixture was stirred at room 
temperature for 18 h and concentrated under 
reduced pressure to remove DMF. The residue was 
subjected to silica gel column chromatography 
eluting EtOAc/EtOH (10/1) to furnish 127 (43.6 
mg, 100%) as a solid.  
1
H-NMR (400 MHz, DMSO-d6): δ = 10.8 (s, 1H, 
NH), 8.25 (d, J = 8.5 Hz, 1H, NH), 8.0 (t, J = 6.0 
Hz, 1H, NH), 7.95 (d, J = 7.0 Hz, 1H, NH), 7.70 (d, 
J = 7.7 Hz, 1H, NH), 7.53 (d, J = 8.0 Hz, 1H, 28-H), 7.32 (d, J = 8.0 Hz, 1H, 31-H), 7.18-7.12 (m, 5H, 
12-H, 13-H, 14-H), 7.14 (overlap, 1H, 26-H), 7.05 (overlap, 1H, 30-H), 7.00 (d, J = 8.5 Hz, 2H, 3-H), 
6.97 (t, J = 7.5 Hz, 1H, 29-H), 6.75 (d, J = 8.5 Hz, 2H, 3-H), 5.83 (m, 1H, 38-H), 5.69 (m, 1H, 37-H), 
4.68 (overlap, 3H, 15-H, 39-H), 4.50 (m, 1H, 6-H), 4.46 (m, 1H, 23-H), 4.23 (m, 1H, 23-H), 4.17 (q, J = 
7.0 Hz, 1H, 8-H), 3.99 (dd, J = 5.0 Hz, J = 11 Hz, 1H, 36-H), 3.75 (m, 1H, 36-H), 3.65 (dd, J = 5.0 Hz, J 
= 17.0 Hz, 1H, 34-H), 3.55 (dd, J = 5.0 Hz, J = 17.0 Hz, 1H, 34-H), 3.50 (m, 1H, 18-H), 3.29 (m, 2H, 16-
H), 3.27 (m, 1H, 18-H), 3.19 (m, 1H, 24-H), 2.98 (m, 1H, 24-H), 2.88 (overlap, 3H, 5-H, 10-H), 2.79 (m, 
1H, 5-H), 1.90 (m, 1H, 20-H), 1.68 (m, 1H, 20-H), 1.66 (m, 2H, 19-H), 1.41 (s, 9H, 42-H). 
13
C-NMR 
(100 MHz, DMSO-d6): δ = 171.2 (7-C), 170.7 (9-C), 170.1 (33-C), 169.7 (17-C), 169.3 (22-C), 168.4 
(35-C), 156.1 (40-C), 154.4 (1-C), 137.1 (4-C), 136.0 (32-C), 131.2 (38-C), 130.9 (37-C), 130.8 (3-C), 
129.7 (12-C), 128.2 (13-C), 127.3 (27-C), 126.7 (14-C), 124.0 (26-C), 121.3 (30-C), 118.7 (28-C), 118.6 
(29-C), 111.7 (31-C), 115.2 (2-C), 78.2 (41-C), 70.2 (36-C), 68.4 (16-C), 67.3 (39-C), 60.2 (21-C), 54.8 
(8-C), 53.7 (6-C), 50.2 (15-C), 47.4 (18-C), 42.5 (34-C), 38.0 (5-C), 36.8 (10-C), 29.2 (20-C), 28.5 (42-
C), 24.4 (19-C). IR (KBr) ν (cm-1): 3433.9, 1653.1. HPLC-ESI-MS: m/z (%) = 907.4 (100) [M+H]+. 
HR-ESI-MS (m/z): calcd. for C48H58N8O10Na [M+Na]
+ 
929.4168; found 929.4160. Rf = 0.58 
(EtOAc/EtOH, 8/1). 
tert-Butyl-N-[(9S,12S,15S)-12-benzyl-9-[(2S)-2-{[(1S)-1-[(carbamoylmethyl)carbamoyl]-2-(1H-
indol-3-yl)ethyl]carbamoyl}pyrrolidine-1-carbonyl]-11,14-dioxo-2,7-dioxa-10,13-diazabicyclo 
[15.2.2]henicosa-1(19),17,20-trie-15-yl]carbamate (TVC-154)  
A suspension of 127 (18 mg, 19.85 µmol) and Pd/C (3.6 mg, 20 wt%) in MeOH/EtOAc (6 mL, 2/1) was 
stirred under a hydrogen atmosphere at room temperature for 20 h. The Pd/C was removed by a filtration 
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over a Celite pad and washed with EtOAc. Removal of solvent afforded TVC-154 (18 mg, 99%) as a 
brown solid. 
1
H-NMR (600 MHz, CD3OD): δ = 7.58 (d, J = 8.6 
Hz, 1H, 28-H), 7.36 (d, J = 8.6 Hz, 1H, 31-H), 
7.18-7.13 (m, 5H, 12-H, 13-H, 14-H), 7.13 
(overlap, 2H, 26-H, 30-H), 7.07 (d, J = 7.5 Hz, 
2H, 3-H), 7.04 (t, J = 7.5 Hz, 1H, 29-H), 6.78 (d, J 
= 7.5 Hz, 2H, 2-H), 4.65 (t, J = 6.5 Hz, 1H, 15-H), 
4.56 (t, J = 7.5 Hz, 23-H), 4.35 (m, 1H, 6-H), 4.31 
(m, 1H, 21-H), 4.26 (t, J = 6.5 Hz, 1H, 8-H), 4.1 
(m, 2H, 39-H), 3.87 (d, J = 17.0 Hz, 1H, 34-H), 3.69 (d, J = 17.0 Hz, 1H, 34-H), 3.58 (m, 1H, 18-H), 3.50 
(m, 1H, 16-H), 3.43 (m, 2H, 16-H, 18-H), 3.39 (m, 2H, 36-H), 3.37 (m, 1H, 24-H), 3.25 (m, 1H, 24-H), 
3.04 (m, 1H, 5-H), 2.93 (m, 1H, 10-H), 2.82 (m, 1H, 5-H), 2.80 (m, 1H, 10-H), 2.07 (m, 1H, 20-H), 1.78 
(m, 3H, 20-H, 19-H), 1.74 (m, 2H, 38-H), 1.62 (m, 2H, 37-H), 1.43 (s, 9H, 42-H). 
13
C-NMR (150 MHz, 
CD3OD): δ = 172.3 (7-C), 171.5 (9-C), 170.2 (22-C), 169.5 (33-C), 168.4 (35-C), 157.6 (40-C), 156.8 (1-
C), 136.7 (32-C), 129.7 (3-C), 127.6 (12-C), 127.5 (13-C), 127.2 (27-C), 126.2 (14-C), 123.0 (26-C), 
121.2 (30-C), 118.5 (29-C), 117.8 (28-C), 114.2 (2-C), 110.0 (31-C), 106.8 (25-C), 79.8 (41-C), 70.6 (16-
C), 68.9 (36-C), 66.8 (39-C), 60.5 (21-C), 56.1 (8-C), 54.7 (23-C), 53.5 (6-C), 51.3 (15-C), 47.2 (18-C), 
42.0 (34-C), 37.7 (5-C), 37.1 (10-C), 28.6 (20-C), 28.3 (42-C), 26.2 (24-C), 25.3 (38-C), 24.6 (37-C), 
24.4 (19-C). IR (KBr) ν (cm-1): 3447.9, 1654.5. HPLC-ESI-MS: m/z (%) = 909.4 (100) [M+H]+. HR-
ESI-MS (m/z): calcd. for C48H60N8O10Na [M+Na]
+ 
931.4325; found 931.4328. Rf = 0.37 (DCM/MeOH, 
15/1). 
General procedure for N-Boc deprotection 
Macrocyclic peptides were treated with TFA/TIPS/H2O (2 mL, 95/4/1) at 0 
o
C for 4 h. The reaction 
mixtures were then concentrated under reduced pressure to dryness. The crude products were subjected to 
silica gel column chromatography using DCM/MeOH (6/1, 0.1% TEA) to provide pure products, which 
were dissolved in ACN/H2O (3 mL, 1/1) and lyophilized to obtain white powders. 
(2S)-2-{[(2S)-1-[(4E,9S,12S,15S)-15-Amino-12-benzyl-11,14-dioxo-2,7-dioxa-10,13-diaza-bicyclo 
[15.2.2]heicosa-1(19),4,17,20-tetraene-9-carbonyl]pyrrolidin-2-yl]formamido}-N-(carbamoyl 
methyl)-3-(1H-indol-3-yl)propanamide (TVC-156, 128) 
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Starting material 127 (24 mg, 26.46 µmol) gave 
product 128 (20 mg, 94%). 
1
H-NMR (600 MHz, CD3OD): δ = 7.65 (d, J = 8.0 
Hz, 1H, 28-H),7.36 (d, J = 8.0 Hz, 1H, 31-H), 7.24-
7.19 (m, 5H, 12-H, 13-H, 14-H), 7.14 (s, 1H, 26-H), 
7.13 (overlap, 1H, 30-H), 7.11 (d, J = 8.4 Hz, 2H, 3-
H), 7.05 (t, J = 7.5 Hz, 1H, 29-H), 6.86 (d, J = 8.4 Hz, 
2H, 2-H), 5.84 (br, 1H, 37-H), 5.71 (br, 1H, 38-H), 
4.71 (bs, 2H, 39-H), 4.63 (t, J = 7.5 Hz, 1H, 23-H), 4.24 (m, 1H, 21-H), 4.60 (t, J = 8.0 Hz, 1H, 6-H), 
4.02 (d, J = 11.0 Hz, 1H, 36-H), 3.84 (d, J = 17.0 Hz, 34-H), 3.73 (d, J = 17.0 Hz, 34-H), 3.66 (t, J = 11.0 
Hz, 1H, 36-H), 3.57 (m, 1H, 18-H), 3.35 (overlap, 2H, 18-H, 24-H), 3.31 (m, 1H, 10-H), 3.14 (m, 1H, 24-
H), 3.06 (d, J = 7.5 Hz, 2H, 5-H), 3.04 (m, 1H, 10-H), 2.03 (m, 1H, 20-H), 1.78 (m, 1H, 19-H), 1.72 (m, 
1H, 20-H), 1.64 (m, 1H, 19-H). 
13
C-NMR (150 MHz, CD3OD): δ = 174.2 (9-C), 174.0 (7-C), 173.9 (22-
C), 171.9 (17-C), 171.1 (33-C), 168.5 (35-C), 159.3 (1-C), 138.0 (11-C), 137.7 (32-C), 132.3 (38-C), 
130.4 (3-C), 130.0 (37-C), 129.1 (12-C), 128.2 (12-C), 126.5 (13-C), 126.0 (27-C), 123.2 (26-C), 121.1 
(30-C), 118.5 (29-C), 117.6 (28-C), 111.0 (31-C), 106.5 (25-C), 70.2 (36-C), 67.5 (16-C), 66.9 (39-C), 
60.5 (21-C), 54.7 (6-C), 54.3 (23-C), 53.2 (8-C), 49.5 (15-C), 47.6 (18-C), 41.9 (34-C), 37.3 (5-C), 35.2 
(35.2), 28.6 (20-C), 26.5 (24-C), 24.6 (19-C). HPLC-ESI-MS: m/z (%) = 708.4 (100) [M+H]
+
. HR-ESI-
MS (m/z): calcd. for C43H51N8O8
 
 [M+H]
+ 
807.3824; found 807.3853. 
(2S)-2-{[(2S)-1-[(9S,12S,15S)-15-Amino-12-benzyl-11,14-dioxo-2,7-dioxa-10,13-diaza-bicyclo[15.2.2] 
henicosa-1(19),17,20-triene-9-carbonyl]-pyrrolidin-2-yl]formamido}-N-(carbamoylmethyl)-3-(1H-
indol-3-yl)propanamide (TVC-157, 129)  
Starting material TVC-154 (18 mg, 26.46 µmol) 
afforded product 129 (15 mg, 94%). 
1
H-NMR (600 MHz, CD3OD): δ = 7.58 (d, J = 8.6 Hz, 
1H, 28-H), 7.36 (d, J = 8.6 Hz, 1H, 31-H), 7.18-7.10 
(m, 5H, 12-H, 13-H, 14-H), 7.13 (overlap, 2H, 26-H, 
30-H), 7.08 (overlap, 2H, 3-H), 7.04 (t, J = 7.5 Hz, 1H, 
29-H), 6.84 (d, J = 7.5 Hz, 2H, 2-H), 4.64 (t, J = 6.5 
Hz, 1H, 15-H), 4.55 (t, J = 7.5 Hz, 23-H), 4.44 (t, J = 
6.5 Hz, 1H, 8-H), 4.29 (m, 1H, 21-H), 4.15 (m, 1H, 6-H), 4.11 (m, 2H, 36-H), 3.87 (d, J = 17.0 Hz, 1H, 
34-H), 3.68 (d, J = 17.0 Hz, 1H, 34-H), 3.55 (m, 1H, 18-H), 3.45 (m, 2H, 18-H), 3.49 (m, 2H, 39-H), 3.40 
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(m, 2H, 16-H), 3.35 (m, 1H, 24-H), 3.25 (m, 1H, 24-H), 3.22 (m, 1H, 5-H), 2.98 (m, 2H, 10-H), 2.94 (m, 
1H, 5-H), 2.07 (m, 1H, 20-H), 1.78 (m, 3H, 20-H, 19-H), 1.74 (m, 2H, 38-H), 1.62 (m, 2H, 37-H). 
13
C-
NMR (150 MHz, CD3OD): δ = 171.5 (9-C), 170.3 (7-C), 170.0 (22-C), 169.2 (33-C), 168.9 (35-C), 155.8 
(1-C), 136.2 (32-C), 130.1 (3-C), 129.2 (13-C), 127.7 (12-C), 127.5 (27-C), 126.5 (14-C), 123.0 (26-C), 
121.3 (30-C), 118.4 (29-C), 117.9 (28-C), 114.9 (2-C), 110.0 (31-C), 106.6 (25-C), 70.5 (36-C), 69.0 (16-
C), 66.7 (39-C), 60.5 (21-C), 54.7 (23-C), 53.9 (8-C), 53.5 (6-C), 51.2 (15-C), 47.4 (18-C), 41.9 (34-C), 
38.0 (10-C), 35.9 (5-C), 28.7 (20-C), 26.6 (24-C), 25.2 (38-C), 24.5 (37-C), 24.5 (19-C). HPLC-ESI-MS: 
m/z (%) = 809.4 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C43H52N8O8Na [M+Na]
+ 
831.3800; found 
831.3819.  
3.14 Hybrid synthesis 
Methyl-(3S)-2-[(2S)-1-[(4E,9S,12S,15S)-12-benzyl-15-{[(tert-butoxy)carbonyl]amino}-11,14-dioxo -
2,7-dioxa-10,13-diazabicyclo[15.2.2]henicosa-1(19),4,17,20-tetraene-9-carbonyl]pyrrolidine-2-
carbonyl]-1,2,3,4,9-pentahydropyrido[3,4-b]indole-3-carboxylate (TVC-189, 130) 
To a solution of 126 (40 mg, 60.17 µmol), 69 (18 
mg, 78.23 µmol) in DMF (1.5 mL), HATU (29.7 
mg, 78.23 µmol) and DIPEA (50 µL, 241 µmol) 
were added. After stirring at room temperature 
for 18 h, the solvent was removed and the crude 
residue was purified by silica gel column 
chromatography using EtOAc as eluent to afford 
product 130 (41 mg, 78%). 
1
H-NMR (400 MHz, CDCl3): δ = 7.37 (d, J = 8.2 
Hz, 1H, 28-H), 7.27 (d, J = 8.2 Hz, 1H, 31-H), 
7.22-7.13 (m, 5H, 12-H, 13-H, 14-H), 7.11 (overlap, 1H, 30-H), 7.05 (overlap, 1H, 29-H), 6.98 (d, J = 8.0 
Hz, 2H, 3-H), 6.68 (d, J = 8.0 Hz, 2H, 2-H), 5.66 (m, 1H, 36-H), 5.56 (m, 1H, 37-H), 5.05 (d, J = 17.1 
Hz, 1H, 34-H), 5.02 (m, 1H, 21-H), 4.81 (t, J = 7.0 Hz, 1H, 15-H), 4.76 (overlap, 1H, 23-H), 4.72 (d, J = 
14.2 Hz, 1H, 34-H), 4.60 (m, 2H, 35-H), 4.42 (t, J = 6.5 Hz, 1H, 8-H), 4.21 (bs, 1H, 6-H), 4.05 (m, 1H, 
38-H), 3.84 (m, 1H, 38-H), 3.74 (br, 1H, 18-H), 3.60 (m, 1H, 18-H), 3.54 (s, 3H, 42-H), 3.38 (m, 1H, 16-
H), 3.32 (m, 1H, 16-H), 3.30 (overlap, 1H, 25-H), 2.93 (m, 2H, 10-H), 2.90 (overlap, 1H, 5-H), 2.80 (m, 
1H, 5-H), 2.73 (m, 1H, 25-H), 2.27 (m, 1H, 20-H), 2.11 (m, 1H, 20-H), 1.97 (m, 2H, 19-H), 1.44 (s, 9H, 
41-H). 
13
C-NMR (100 MHz, CDCl3): δ = 172.3 (7-C), 171.5 (9-C), 170.1 (17-C), 169.6 (22-C), 168.5 
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(24-C), 156.3 (39-C), 155.2 (1-C), 136.5 (32-C), 135.9 (33-C), 130.7 (36-C), 130.0 (3-C), 129.5 (37-C), 
129.3 (12-C), 128.5 (13-C), 126.9 (14-C), 121.8 (30-C), 119.4 (29-C), 118.0 (28-C), 115.4 (2-C), 111.1 
(31-C), 105.6 (26-C), 70.5 (38-C), 68.0 (16-C), 66.8 (35-C), 57.7 (21-C), 55.5 (6-C), 54.1 (8-C), 52.3 (42-
C), 50.7 (15-C), 50.2 (23-C), 47.4 (18-C), 42.2 (34-C), 37.8 (5-C), 37.6 (10-C), 28.3 (41-C), 27.9 (20-C), 
24.3 (19-C), 22.1 (25-C). IR (KBr) ν (cm-1): 3421.3, 1653.1. HPLC-ESI-MS: m/z (%) = 877.4 (100) 
[M+H]
+
. HR-ESI-MS (m/z): calcd. for C48H56N6O10Na [M+Na]
+ 
899.3950; found 899.3950. Rf = 0.21 
(EtOAc). 
(3S)-2-[(2S)-1-[(4E,9S,12S,15S)-12-Benzyl-15-{[(tert-butoxy)carbonyl]amino}-11,14-dioxo-2,7-dioxa-
10,13-diazabicyclo[15.2.2]henicosa-1(19),4,17,20-tetraene-9-carbonyl]pyrrolidine-2-carbonyl]-
1,2,3,4,9-pentahydropyrido[3,4-b]indole-3-carboxylic acid (TVC-191, 131) 
 
Methyl ester 130 (34 mg, 38.7 µmol) in THF (1 
mL) was treated with 4% aqueous LiOH (0.4 mL) 
at room temperature for 5 h. The reaction mixture 
was then acidified with 1N HCl at 0 
oC to pH≈4 
and extracted with EtOAc (3x40 mL). The 
combined organic phases were washed with H2O, 
brine solution and dried over Na2SO4. Removal of 
the solvent yielded 131 (30.5 mg, 91%) as a solid. 
1
H-NMR (400 MHz, CD3OD): δ = 7.44 (d, J = 8.2 Hz, 1H, 28-H), 7.27 (d, J = 8.2 Hz, 1H, 31-H), 7.25-
7.17 (m, 5H, 12-H, 13-H, 14-H), 7.14 (overlap, 1H, 30-H), 7.09 (overlap, 1H, 29-H), 7.06 (d, J = 8.0 Hz, 
2H, 3-H), 6.78 (d, J = 8.0 Hz, 2H, 2-H), 5.76 (m, 2H, 36-H, 37-H), 5.15 (m, 1H, 34-H), 5.04 (m, 1H, 21-
H), 4.84 (overlap, 1H, 15-H), 4.63 (overlap, 1H, 23-H), 4.82 (overlap, 1H, 34-H), 4.66 (br, 2H, 35-H), 
4.56 (t, J = 6.5 Hz, 1H, 8-H), 4.31 (m, 1H, 6-H), 4.10 (m, 1H, 38-H), 3.81 (m, 1H, 38-H), 3.76 (br, 1H, 
18-H), 3.63 (m, 1H, 18-H), 3.41 (m, 1H, 16-H), 3.35 (m, 1H, 16-H), 3.36 (overlap, 1H, 25-H), 2.98 (m, 
2H, 10-H), 2.90 (overlap, 1H, 5-H), 2.84 (m, 1H, 5-H), 2.78 (m, 1H, 25-H), 2.31 (m, 1H, 20-H), 2.21 (m, 
1H, 20-H), 1.97 (m, 2H, 19-H), 1.44 (s, 9H, 41-H). 
13
C-NMR (100 MHz, CD3OD): δ = 171.3 (7-C), 
171.0 (9-C), 170.6 (17-C), 156.7 (39-C), 154.9 (1-C), 136.7 (32-C), 135.2 (33-C), 130.8 (3-C), 130.3 (36-
C, 37-C), 129.6 (12-C), 128.5 (13-C), 127.6 (14-C), 122.5 (30-C), 119.8 (29-C), 118.4 (28-C), 116.2 (2-
C), 111.7 (31-C), 106.6 (26-C), 70.0 (38-C), 66.8 (35-C), 66.7 (16-C), 57.7 (21-C), 55.3 (6-C), 54.9 (8-
C), 50.3 (15-C), 49.8 (23-C), 47.6 (18-C), 41.2 (34-C), 37.4 (5-C), 37.2 (10-C), 28.6 (41-C), 28.2 (20-C), 
24.4 (19-C), 22.6 (25-C). IR (KBr) ν (cm-1): 3426.6, 1716.3, 1646.8. HPLC-ESI-MS: m/z (%) = 863.4 
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[M+H]
+
. HR-ESI-MS (m/z): calcd. for C47H54N6O10Na [M+Na]
+ 
885.3794; found 885.3793. Rf = 0.12 
(EtOAc/EtOH, 7/1). 
tert-Butyl-N-[(4E,9S,12S,15S)-12-benzyl-9-[(2S)-2-[(3S)-3-[(carbamoylmethyl)carba-moyl]-1,2,3,4,9- 
pentahydropyrido[3,4-b]indole-2-carbonyl]pyrrolidine-1-carbonyl]-11,14-dioxo-2,7-dioxa-10,13- 
diazabicyclo[15.2.2]henicosa-1(19),4,17,20-tetraen-15- yl]carbamate (TVC-193) 
 
A stirred solution of 131 (28 mg, 32.45 µmol), 
HCl*H-Gly-NH2 (4.7 mg, 42.2 µmol) and TBTU 
(12.5 mg, 38.9 µmol) in DMF (2 mL) was added 
DIPEA (0.03 mL, 0.23 mmol). The reaction was 
stirred at room temperature for 20 h and the 
solvent was removed under reduced pressure. The 
crude product was purified by silica gel column 
chromatography using EtOAc/EtOH (7/1) to 
obtain TVC-193 (23 mg, 77%) as a solid product.  
1
H-NMR (400 MHz, CD3OD): δ = 7.46 (d, J = 
8.0 Hz, 1H, 28-H), 7.29 (d, J = 8.0 Hz, 1H, 31-H), 
7.26-7.17 (m, 5H, 12-H, 13-H, 14-H), 7.07 (overlap, 1H, 30-H, 3-H), 7.01 (overlap, 1H, 29-H), 6.78 (d, J 
= 8.0 Hz, 2H, 2-H), 5.76 (m, 2H, 36-H, 37-H), 5.11 (m, 1H, 34-H), 5.01 (m, 1H, 21-H), 4.81 (overlap, 
1H, 15-H), 4.88 (overlap, 1H, 34-H), 4.82 (overlap, 1H, 23-H), 4.67 (br, 2H, 35-H), 4.54 (m, 1H, 6-H), 
4.30 (m, 1H, 8-H), 3.87 (m, 2H, 38-H, 39-H), 3.71 (m, 2H, 38-H, 39-H), 3.73 (br, 1H, 18-H), 3.61 (m, 
1H, 18-H), 3.41 (m, 2H, 16-H), 3.40 (overlap, 1H, 25-H), 3.01 (m, 1H, 25-H), 2.99 (m, 2H, 10-H), 2.91 
(overlap, 2H, 5-H), 2.33 (m, 1H, 20-H), 1.92 (m, 1H, 20-H), 1.99-1.92 (m, 2H, 19-H), 1.46 (s, 9H, 41-H). 
13
C-NMR (100 MHz, CD3OD): δ = 174.1 (9-C), 173.3 (7-C), 172.1 (24-C), 171.6 (17-C), 170.9 (22-C), 
169.8 (40-C), 158.1 (41-C), 157.2 (1-C), 138.9 (32-C), 138.2 (33-C), 130.0 (3-C), 130.2 (36-C, 37-C), 
129.0 (12-C), 128.0 (13-C), 126.4 (14-C), 121.1 (30-C), 118.5 (29-C), 117.4 (28-C), 114.9 (2-C), 110.7 
(31-C), 106.4 (26-C), 70.0 (38-C), 66.9 (35-C), 67.5 (16-C), 57.8 (21-C), 55.6 (8-C), 54.2 (6-C), 50.3 (15-
C), 49.2 (23-C), 47.0 (18-C), 42.2 (39-C), 41.9 (34-C), 37.3 (5-C), 37.1 (10-C), 28.6 (43-C), 28.9 (20-C), 
24.9 (19-C), 22.4 (25-C). IR (KBr) ν (cm-1): 3421.0, 2932.8, 1662.5. HPLC-ESI-MS: m/z (%) = 919.4 
(100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C49H58N8O10Na [M+Na]
+ 
 941.4168; found 941.4167. Rf = 
0.28 (EtOAc/EtOH, 7/1).  
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2-{[(3S)-2-[(2S)-1-[(4E,9S,12S,15S)-15-Amino-12-benzyl-11,14-dioxo-2,7-dioxa-10,13-diazabicyclo- 
[15.2.2]henicosa-1(19),4,17,20-tetraene-9-carbonyl]pyrrolidine-2-carbonyl]-1,2,3,4,9-pentahydro-
pyrido[3,4-b]indol-3-yl]formamido}acetamide (TVC-199, 132) 
Cyclic peptide TVC-193 (30 mg, 30 µmol) was treated with TFA/TIPS/H2O (2 mL, 95/4/1) at 0 
o
C for 3 
h. The solvent was removed under reduced pressure and the crude product was purified by silica gel 
column chromatography eluting DCM/MeOH (8/1, 0.1% TEA) to afford pure product 132 (23 mg, 86%), 
which was dissolved in ACN/H2O (2 mL, 1/1) and lyophilized to afford white powder. 
1
H-NMR (600 MHz, CD3OD): δ = 7.47 (d, J = 8.0 
Hz, 1/2H, 28-H), 7.43 (d, J = 8.0 Hz, 1/2H, 28-H), 
7.29 (overlap, 1H, 31-H), 7.26-7.18 (m, 5H, 12-H, 
13-H, 14-H), 7.08 (overlap, 1H, 30-H, 3-H), 7.00 
(overlap, 1H, 29-H), 6.82 (d, J = 8.0 Hz, 2H, 2-H), 
5.77 (m, 1H, 36-H), 5.73 (m, 1H, 37-H), 5.41 (m, 1H, 
34-H), 4.97 (m, 1H, 21-H), 4.85 (overlap, 1H, 15-H), 
4.52 (m, 1H, 34-H), 4.71 (overlap, 1H, 23-H), 4.69 
(br, 2H, 35-H), 4.62 (m, 1H, 8-H), 4.11 (m, 1H, 38-
H), 3.94 (m, 2H, 6-H, 39-H), 3.87 (m, 2H, 38-H, 39-
H), 3.79 (m, 2H, 38-H, 39-H), 3.74 (m, 1H, 18-H), 
3.69 (overlap, 1H, 25-H), 3.65 (m, 1H, 18-H), 3.58 (m, 1H, 25-H), 3.38 (m, 2H, 16-H), 2.99 (m, 2H, 10-
H), 2.91 (overlap, 2H, 5-H), 2.34 (m, 1H, 20-H), 2.13 (m, 1H, 19-H),  1.94 (m, 1H, 20-H), 1.94 (m, 1H, 
20-H). 
13
C-NMR (150 MHz, CD3OD): δ = 174.2 (9-C), 173.7 (7-C), 173.2 (24-C), 172.9 (17-C), 170.9 
(22-C), 169.8 (40-C), 156.0 (1-C), 138.4 (32-C), 137.4 (33-C), 132.0 (3-C), 131.1 (37-C), 129.8 (36-C), 
129.0 (12-C), 128.0 (13-C), 126.3 (14-C), 121.1 (30-C), 118.6 (29-C), 117.2 (28-C), 115.1 (2-C), 110.6 
(31-C), 105.0 (26-C), 69.9 (38-C), 67.4 (16-C), 67.1 (35-C), 57.4 (21-C), 54.6 (23-C), 54.4 (8-C), 53.9 (6-
C), 49.0 (15-C), 47.0 (18-C), 42.0 (39-C), 39.0 (34-C), 37.5 (10-C), 36.8 (5-C), 28.6 (20-C), 24.7 (19-C), 
22.2 (25-C). HPLC-ESI-MS: m/z (%) = 819.4 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C44H51N8O8
 
[M+H]
+ 
819.3824; found 819.3830.  
3.15 Macrocylic ether synthesis 
(R)-3-tert-Butyl-4-methyl-2,2-dimethyloxazolidine-3,4-dicarboxylate (TVC-261, 151) 
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To a solution of methyl-(2R)-2-{[(tert-butoxy)carbonyl]amino}-3-hydroxy-
propanoate (1.5 g, 6.84 mmol) in acetone (10 mL) at 0 
o
C, 2,2-dimethoxypropane 
(4.2 mL, 30 mmol) was added and followed by addition of BF3.Et2O (49 mg, 0.34 
mmol). The reaction mixture was allowed to stir for 2 h at room temperature and 
concentrated to dryness. The residue was dissolved in EtOAc (150 mL), washed 
with saturated NaHCO3 and dried over MgSO4. Removal of the solvent yielded product TVC-261 (1.76 
mg, 98%) as a yellow oil. 
1
H-NMR (400 MHz, CDCl3): δ = 4.49 (d, J = 6.6 Hz, 1/2H, 1-H), 4.38 (d, J = 6.6 Hz, 1/2H, 1-H), 4.14 
(m, 1H, 2-H), 4.05 (t, J = 8.5 Hz, 1H, 2-H), 3.76 (s, 3H, 9-H), 1.68 (s, 3H, 8-H), 1.54 (s, 3H, 8-H), 1.43 
(s, 9H, 6-H). 
13
C-NMR (100 MHz, CDCl3): δ = 171.6 (3-C), 152.0 (4-C), 95.0 (7-C), 80.8 (5-C), 65.9 (2-
C), 59.3 (1-C), 52.3 (9-C), 28.3 (6-C), 24.8 (8-C). IR (neat) ν (cm-1): 1754.9, 1702.8. HPLC-ESI-MS: 
m/z (%) = 282.1 (10) [M+Na]
+
, 541.3 (15) [2M+Na]
+
. HR-ESI-MS (m/z): calcd. for C12H21NO5Na 
[M+Na]
+
 282.1312; found 282.1308. Rf = 0.36 (CyH/EtOAc, 8/1). 
(S)-tert-Butyl-4-(hydroxymethyl)-2,2-dimethyloxazolidine-3-carboxylate (TVC-233, 152) 
To a suspension solution of LAH (111 mg, 2.9 mmol) in dry THF (5 mL) at 0 
o
C, 
a solution of 151 (0.5 g, 1.93 mmol) in THF (8 mL) was added. The reaction 
mixture was allowed to warm up to room temperature and stirred for 20 min. 
Afterward, the mixture was cooled with an ice-water bath while 10% NaOH (3 
mL) was added. After stirring further for 1 h at room temperature, the white precipitate was removed by 
filtration over a Celite pad and washed with EtOAc. The filtrate was concentrated under reduced pressure 
to obtain alcohol 152 (445 mg, 99%) as a yellow oil. 
1
H-NMR (400 MHz, CDCl3): δ = 4.10 (m, 1H, 1-H), 4.01 (m, 1H, 2-H), 3.76 (m, 2H, 2-H, 3-H), 3.63 (m, 
1H, 3-H), 1.56 (s, 3H, 8-H), 1.49 (overlap, 12H, 8-H, 6-H). 
13
C-NMR (100 MHz, CDCl3): δ = 154.3 (4-
C), 94.1 (7-C), 81.1 (5-C), 65.33 (2-C, 3-C), 59.7 (1-C), 28.5 (6-C), 26.9 (8-C). IR (neat) ν (cm-1): 
3443.2, 1695.1. HPLC-ESI-MS: m/z (%) = 254.2 (10) [M+Na]
+
, 485.4 (13) [2M+Na]
+
. HR-ESI-MS 
(m/z): calcd. for C9H17NO3Na [M+Na]
+
 254.1163; found 254.1163.     
   = -22.8 (c 1.5, MeOH). Rf = 0.4 
(CyH/EtOAc, 3/1). 
(S)-tert-Butyl-2-(((benzyloxy)carbonyl)amino)-3-(4-hydroxyphenyl)propanoate (TVC-197) 
A solution of (S)-tyrosine-tert-butyl ester (200 mg, 0.84 mmol) in a two-phase mixture of water (10 mL) 
and ether (8 mL) at room temperature was treated with Na2CO3 (268 mg, 2.53 mmol) and benzyl 
chloroformate (151.4 mg, 0.84 mmol). The resulting solution was stirred at room temperature for 3 h and 
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the ether layer was separated. The aqueous phase was extracted with 
ether (2x50 mL). The combined organic phases were washed with 
brine solution and dried over MgSO4. Removal of the solvent and 
silica gel column chromatography using CyH/EtOAc (10/1) provided 
TVC-197 (290 mg, 93%) as a colourless oil. 
1
H-NMR (400 MHz, CDCl3): δ = 7.36-7.32 (m, 5H, 11-H, 12-H, 13-
H), 7.02 (d, J = 8.5 Hz, 2H, 5-H), 6.70 (d, J = 8.5 Hz, 2H, 6-H), 5.11 (d, J = 5.0 Hz, 2H, 9-H), 4.50 (d, J = 
8.5 Hz, 1H, 2-H), 3.05 (t, J = 6.0 Hz, 2H, 3-H). 1.44 (s, 9H, 15-H). 
13
C-NMR (100 MHz, CDCl3): δ = 
170.1 (1-C), 155.7 (8-C), 130.8 (5-C), 128.6 (11-C, 12-C, 13-C), 115.2 (6-C), 82.4 (14-C), 67.1 (9-C), 
55.3 (2-C), 37.6 (3-C), 28.1 (15-C). IR (neat) ν (cm-1): 3334.3, 1691.3. HPLC-ESI-MS: m/z (%) = 372.1 
(100) [M+H]
+
. HR-ESI-MS (m/z): Calcd for C21H25NO5Na [M+Na]
+
 394.1624; found 394.1625. Rf = 
0.34 (CyH/EtOAc, 5/1). 
Methyl-(2S)-3-hydroxy-2-[(triphenylmethyl)amino]propanoate (TVC-200, 141) 
To a cooled solution of L-serine methyl ester hydrochloride (300 mg, 1.93 
mmol) and Et3N (0.54 mL, 3.86 mmol) in DCM (8 mL), a solution of TrCl 
(564.4 mg, 2.02 mmol) in DCM (2 mL) was added dropwise. The resulting 
mixture was allowed to stir at room temperature for 18 h and then successively 
quenched with DCM (300 mL). The mixture was washed with brine solution and 
dried over MgSO4. Removal of the solvent and flash chromatography (CyH/EtOAc, 3/1) afforded 141 
(480.0 mg, 69%) as a white solid. 
1
H-NMR (400 MHz, CDCl3): δ = 7.52 (d, J = 8.0 Hz, 6H, 7-H), 7.30 (t, J = 8.0 Hz, 6H, 8-H), 7.21 (m, 
3H, 9-H), 3.75 (m, 1H, 3-H), 3.59 (m, 2H, 2-H, 3-H), 3.32 (s, 3H, 4-H), 2.33 (br, 1H, OH). 
13
C-NMR 
(100 MHz, CDCl3): δ = 173.9 (1-C), 145.6 (6-C), 128.9 (7-C), 128.1 (8-C), 126.7 (9-C), 70.9 (5-C), 65.0 
(3-C), 58.0 (2-C), 52.2 (4-C). IR (KBr) ν (cm-1): 3455.2, 1702.6. HPLC-ESI-MS: m/z (%) = 384.2 (10) 
[M+Na]
+
, 745.2 (10) [2M+Na]
+
. HR-ESI-MS (m/z): calcd. for C23H23NO3Na [M+Na]
+
 384.1570; found 
384.1576. Rf = 0.19 (CyH/EtOAc, 2/1). 
Methyl-(2S)-3-(4-iodophenoxy)-2-[(triphenylmethyl)amino]propanoate (TVC-203, 144) 
A stirred solution of 141 (30 mg, 83 µmol), 4-iodophenol (27.4 mg, 125 µmol) and PPh3 (32 mg, 124.5 
µmol) in dry benzene (1 mL) at 0 
o
C was added DEAD (22 mg, 124.5 µmol) in benzene under argon 
atmosphere. The reaction was kept at room temperature overnight. Removal of the solvent and flash 
chromatography (CyH/EtOAc, 10/1) afforded product 144 (39 mg, 83%) as a white solid. 
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1
H-NMR (400 MHz, CDCl3): δ = 7.56 (d, J = 9.3 Hz, 2H, 12-H), 7.45 (d, 
J = 7.8 Hz, 6H, 7-H), 7.30 (t, J = 7.8 Hz, 6H, 8-H), 7.22 (t, J = 7.8 Hz, 3H, 
9-H), 6.68 (d, J = 9.3 Hz, 2H, 11-H), 4.23 (dd, J = 5.0 Hz, J = 9.4 Hz, 1H, 
3-H), 3.99 (dd, J = 5.0 Hz, J = 9.4 Hz, 1H, 3-H), 3.75 (t, J = 6.0 Hz, 1H, 
2-H), 3.27 (s, 3H, 4-H). 
13
C-NMR (100 MHz, CDCl3): δ = 173.3 (1-C), 
158.4 (10-C), 145.6 (6-C), 138.3 (12-C), 129.0 (7-C), 127.9 (8-C), 126.6 
(9-C), 117.1 (11-C), 83.2 (13-C), 70.9 (5-C), 70.6 (3-C), 56.0 (2-C), 51.9 (4-C).  IR (KBr) ν (cm-1): 
3447.5, 1735.0. HPLC-ESI-MS: 438.1 (10) [M-I]
+
. HR-ESI-MS (m/z): calcd. for C29H26NO3Na 
[M+Na]
+
 586.0856; found 586.0850. Rf = 0.18 (CyH/EtOAc, 20/1). 
Benzyl-(2S)-2-{[(tert-butoxy)carbonyl]amino}-3-(methanesulfonyloxy)propanoate (TVC-209) 
Mesyl chloride (0.02 mL,0.25 mmol) was added dropwise to a cooled 
solution of BocSerOBn (50 mg, 0.17 mmol) and triethylamine (0.035 
mL, 0.25 mmol) in CH2Cl2 (1.5mL). The reaction mixture was stirred 
at 0 °C for 30 min and concentrated under reduced pressure. The 
crude product was purified by silica gel column chromatography 
using CyH/EtOAc (3/1) to obtain the pure product TVC-209 (62.5 mg, 98%). 
1
H-NMR (400 MHz, CDCl3): δ = 7.39 (m, 5H, 6-H, 7-H, 8-H), 5.21 (q, J = 11.0 Hz, 2H, 4-H), 4.65 (bs, 
1H, 2-H), 4.62 (m, 1H, 3-H), 4.52 (m, 1H, 3-H), 2.90 (s, 3H, 12-H), 1.47 (s, 9H, 11-H). 
13
C-NMR (100 
MHz, CDCl3): δ = 168.5 (1-C), 155.0 (9-C), 134.8 (5-C), 128.6 (6, 7, 8-C) 68.2 (3-C), 67.9 (4-C), 53.2 
(2-C), 37.3 (12-C), 28.4 (11-C). IR (KBr) ν = 1745.6. HPLC-ESI-MS: 374.1 [M+H]+.HR-ESI-MS 
(m/z): calcd. for C16H23NO7SNa [M+Na]
+
 396.1087; found 396.1090. Rf = 0.20 (CyH/EtOAc, 20/1). 
Benzyl-(2R)-2-{[(tert-butoxy)carbonyl]amino}-3-iodopropanoate (TVC-208, 146) 
A solution of sodium iodide (60 mg, 0.4 mmol) in acetone (1 mL) 
was added dropwise to a solution of the mesylate TVC-209 (50 mg, 
0.13 mmol) in acetone (1 mL). The resulting yellow solution was 
stirred overnight at room temperature. The reaction mixture was 
filtered over Celite pad and the filtrate was concentrated under reduced pressure to yield product 146 
(48.4 mg, 89%) as a yellow oil . 
1
H-NMR (400 MHz, CDCl3): δ = 7.39 (m, 5H, 6-H, 7-H, 8-H), 5.38 (d, J = 7.2 Hz, 1H, NH), 5.23 (d, J = 
6.0 Hz, 2H, 4-H), 4.57 (d, J = 7.2 Hz, 1H, 2-H), 3.60 (m, 2H, 3-H), 1.45 (s, 9H, 11-H). 
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C-NMR (100 
NH
O
O
I
O 1
2
3
4
5
6
7
8
9
10
11
12
13
S
O
O
O
N
H
O
O
O
O
1
2
3
4
5
6
7
8
9
10
11
12
I
N
H
O
O
O
O
1
2
3
4
5
6
7
8
9
10
11
159 
 
MHz, CDCl3): δ = 169.2 (1-C), 154.8 (9-C), 134.9 (5-C), 128.8 (6,7,8-C), 80.5 (10-C), 68.0 (4-C), 62.6 
(3-C), 54.2 (2-C), 28.3 (11-C). IR (KBr) ν: 1733.7. HPLC-ESI-MS: 406.1 (10) [M+H]+, 428 (80) 
[M+Na]
+
. Rf = 0.16 (CyH/EtOAc, 20/1). 
(S)-tert-Butyl-4-((4-((S)-2-(((benzyloxy)carbonyl)amino)-3-(tert-butoxy)-3-oxopropyl)phenoxy) 
methyl)-2,2-dimethyloxazolidine-3-carboxylate (TVC-254, 153) 
To a cooled solution of TVC-197 (53 mg, 142.7 µmol), 152 
(22.0 mg, 95.1 µmol) and PPh3 (37.4 mg,142.7 µmol) in dry 
toluene (1.5 mL) under argon atmosphere, a solution of 
DEAD (25.6 mg, 142.7 µmol) in toluene (0.5 mL) was added 
dropwise. The resulting solution was then heated at 90 
o
C for 
48 h. The solvent was removed under reduced pressure and the residue was subjected to silica gel column 
chromatography using CyH/EtOAc (4/1) to provide 153 (36 mg, 65%) as a yellow solid product. 
1
H-NMR (400 MHz, CDCl3): δ = 7.38-7.34 (m, 5H, 14-H, 15-H, 16-H), 7.05 (d, J = 8.0 Hz, 2H, 5-H), 
6.86 (m, 2H, 6-H), 5.23 (s, 1H, NH), 5.11 (d, J = 4.5 Hz, 2H, 12-H), 4.5 (d, J = 6.0 Hz, 1H, 2-H), 4.29 
(br, 1/2H, 9-H), 4.17 (br, 1/2H, 9-H), 4.10 (overlap, 1H, 10-H), 4.08 (overlap, 1H, 8-H), 4.01 (m, 1H, 10-
H), 3.84 (m, 1H, 8-H), 3.04 (bs, 2H, 3-H), 1.61 (s, 3H, 8-H), 1.51 (overlap, 12H, 8-H, 18-H), 1.43 (s, 9H, 
21-H). 
13
C-NMR (100 MHz, CDCl3): δ = 170.6 (1-C), 157.5 (11-C), 155.6 (19-C), 152.3 (7- C), 136.4 
(13-C), 130.5 (5-C), 128.3 (14-C, 15-C, 16-C), 128.0 (4-C), 114.5 (6-C), 94.0 (22-C), 82.2 (17-C), 80.4 
(20-C), 66.8 (12-C), 66.5 (8-C), 65.3 (10-C), 55.9 (9-C), 55.2 (2-C), 37.6 (3-C), 28.3 (18-C), 27.9 (21-C), 
27.0, 23.1 (23-C). IR (KBr) ν (cm-1): 3434.1, 2978.7, 1701.0, 1245.5. HPLC-ESI-MS: m/z (%) = 585.3 
(10) [M+H]
+
, 602.3 (100) [M+NH4]
+
. HR-ESI-MS (m/z): calcd. for C32H44N2O8Na [M+Na]
+
 607.2990; 
found 607.2990. Rf = 0.31 (CyH/EtOAc, 4/1). 
tert-Butyl-(2S)-2-[(2S)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-3-(4-hydroxyphenyl)-
propanamido]-3-phenylpropanoate (TVC-277, 157) 
A solution of Fmoc-Tyr-OH (600 mg, 1.49 mmol), Phe-OtBu (422 mg, 1.64 mmol) and HATU (685 mg, 
1.80 mmol) in DMF (4 mL) was added DIPEA (1 mL, 5.9 mmol). After being stirred at room temperature 
for 18 h, the solvent was removed under reduced pressure. Flash chromatography (CyH/EtOAc, 4/1) 
provided 157 (760 mg, 84%) as a white solid. 
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1
H-NMR (400 MHz, CDCl3): δ = 7.78 (d, J = 7.5 Hz, 2H, 18-H), 7.55 
(t, J = 7.5 Hz, 2H, 21-H), 7.42 (t, J = 7.5 Hz, 2H, 19-H), 7.32 (m, 2H, 
20-H), 7.21 (m, 3H, 12-H, 13-H), 7.06 (d, J = 7.0 Hz, 2H, 11-H), 7.02 
(overlap, 2H, 3-H), 6.73 (d, J = 8.0 Hz, 2H, 2-H), 6.32 (s, 1H, NH), 5.76 
(s, 1H, NH), 5.34 (br, 1H, OH), 4.67 (d, J = 7.5 Hz, 1H, 6-H), 4.45 (m, 
1H, 15-H), 4.38 (overlap, 1H, 8-H), 4.33 (m, 1H, 15-H), 4.20 (t, J = 7.5 
Hz, 1H, 16-H), 3.04 (d, J = 5.8 Hz, 2H, 5-H), 2.98 (br, 2H, 9-H), 1.38 (s, 
9H, 25-H). 
13
C-NMR (100 MHz, CDCl3): δ = 170.3 (23-C), 155.5 (14-
C), 155.0 (1-C), 143.7 (17-C), 141.8 (22-C), 135.8 (10-C), 130.6 (3-C), 
129.5 (11-C), 128.4 (12-C), 127.7 (19-C), 127.2 (20-C), 127.1 (13-C), 125.1 (21-C), 119.9 (18-C), 115.6 
(2-C), 67.2 (15-C), 56.2 (8-C), 53.8 (6-C), 46.9 (16-C), 38.0 (5-C), 37.6 (9-C), 28.0 (25-C). IR (KBr) ν 
(cm
-1
): 3342.6, 2977.6, 1725.3, 1699.0, 1660.5. HPLC-ESI-MS: m/z (%) = 607.3 (60) [M+H]
+
. HR-ESI-
MS (m/z): calcd. for C37H37N2O6Na [M+Na]
+
 629.2621; found 629.2622. Rf = 0.29 (CyH/EtOAc, 2/1). 
tert-Butyl-(4S)-4-{4-[(2S)-2-{[(2S)-1-(tert-butoxy)-1-oxo-3-phenylpropan-2-yl]carbamoyl}-2- {[(9H-
fluoren-9-ylmethoxy)carbonyl]amino}ethyl]phenoxymethyl}-2,2-dimethyl-1,3-oxazolidine-3-
carboxylate (TVC-278, 158) 
To a cooled solution of 157 (330 mg, 543.9 µmol), 152 (163 mg, 
707.1 µmol) and PPh3 (214 mg, 820 µmol) in dry toluene (8 mL) 
under argon atmosphere, DEAD (0.13 mL, 816 µmol) was added. The 
reaction mixture was refluxed for 48 h and concentrated under 
reduced pressure to dryness. The crude product was purified by silica 
gel column chromatography (CyH/EtOAc, 8/1) to give 158 (239 mg, 
54%) as a yellow solid product. 
1
H-NMR (400 MHz, CDCl3): δ = 7.69 (d, J = 7.5 Hz, 2H, 18-H), 
7.46 (t, J = 7.5 Hz, 2H, 21-H), 7.33 (t, J = 7.5 Hz, 2H, 19-H), 7.23 (t, 
J = 7.5 Hz, 20-H), 7.11-7.09 (m, 3H, 12-H, 13-H), 7.0 (overlap, 2H, 
3-H), 6.97 (overlap, 2H, 11-H), 6.77 (t, J = 8.0 Hz, 2H, 2-H), 6.17 (s, 
1H, NH), 5.18 (s, 1H, NH), 4.57 (q, J = 7.2 Hz, 1H, 6-H), 4.35 (m, 
1H, 15-H), 4.29 (m, 1/2H, 27-H), 4.24 (m, 1H, 15-H), 4.19 (m, 1/2H, 27-H), 4.12 (overlap, 1H, 8-H), 4.11 
(br, 2H, 28-H), 4.07 (overlap, 1H, 16-H), 3.97 (br, 1H, 26-H), 3.89 (br, 1H, 26-H), 2.95 (d, J = 5.8 Hz, 
4H, 5-H, 9-H), 1.53, 1.41 (s, 6H, 30-H), 1.40 (s, 9H, 25-H), 1.30 (s, 9H, 33-H). 
13
C-NMR (100 MHz, 
CDCl3): δ = 170. 1 (23-C), 169.9 (7-C), 143.7 (17-C), 141.3 (22-C), 135.8 (10-C), 130.5 (3-C), 129.4 
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(11-C), 128.4 (12-C), 127.7 (4-C), 127.0 (19-C), 126.9 (13-C), 126.2 (20-C), 125.0 (21-C), 119.9 (18-C), 
114.8 (2-C), 94.1 (29-C), 82.4 (24-C), 80.5 (32-C), 67.0 (15-C), 65.2 (26-C), 61.8 (28-C), 56.0 (27-C), 
55.7 (16-C), 53.6 (6-C), 37.9 (5-C, 9-C), 28.3 (25-C), 27.8 (33-C), 27.1, 24.1 (30-C). IR (KBr) ν (cm-1): 
3319.2, 1701.0,1256.8. HPLC-ESI-MS: m/z (%) = 820.4 (15) [M+H]
+
, 837.4 (30) [M+NH4]
+
. HR-ESI-
MS (m/z): calcd. for C48H57N3O9Na [M+Na]
+
 842.3989; found 842.3987. Rf = 0.24 (CyH/EtOAc, 6/1). 
(2S)-2-[(2S)-2-{[(9H-Fluoren-9-ylmethoxy)carbonyl]amino}-3-{4-[(2R)-3-hydroxy-2-methylprop-
oxy]phenyl}propanamido]-3-phenylpropanoic acid trifluoroacetate (TVC-279, 159) 
Compound 158 (150 mg, 0.18 mmol) in TFA/TIPS/H2O (2 mL, 95/2.5/2.5) was stirred at 0 
o
C for 3 h. 
The reaction mixture was concentrated under reduced pressure to obtain product 159 (134.8 mg, 100%) as 
a TFA salt. 
1
H-NMR (400 MHz, CD3OD): δ = 7.80 (d, J = 7.3 Hz, 2H, 18-H), 
7.59 (t, J = 7.3 Hz, 2H, 21-H), 7.41 (t, J = 7.3 Hz, 2H, 19-H), 7.31 
(t, J = 7.3 Hz, 2H, 20-H), 7.19 (d, J = 8.9 Hz, 2H, 3-H), 6.88 (d, J = 
8.9 Hz, 2H, 2-H), 4.69 (q, J = 5.5 Hz, 1H, 6-H), 4.36 (m, 1H, 8-H), 
4.28 (m, 1H, 15-H), 4.19 (overlap, 1H, 15-H), 4.11 (overlap, 3H, 
16-H, 24-H), 3.79 (m, 1H, 26-H), 3.68 (q, J = 6.0 Hz, 1H, 26-H), 
3.58 (m, 1/2H, 25-H), 3.51 (m, 1/2H, 25-H), 3.23 (q, J = 5.5 Hz, 
1H, 5-H), 3.03 (overlap, 2H, 5-H, 9-H), 2.77 (q, J = 5.5 Hz, 1H, 9-
H). 
13
C-NMR (100 MHz, CD3OD): δ = 172.9 (7-C), 172.4 (23-C), 
156.9 (14-C), 151.7 (1-C), 143.9 (17-C), 141.2 (22-C), 138.1 (10-C), 130.2 (3-C), 128.9 (11-C), 128.1 
(12-C), 127.4 (19-C), 126.8 (20-C), 126.5 (13-C), 124.8 (21-C), 119.6 (18-C), 114.3 (2-C), 66.8 (15-C), 
65.1 (24-C), 58.9 (26-C), 56.3 (8-C), 53.5 (6-C), 52.4, 51.3 (25-C), 46.8 (16-C), 36.9 (5-C), 36.7 (9-C). 
IR (KBr) ν (cm-1): 3424.7, 2944.6, 1674.6, 1203.7. HPLC-ESI-MS: m/z (%) = 624.3 (100) [M+H-
CF3COOH]
+
, HR-ESI-MS (m/z): calcd. for C36H38N3O7 [M+H]
+
 624.2704; found 624.2704. 
3.16 Synthesis of β-proline amino acid 
(R)-tert-Butyl-3-hydroxypyrrolidine-1-carboxylate (TVC-238, 162) 
A suspension of 4-(R)-hydroxy-(L)-proline (2 g, 15.25 mmol) and 2-cyclohexen-1-one (0,2 mL, 2.08 
mmol) in cyclohexanol (10 mL) was heated at 160°C for 6 h, until all the solid was dissolved. The 
resulting red solution was cooled to room temperature and an aqueous solution of acetic acid (20%, 10 
mL) and toluene (10 mL) were added. The aqueous layer was washed twice with toluene (2x10 mL), then 
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solid K2CO3 (6 g) was added until pH≈9 and followed by addition of Boc2O (3.33 g, 15.3 
mmol) in THF (20 mL). After stirring at room temperature for 20 h, the reaction mixture 
was extracted twice with EtOAc (2x100 mL). The combined organic layers were 
concentrated and ethanol (40 mL) was added. The solution was heated under reflux for 
20 h and the solvent was evaporated. Flash chromatography using (CyH/EtOAc, 1/1) 
gave the desired product 162 (2.4 g, 84%) as a brown solid. 
1
H-NMR (400 MHz, CDCl3): δ = 4.45 (m, 1H, 2-H), 3.48 (overlap, 3H, 4-H, 1-H), 3.37 (m, 1H, 1-H), 
1.93 (m, 2H, 3-H), 1.47 (s, 9H, 7-H). 
13
C-NMR (100 MHz, CDCl3): δ = 154.7 (5-C), 79.3 (6-C), 71.0 (2-
C), 54.2 (1-C), 43.7 (4-C), 33.7 (3-C), 28.4 (7-C). IR (neat) ν (cm-1): 3396.0, 1652.7. HPLC-ESI-MS: 
m/z (%) = 210.1 (10) [M+Na]
+
. HR-ESI-MS (m/z): calcd. for C9H17NO3Na [M+Na]
+
 210.1101; found 
210.1101.     
   = -22.8 (c 1.5, MeOH). Rf = 0.21 (CyH/EtOAc, 1/1). 
(R)-tert-Butyl-3-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate (TVC-241) 
To a solution of 162 (150 mg, 0.8 mmol) and TEA (122 µL, 0.88 mmol) in DCM (15 
mL) at 0 
o
C, TsCl (275 mg, 1.44 mmol) in DCM (10 mL) was added dropwise. After 
stirring at 0 °C for 2.h, the mixture was allowed to warm up to room temperature and 
further stirred for 18 h. Removal of the solvent and column chromatography on silica 
gel using EtOAc/CyH (10/1) as eluent yielded product TVC-241 (170 mg, 62%) as a 
colourless oil. 
1
H-NMR (400 MHz, CDCl3): δ = 7.80 (d, J = 8.3 Hz, 2H, 9-H), 7.36 (d, J = 8.3 Hz, 2H, 
10-H), 5.06 (bs, 1H, 2-H), 3.47 (m, 4H, 1-H, 4-H), 2.48 (s, 3H, 12-H), 2.21 (m, 1H, 3-
H), 2.05 (m, 1H, 3-H), 1.45 (s, 9H, 7-H). 
13
C-NMR (100 MHz, CDCl3): δ = 154.1 (5-C), 145.0 (8-C), 
130.1 (10-C), 127.7 (9-C), 80.9 (2-C), 79.5 (6-C), 52.3 (4-C), 43.8 (1-C), 31.7 (3-C), 28.7 (7-C), 21.8 (12-
C). IR (neat) ν (cm-1): 1691.3. HPLC-ESI-MS: m/z (%) = 359.2 (16) [M+NH4]
+
, 705.2 (8) [2M+Na]
+
. 
HR-ESI-MS (m/z): calcd. for C16H23N2O5Na [M+Na]
+
 364.1505; found 364.1188. Rf = 0.5 (CyH/EtOAc, 
1/1). 
(S)-tert-Butyl-3-cyanopyrrolidine-1-carboxylate (TVC-242, 163) 
 A suspension of tosylate TVC-241 (910 mg, 2.67 mmol) and NaCN (288 mg, 5.86 mmol) in dry DMSO 
(10 mL) was warmed up to 80 °C for 21 h. Afterward, a saturated aqueous NaHCO3 was added and the 
mixture was extracted with EtOAc (3x100 mL). The combined organic layers were washed with H2O, 
brine solution and dried over MgSO4. The solvent was evaporated in vacuo and the crude material was 
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purified by silica gel column chromatography eluting CyH/EtOAc (3/1) to provide the 
desired cyanate 163 (334.4 mg, 64%). as a yellow oil. 
1
H-NMR (400 MHz, CDCl3): δ = 3.67 (m, 1H, 1-H), 3.59 (m, 1H, 1-H), 3.55 (m, 1H, 4-
H), 3.45 (m, 1H, 4-H), 3.1 (m, 1H, 2-H), 2.25 (m, 2H, 3-H), 1.47 (s, 9H, 8-H). 
13
C-NMR 
(100 MHz, CDCl3): δ = 153.8 (6-C), 119.9 (5-C), 80.1 (7-C), 48.7 (1-C), 44.4 (4-C), 29.7 
(3-C), 28.6 (2-C), 28.3 (8-C). IR (neat) ν (cm-1): 1695.1 (CO). HPLC-ESI-MS: m/z (%) = 
214.1 (100) [M+NH4]
+
. HR-ESI-MS (m/z): calcd. for C10H16N2O2Na [M+Na]
+
 219.1092; found: 
219.1104.     
  = + 25.6 (c 1.4, MeOH). Rf = 0.27 (CyH/EtOAc, 3/1). 
(S)-1-(tert-Butoxycarbonyl)pyrrolidine-3-carboxylic acid (TVC-247, 164) 
Cyanate 163 (44 mg, 22 mmol) in 35% HCl (3 mL) was refluxed for 5 h. The reaction 
mixture was concentrated to dryness. The residue was dissolved in H2O (1 mL) and 
followed by addition of NaHCO3 (55.4 mg, 0.66 mmol) and Boc2O (53 mg, 0.24 mmol) 
in THF (2 mL). After stirring at room temperature for 18 h, the reaction mixture was 
extracted with EtOAc (2x100 mL). The combined organic layers were washed with brine 
solution and dried over MgSO4. Removal of the solvent afforded desired acid 164 (46.3 
mg, 98%) as white powder.
 
1
H-NMR (400 MHz, CDCl3): δ = 3.59 (m, 2H, 4-H), 3.50 (m, 1H, 1-H), 3.37 (m, 1H, 1-H), 3.08 (br, 1H, 
2-H), 2.15 (m, 2H, 3-H), 1.46 (s, 9H, 8-H). 
13
C-NMR (100 MHz, CDCl3): δ = 177.7 (5-C), 154.7 (6-C), 
47.9 (4-C), 45.2 (1-C), 42.9 (2-C), 28.5 (3-C), 28.4 (8-C). IR (neat) ν (cm-1): 3196.3, 1739.5, 1664.3. 
HPLC-ESI-MS: m/z (%) = 238.1 (100) [M+Na]
+
. HR-ESI-MS (m/z): calcd. for C10H17NO4Na [M+Na]
+
 
238.1050; found 238.1050.     
   = + 19.2 (c 0.27, MeOH). Rf  = 0.14 (CyH/EtOAc, 3/2). 
(S)-tert-Butyl-3-(((S)-1-((2-amino-2-oxoethyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-carbamo-
yl)pyrrolidine-1-carboxylate (TVC-252, 165) 
To a solution of (S)-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid 
164 (33 mg, 0.15 mmol) and TFA*H-Trp-Gly-NH2 (68.8 mg, 0.18 mmol) 
in DMF (2 mL), HATU (64 mg, 0.17 mmol) and DIPEA (91 µL, 0.61 
mmol) were added. The reaction mixture was stirred at room temperature 
for 24 h and quenched with EtOAc (100 mL). The resulting solution was 
washed with H2O (2x10 mL), brine solution (20 mL) and dried over 
Na2SO4. Removal of the solvent and flash chromatography using 
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EtOAc/EtOH (20/1) gave the desired product 165 (53.3 mg, 76%) as a solid. 
1
H-NMR (400 MHz, CD3OD): δ = 7.53 (d, J = 7.6 Hz, 1H, 12-H), 7.31 (d, J = 8.6 Hz, 1H, 9-H), 7.10 (t, J 
= 7.0 Hz, 1H, 10-H), 7.03 (overlap, 2H, 7-H, 11-H), 4.58 (bs, 1H, 4-H), 3.79 (d, J = 17.0 Hz, 1H, 2-H), 
3.63 (d, J = 17.0 Hz, 1H, 2-H), 3.43 (br, 1H, 18-H), 3.35 (br, 1H, 17-H), 3.30 (overlap, 1H, 18-H), 3.20 
(overlap, 1H, 5-H), 3.18 (m, 1H, 17-H), 3.12 (overlap, 1H, 5-H), 2.82 (bs, 1H, 15-H), 1.93-1.89 (m, 2H, 
16-H), 1.38 (s, 9H, 21-H). 
13
C-NMR (100 MHz, CD3OD): δ = 140.1 (8-C), 127.2 (11-C), 125.8 (10-C), 
123.1 (7-C), 122.1 (12-C), 115.3 (9-C), 82.2 (20-C), 58.7 (4-C), 51.8 (18-C), 49.6 (17-C), 48.0 (15-C), 
45.8 (2-C), 32.3 (16-C), 32.2 (21-C), 31.1 (5-C). IR (KBr) ν (cm-1): 3397.9, 1670.6. HPLC-ESI-MS: 
m/z(%) = 458 (32) [M+H]
+
, 915 (30) [2M+H]
+
. HR-ESI-MS: Calcd for C23H31N5O5Na [M+Na]
+
 
480.2223; found 480.2213. Rf = 0.25 (EtOAc/EtOH, 10/1). 
(S)-3-(((S)-1-((2-Amino-2-oxoethyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)carbamoyl)-
pyrrolidin-1-ium triflouroacetate (TVC-264) 
Tripeptide 165 (45 mg, 0.1 mmol) was treated with TFA/TIPS/H2O (2 mL, 
95/2.5/2.5) at 0 
o
C for 3 h. The reaction mixture was concentrated to 
dryness to obtain TVC-264 (46 mg, 100%) as a TFA salt. 
1
H-NMR (400 MHz, CD3OD): δ = 7.63 (dd, J = 3.2 Hz, J = 7.8 Hz, 1H, 
12-H), 7.37 (d, J = 8.0 Hz, 1H, 9-H), 7.16 (s, 1H, 7-H), 7.13 (d, J = 7.0 Hz, 
1H, 10-H), 7.05 (t, J = 7.8 Hz, 1H, 11-H), 4.72 (t, J = 7.2 Hz, 1/2H, 4-H), 
4.62 (t, J = 7.2 Hz, 1/2H, 4-H), 3. 9 (dd, J = 4.2 Hz, J = 17.0 Hz, 1H, 2-H), 
3.70 (dd, J = 3.2 Hz, J = 17.0 Hz, 1H, 2-H), 3.37 (overlap, 1H, 5-H), 3.33 
(overlap, 1H, 17-H), 3.32 (overlap, 1H, 18-H), 3.25 (overlap, 1H, 18-H), 3.20 (overlap, 1H, 15-H), 3.18 
(m, 2H, 17-H, 5-H), 2.28 (m, 1H, 18-H), 2.18 (m, 2H, 16-H). 
13
C-NMR (100 MHz, CD3OD): δ = 176.9 
(14-C), 176.8 (3-C), 140.5 (8-C), 127.2 (7-C), 125.1 (10-C), 122.8 (11-C), 121.9 (12-C), 114.9 (9-C), 
58.9 (4-C), 51.2 (18-C), 48.8 (17-C), 46.1 (15-C), 45.2 (2-C), 32.4 (16-C), 31.0 (5-C). IR (KBr) ν (cm-1): 
3420.3, 1670.5. HPLC-ESI-MS: m/z (%) = 358 (100) [M+H]
+
, 715 (30) [2M+H]
+
. HR-ESI-MS: Calcd 
for C23H31N5O5Na [M+Na]
+
 380.1699; found 380.1692. 
tert-Butyl-((S)-1-(((S)-1-(((S)-1-((S)-3-(((S)-1-((2-amino-2-oxoethyl)amino)-3-(1H-indol-3-yl)-1-oxo-
propan-2-yl)carbamoyl)pyrrolidin-1-yl)-3-(tert-butoxy)-1-oxopropan-2-yl)amino)-1-oxo-3-phenyl-
propan-2-yl)amino)-3-(4-(tert-butoxy)phenyl)-1-oxopropan-2-yl)carbamate (TVC-266) 
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To a solution of TVC-264 (40 mg, 85 µmol) 
and tripeptide Boc-Tyr(tBu)-Phe-Ser(tBu)-
OH (69.2 mg, 110.3 µmol) in DMF (2 mL), 
HATU (48.4 mg, 127 µmol) and DIPEA (57 
µL, 339 µmol) were added. After being 
stirred for 18 h at room temperature, the 
solvent was removed under reduced pressure. 
The residue was subjected to silica gel 
column chromatography using EtOAc/EtOH 
(6/1) to afford peptide TVC-266 (71.2 mg, 
87%) as a white solid. 
1
H-NMR (400 MHz, CD3OD): δ = 7.68 (m, 1H, 12-H), 7.35 (m, 1H, 9-H), 7.26-7.20 (m, 5H, 26-H, 27-H, 
28-H), 7.13 (m, 1H, 10-H), 7.12 (overlap, 3H, 7-H), 7.18 (overlap, 1H, 34-H), 7.05 (m, 1H, 11-H), 6.90 
(d, J = 7.4 Hz, 2H, 34-H), 4.68 (m, 1H, 23-H), 4.66 (m, 1H, 20-H), 4.61 (m, 1H, 4-H), 4.26 (m, 1H, 30-
H), 3.87 (overlap, 1H, 2-H), 3.68 (overlap, 1H, 2-H), 3.58 (overlap, 1H, 21-H), 3.51 (overlap, 1H, 18-H), 
3.51 (overlap, 1H, 21-H), 3.62 (overlap, 1H, 17-H), 3.60 (m, 1H, 18-H), 3.54 (overlap, 1H, 17-H), 3.43 
(m, 1H, 5-H), 3.18 (overlap, 1H, 5-H), 3.08 (m, 1H, 24-H), 2.99 (overlap, 1H, 31-H), 3.05-3.00 (overlap, 
1H, 15-H), 2.94 (overlap, 1H, 24-H), 2.70 (overlap, 1H, 31-H), 2.16 (m, 1H, 16-H), 1.99 (m, 1H, 16-H), 
1.36 (s, 9H, 37-H), 1.34 (s, 9H, 39-H), 1.16 (s, 9H, 42-H). 
13
C-NMR (100 MHz, CD3OD): δ = 175.6 (19-
C), 174.7 (22-C), 174.6 (29-C), 174.0 (14-C), 172.7 (3-C), 170.6 (1-C), 155.2 (40-C), 142.8 (35-C), 133.7 
(8-C), 129.5 (34-C), 129.1 (27-C), 128.7 (32-C),128.2 (26-C), 127.9 (13-C), 126.5 (28-C), 123.7 (33-C), 
121.2 (7-C), 123.1 (10-C), 118.6 (11-C), 118.0 (12-C), 111.1 (9-C), 107 (6-C), 83.6 (36-C), 82.7 (38-C), 
80.7 (41-C), 61.7 (21-C), 56.1 (30-C), 54.8 (4-C), 54.2 (23-C), 51.2 (20-C), 48.4 (18-C), 45.9 (17-C), 
43.7 (15-C), 41.9 (2-C), 37.5 (24-C), 37.2 (31-C), 29.2 (37-C), 29.1 (16-C), 28.8 (39-C), 27.6 (42-C), 
26.9 (5-C). IR (neat) ν (cm-1): 3278.4, 1657.8. HPLC-ESI-MS: m/z (%) = 967.5 (100) [M+H]+. HR-
ESI-MS: Calcd for C52H71N8O10 [M+H]
+ 
967.5293; found 967.5288. Rf = 0.34 (EtOAc/EtOH, 5/1). 
(2S)-2-[(2S)-2-Amino-3-(4-hydroxyphenyl)propanamido]-N-[(2S)-1-[(3S)-3-{[(1S)-1-[(carbamoylme-
thyl)carbamoyl]-2-(1H-indol-3-yl)ethyl]carbamoyl}pyrrolidin-1-yl]-3-hydroxy-1-oxopropan-2-yl]-3-
phenylpropanamide (TVC-268, 166) 
Hexapeptide TVC-266 (29 mg, 20 µmol) in TFA/TIPS/H2O (2 mL, 95/2.5/2.5) was stirred at 0 
o
C for 4 h. 
The mixture was concentrated to dryness. The residue was chromatographed using DCM/MeOH (6/1, 
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0.1% TEA) as eluent to provide pure product (13.5 
mg, 86%), which was dissolved in ACN/H2O (3 mL, 
2/1) and lyophilized to obtain white powder. 
1
H-NMR (400 MHz, CD3OD): δ = 7.60 (m, 1H, 12-
H), 7.36 (t, J = 7.5 Hz, 1H, 9-H), 7.29-7.22 (m, 5H, 
26-H, 27-H, 28-H), 7.14 (m, 1H, 10-H), 7.11 
(overlap, 3H, 7-H, 34-H), 7.04 (t, J = 7.4 Hz, 1H, 11-
H), 6.78 (d, J = 7.4 Hz, 2H, 34-H), 4.70 (m, 1H, 23-
H), 4.69 (m, 1H, 20-H), 4.61 (m, 1H, 4-H), 4.02 (m, 1H, 30-H), 3.89 (overlap, 1H, 2-H), 3.76 (overlap, 
1H, 21-H), 3.71 (overlap, 1H, 18-H), 3.69 (overlap, 1H, 21-H), 3.67 (overlap, 1H, 17-H), 3.65 (overlap, 
1H, 2-H), 3.58 (m, 1H, 18-H), 3.56 (overlap, 1H, 17-H), 3.35 (m, 1H, 5-H), 3.18 (overlap, 1H, 5-H), 3.18 
(overlap, 1H, 31-H), 3.15 (m, 1H, 24-H), 3.10 (overlap, 1H, 15-H), 2.96 (overlap, 1H, 24-H), 2.93 
(overlap, 1H, 31-H), 2.16 (m, 1H, 16-H), 2.03 (m, 1H, 16-H). 
13
C-NMR (100 MHz, CD3OD): δ = 175.7 
(19-C), 174.9 (22-C), 172.9 (29-C), 170.3 (14-C), 169.8 (3-C), 162 (1-C), 158.3 (35-C), 142.8 (25-C), 
138.0 (8-C), 130.4 (34-C), 128.8 (27-C), 128.7 (32-C),128.3 (26-C), 126.5 (28-C), 127.9 (13-C), 123.3 
(10-C), 121.2 (7-C), 115.5 (33-C), 118.5(11-C), 118.2 (12-C), 111.0 (9-C), 61.2 (21-C), 54.9 (4-C), 54.5 
(23-C), 54.3 (30-C), 53.1 (20-C), 48.4 (18-C), 45.9 (17-C), 43.7 (15-C), 41.8 (2-C), 37.5 (24-C), 36.3 (31-
C), 29.3 (16-C), 26.8 (5-C). HPLC-ESI-MS: m/z (%) = 755.4 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. 
for C39H47N8O8 [M+H]
+
 755.3511; found 755.3509. 
3.17 Spirolactam-Scan  
3.17.1 Spirolactamscan of Trp-Pro 
 
tert-Butyl-5-[(carbamoylmethyl)carbamoyl]-2-oxo-1,2-dihydrospiro[indole-3,4'-piperidine]-1'-
carboxylate (TVC-159, 168) 
 
To a solution of 1'-[(tert-butoxy)carbonyl]-2-oxo-1,2-dihydro-
spiro[indole- 3,4'-piperidine]-5-carboxylic acid 167 (200 mg, 0.58 
mmol), glycinamide hydrochloride (83 mg, 0.75 mmol) and TBTU 
(222.5 mg, 0.69 mmol) in DMF (4 mL), DIPEA (0.38 mL, 2.31 mmol) 
was added. The reaction mixture was stirred at room temperature for 
18 h and quenched with EtOAc (200 mL). The resulting solution was 
washed with H2O, brine solution and dried over MgSO4. Removal of 
the solvent gave the desired product 168 (217 mg, 94%) as a white solid. 
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1
H-NMR (400 MHz, CDCl3): δ = 7.96 (s, 1H, NH), 7.79 (m, 1H, 5-H),7.73 (dd, J = 2.0 Hz, J = 8.0 Hz, 
1H, 8-H), 6.9 (d, J = 8.0 Hz, 1H, 9-H), 4.05 (s, 2H, 2-H), 3.77 (br, 4H, 13-H), 1.89 (m, 4H, 12-H), 1.47 (s, 
9H, 16-H). 
13
C-NMR (400 MHz, CDCl3): δ = 181.9 (10-C), 172.1 (3-C), 167.7 (1-C), 155.0 (14-C), 
143.7 (7-C), 134.4 (6-C), 127.8 (8-C), 122.8 (5-C), 109.4 (9-C), 79.9 (15-C), 45.4 (11-C), 42.4 (2-C), 
38.7 (13-C), 32.3 (12-C), 28.3 (16-C). IR (KBr) ν (cm-1): 3338.1, 1666.4. HPLC-ESI-MS: m/z (%) = 
403.2 (15) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C20H26N4O5Na [M+Na]
+
 425.1801; found 425.1796. Rf 
= 0.35 (EtOAc/EtOH, 6/1). 
 
5-[(Carbamoylmethyl)carbamoyl]-2-oxo-1,2-dihydrospiro[indole-3,4'-piperidi]-1'-ium-trifluoro-
acetate (TVC-160, 169) 
Compound 168 (60 mg, 26.46 µmol) was treated with TFA/TIPS/H2O (2 
mL, 95/4/1) at 0 
o
C for 4 h. After that, the solvent was removed to 
dryness to afford product 169 (60.9 mg, 98%) as a TFA salt. 
1
H-NMR (400 MHz, CD3OD): δ = 7.88 (d, J = 1.7 Hz, 1H, 5-H), 7.86 
(dd, J = 1.7 Hz, J = 8.0 Hz, 1H, 9-H), 7.02 (d, J = 8.0 Hz, 1H, 8-H), 4.06 
(s, 2H, 2-H), 3.83 (m, 2H, 13-H), 3.45 (m, 2H, 13-H), 2.2-2.1 (m, 4H, 
12-H). 
13
C-NMR (400 MHz, CD3OD): δ = 182.0 (10-C), 174.5 (3-C), 169.0 (1-C), 128.2 (9-C), 122.3 (5-
C), 109.2 (8-C), 44.4 (11-C), 42.1 (2-C), 38.8 (13-C), 28.9 (12-C). IR (KBr) ν (cm-1): 3420.1, 1683.4. 
HPLC-ESI-MS: m/z (%) = 303.2 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C15H19N4O3 [M+H]
+
 
303.1457; found 303.1452. Rf = 0.36 (EtOAc/EtOH, 6/1). 
tert-Butyl-N-[(1S)-1-{[(1S)-1-{[(2S)-3-(tert-butoxy)-1-{5-[(carbamoylmethyl)carbamoyl]-2-oxo-1,2-
dihydrospiro[indole-3,4'-piperidine]-1'-yl}-1-oxopropan-2-yl]carbamoyl}-2-phenylethyl]carbamo-
yl}-2-[4-(tert-butoxy)phenyl]ethyl]carbamate (TVC-169, 170) 
To a stirred solution of dipeptide 169 (40 mg, 96.1 
µmol) and tripeptide Boc-Tyr(tBu)-Phe-Ser(tBu)-
OH (60.3 mg, 96.1 µmol) in DMF (2 mL), HATU 
(40.2 mg, 106 µmol) and DIPEA (71 µL, 480 
µmol) were added. The reaction mixture was 
stirred at room temperature for 20 h. Removal of 
the solvent and flash chromatography (eluent: 
N
H
2
+
N
H
O
N
HO
NH
2
O
O
O
F
F
F
12
3
4
5
7
8
910
11
12
13
6
N
H
N
NH
O
O
N
H
N
H
O
O
O
O O
N
H
O
O
NH
2
O
25
26
27
28
29
30
1
2
3
4 5
6
78
9
10
12
13
14
15
16
17
18
20
21
22
23
24
11
31
32
33
34
35
36
37
19
168 
 
EtOAc/EtOH, 7/1) provided product 170 (60 mg, 69%) as a solid.  
1
H-NMR (600 MHz, CD3OD): δ = 7.97 (s, 1H, 9-H), 7.86 (t, J = 8.3 Hz, 1H, 5-H), 7.3-7.2 (m, 5H, 21-H, 
22-H, 23-H), 7.13 (t, J = 7.7 Hz, 2H, 28-H), 7.02 (d, J = 8.3 Hz, 1H, 6-H), 6.89 (t, J = 7.7 Hz, 2H, 29-H), 
5.03 (t, J = 7.4 Hz, 1H, 15-H), 4.73 (t, J = 7.5 Hz, 1H, 18-H), 4.32 (bs, 1H, 25-H), 4.12 (m, 2H, 13-H), 
4.07-4.02 (overlap, 2H, 2-H), 3.93 (m, 2H, 13-H), 3.60 (m, 1H, 16-H), 3.57 (m, 1H, 16-H), 3.15 (m, 1H, 
19-H), 3.01 (overlap, 1H, 26-H), 3.00 (overlap, 1H, 19-H), 2.76 (m, 1H, 26-H), 1.94 (m, 2H, 12-H), 1.85 
(br, 2H, 12-H), 1.36 (s, 9H, 32-H), 1.30 (s, 9H, 34-H), 1.22 (9H, 37-H). 
13
C-NMR (150 MHz, CD3OD): δ 
= 183.5 (10-C), 174.5 (14-C), 172.7 117-C), 171.0 (24-C), 169.9 (1-C), 167.4 (3-C), 157.5 (35-C), 155.2 
(30-C), 145.5 (7-C), 138.1 (8-C), 135.6 (20-C), 133.7 (4-C), 130.9 (28-C), 130.4 (22-C), 129.4 (21-C), 
128.9 (5-C), 127.6 (23-C), 125.1 (29-C), 123.9 (9-C), 110.5 (6-C), 80.6 (31-C), 79.4 (33-C), 74.8 (36-C), 
63.4 (16-C), 57.4 (11-C), 57.3 (25-C), 55.3 (18-C), 50.6 (15-C), 42.5 (2-C), 39.6 (19-C), 38.8 (13-C), 
38.5 (26-C), 33.5 (12-C), 29.1 (34-C), 28.6 (32-C), 27.8 (37-C). IR(KBr) ν (cm-1): 3405.5, 1662.7. 
HPLC-ESI-MS: m/z (%) = 912.5 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C49H65N7O10Na [M+Na]
+ 
934.4690; found 934.4685. Rf = 0.39 (EtOAc/EtOH, 7/1). 
(2S)-2-[(2S)-2-Amino-3-(4-hydroxyphenyl)propanamido]-N-[(2S)-1-{5-[(carbamoylmethyl)-
carbamoyl]-2-oxo-1,2-dihydrospiro[indole-3,4'-piperidine]-1'-yl}-3-hydroxy-1-oxopropan-2-yl]-3-
phenylpropanamide (TVC-174, 171)  
Peptide 170 (36 mg, 39.5 µmol) was treated with 
TFA/TIPS/H2O (2 mL, 95/4/1) at 0 
o
C for 5 h. The mixture 
was then concentrated under reduced pressure to dryness. 
The crude product was chromatographed using 
DCM/MeOH (5/1, 0.1% TEA) to yield 171 (24 mg, 88%), 
which was dissolved in ACN/H2O (2 mL, 1/1) and 
lyophilized to obtain white powder. 
1
H-NMR (600 MHz, CD3OD): δ = 7.93 (d, J = 3.0 Hz, 1H, 
9-H), 7.85 (dd, J = 1.5 Hz, J = 8.2 Hz, 1H, 5-H), 7.3-7.2 (m, 
5H, 21-H, 22-H, 23-H), 7.04 (overlap, 2H, 28-H), 7.01 (overlap, 1H, 6-H), 6.75 (t, J = 8.7 Hz, 2H, 29-H), 
5.02 (t, J = 6.0 Hz, 1H, 15-H), 4.73 (m, 1H, 18-H), 4.14 (m ,1H, 13-H), 4.04 (overlap, 1H, 2-H), 3.95 
(overlap, 1H, 2-H), 3.91 (m, 1H, 13-H), 3.83 (m, 1H, 16-H), 3.76 (m, 1H, 16-H), 3.72 (m, 1H, 25-H), 
3.14 (m, 1H, 19-H), 2.99 (m, 1H, 19-H), 2.98 (m, 1H, 26-H), 2.73 (m, 1H, 26-H), 2.03 (m ,1H, 12-H), 
1.86 (m, 1H, 12-H). 
13
C-NMR (150 MHz, CD3OD): δ = 183.7 (10-C), 174.6 (14-C), 174.3 (17-C), 172.9 
(24-C), 170.6 (3-C), 170.0 (1-C), 157.6 (30-C), 145.6 (7-C), 138.1 (8-C), 135.6 (20-C), 130.4 (27-C), 
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130.1 (28-C), 129.5 (4-C), 128.9 (22-C), 128.1 (21-C), 128.0 (5-C), 126.5 (23-C), 122.5 (9-C), 115.1 (29-
C), 108.9 (6-C), 61.7 (16-C), 55.8 (11-C), 55.3 (25-C), 54.5 (18-C), 50.8 (15-C), 40.9 (2-C), 38.4 (26-C), 
37.6 (19-C), 37.5 (13-C), 32.4 (12-C). HPLC-ESI-MS: m/z (%) = 700.3 (100) [M+H]
+
. HR-ESI-MS 
(m/z): calcd. for C36H42N7O8
 
[M+H]
+ 
700.3088; found 700.3089.  
3.17.2 Spirolactamscan of Trp 
9H-Fluoren-9-ylmethyl-(2S)-2-({5-[(carbamoylmethyl)carbamoyl]-2-oxo-1,2-dihydro-spiro[indole-
3,4'- piperidine]-1'-yl}carbonyl)pyrrolidine-1-carboxylate (TVC-162, 172) 
To a stirred solution of 169 (121 mg, 0.29 mmol) and 
Fmoc-Pro-OH (95.1 mg, 0.28 mmol) in DMF (3 mL), 
HATU (121.6 mg, 0.32 mmol) and DIPEA (0.17 mL, 
1.16 mmol) were added dropwise. After stirring at 
room temperature for 20 h, the solvent was removed. 
Flash chromatography (EtOAc/EtOH, 6/1) afforded 
172 (151 mg, 86%) as a white solid product. 
1
H-NMR (400 MHz, CD3OD): δ = 7.87 (overlap, 1H, 9-H), 7.85 (overlap, 1H, 6-H), 7.83 (m, 2H, 25-H), 
7.62 (d, J = 7.8 Hz, 2H, 26-H), 7.42 (m, 2H, 24-H), 7.35 (m, 2H, 23-H), 7.01 (d, J = 8.5 Hz, 1H, 5-H), 
4.84 (overlap, 1/2H, 15-H), 4.6 (d, J = 5.0 Hz, 1/2H, 15-H), 4.5 (m, 1H, 20-H), 4.4 (m, 1H, 20-H), 4.3 (t, 
J = 6.2 Hz, 1/2H, 21-H), 4.2 (d, J = 7.0 Hz, 1/2H, 21-H), 4.09 (m, 2H, 13-H), 4.08 (overlap, 1H, 2-H), 
3.95 (overlap, 1H, 2-H), 3.78 (overlap, 2H, 13-H), 3.63 (m, 1H, 18-H), 3.53 (m, 1H, 18-H), 2.3 (m, 2H, 
16-H), 1.94 (m, 2H, 17-H), 1.93 (overlap, 2H, 12-H), 1.82 (m, 2H, 12-H). 
13
C-NMR (100 MHz, CD3OD): 
δ = 180.2 (10-C), 172.7 (3-C), 169.8 (14-C), 167.3 (1-C), 156.3 (19-C),128.1 (9-C), 127.5 (24-C), 126.9 
(23-C), 124.6 (26-C), 119.7 (6-C), 119.6 (25-C), 109.2 (5-C), 67.0 (20-C), 57.1 (15-C), 47.3 (21-C), 46.6 
(18-C), 40.5 (2-C), 37.3 (13-C), 32.2 (12-C), 30.3 (16-C), 29.7 (17-C). IR (KBr) ν (cm-1): 3420.7, 1683.4. 
HPLC-ESI-MS: m/z (%) = 622.2 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C35H35N5O6Na [M+Na]
+ 
644.2481; found 644.2480. Rf = 0.26 (EtOAc/EtOH, 6/1). 
2-{2-Oxo-1'-[(2S)-pyrrolidine-2-carbonyl]-1,2-dihydrospiro[indole-3,4'-piperidine]-5-yl-formami-
do}acetamide (TVC-167, 174) 
Peptide 172 (38 mg, 0.06 mmol ) in DCM (5 mL) was treated with piperidine (60 µL, 0.60 mmol) at room 
temperature for 1 h. The reaction mixture was concentrated and subjected to silica gel column 
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chromatography using DCM/MeOH (5/1, 1% TEA). The pure 
product 174 (23.6 mg, 97%) was obtained as a white solid. 
1
H-NMR (400 MHz, CD3OD): δ = 7.97 (dd, J = 1.3 Hz, J = 12.0 Hz, 
1H, 9-H), 7.87 (m, 1H, 6-H), 7.04 (dd, J = 1.3 Hz, J = 12.0 Hz, 1H, 
5-H), 4.15 (m, 2H, 13-H), 4.06 (overlap, 2H, 2-H), 4.05 (overlap, 1H, 
18-H), 3.99 (m, 2H, 13-H), 3.88 (m, 1H, 18-H), 2.44 (m, 1H, 16-H), 
2.01 (m, 1H, 17-H), 1.99 (m, 2H, 12-H), 1.92 (m, 1H, 17-H), 1.91 (m, 2H, 12-H), 1.90 (m, 1H, 16-H). 
13
C-NMR (100 MHz, CD3OD): δ = 183.4 (10-C), 174.4 (14-C), 170.9 (1-C), 169.9 (3-C), 145.6 (7-C), 
135.4 (8-C), 126.8 (6-C), 121.0 (9-C), 107.8 (5-C), 56.5 (15-C), 53.7 (11-C), 40.6 (2-C),  38.8 (18-C), 
36.1 (13-C), 30.7 (12-C), 28.2 (16-C), 23.3 (17-C). IR (KBr) ν (cm-1): 3422.5, 1701.2, 1647.3. HPLC-
ESI-MS: m/z (%) = 400.2 (100) [M+H]
+
, 799.0 [2M+H]
+
. HR-ESI-MS (m/z): calcd. for C20H26N5O4
 
[M+H]
+ 
400.1979; found 400.1979. Rf = 0.24 (DCM/MeOH, 3/1).  
tert-Butyl-N-[(1S)-1-{[(1S)-1-{[(2S)-3-(tert-butoxy)-1-[(2S)-2-({5-[(carbamoylmethyl)carba-moyl]-2-
oxo-1,2-dihydrospiro[indole-3,4'-piperidine]-1'-yl}carbonyl)pyrrolidin-1-yl]-1-oxopropan-2-yl]- 
carbamoyl}-2-phenylethyl]carbamoyl}-2-[4-(tert-butoxy)phenyl]ethyl]-carbamate (TVC-170, 175) 
A stirred solution of amine 174 (25 mg, 62.6 
µmol), tripeptide Boc-Tyr(tBu)-Phe-Ser(tBu)-
OH (29.3 mg, 62.6 µmol) and HATU (26.2 mg, 
68.8 µmol) in DMF (2 mL) was added DIPEA 
(46 µL, 313 µmol). The reaction mixture was 
stirred at room temperature for 20 h and 
concentrated to dryness. The crude product was 
purified by silica gel column chromatography 
(EtOAc/EtOH, 6/1) to afford 175 (36.2 mg, 
57%) as a yellow solid product. 
1
H-NMR (600 MHz, CD3OD): δ = 8.03 (s, 1H, 
9-H), 7.86 (dd, J = 1.5 Hz, J = 8.4 Hz, 1H, 6-H), 7.25-7.16 (m, 5H, 26-H, 27-H, 28-H), 7.06 (overlap, 1H, 
33-H), 6.86 (d, J = 8.4 Hz, 1H, 34-H), 7.02 (t, J = 8.5 Hz, 1H, 5-H), 4.94 (m, 1H, 15-H), 4.74 (m, 1H, 20-
H), 4.44 (bs, 1H, 30-H), 4.27 (m, 1H, 23-H), 4.08 (m, 2H, 13-H), 4.06 (overlap, 1H, 18-H), 3.94 (m, 2H, 
13-H), 3.85 (overlap, 1H 2-H), 3.78 (overlap, 2H, 2-H, 21-H), 3.58 (m, 1H, 21-H), 3.54 (m, 1H, 18-H), 
3.0 (m, 1H, 24-H), 2.96 (m, 1H, 31-H), 2.71 (m, 1H, 31-H), 2.69 (m, 1H, 24-H), 2.32 (m, 1H, 16-H), 2.15 
(m, 1H, 17-H), 2.04 (m, 1H, 17-H), 1.98 (m, 2H, 12-H), 1.91 (m, 1H, 16-H), 1.75 (m, 2H, 12-H), 1.36 (s, 
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9H, 37-H), 1.31 (s, 9H, 42-H), 1.24 (s, 9H, 40-H). 
13
C-NMR (150 MHz, CD3OD): δ = 183.2 (10-C), 
175.8 (3-C), 174.4 (19-C), 174.1 (14-C), 172.8 (1-C), 170.2 (22-C), 169.2 (29-C), 157.6 (38-C), 145.5 
(35-C), 143.3 (7-C), 135.8 (8-C), 133.7 (25-C), 130.5 (4-C), 129.7 (32-C), 129.4 (33-C), 129.3 (26-C), 
128.1 (6-C), 127.9 (27-C), 126.2 (28-C), 123.7 (34-C), 122.3 (9-C), 108.9 (5-C), 79.5 (36-C), 75.4 (41-
C), 74.8 (39-C), 61.5 (21-C), 56.8 (15-C), 55.9 (23-C), 55.8 (11-C, 30-C), 54.0 (20-C), 47.2 (18-C), 42.3 
(2-C), 37.5 (24-C), 37.4 (31-C), 37.2 (13-C), 31.8 (12-C), 28.7 (16-C), 27.7 (42-C), 27.2 (37-C), 26.3 (40-
C), 24.4 (17-C). IR (KBr) ν (cm-1): 3420.6, 1654.7. HPLC-ESI-MS: m/z (%) = 1009.5 (100) [M+H]+. 
HR-ESI-MS (m/z): calcd. for C54H72N8O11Na [M+Na]
+ 
1031.5213; found 1031.5192. Rf = 0.38 
(EtOAc/EtOH, 5/1). 
(2S)-2-[(2S)-2-Amino-3-(4-hydroxyphenyl)propanamido]-N-[(2S)-1-[(2S)-2-({5-[(carbamo-ylmethyl) 
carbamoyl]-2-oxo-1,2-dihydrospiro[indole-3,4'-piperidine]-1'-yl}carbonyl)-pyrrolidin-1-yl]-3-
hydroxy-1-oxopropan-2-yl]-3-phenylpropanamide (TVC-175, 176) 
Hexapeptide 175 (26 mg, 25.8 µmol) was treated with 
TFA/TIPS/H2O (2 mL, 95/4/1) at 0 
o
C for 4 h. The 
reaction mixture was concentrated under diminished 
pressure to dryness and subjected to silica gel column 
chromatography using (DCM/MeOH, 5/1, 0.1% TEA). 
The pure product 176 (18 mg, 89%) was dissolved in 
ACN/H2O (2 mL, 1/1) and lyophilized to obtain white 
powder. 
1
H-NMR (600 MHz, CD3OD): δ = 8.02 (s, 1H, 9-H), 
7.86 (m, 1H, 6-H), 7.25 (m, 4H, 26-H, 27-H), 7.19 (m, 
1H, 28-H), 7.01 (overlap, 3H, 5-H, 33-H), 6.72 (d, J = 8.0 Hz, 2H, 34-H), 4.98 (dd, J = 5.2 Hz, J = 8.2 
Hz), 4.93 (dd, J = 5.2 Hz, J = 8.2 Hz), 4.82 (m, 1H, 20-H), 4.80 (m, 1H, 23-H), 4.13 (bs, 1H, 2-H), 3.97 
(m, 1H, 2-H), 3.92 (m, 1H, 30-H), 3.88 (m, 1H, 18-H), 3.80 (overlap, 1H, 18-H), 3.87-3.80 (overlap, 2H, 
21-H), 3.75 (m, 2H, 12-H), 3.63 (m, 2H, 12-H), 3.18 (m, 1H, 24-H), 3.10 (m, 1H, 31-H), 3.00 (m, 1H, 24-
H), 2.86 (m, 1H, 31-H), 2.35-2.38 (m, 1H, 16-H), 2.13 (overlap, 1H, 17-H), 2.04 (m, 1H, 17-H), 1.99 (m, 
2H, 12-H), 1.98 (m, 1H, 16-H), 1.74 (m, 2H, 12-H). 
13
C-NMR (150 MHz, CD3OD): δ = 182.5 (10-C), 
173.1 (14-C), 171.5 (19-C), 171.4 (22-C), 170.8 (29-C), 168.8 (1-C), 168.4 (3-C), 156.5 (35-C), 144.1 (7-
C), 136.6 (8-C), 134.3 (25-C), 133.9 (32-C), 130.1 (33-C), 128.9 (4-C), 128.8 (27-C), 128.1 (6-C, 26-C), 
126.4 (28-C), 122.4 (9-C), 115.2 (34-C), 109.0 (5-C), 61.7 (21-C), 57.3 (15-C), 54.9 (23-C), 54.8 (11-C), 
54.4 (30-C), 53.4 (20-C), 47.2 (18-C), 46.6 (13-C), 40.8 (2-C), 37.4 (24-C), 37.1 (31-C), 31.9 (12-C), 
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28.7 (16-C), 24.5 (17-C). HPLC-ESI-MS: m/z (%) = 797.4 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for 
C41H49N8O9
 
[M+H]
+
 797.3617; found 797.3618. 
3.17.3 Spirolactamscan of Pro 
tert-Butyl-5-{[(1S)-1-[(carbamoylmethyl)carbamoyl]-2-(1H-indol-3-yl)ethyl]carbamoyl}-2-oxo-1,2-
dihydrospiro[indole-3,4'-piperidine]-1'-carboxylate (TVC-161, 177) 
To a stirred solution of dipeptide TFA*H-Trp-Gly-NH2 (128 mg, 0.34 mmol) and 1'-[(tert-butoxy) 
carbonyl]-2-oxo-1,2-dihydrospiro[indole-3,4'- piperidine]-5-carboxylic acid 167 (106 mg, 0.31 mmol) in 
DMF (6 mL), TBTU (109 mg, 0.34 mmol) and DIPEA (0.23 mL, 1.37 mmol) were added. After  stirring 
for 20 h, the solvent was removed and flash chromatography (EtOAc/EtOH, 5/1) provided solid product 
177 (168.7 mg, 84%). 
1
H-NMR (400 MHz, CD3OD): δ = 7.7 (dd, J = 2.0 Hz, J = 8.0 Hz, 
1H, 16-H), 7.65 (d, J = 8.7 Hz, 1H, 9-H), 7.6 (d, J = 2.0 Hz, 1H, 20-
H), 7.35 (d, J = 8.7 Hz, 1H, 12-H), 7.2 (s, 1H, 7-H), 7.12 (t, J = 6.9 
Hz, 1H, 11-H), 7.02 (t, J = 6.9 Hz, 1H, 10-H), 6.9 (d, J = 8.0 Hz, 1H, 
17-H), 3.9 (d, J = 17.0 Hz, 1H, 2-H), 3.8 (br, 4H, 24-H), 3.7 (d, J = 
17.0 Hz, 1H, 2-H), 3.4 (m, 2H, 5-H), 1.75 (m, 4H, 23-H), 1.54 (s, 9H, 
27-H). 
13
C-NMR (100 MHz, CD3OD): δ = 183.5 (21-C), 174.9 (3-
C), 174.3 (14-C), 170.0 (1-C), 156.0 (25-C), 145.6 (18-C), 138.0 (13-
C), 135.6 (19-C), 128.2 (16-C), 127.3 (6-C), 123.4 (7-C), 122.2 (20-C), 121.0 (11-C), 118.6 (10-C), 117.7 
(9-C), 110.9 (12-C), 110.5 (17-C), 119.2 (8-C), 81.0 (26-C), 55.6 (4-C), 41.7 (2-C), 38.9 (24-C), 31.8 (23-
C), 27.2 (27-C), 26.6 (5-C). IR (KBr) ν (cm-1): 3336.7, 1670.3. HPLC-ESI-MS: m/z (%) = 589.3 (100) 
[M+H]
+
. HR-ESI-MS (m/z): calcd. for C31H36N6O6Na [M+Na]
+
 611.2591; found 611.2589. Rf = 0.45 
(EtOAc/EtOH, 6/1). 
5-{[(1S)-1-[(Carbamoylmethyl)carbamoyl]-2-(1H-indol-3-yl)ethyl]carbamoyl}-2-oxo-1,2-dihydro-
spiro[indole-3,4'-piperidin]-1'-ium trifluoroacetate (TVC-165, 178) 
Peptide 177 (130 mg, 220.8 µmol) was treated with TFA/TIPS/H2O (2 mL, 95/4/1) at 0 
o
C for 4 
h. The solvent was evaporated under reduced pressure to give product 178 (126 mg, 95%) as a 
TFA salt. 
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1
H-NMR (400 MHz, CD3OD): δ = 7.73 (d, J = 2.0 Hz, 1H, 20-H), 
7.69 (dd, J = 2.0 Hz, J = 8.0 Hz, 1H, 16-H), 7.65 (d, J = 8.0 Hz, 1H, 9-
H), 7.34 (d, J = 8.7 Hz, 1H, 12-H), 7.19 (s, 1H, 7-H), 7.09 (t, J = 7.6 
Hz, 1H, 11-H), 7.01 (t, J = 7.6 Hz, 1H, 10-H), 6.94 (d, J = 8.0 Hz, 1H, 
17-H), 4.85 (t, J = 7.5 Hz, 1H, 4-H), 3.94 (d, J = 17.5 Hz, 1H, 2-H), 
3.82 (m, 2H, 24-H), 3.71 (d, J = 17.5 Hz, 1H, 2-H), 3.44 (bs, 1H, 5-H), 
3.42 (m, 2H, 24-H), 3.34 (bs, 1H, 5-H), 2.17 (m, 2H, 23-H), 2.01 (m, 
2H, 23-H). 
13
C-NMR (100 MHz, CD3OD): δ = 129.9 (15-C), 129.3 (8-
C), 128.4 (6-C), 128.6 (16-C), 123.3 (7-C), 122.1 (20-C), 121.0 (11-C), 118.4 (10-C), 118.0 (9-C), 111.0 
(12-C), 109.2 (17-C), 55.6 (4-C), 41.6 (2-C), 38.9 (24-C), 28.8 (23-C), 27.2 (5-C). IR (KBr) ν (cm-1): 
3408.9, 1672.2. HPLC-ESI-MS: m/z (%) = 489.2 (100) [M-CF3COOH+H]
+
. HR-ESI-MS (m/z): calcd. 
for C26H28N6O4Na [M+Na]
+
 511.2063; found 511.2063.  
tert-Butyl-N-[(1S)-1-{[(1S)-1-{[(2S)-3-(tert-butoxy)-1-(5-{[(1S)-1-[(carbamoylmethyl)carba-moyl]-2-
(1H-indol-3-yl)ethyl]carbamoyl}-2-oxo-1,2-dihydrospiro[indole-3,4'-piperidine]-1'-yl)-1-oxopropan-
2-yl]carbamoyl}-2-phenylethyl]carbamoyl}-2-[4-(tert-butoxy)phenyl]-ethyl]carbamate (TVC-168, 
179) 
 
A solution of 178 (27 mg, 44.8 µmol), 
tripeptide Boc-Tyr(tBu)-Phe-Ser(tBu)-OH 
(28.2 mg, 44.8 µmol) and HATU (18.7 mg, 
49.3 µmol) in DMF (2 mL) was added 
DIPEA (33 µL, 224 µmol). After being 
stirred at room temperature for 20 h, the 
solvent was removed. The residue was 
purified by silica gel column chromatography 
(EtOAc/EtOH, 5/1) to obtain 179 (32 mg, 
65%) as a solid product. 
1
H-NMR (600 MHz, CD3OD): δ = 7.73 (d, J = 8.5 Hz, 1H, 16-H), 7.67 (s, 1H, 20-H), 7.63 (d, J = 8.0 
Hz, 1H, 9-H), 7.35 (t, J = 8.0 Hz, 1H, 12-H), 7.25-7.22 (m, 5H, 32-H, 33-H, 34-H), 7.20 (s, 1H, 7-H), 
7.10 (overlap, 1H, 11-H), 7.08 (overlap, 2H, 39-H), 7.02 (overlap, 1H, 10-H), 6.96 (br, 1H, 17-H), 6.88 
(m, 2H, 40-H), 5.06 (br, 1H, 25-H), 4.81 (overlap, 1H, 4-H), 4.79 (br, 1H,36-H), 4.30 (s, 1H, 29-H), 3.96 
(m, 2H, 24-H), 3.90 (overlap, 1H, 2-H), 3.87 (m, 2H, 24-H), 3.73 (overlap, 1H, 2-H), 3.44 (m, 1H, 5-H), 
3.32 (overlap, 1H, 5-H), 3.16 (br, 1H, 37-H), 2.97 (m, 1H, 37-H), 2.95 (m, 1H, 30-H), 2.69 (br, 1H, 30-
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H), 1.93 (m, 2H, 23-H), 1.78 (m, 2H, 23-H), 1.29 (s, 9H, 43-H), 1.28 (s, 9H, 48-H), 1.21 (s, 9H, 46-H). 
13
C-NMR (150 MHz, CD3OD): δ = 183.6 (21-C), 176.1 (25-C), 175.0 (3-C), 174.4 (14-C), 173.5 (1-C), 
172.9 (35-C), 171.1 (28-C), 155.2 (44-C), 145.6 (41-C), 142.6 (18-C), 138.1 (19-C), 135.4 (13-C), 133.7 
(31-C), 130.4 (15-C), 129.3 (39-C), 129.2 (32-C), 129.0 (38-C), 128.2 (16-C), 127.9 (33-C), 127.8 (8-C), 
123.5 (40-C), 123.2 (7-C), 122.5 (20-C), 121.0 (11-C), 118.6 (10-C), 117.8 (9-C), 111.0 (12-C), 108.9 
(17-C), 108.2 (6-C), 80.7 (42-C), 79.5 (47-C), 74.9 (45-C), 61.9 (27-C), 55.9 (29-C), 55.5 (4-C), 55.4 (22-
C), 54.1 (36-C), 49.5 (26-C), 41.7 (2-C), 37.8 (24-C), 37.4 (37-C), 37.1 (30-C), 32.4 (23-C), 27.3 (43-C), 
27.2 (48-C), 26.8 (5-C), 26.3 (46-C). IR (KBr) ν (cm-1): 3446.2, 1653.1. HPLC-ESI-MS: m/z (%) = 
1098.6 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C60H75N9O11Na [M+Na]
+ 
1120.5478; found 
1120.5482. Rf = 0.37 (EtOAc/EtOH, 7/1). 
(2S)-2-[(2S)-2-Amino-3-(4-hydroxyphenyl)propanamido]-N-[(2S)-1-(5-{[(1S)-1-[(carbamo-ylmethyl) 
carbamoyl]-2-(1H-indol-3-yl)ethyl]carbamoyl}-2-oxo-1,2-dihydrospiro[indole-3,4'-piperidine]-1'-yl) 
-3-hydroxy-1-oxopropan-2-yl]-3-phenylpropanamide (TVC-176, 180) 
Hexapeptide 179 (21 mg, 18.2 µmol) was treated 
with TFA/TIPS/H2O (2 mL, 95/4/1) at 0
 o
C for 6 h. 
After that, the reaction mixture was concentrated 
and purified by silica gel column chromatography 
(DCM/MeOH, 5/1, 0.1% TEA) to afford pure 
product 180 (10 mg, 62%). 
1
H-NMR (600 MHz, CD3OD): δ = 7.71 (t, J = 9.0 
Hz, 1H, 17-H), 7.69 (overlap, 1H, 20-H), 7.65 (m, 
1H, 9-H), 7.35 (d, J = 7.5 Hz, 1H, 12-H), 7.30-7.25 
(m, 5H, 32-H, 33-H, 34-H), 7.19 (s, 1H, 7-H), 7.12 (t, J = 7.7 Hz, 1H, 11-H), 7.08 (d, J = 7.6 Hz, 2H, 39-
H), 7.01 (overlap, 1H, 10-H), 6.96 (t, J = 7.0 Hz, 1H, 16-H), 6.77 (d, J = 7.6 Hz, 2H, 40-H), 5.04 (m, 1H, 
26-H), 4.78 (overlap, 1H, 4-H), 4.72 (m, 1H, 29-H), 3.97 (overlap, 2H, 24-H), 3.91 (m, 1H, 2-H), 3.86 
(overlap, 2H, 24-H), 3.84 (overlap, 1H, 36-H), 3.80-3.78 (m, 2H, 27-H), 3.71 (m, 1H, 2-H), 3.44 (m, 1H, 
5-H), 3.32 (m, 1H, 5-H), 3.15 (m, 1H, 30-H), 3.05 (m, 1H, 37-H), 2.99 (m, 1H, 30-H), 2.78 (m, 1H, 37-
H), 1.80-1.79 (m, 4H, 23-H). 
13
C-NMR (150 MHz, CD3OD): δ = 183.5 (21-C), 174.9 (25-C), 174.5 (28-
C), 172.6 (14-C), 172.4 (35-C), 170.2 (1-C), 167.6 (3-C), 157.9 (41-C), 145.6 (18-C), 138.1 (19-C), 138.0 
(13-C), 135.4 (31-C), 130.2 (39-C), 129.6 (15-C, 38-C), 128.9 (33-C), 128.3 (32-C), 128.1 (17-C), 127.9 
(8-C), 126.6 (34-C), 123.2 (7-C), 121.0 (11-C), 118.4 (10-C), 117.9 (9-C), 115.2 (40-C), 111.2 (12-C), 
110.5 (6-C), 109.0 (16-C), 61.7 (27-C), 55.9 (22-C), 55.6 (4-C), 54.8 (36-C), 54.6 (29-C), 51.0 (26-C), 
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41.9 (2-C), 41.2 (24-C), 37.5 (30-C), 37.3 (37-C), 31.9 (23-C), 26.8 (5-C). HPLC-ESI-MS: m/z (%) = 
886.4 (50) [M+H]
+
. HR-ESI-MS (m/z): calcd. For C47H51N9O9Na [M+Na]
+ 
908.3702; found 908.3706. 
3.17.4 Spirolactamscan of Phe 
tert-Butyl-(2S)-2-({1-[(carbamoylmethyl)carbamoyl]-2-(1H-indol-3-yl)ethyl}carbamoyl)-pyrrolidine 
-1-carboxylate (TVC-163, 182) 
A solution of dipeptide TFA*H-Trp-Gly-NH2 (300 mg, 0.80 mmol), Boc-Pro-OH (190 mg, 0.88 mmol) 
and TBTU (309 mg, 0.96 mmol) in DMF (6 mL) was added dropwise DIPEA (0.6 mL). The reaction 
mixture was then stirred at room temperature for 20 h. Removal of 
the solvent to dryness and flash chromatography (EtOAc/EtOH, 
10/1) afforded solid product 182 (338 mg, 92%). 
1
H-NMR (600 MHz, CD3OD): δ = 7.6 (dd, J = 1.8 Hz, J = 8.8 Hz, 
1H, 9-H), 7.36 (t, J = 8.8 Hz, 1H, 12-H), 7.17 (s, 1H, 7-H), 7.13 
(overlap, 1H, 11-H), 7.05 (t, J = 7.5 Hz, 1H, 10-H), 4.6 (t, J = 7.5 
Hz, 1H, 4-H), 4.16-4.10 (m, 1H, 15-H), 3.87 (d, J = 17.0 Hz, 1H, 2-
H), 3.65 (d, J = 17.0 Hz, 1H, 2-H), 3.34 (br, 2H, 18-H), 3.3 (m, 1H, 5-H), 3.12 (m, 1H, 5-H), 2.18 (m, 1H, 
16-H), 2.08 (m, 1H, 16-H), 1.75 (br, 2H, 17-H), 1.38 (s, 9H, 21-H). 
13
C-NMR (150 MHz, CD3OD): δ = 
150.7 (19-C), 123.3 (7-C), 121.0 (11-C), 118.3 (10-C), 117.6 (9-C), 111.1 (12-C), 60.5 (15-C), 54.6 (4-
C), 46.7 (18C), 41.8 (2-C), 30.8 (16-C), 27.5 (21-C), 27.2 (5-C), 23.5 (17-C). IR (KBr) ν (cm-1): 3419.6, 
1669.8. HPLC-ESI-MS: m/z (%) = 458.2 (95) [M+H]
+
, 358.2 (100) [M-Boc+H]
+
. HR-ESI-MS (m/z): 
calcd. for C23H31N5O5Na [M+Na]
+ 
480.2217; found 480.2209.  Rf = 0.17 (EtOAc/EtOH, 6/1). 
(2S)-2-{[(1S)-1-[(Carbamoylmethyl)carbamoyl]-2-(1H-indol-3-yl)ethyl]carbamoyl}-pyrrolidin-1-
ium trifluoroacetate (TVC-164, 183) 
Tripeptide 182 (300 mg, 0.66 mmol) in TFA/TIPS/H2O (2 mL, 95/4/1) 
was stirred at 0 
o
C for 4 h. After that time, the solvent was removed 
under reduced pressure to dryness to provide product 183 (290 mg, 
96%) as a TFA salt. 
1
H-NMR (600 MHz, CD3OD): δ = 7.6 (d, J = 7.5 Hz, 1H, 9-H), 7.36 (d, 
J = 8.3 Hz, 1H, 12-H), 7.17 (s, 1H, 7-H), 7.11 (t, J = 7.5 Hz, 1H, 11-H), 
7.04 (t, J = 7.5 Hz, 1H, 10-H), 4.66 (t, J = 7.8 Hz, 1H, 4-H), 4.25 (t, J = 
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7.8 Hz, 1H, 15-H), 3.87 (d, J = 17.2 Hz, 1H, 2-H), 3.65 (d, J = 17.2 Hz, 1H, 2-H), 3.38 (m, 2H, 18-H), 
3.34 (m, 1H, 5-H), 3.22 (m, 1H, 5-H), 2.40 (m, 1H, 16-H), 2.09 (m, 1H, 16-H), 2.08 (overlap, 1H, 17-H), 
2.01 (br, 1H, 17-H). 
13
C-NMR (150 MHz, CD3OD): δ = 176.3 (14-C), 174.5 (3-C), 174.3 (1-C), 138.4 
(13-C), 128.6 (8-C), 124.8 (6-C), 123.0 (7-C), 121.1 (11-C), 118.3 (10-C), 117.8 (9-C), 111.0 (12-C), 
59.5 (15-C), 55.2 (4-C), 45.8 (18-C), 41.9 (2-C), 29.2 (16-C), 26.9 (5-C), 23.6 (17-C). IR (KBr) ν (cm-1): 
3420.8, 2919.2, 1653.1. HPLC-ESI-MS: m/z (%) = 358.2 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for 
C18H23N5O3Na: 380.1699; found 380.1693. Rf = 0.12 (DCM/MeOH, 5/1). 
9H-Fluoren-9-yl-methyl-N-[(2S)-3-(tert-butoxy)-1-[(2S)-2-{[(1S)-1-[(carbamoylmethyl)car-bamoyl]-
2-(1H-indol-3-yl)ethyl]carbamoyl}pyrrolidin-1-yl]-1-oxopropan-2-yl]carbamate (TVC-166, 184) 
To a stirred solution of 183 (120 mg, 0.25 mmol), 
Fmoc-Ser(tBu)-OH (88 mg, 0.23 mmol) and HATU 
(97 mg, 0.25 mmol) in DMF (2 mL), DIPEA (0.26 
mL, 1.53 mmol) was added. The reaction mixture was 
then stirred at room temperature for 20 h and 
concentrated. The residue was purified by silica gel 
column chromatography (EtOAc/EtOH, 10/1) to 
afford 184 (150 mg, 83%) as a solid product. 
1
H-NMR (600 MHz, CD3OD): δ = 7.80 (m, 2H, 32-H), 7.60 (m, 2H, 28-H), 7.59 (overlap, 1H, 9-H), 7.40 
(m, 2H, 30-H), 7.35 (overlap, 1H, 12-H), 7.32 (m, 2H, 29-H), 7.14 (s, 1H, 7-H), 7.11 (t, J = 7.5 Hz, 1H, 
11-H), 7.03 (t, J = 7.5 Hz, 1H, 10-H), 4.58 (m, 1H, 4-H), 4.47 (m, 1H, 20-H), 4.41 (m, 2H, 25-H), 4.36 
(m, 1H, 15-H), 4.25 (m, 1H, 26-H), 3.87 (d, J = 17.0 Hz, 1H, 2-H), 3.75 (m, 1H, 18-H), 3.71 (d, J = 17.0 
Hz, 1H, 2-H), 3.62 (m, 1H, 21-H), 3.52 (m, 1H, 21-H), 3.49 (m, 1H, 18-H), 3.39 (dd, J = 5.6 Hz, J= 13.5 
Hz, 1H, 5-H), 3.26 (dd, J = 5.6 Hz, J= 13.5 Hz, 1H, 5-H), 2.07 (m, 1H, 17-H), 2.05 (m, 1H, 16-H), 1.92 
(m, 1H, 16-H), 1.76 (m, 1H, 17-H), 1.17 (s, 9H, 23-H). 
13
C-NMR (150 MHz, CD3OD): δ = 174.4 (19-C), 
174.1 (3-C), 173.7 (14-C), 172.5 (1-C), 158.0 (24-C), 145.2 (27-C), 142.5 (32-C), 138.1 (13-C), 128.5 (8-
C), 127.3 (29-C), 126.7 (30-C), 124.7 (28-C), 124.6 (12-C), 122.9 (7-C), 121.1 (11-C), 119.5 (31-C), 
118.4 (10-C), 117.7 (9-C), 111.1 (6-C), 74.9 (22-C), 66.7 (25-C), 61.8 (21-C), 60.5 (15-C), 54.5 (4-C), 
53.2 (20-C), 47.2 (18-C), 47.0 (26-C), 41.9 (2-C), 30.7 (16-C), 28.4 (17-C), 26.3 (5-C), 26.1 (23-C). IR 
(KBr) ν (cm-1): 3429.8, 2973.8, 1662.6. HPLC-ESI-MS: m/z (%) = 723.3 (100) [M+H]+. HR-ESI-MS 
(m/z): calcd. for C40H46N6O7Na [M+Na]
+ 
745.3320; found 745.3321. Rf = 0.45 (EtOAc/EtOH, 7/1). 
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(2S)-2-{[(2S)-1-[(2S)-2-Amino-3-(tert-butoxy)propanoyl]pyrrolidin-2-yl]formamido}-N-(carbamoyl- 
methyl)-3-(1H-indol-3-yl)propanamide (TVC-171, 185) 
A solution of 184 (150 mg, 0.02 mmol) in DCM (5 mL) was 
treated with piperidine (0.02 ml, 021 mmol) at room temperature 
for 20 min. Afterward, the solvent was removed and the crude 
product was subjected to silica gel column chromatography eluting 
DCM/MeOH (4/1) to obtain peptide 185 (96 mg, 92%). 
1
H-NMR (400 MHz, CD3OD): δ = 7.6 (d, J = 8.0 Hz, 1H, 9-H), 
7.36 (d, J = 7.2 Hz, 1H, 12-H), 1.17 (s, 1H, 7-H), 7.11 (t, J = 7.0 
Hz, 1H, 11-H), 7.04 (t, J = 7.0 Hz, 10-H), 4.77 (m, 1H, 20-H), 4.53 
(m, 1H, 4-H), 4.44 (m, 1H, 15-H), 3.9 (d, J = 17.0 Hz, 1H, 2-H), 3.72-3.68 (m, 2H, 18-H), 3.66 (d, J = 
17.0 Hz, 1H, 2-H), 2.09 (m, 1H, 16-H), 2.08 (m, 1H, 17-H), 1.91 (m, 1H, 17-H), 1.90 (m, 1H, 16-H), 1.22 
(s, 9H, 23-H). 
13
C-NMR (100 MHz, CD3OD): δ = 174.6 (19-C), 174.5 (14-C), 174.4 (3-C), 174.3 (1-C), 
128.7 (8-C), 123.3 (7-C), 121.2 (11-C), 118.3 (10-C), 117.9 (9-C), 110.9 (12-C), 112.4 (6-C), 75.1 (22-
C), 60.3 (15-C), 54.9 (4-C), 54.4 (20-C), 47.1 (18-C), 41.8 (2-C), 31.1 (16-C), 28.6 (17-C), 26.7 (5-C), 
26.3 (23-C). IR (KBr) ν (cm-1): 3365.7, 1662.2. HPLC-ESI-MS: m/z (%) = 501.2 (100) [M+H]+. HR-
ESI-MS (m/z): calcd. for C25H36N6O5Na: 523.2639; found 523.2648. Rf = 0.14 (DCM/MeOH, 5/1). 
5-(Methoxycarbonyl)-2-oxo-1,2-dihydrospiro[indole-3,4'-piperidin]-1'-ium chloride (TVC-181, 188) 
To a solution of 1'-[(tert-butoxy)carbonyl]-2-oxo-1,2-dihydrospiro[indole-3,4'- 
piperidine]-5-carboxylic acid 167 (200 mg, 0.58 mmol) in MeOH (5 mL) at 0 
o
C, 
SOCl2 (50 µL, 0.64 mmol) was added dropwise. The reaction mixture was 
allowed to warm up to room temperature and stirred for 20 h. After that the 
solvent was removed to dryness. The residue was dissolved in MeOH/TBME (5.5 
mL, 1/10) and collected. The ester 188 (151 mg, 88%) was obtained as a white 
solid. 
1
H-NMR (400 MHz, CD3OD): δ = 8.01 (m, 1H, 7-H), 7.99 (br, 1H, 4-H), 7.03 (d, J = 8.0 Hz, 1H, 3-H), 
3.9 (s, 3H, 12-H), 3.85 (dt, J = 3.5 Hz, J = 12.0 Hz, 2H, 11-H), 3.44 (dt, J = 3.5 Hz, J = 12.0 Hz, 2H, 11-
H), 2.27 (m, 2H, 10-H), 2.06 (br, 2H, 10-H). 
13
C-NMR (100 MHz, CD3OD): δ = 168.2 (1-C), 146.9 (5-
C), 134.5 (6-C), 131.1 (7-C), 126.2 (2-C), 123.7 (4-C), 109.5 (3-C), 52.6 (9-C), 44.2 (12-C), 40.5 (11-C), 
30.5 (10-C). IR (KBr) ν (cm-1): 3429.1, 1707.3. HPLC-ESI-MS: m/z (%) = 261.1 (100) [M+H]+. HR-
ESI-MS (m/z): calcd. for C14H17N2O3
 
[M+H]
+ 
261.1234; found 261.1234. 
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Methyl-1'-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-3-[4-(tert-butoxy)phenyl]propanoyl]-2-oxo-1,2-
dihydrospiro[indole-3,4'-piperidine]-5-carboxylate (TVC-183, 189) 
To a solution of amine 188 (50 mg, 0.17 mmol), Boc-Tyr(tBu)-OH 
(65.4 mg, 0.19 mmol) and HATU (77 mg, 0.21 mmol) in DMF (2 mL), 
DIPEA (0.12 mL, 0.84 mmol) was added. After being stirred at room 
temperature for 20 h, the solvent was removed and flash 
chromatography (eluent: EtOAc/CyH, 1/1) yielded 189 (72 mg, 74%) 
as a white solid product. 
1
H-NMR (400 MHz, CDCl3): δ = 7.98 (d, J = 7.8 Hz, 1H, 4-H), 7.83 
(d, J = 7.8 Hz, 1H, 7-H), 7.12 (d, J = 8.8 Hz, 2H, 17-H), 6.94 (overlap, 
3H, 3-H, 17-H), 4.9 (br, 1H, 13-H), 3.95 (s, 3H, 24-H), 3.01 (m, 1H, 14-H), 2.96 (m, 1H, 14-H), 1.45 (s, 
9H, 20-H), 1.34 (s, 9H, 23-H). 
13
C-NMR (100 MHz, CDCl3): δ = 170.5 (12-C), 166.5 (1-C), 154.5 (18-
C), 154.1 (18-C), 144.0 (5-C), 133.7 (6-C), 131.4 (15-C), 130.9 (4-C), 130.0 (16-C), 124.7 (2-C), 124.4 
(7-C), 124.2 (17-C), 109.4 (3-C), 79.6 (19-C), 78.4 (22-C), 53.4 (9-C), 52.0 (24-C), 51.2 (13-C), 41.0 (11-
C), 39.7 (14-C), 32.4 (10-C), 28.7 (23-C), 28.1 (20-C). IR (KBr) ν (cm-1): 3428.3, 2977.2, 1714.8, 
1621.7. HPLC-ESI-MS: m/z (%) = 580.3 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for C32H41N3O7Na 
[M+Na]
+ 
602.2837; found 602.2839. Rf = 0.28 (CyH/EtOAc, 1/1). 
1'-[(2S)-2-{[(tert-Butoxy)carbonyl]amino}-3-[4-(tert-butoxy)phenyl]propanoyl]-2-oxo-1,2-dihydro- 
spiro[indole-3,4'-piperidine]-5-carboxylic acid (TVC-185, 190) 
Methyl ester 189 (50 mg, 90 µmol ) in MeOH (2 mL) was treated with 
1N NaOH (5.2 mg, 130 µmol) at room temperature for 24 h. The 
resulting solution was acidified with 1N HCl to pH≈4 at 0 oC and 
extracted with EtOAc (3x60 mL). The combined organic phases were 
washed H2O, brine solution and dried over MgSO4. Removal of the 
solvent gave acid TVC-185 (46 mg, 94%) as a white solid. 
1
H-NMR (400 MHz, CDCl3): δ = 9.0 (s, 1H, NH), 8.05 (d, J = 8.8 Hz, 
1H, 4-H), 7.97 (s, 1H, 7-H), 7.14 (d, J = 8.8 Hz, 2H, 16-H), 6.98 
(overlap, 1H, 3-H), 6.94 (d, J = 8.8 Hz, 2H, 17-H), 5.72 (s, 1H, NH), 4.95 (br, 1H, 13-H), 3.75 (br, 2H, 
11-H), 3.63 (br, 2H, 11-H), 3.04 (m, 1H, 14-H), 2.95 (m, 1H, 14-H), 1.99 (br, 2H, 10-H), 1.81 (br, 2H, 
10-H), 1.43 (s, 9H, 20-H), 1.34 (s, 9H, 23-H). 
13
C-NMR (100 MHz, CDCl3): δ = 182.3 (8-C), 170.1 (12-
C), 169.7 (1-C), 155.3 (21-C), 154.2 (18-C), 144.5 (5-C), 140.0 (6-C), 131.5 (4-C), 130.1 (15-C), 129.9 
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(16-C), 125.2 (7-C), 124.3 (17-C), 124.2 (2-C), 109.5 (3-C), 79.8 (19-C), 78.5 (22-C), 58.7 (9-C), 51.2 
(13-C), 41.1 (11-C), 39.5 (14-C), 32.4 (10-C), 28.7 (23-C), 28.2 (20-C). IR (KBr) ν (cm-1): 3421.8, 
2976.8, 1710.3, 1619.2. HPLC-ESI-MS: m/z (%) = 566.3 (100) [M+H]
+
. HR-ESI-MS (m/z): calcd. for 
C31H39N3O7Na [M+Na]
+ 
588.2680; found 588.2681. Rf = 0.30 (EtOAc). 
tert-Butyl-N-[(2S)-1-(5-{[(2S)-3-(tert-butoxy)-1-[(2S)-2-{[(1S)-1-[(carbamoylmethyl)carba-moyl]-2-
(1H-indol-3-yl)ethyl]carbamoyl}pyrrolidin-1-yl]-1-oxopropan-2-yl]carbamoyl}-2-oxo-1,2-dihydro-
spiro[indole-3,4'-piperidine]-1'-yl)-3-[4-(tert-butoxy)phenyl]-1-oxopropan-2-yl]carbamate (TVC-
179, 191) 
A solution of 190 (25 mg, 44.2 µmol), tripeptide 185 (26.5 mg, 53.0 µmol) and HATU (20.2 mg, 53.0 
µmol) in DMF (3 mL) was added DIPEA (33 µL, 221 µmol). After stirring at room temperature for 20 h, 
the solvent was removed under reduced pressure. Flash chromatography eluting EtOAc/EtOH (6/1) 
provided peptide 191 (24 mg, 52%) as a solid. 
1
H-NMR (600 MHz, CD3OD): δ = 7.86 (t, 
J = 7.2 Hz, 1H, 25-H), 7.6 (t, J = 7.7 Hz, 
1H, 9-H), 7.33 (bs, 1H, 12-H), 7.18 
(overlap, 1H, 7-H), 7.16 (overlap, 2H, 37-
H), 7.09 (overlap, 1H, 11-H), 7.01 
(overlap, 1H, 24-H), 6.99 (overlap, 1H, 10-
H), 6.91 (br, 2H, 38-H), 5.03 (t, J = 8.3 Hz, 
1H, 15-H), 4.85 (overlap, 1H, 20-H), 4.78 
(m, 1H, 34-H), 4.57 (m, 1H, 4-H), 3.9 (m, 
1H, 2-H), 3.84 (m, 2H, 32-H), 3.80 (m, 1H, 
21-H), 3.73 (overlap, 1H, 32-H), 3.71 (m, 2H, 2-H, 21-H), 3.39 (overlap, 1H, 5-H), 3.23 (m, 1H, 5-H), 
2.97 (br, 1H, 35-H), 2.89 (m, 1H, 35-H), 2.06 (m, 1H, 16-H), 1.93 (m, 1H, 16-H), 1.86 (m, 2H, 31-H), 
1.85 (overlap, 2H, 17-H), 1.77 (m, 2H, 31-H), 1.39 (s, 9H, 41-H), 1.34 (s, 9H, 43-H), 1.22 (s, 9H, 46-H). 
13
C-NMR (150 MHz, CD3OD): δ = 183.2 (30-C), 175.2 (19-C), 174.7 (33-C), 174.1 (22-C), 173.6 (14-
C), 172.4 (1-C), 169.9 (3-C), 157.1 (44-C), 155.4 (39-C), 145.8 (26-C), 138.1 (28-C), 135.6 (13-C), 129.8 
(23-C), 129.6 (37-C), 128.6 (8-C), 128.4 (25-C), 123.6 (38-C), 122.9 (7-C), 122.3 (27-C), 121.1 (11-C), 
118.7 (10-C), 117.8 (9-C), 110.9 (12-C), 110.6 (6-C), 109.1 (24-C), 79.5 (40-C), 75.1 (42-C), 74.9 (45-
C), 62.1 (21-C), 60.5 (15-C), 54.8 (4-C), 54.0 (29-C), 52.6 (34-C), 51.7 (20-C), 47.5 (18-C), 41.9 (2-C), 
40.8 (32-C), 37.7 (35-C), 31.9 (31-C), 30.1 (16-C), 27.7 (43-C), 27.3 (41-C), 26.6 (5-C), 26.2 (46-C), 
24.6 (17-C). IR (KBr) ν (cm-1): 3415.1, 2975.4, 1636.8. HPLC-ESI-MS: m/z (%) = 1048.5 (100) 
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[M+H]
+
. HR-ESI-MS (m/z): calcd. for C56H73N9O11Na [M+Na]
+ 
1070.5317; found 1070.5322. Rf = 0.27 
(EtOAc/EtOH, 6/1). 
1'-[(2S)-2-Amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[(2S)-2-{[(1S)-1-[(carbamoylmethyl)- 
carbamoyl]-2-(1H-indol-3-yl)ethyl]carbamoyl}pyrrolidin-1-yl]-3-hydroxy-1-oxo-propan-2-yl]-2-oxo 
-1,2-dihydrospiro[indole-3,4'-piperidine]-5-carboxamide (TVC-187, 192) 
Peptide 191 (13 mg, 12.4 µmol) was dissolved in TFA/TIPS/H2O (1 mL, 95/4/1) and stirred at 0 
o
C for 4 
h. The reaction mixture was concentrated under reduced pressure to dryness. The residue was subjected to 
silica gel column chromatography eluting DCM/MeOH (4/1, 0.1% TEA). The white power product 192 
(10 mg, 96%) was obtained from lyophilization in ACN/H2O (3 mL, 2/1). 
1
H-NMR (400 MHz, CD3OD): δ = 7.84 (s, 1H, 
27-H), 7.79 (dd, J = 2.0 Hz, J = 7.8 Hz, 1H, 25-
H), 7.60 (d, J = 8.0 Hz, 1H, 9-H), 7.56 (s, 1H, 7-
H), 7.36 (d, J = 8.0 Hz, 1H, 12-H), 7.17 (d, J = 
8.0 Hz, 2H, 37-H), 7.11 (overlap, 1H, 11-H), 
7.03 (overlap, 1H, 10-H), 6.96 (overlap, 1H, 24-
H), 6.95 (d, J = 8.0 Hz, 2H, 38-H), 5.08 (t, J = 
7.2 Hz, 1H, 20-H), 4.66 (dd, J = 5.1 Hz, J = 10.1 
Hz, 1H, 4-H), 4.43 (dd, J = 5.0 Hz, J = 8.2 Hz, 
1H, 15-H), 4.35 (m, 1H, 34-H), 4.03 (m, 1H, 21-
H), 3.94 (d, J = 17.0 Hz, 2H, 2-H, 21-H), 3.92 (m, 1H, 18-H), 3.74 (d, J = 17.0 Hz, 1H, 2-H), 3.72 (m, 
3H, 18-H, 32-H), 3.44 (m, 2H, 32-H), 3.42 (dd, J = 5.1 Hz, J = 14.5 Hz, 1H, 5-H), 3.1 (m, 1H, 5-H), 3.01 
(m, 1H, 35-H), 2.87 (m, 1H, 35-H), 2.03 (m, 1H, 16-H), 1.81 (m, 1H, 17-H), 1.63-1.56 (m, 4H, 31-H), 
1.54 (m, 1H, 17-H), 1.51 (m, 1H, 16-H). 
13
C-NMR (100 MHz, CD3OD): δ = 183.3 (30-C), 174.3 (33-C), 
174.2 (3-C), 173.4 (14-C), 172.7 (22-C), 170.1 (1-C), 157.7 (39-C), 145.7 (26-C), 138.0 (28-C), 135.3 
(13-C), 132.0 (36-C), 130.7 (37-C), 129.7 (23-C), 128.8 (8-C), 128.6 (25-C), 123.0 (11-C), 122.4 (27-C), 
122.0 (7-C), 118.5 (10-C), 117.9 (9-C), 115.8 (38-C), 112.4 (6-C), 111.1 (12-C), 109.2 (24-C), 61.8 (21-
C), 61.0 (15-C), 54.6 (4-C), 54.3 (29-C), 53.6 (20-C), 50.9 (34-C), 47.6 (18-C), 41.9 (2-C), 40.6 (32-C), 
39.9 (35-C), 31.6 (31-C), 28.6 (16-C), 26.4 (5-C), 23.9 (17-C). HPLC-ESI-MS: m/z (%) = 836.4 (100) 
[M+H]
+
. HR-ESI-MS (m/z): calcd. for C43H49N9O9Na [M+Na]
+ 
858.3549; found 858.3546. 
3.17.5 Spirolactamscan of Tyr 
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tert-Butyl-5-{[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]carbamoyl}-2-oxo-1,2-dihydro-spiro-
[indole-3,4'-piperidine]-1'-carboxylate (TVC-182, 193) 
To a stirred solution of phenylalanine methylester (137 mg, 0.64 
mmol), 1'-[(tert-butoxy)carbonyl]-2-oxo-1,2-dihydrospiro[indole-
3,4'-piperidine]-5-carboxylic acid 167 (200 mg, 0.58 mmol) and 
TBTU (204 mg, 0.64 mmol) in DMF (4 mL), DIPEA (0.38 mL, 2.3 
mmol) was added dropwise. After stirring for 20 h at room 
temperature, the solvent was removed and crude product was 
chromatographed (EtOAc/CyH, 3/2) to provide 193 (286 mg, 98%) 
as a white solid. 
1
H-NMR (600 MHz, CDCl3): δ = 7.70 (s, 1H, 14-H), 7.57 (d, J = 8.0 Hz, 1H, 11-H), 7.33-7.26 (m, 3H, 
6-H, 7-H), 7.16 (m, 2H, 5-H), 6.95 (d, J = 8.0 Hz, 1H, 10-H), 5.07 (q, J = 7.4 Hz, 1H, 2-H), 3.83 (m, 4H, 
18-H), 3.78 (s, 3H, 22-H), 3.27 (m, 2H, 3-H), 1.85 (m, 4H, 17-H), 1.53 (s, 9H, 21-H). 
13
C-NMR (150 
MHz, CDCl3): δ = 181.8 (15-C), 172.3 (8-C), 166.6 (1-C), 154.9 (19-C), 143.4 (12-C), 135.9 (4-C), 134.6 
(13-C), 129.4 (5-C), 128.8 (6-C), 128.1 (9-C), 127.3 (11-C), 127.1 (7-C), 122.8 (14-C), 109.5 (10-C), 
79.8 (20-C), 53.5 (2-C), 52.6 (22-C), 45.4 (16-C), 38.9 (18-C), 37.7 (3-C), 32.2 (17-C), 28.3 (21-C). IR 
(KBr) ν (cm-1): 3406.2, 2937.5, 1717.4. HPLC-ESI-MS: m/z (%) = 508.2 (10) [M+H]+. HR-ESI-MS 
(m/z): calcd. For C28H33N3O6Na [M+Na]
+ 
530.2265; found 530.2262. Rf = 0.24 (CyH/EtOAc, 2/3). 
(2S)-2-{1’-[(tert-Butoxy)carbonyl]-2-oxo-1,2-dihydrospiro[indole-3,4’-piperidine]-5-yl-formamido}-
3-phenylpropanoic acid (TVC-184, 194) 
Methyl ester 193 (63 mg, 0.12 mmol) in MeOH (2 mL) was treated 
with 1N NaOH (7.4 mg, 0.19 mmol) at room temperature for 24 h. 
After that time the reaction mixture was acidified with 1N HCl at 0 
oC to pH≈4. The resulting solution was extracted with EtOAc (3x60 
mL). The combined organic phases were washed with brine 
solution and dried over MgSO4. Removal of the solvent gave 
product 194 (57 mg, 93%) as a yellow solid. 
H-NMR (400 MHz, CD3OD): δ = 7.71 (s, 1H, 14-H), 7.69 (d, J = 8.0 Hz, 1H, 11-H), 7.32-7.26 (m, 3H, 
6-H, 7-H), 7.21 (m, 2H, 5-H), 6.96 (d, J = 8.0 Hz, 1H, 10-H), 4.87 (overlap, 1H, 2-H), 3.88 (m, 2H, 18-
H), 3.76 (m, 2H, 18-H), 3.36 (d, J = 9.9 Hz, 1H, 3-H), 3.14 (d, J = 9.9 Hz, 1H, 3-H), 1.84-1.75 (br, 4H, 
17-H), 1.54 (s, 9H, 21-H). 
13
C-NMR (100 MHz, CD3OD): δ = 182.6 (15-C), 174.0 (8-C), 168.9 (1-C), 
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119-C), 55.7 ( 144.5 (12-C), 137.9 (13-C), 134.6 (4-C), 129.3 (9-C), 128.8 (6-C), 128.1 (5-C, 11-C), 
126.3 (7-C), 122.5 (14-C), 109.2 (10-C), 80.3 (20-C), 60.5 (16-C), 54.5 (2-C), 38.7 (18-C), 36.7 (3-C), 
32.1 (17-C), 27.8 (21-C). IR (KBr) ν (cm-1): 3377.9, 2831.9, 1717.8, 1642.2. HPLC-ESI-MS: m/z (%) = 
494.2 (10) [M+H]
+
, 394.2 (30) [M-Boc+H]
+
. HR-ESI-MS (m/z): calcd. For C27H31N3O6Na [M+Na]
+ 
516.2105; found 516.2101. Rf = 0.26 (EtOAc/EtOH, 7/1). 
Tert-Butyl-5-{[(1S)-1-{[(2S)-3-(tert-butoxy)-1-[(2S)-2-{[(1S)-1-[(carbamoylmethyl)carbamo-yl]-2-
(1H-indol-3-yl)ethyl]carbamoyl}pyrrolidin-1-yl]-1-oxopropan-2-yl]carbamoyl}-2-phenylethyl] 
carbamoyl}-2-oxo-1,2-dihydrospiro[indole-3,4’-piperidine]-1’-carboxylate (TVC-180, 195) 
To a stirred solution of 194 (35.5 mg, 71.9 µmol), 185 (30 mg, 60 µmol) and TBTU (23 mg, 72 µmol) in 
DMF (2 mL), DIPEA (0.04 mL, 0.24 mmol) was added. After stirring for 20 h, the solvent was removed 
under reduced pressure. The crude product was purified by silica gel column chromatography using 
EtOAc/EtOH (6/1) to afford the desired product 195 (36 mg, 62%) as a white solid. 
1
H-NMR (400 MHz, CD3OD): δ = 7.89 (d, 
J = 8.3 Hz, 1H, 9-H), 7.76 (d, J = 8.3 Hz, 
1H, 12-H), 7.72 (m, 1H, 35-H), 7.70 (m, 
1H, 32-H), 7.57 (t, J = 6.8 Hz, 1H, 11-H), 
7.51 (t, J = 6.8 Hz, 1H, 10-H), 7.33-7.23 
(m, 5H, 26-H, 27-H, 28-H), 7.23 (overlap, 
1H, 7-H), 6.91 (m, 1H, 31-H), 4.91 
(overlap, 1H, 23-H), 4.65 (m, 1H, 20-H), 
4.55 (m, 1H, 4-H), 4.36 (m, 1H, 15-H), 3.92 
(overlap, 1H, 2-H), 3.76 (overlap, 1H, 2-H), 3.70 (overlap, 2H, 39-H), 3.67 (m, 1H, 18-H), 3.66 (m, 1H, 
21-H), 3.65 (m, 2H, 39-H), 3.61 (m, 1H, 18-H), 3.57 (m, 1H, 21-H), 3.33 (overlap, 1H, 5-H), 3.29 (m, 
1H, 24-H), 3.26 (overlap, 1H, 5-H), 3.11 (m, 1H, 24-H), 2.04 (overlap, 2H, 16-H, 17-H), 1.91 (m, 1H, 16-
H), 1.83 (m, 2H, 38-H), 1.81 (m, 1H, 17-H), 1.68 (m, 2H, 38-H), 1.53 (s, 9H, 44-H), 1.15 (s, 9H, 42-H). 
13
C-NMR (100 MHz, CD3OD): δ = 183.5 (36-C), 174.4 (19-C), 173.9 (22-C), 173.7 (14-C) 173.0 (29-
C),, 171.5 (1-C), 169.8 (3-C), 156.6 (40-C), 145.5 (33-C), 138.8 (34-C), 137.9 (13-C), 135.6 (25-C), 
130.4 (30-C), 129.1 (27-C), 128.2 (32-C), 128.1 (26-C), 127.8 (8-C), 126.9 (11-C), 126.4 (28-C), 125.8 
(10-C), 122.6 (35-C), 117.0 (9-C), 111.2 (6-C), 110.4 (12-C), 109.2 (31-C), 81.3 (43-C), 74.9 (41-C), 
61.5 (21-C), 60.6 (15-C), 55.0 (4-C), 54.7 (23-C), 54.1 (37-C), 52.2 (20-C), 47.4 (18-C), 42.0 (2-C), 41.8 
(39-C), 37.1 (24-C), 31.7 (38-C), 30.8 (16-C), 28.4 (17-C), 27.3 (44-C), 26.5 (5-C), 26.3 (42-C). IR 
N
N
H
O
O
O
N
N
H
NH
2
N
H
O
O
O
NH
O
N
H
O
N
H
O
O
20
21
22
23 19
24
25
26
27
28
43
44
1
23
4
5 6
7
8
9
10
12
13
14
15
16
17
18
11
29
30
31
32
33
34
35
36
37
38
39
40
41
42
183 
 
(KBr) ν (cm-1): 3420.0, 1653.3. HPLC-ESI-MS: m/z (%) = 976.4 (100) [M+H]+. HR-ESI-MS (m/z): 
calcd. for C52H65N9O10Na [M+Na]
+ 
998.4747; found 998.4816. Rf = 0.21 (EtOAc/EtOH, 5/1). 
(2S)-N-[(2S)-1-[(2S)-2-{[(1S)-1-[(Carbamoylmethyl)carbamoyl]-2-(1H-indol-3-yl)ethyl]carbamoyl}- 
pyrrolidin-1-yl]-3-hydroxy-1-oxopropan-2-yl]-2-{2-oxo-1,2-dihydrospiro-[indole-3,4'-piperidine]-5-
ylformamido}-3-phenylpropanamide (TVC-186, 196) 
Peptide 195 (21 mg, 18.2 µmol) was treated with TFA/TIPS/H2O (2 mL, 95/4/1) at 0 
o
C for 6 h. The 
solvent was removed under reduced pressure. The crude product was subjected to silica gel column 
chromatography (eluent: DCM/MeOH, 6/1, 0.1% TEA) to furnish product 196 (12 mg, 71%), which was 
lyophilized in ACN/H2O (2 mL, 1/1) to afford white powder. 
1
H-NMR (400 MHz, CD3OD): δ = 7.80 (s, 
1H, 35-H), 7.69 (d, J = 9.2 Hz, 1H, 32-H), 
7.59 (d, J = 8.0 Hz, 1H, 9-H), 7.35 (d, J = 8.0 
Hz, 1H, 12-H), 7.30-7.22 (m, 4H, 26-H, 27-
H), 7.19 (m, 1H, 28-H), 7.11 (t, J = 7.5 Hz, 
1H, 11-H), 7.03 (t, J = 7.5 Hz, 1H, 10-H), 
6.95 (d, J = 9.2 Hz, 1H, 31-H), 4.88 (overlap, 
1H, 23-H), 4.82 (overlap, 1H, 20-H), 4.64 (q, 
J = 5.3 Hz, 1H, 4-H), 4.30 (d, J = 7.5 Hz, 1H, 15-H), 3.97 (d, J = 17.0 Hz, 1H, 2-H), 3.91 (m, 1H, 21-H), 
3.82 (m, 1H, 21-H), 3.74 (d, J = 17.0 Hz, 1H, 2-H), 3.71 (m, 1H, 18-H), 3.61 (m, 1H, 18-H), 3.57 
(overlap, 2H, 39-H), 3.43 (d, J = 5.3 Hz, 1H, 5-H), 3.40 (d, J = 5.3 Hz, 1H, 5-H), 3.27 (overlap, 1H, 24-
H), 3.23 (m, 2H, 39-H), 3.09 (m, 1H, 24-H), 2.04 (m, 1H, 16-H), 2.01-1.96 (m, 4H, 38-H), 1.76 (m, 1H, 
17-H), 1.52 (m, 1H, 17-H), 1.44 (m, 1H, 16-H). 
13
C-NMR (100 MHz, CD3OD): δ = 183.1 (36-C), 174.2 
(3-C), 173.7 (22-C), 172.5 (14-C), 172.3 (19-C), 169.8 (1-C), 169.7 (29-C), 145.6 (33-C), 138.6 (34-C), 
138.0 (13-C), 135.4 (25-C), 131.5 (26-C), 130.5 (27-C), 129.1 (30-C), 128.8 (28-C), 127.8 (8-C), 125.7 
(11-C), 124.9 (35-C), 123.7 (7-C), 121.0 (10-C), 120.2 (9-C), 113.4 (12-C), 110.5 (6-C), 64.3 (21-C), 
63.3 (15-C), 57.6 (23-C), 56.6 (4-C), 55.1 (20-C), 54.1 (37-C), 49.9 (18-C), 44.3 (2-C), 42.0 (39-C), 39.7 
(24-C), 33.0 (38-C), 31.0 (16-C), 29.1 (5-C), 26.4 (17-C). HPLC-ESI-MS: m/z (%) = 820.4 (100) 
[M+H]
+
. HR-ESI-MS (m/z): calcd. for C43H49N9O8Na [M+Na]
+ 
842.3596; found 842.3619. 
3.18 Synthesis of C-terminal hydrazide helicokinin analogue TVC-031 (198) 
General procedure for solid phase peptide synthesis 
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In a vessel reactor, 2-chlorotritylchloride resin (498 mg, 0.8 mmol/g) was swollen in DMF (4mL) for 30 
min. After removing the solvent, the resin was treated with the first amino acid (5.0 equiv.) and DIPEA 
(10 equiv.). After shaking for 3 h, the excess of reagents was removed by filtration and the resin was 
washed with DMF (2x5 mL). The coupling steps were repeated once. The unreacted chloride atoms were 
neutralized by treatment with dry MeOH/DIPEA/DCM (7 mL, 1/1/5) for 30 min. Afterward, the resin 
was washed with DMF (3x5 mL), MeOH (3x5 mL), DCM (3x5 mL) and followed by removal of Fmoc 
group (30% piperidine in DMF, 2x4 mL, 2x15 min). The resin was again washed with DMF(3x5 mL), 
MeOH (3x5 mL), DCM (3x5 mL). Subsequent amino acids were introduced by double couplings for each 
step (2x8 h) using Fmoc-amino acids (2.5 equiv.), TBTU (2.5 equiv.) and DIPEA (5.0 equiv.) in DMF 
(8.0 mL). After each coupling- and Fmoc-cleavage step, the resin was washed with DMF (3x5 mL), 
MeOH (3x5 mL), DCM (3x5 mL). Coupling- and Fmoc-cleavage steps were confirmed by chloroanil-test 
in the presence of acetaldehyde. The side chain-protected acid products were obtained by treatments of 
the resin in AcOH/TFE/DCM (2x7 mL, 1/1/3) for 2 h, filtered and washed with DCM (2x5 mL). The 
filtrate was concentrated under reduced pressure to obtain pure product, which was lyophilized in 
ACN/H2O (1/1, 6 mL) to afford white powder. 
(2S)-3-(tert-Butoxy)-2-[(2S)-2-[(2S)-3-[4-(tert-butoxy)phenyl]-2-{[(9H-fluoren-9-yl-methoxy) 
carbonyl]amino}propanamido]-3-phenylpropanamido]propanoic acid (TVC-027) 
2-Chlorotrityl resin (800 mg, 0.8 mmol/g) afforded 
TVC-027 (750 mg, purity 96%, HPLC). 
 1
H-NMR (400 MHz, CDCl3): δ = 7.7 (d, J = 7.5 Hz, 
2H, 28-H), 7.5 (d, J = 7.3 Hz, 2H, 25-H), 7.4 (t, J = 7.4 
Hz, 2H, 27-H), 7.3 (t, J = 7.4 Hz, 2H, 26-H), 7.20 (t, J = 
7.1 Hz, 2H, 9-H), 7.16-7.14 (m, 3H, 8-H, 10-H), 7.02 (d, 
J = 6.7 Hz, 2H, 15-H), 6.8 (d, J = 8.3 Hz, 2H, 16-H), 
6.57 (d, J = 7.3 Hz, 1H, NH), 5.3 (d, J = 7.9 Hz, 1H, NH), 4.66 (q, J = 6.8 Hz, 1H, 5-H), 4.55 (br, 1H, 2-
H), 4.43 (br, 1H, 12-H), 4.39 (dd, J = 7 Hz, 1H, 22-H), 4.27 (t, J = 6.7 Hz, 1H, 22-H), 4.15 (t, J = 7 Hz, 
1H, 23-H), 3.81-3.78 (m, 1H, 3-H), 3.5 (br, 1H, 3-H), 3.04-3.02 (m, 2H, 6-H), 2.98-2.96 (m, 2H, 13-H), 
1.28 (s, 9H, 21-H), 1.12 (s, 9H, 4-H). 
13
C-NMR (100 MHz, CDCl3):δ = 172.4, 170.9, 170.6, 154.4 (CO), 
154.4 (17-C), 143.7 (24-C), 141.3 (29-C), 136.1 (7-C), 130.9 (14-C), 129.8 (15-C), 129.4 (9-C), 128.6 (8-
C), 127.7 (27-C), 127.1 (26-C), 125.09 (10-C), 125.04 (25-C), 124.3 (16-C), 14.9 (28-C), 78.4 (18-C), 
74.3 (20-C), 67.2 (22-C), 61.07 (3-C), 55.9 (12-C), 54.5 (5-C), 52.9 (2-C), 47.06 (23-C), 38.5 (6-C), 37.7 
(13-C), 28.8 (4-C), 27.2 (21-C). IR (KBr) ν (cm-1): 3304.9 (NH), 1649.7 (CO). HPLC-ESI-MS: m/z (%) 
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= 750.4 (100) [M+H]
+
, 772.4 (15) [M+Na]
+
. HR-ESI-MS (m/z): calcd. for C44H51N3O8Na [M+Na]
+
 
772.3574; found 772.3568. Rf = 0.4 (DCM/MeOH, 10/1). 
2-((S)-2-((S)-1-((6S,9S,12S)-9-Benzyl-6-(4-(tert-butoxy)benzyl)-12-(tert-butoxymethyl)-2,2-dimethyl-
4,7,10-trioxo-3-oxa-5,8,11-triazatridecan-13-oyl)pyrrolidine-2-carboxamido)-3-(1H-indol-3-yl)-
propan-amido)acetic acid (TVC-015, 197) 
2-Chlorotritylchloride resin (498 mg, 0.8 mmol/g) afforded acid 197 (340 mg, purity: 98%, HPLC).
 
1
H-NMR (400 MHz, CD3CN): δ = 9.2 (br, 
1H, NH), 7.6 (d, J = 7.9 Hz, 1H, 9-H), 7.37 
(d, J = 8.1 Hz, 1H, 12-H), 7.39-7.21 (m, 3H, 
27-H, 28-H), 7.17 (m, 1H, 11-H), 7.11-7.04 
(m, 3H, 26-H, 7-H), 7.04 (m, 1H, 10-H), 
5.56 (m, 1H, 4-H), 4.70-4.56 (br, 3H, 20-H, 
23-H, 30-H), 4.22 (t, J = 7.4 Hz, 1H, 15-H), 
3.93 (d, J = 5.8 Hz, 1/2 H, 2-H), 3.9 (d, J = 
6.6 Hz, 1/2 H, 2-H), 3.8 (d, J = 5.5 Hz, 1H, 
2-H), 3.8 (overlap, 1H, 24-H), 3.61-3.56 (m, 2H, 18-H), 3.56 (m, 1H, 21-H), 3.49 (m, 1H, 21-H), 3.45 (m, 
1H, 24-H), 3.34 (m, 1H, 31-H), 3.05 (m, 1H, 31-H), 2.92, 2.66 (m, 2H, 5-H),  2.01 (m, 1H, 16-H), 1.78-
1.72 (m, 2H, 17-H), 1.59 (m, 1H, 16-H), 1.28, 1.10, 1.07 (s, 27H, 41-H, 38-H, 36-H). 
13
C-NMR (100 
MHz, CD3CN): δ = 172.7 (29-C), 172.4 (22-C), 171.6 (3-C), 171.5 (19-C), 171.4 (14-C), 171.3 (1-C), 
155.2 (39-C), 133.0 (27-C), 130.5 (26-C), 124.6 (28-C), 137.9 (33-C), 130.2 (32-C), 127.4 (34-C), 137.3 
(13-C), 128.5 (8-C), 124.2 (12-C), 122.3 (7-C), 114.8 (9-C), 112.2 (10-C), 111.5 (11-C), 78.8 (35-C), 
74.7 (37-C), 74.4 (40-C), 63.2, (21-C), 62.1 (15-C), 55.6 (23-C), 54.6 (20-C), 54.4 (30-C), 53.4 (4-C), 
48.6 (18-C), 41.9 (2-C), 38.3 (24-C), 37.7 (31-C), 29.3 (16-C), 28.9 (36-C, 38-C), 27.9 (5-C), 27.4 (41-
C), 25.5 (17-C). IR (KBr) ν (cm-1): 3315.8 (NH), 1654.4 (CO). HPLC-ESI-MS: m/z (%) = 968.6 (100) 
[M+H]
+
, 986.6 (57.3) [M+NH4]
+
, 991.6 (16.3) [M+Na]
+
. HR-ESI-MS (m/z): calcd. for C52H69N7O11Na 
[M+Na]
+
 990.4953; found 990.4947. Rf = 0.13 (DCM/MeOH, 5/1). 
tert-Butyl-2-(2-((S)-2-((S)-1-((6S,9S,12S)-9-benzyl-6-(4-(tert-butoxy)benzyl)-12-(tert-butoxy-methyl)-
2,2-dimethyl-4,7,10-trioxo-3-oxa-5,8,11-triazatridecan-13-oyl)pyrrolidine-2-carboxamido)-3-(1H-
indol-3-yl)propanamido)acetyl)hydrazinecarboxylate (TVC-016) 
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A stirred solution of 197 (200 mg, 0.21 
mmol), tert-butyl carbazate (35.5 mg, 
0.27 mmol) in DMF (8 mL) was added 
TBTU (86.2 mg, 0.27 mmol), followed 
by addition of DIPEA (0.1 mL, 0.62 
mmol). The reaction mixture was 
stirred at room temperature for 22 h 
and quenched with EtOAc (120 mL). 
The organic layer was washed with H2O (3x15 mL), brine solution (30 mL) and dried over Na2SO4. 
Removal of the solvent afforded TVC-016 (220 mg, 98%) as a solid product. 
1
H-NMR (600 MHz, CDCl3): δ = 9.2, 8.9, 8.7, 7.8, 7.4, 6.7 (s, NH), 7.6 (t, J = 7.5 Hz, 1H, 9-H), 7.31 (m, 
1H, 12-H), 7.22-7.17 (m, 3H, 7-H, 27-H), 7.11 (t, J = 11 Hz, 11-H), 7.08 (m, 1H, 10-H), 7.06-7.04 (m, 
3H, 26-H, 28-H), 7.03 (overlap, 2H, 33-H), 6.9 (d, J = 8.0 Hz, 2H, 34-H), 4.85 (m, 2/5 H, 15-H), 4.7 (m, 
1/2H, 4-H), 4.67 (m, 1/2H, 23-H), 4.62 (m, 1/2H, 4-H), 4.60 (br, 1H, 20-H), 4.26 (m, 1/2H, 30-H), 4.04 
(m, 1/2H, 23-H), 4.02 (m, 3/5 H, 15-H), 4.18 (br, 1H, 2-H), 3.89 (m, 1/2H, 2-H), 3.56 (dd, J = 4.5 Hz, J = 
9.3 Hz, 1H, 21-H), 3.4 (m, 1H, 21-H), 3.38 (m, 1H, 5-H), 3.31 (m, 1H, 5-H), 2.1 (m, 16-H), 3.09 (m, 2H, 
24-H), 2.94 (m, 1H, 31-H), 2.85 (m, 1H, 31-H), 1.42, 1.31, 1.04 (36H, 44-H, 41-H, 38-H, 36-H). 
13
C-
NMR (150 MHz, CDCl3): δ = 172.6 (29-C), 172.1 (22-C), 171.8 (3-C), 171.7 (1-C), 171.3 (14-C), 170.8 
(19-C), 169.7 (42-C), 155.6 (39-C), 129.6 (33-C), 124.3 (34-C), 136.2 (25-C), 129.2 (27-C), 128.6 (26-
C), 127.0 (28-C), 136.1 (13-C), 127.7 (8-C), 123.9 (7-C), 122.0/121.8 (10-C), 114.6/114.3 (11-C), 118.5 
(9-C), 62.5, 61.7 (21-C), 61.5, 61.0 (15-C), 55.9 (30-C), 54.8 (23-C), 54.5 (20-C), 53.9 (4-C), 47.9 (18-
C), 42.1 (2-C), 37.2 (24-C), 36.9 (31-C), 31.4 (16-C), 28.8 (36-C), 28.2 (38-C), 27.2 (44-C, 41-C), 27.2, 
27.1 (5-C), 25.2 (17-C). IR (KBr) ν (cm-1): 3299.9 (NH), 1655.1 (CO). HPLC-ESI-MS: m/z (%) = 
1082.6 (65) [M+H]
+
, 1099.6 (100) [M+NH4]
+
. HR-ESI-MS (m/z): calcd. for C57H79N9O12Na [M+Na]
+ 
1104.5746; found 1104.5740. Rf = 0.43 (DCM/MeOH, 15/1). 
(S)-1-((S)-2-((S)-2-((S)-2-Amino-3-(4-hydroxyphenyl)propanamido)-3-phenylpropanamido)-3-
hydroxy-propanoyl)-N-((S)-1-((2-hydrazinyl-2-oxoethyl)amino)-3-(1H-indol-3-yl)-1-oxo-propan-2-
yl)pyrrolidine-2-carboxamide (TVC-031, 198) 
Compound TVC-016 (200 mg, 0.18 mmol) was treated with TFA/TIPS/H2O (5 mL, 95/2.5/2.5) at 0 
o
C 
for 2 h. Afterward, the reaction mixture was concentrated under reduced pressure and purified on silica 
gel column chromatography. The product 198 (135 mg, 94%) was lyophilized in ACN/H2O (3 mL, 2/1) to 
yield white powder. 
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1
H-NMR (600 MHz, DMSO-d6): δ = 10.8 (br, 
1H, NH), 9.26 (s, 1H, NH), 8.48 (d, J = 7 Hz, 
1H, NH), 8.4 (br, 1H, NH), 7.58 (m, 1H, 9-H), 
7.31 (m, 1H, 12-H), 7.23-7.21 (m, 2H, 27-H), 
7.18-7.14 (m, 3H, 26-H, 28-H), 7.12 (br, 1H, 7-
H), 7.05 (m, 1H, 11-H), 6.99 (overlap, 1H, 10-
H), 6.99 (m, 2H, 33-H), 6.67 (m, 2H, 34-H), 
4.73 (m, 2/5H, 20-H), 4.67 (m, 3/5H, 20-H), 4.66 (m, 1/2H, 23-H), 4.57 (m, 1/2 H, 4-H), 4.52 (m, 1/2H, 
23-H), 4.46 (m, 1/2H, 4-H), 4.3 (m, 1/2H, 15-H), 4.2 (m, 1/2H, 15-H), 3.95 (dd, J = 6.3 Hz, J = 16.0 Hz, 
1/2H, 2-H), 3.75 (m, 1/2H, 2-H), 3.74 (m, 1/2H, 30-H), 3.72 (m, 1H, 21-H), 3.68 (m, 1H, 21-H), 3.66 (m, 
1/2H, 30-H), 3.67 (m, 1/2H, 2-H), 3.64 (m, 1H, 18-H), 3.61 (m, 1/2H, 2-H), 3.59 (m, 1H, 18-H), 3.21 (m, 
1H, 5-H), 2.99 (m, 1H, 23-H), 2.89 (m, 1H, 5-H), 2.89 (m, 1H, 31-H), 2.82 (m, 1H, 24-H), 2.62 (m, 1H, 
31-H), 1.92 (m, 1H, 16-H), 1.66 (m, 1H, 17-H), 1.56 (m, 1H, 17-H), 1.35 (m, 1H, 16-H). 
13
C-NMR (150 
MHz, DMSO-d6): δ = 171.3 (22-C), 170.6 (29-C), 170.5 (3-C), 170.4 (19-C), 170.3 (14-C), 169.7 (1-C), 
156.2/156.1 (35-C), 135.9 (32-C), 130.3 (33-C), 115.1 (34-C), 137.3 (25-C), 129.2 (27-C), 127.9 (26-C), 
126.2 (28-C), 137.2 (13-C), 127.2 (8-C), 123.4/123.3 (7-C), 120.8 (9-C), 118.23/118.2 (11-C), 
118.0/118.1 (10-C), 110.1 (12-C), 61.8, 61.5 (21-C), 60.2, 59.9 (15-C), 54.4, 54.1 (30-C), 53.9, 53.8 (4-
C), 53.4, 53.2 (23-C), 52.4, 52.1 (20-C), 47.1, 46.9 (18-C), 40.9 (2-C), 37.6 (24-C), 37.4 (31-C), 28.7, 
28.6 (16-C), 27.1 (5-C), 23.9 (17-C). IR (KBr): ν (cm-1): 3407.9 (NH), 1676.2 (CO). HPLC-ESI-MS: 
m/z (%) = 770.3 (100) [M+H]
+
, 792.3 [M+Na]
+
. HR-ESI-MS (m/z): calcd. for C39H48N9O8 [M+H]
+
 
770.3626; found 770.3620. 
3.19 Chemical shift of the membrane-bound peptides 
Chemical shifts of peptide TVC-135 (34a) in DPC micelles 
AA NH Hα Hβ Other protons 
Tyr
1
 - 3.96 2.88 δ: 6.89, ε: 6.71 
Phe
2
 / 4.47 2.96, 3.05 δ: 7.21, ε: /, ζ: / 
Apy
4
 8.15 4.06 1.57, 2.02 γ: 4.23 
Trp
5
 8.58 4.71 3.12, 3.30 
δ1: 7.22, ε1: / , ζ2: 7.40, η2: 7.00, ζ3: 6.95, 
ε3: 7.55 
Gly
6
 8.53 3.81 -- -- 
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Chemical shifts of peptide TVC-134 (34b) in DPC micelles 
AA NH Hα Hβ Other protons 
Tyr
1
 - 4.01 2.95 δ: 6.98, ε: 6.74 
Phe
2
 / 4.40 3.02 δ: 7.21, ε: /, ζ: / 
Apy
4
 8.07 3.97 1.60, 1.82 γ: 4.05 
Trp
5
 8.15 4.68 3.16, 3.38 
δ1: 7.21, ε1: / , ζ2: 7.37, η2: 7.02, ζ3: 7.00, 
ε3: 7.56 
Gly
6
 8.45 3.75, 3.88 -- -- 
Chemical shifts of peptide TVC-119 (35a) in DPC micelles 
AA NH Hα Hβ Other protons 
Tyr
1
 - 3.99 2.88 δ: 6.92, ε: 6.76 
Phe
2
 7.33 4.55 3.07, 3.23 δ: 7.25, ε: /, ζ: / 
Ser
3
 8.35 4.34 3.22, 3.79 -- 
Apy
4
 8.08 4.18 1.82, 2.25 γ: 4.33 
Trp
5
 8.65 4.75 3.16, 3.34 
δ1: 7.24, ε1: 10.48 , ζ2: 7.38, η2: /, ζ3: /, ε3: 
7.57 
Gly
6
 8.49 3.89 -- -- 
Chemical shifts of peptideTVC-117 (35b) in DPC micelles 
AA NH Hα Hβ Other protons 
Tyr
1
 - 3.95 2.87, 2.92 δ: 6.88, ε: 6.74 
Phe
2
 7.35 4.55 3.04, 3.24 δ: 7.27, ε: /, ζ: / 
Ser
3
 8.40 4.35 3.79 -- 
Apy
4
 8.05 3.88 1.96, 2.21 γ: 4.21  
Trp
5
 8.20 4.73 3.20, 3.38 
δ1: 7.23, ε1: 10.41 , ζ2: 7.41, η2: /, ζ3: /, ε3: 
7.58 
Gly
6
 8.49 3.80, 3.90 -- -- 
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Chemical shifts of peptide 47 in DPC micelles 
AA NH Hα Hβ Other protons 
Tyr
1
 - 4.04 2.97 δ: 7.04 , ε: 6.81 
Phe
2
 8.22 4.53 3.04, 2.95 δ: 7.17, ε: /, ζ: / 
Ser
3
 8.22 4.80 3.65, 3.70 -- 
Oxopiperazine
4
 / 4.42 1.36 γ: 0.55, 2xCH2: 3.24, 3.41, 3.59, 3.89  
Trp
5
 / 5.57 3.12, 3.46 
δ1: 7.30, ε1: 10.62 , ζ2: 7.42, η2: /, 
ζ3: /, ε3: 7.57  
Gly
6
 8.47 3.88 -- -- 
 
Chemical shifts of peptide TVC-044 (79) in DPC micelles 
AA NH Hα Hβ Other protons 
Tyr
1
 -- 4.20 3.10 δ: 7.11, ε:6.83  
Phe
2
 8.54 4.59 3.09, 3.00 δ: 7.26, ε: /, ζ: / 
Ser
3
 8.22 4.64 3.52, 3.73 -- 
Pro
4
 -- 4.59 2.04 γ: 1.85, δ 3.62  
Trp
5
 -- 5.20 3.31, 3.13 
ε1: 11.14, ζ2: 7.51, η2: 7.15, ζ3: 6.99, ε3: 
7.34 
Gly
6 
-- 4.33, 3.63 -- -- 
NH2 7.41 -- -- -- 
others -- -- -- CH2: 4.04, 3.59, CH: 5.97 
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